

2026 ESC Guidelines for the management of heart failure

Developed by the task force for the management of heart failure of the European Society of Cardiology (ESC)

With the special contribution of the Heart Failure Association (HFA) of the ESC

Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)

Authors/Task Force Members: Lars Køber ^{*†}, (Chairperson) (Denmark), Marianna Adamo ^{*†}, (Chairperson) (Italy), Anne-Christine Ruwald [‡], (Task Force Co-ordinator) (Denmark), Daniela Tomasoni [‡], (Task Force Co-ordinator) (Italy), Lisa J. Anderson  (United Kingdom), Charlotte Andersson  (United States of America), Jasper J. Brugts  (Netherlands), Ovidiu Chioncel  (Romania), Erwan Donal  (France), Peter Ferdinandy  (Hungary), Pardeep S. Jhund  (United Kingdom), Francisco Leyva  (United Kingdom), Roberto Lorusso  (Netherlands), Michael Madigan (Ireland), Wilfried Mullens  (Belgium), Stefania Paolillo  (Italy), Nicola Ryan  (United Kingdom), Maggie Simpson  (United Kingdom), Holger Thiele  (Germany), Jens Jakob Thune  (Denmark), Emeline M. Van Craenenbroeck  (Belgium), Linda W. Van Laake  (Netherlands), Mariette Verbakel  (Netherlands), and ESC Guidelines Advisory Group

^{*} Corresponding authors: Lars Køber, Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, and Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark, and Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. Tel: +45 3545 3519, E-mail: lars.koeber.01@regionh.dk; Marianna Adamo, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy, and Cardiothoracic Department, ASST Spedali Civili di Brescia, Brescia, Italy. Tel: +393897834503, E-mail: mariannaadamohotmail.com

[†] The two Chairpersons contributed equally to the document and are joint corresponding authors.

[‡] The two Task Force Co-ordinators contributed equally to the document.

Author/Task Force Member affiliations are listed in author information.

ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.

ESC subspecialty communities having participated in the development of this document:

Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Cardiology Practice, Cardiovascular Genomics, Valvular Heart Disease.

Working Groups: Adult Congenital Heart Disease, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function.

Patient Forum

© The European Society of Cardiology 2026. All rights reserved. For permissions, please email: journals.permissions@oup.com.

No part of this publication may be reproduced, stored in a retrieval system, transmitted, used for text and data mining, or used for training artificial intelligence, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by license or under terms agreed with the appropriate reprographics rights organization. Inquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above.

ESC Guidelines are protected by copyright. As per opt out option under Article 4(3) of EU Directive 2019/790, the European Society of Cardiology (ESC) reserves all rights to license uses of ESC Guidelines to train or develop generative artificial intelligence (AI) models, large language models or other deep learning or machine learning models.

Document Reviewers: Christina Christersson, (CPG Review Coordinator) (Sweden), Massimo F. Piepoli, (CPG Review Coordinator) (Italy), Ana Abreu (Portugal), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Claudio Ceconi (Italy), Christina Chrysoshoou (Greece), Kevin Damman (Netherlands), Jean-Claude Deharo (France), Victoria Delgado (Spain), Fernando Dominguez (Spain), Gloria Färber (Germany), Daniel Fernandez-Berges (Spain), Marc Ferrini (France), Estelle Gandjbakhch (France), Luna Gargani (Italy), Bettina Heidecker (Germany), Borja Ibanez (Spain), Massimo Imazio (Italy), Stefan James (Sweden), Ulf Landmesser (Germany), Gregory Y. H. Lip (United Kingdom), Lars H. Lund (Sweden), Sharon MacDonald (United Kingdom), John William McEvoy (Ireland), Lorenzo Menicanti (Italy), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Christian E. Mueller (Switzerland), Lis Neubeck (United Kingdom), Daniela Pini (Italy), Evgenij V. Potapov¹ (Germany), Anne-Catherine Pouleur (Belgium), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Hatem Soliman Aboumarie (United Kingdom), Felix C. Tanner (Switzerland), Izabella Uchmanowicz (Poland), Mattias Van Heetvelde (Belgium), Matthias Wilhelm (Switzerland), Stefanos Zafeiropoulos (Switzerland), Katja Zeppenfeld (Netherlands), and Daniel Zimpfer¹ (Austria)

¹ Representing the European Association for Cardio-Thoracic Surgery (EACTS)

 All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the *European Heart Journal* online or <https://www.escardio.org/Guidelines> for supplementary documents as well as evidence tables.

Disclaimer: The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their development. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

Permissions: The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the *European Heart Journal* and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).

Keywords

Guidelines • European Society of Cardiology (ESC) • Heart failure • Heart failure with reduced ejection fraction (HFrEF) • Heart failure with preserved ejection fraction (HFpEF) • Decompensated heart failure • Advanced heart failure • Stages of heart failure • Heart failure phenotypes • Treatment • Prevention • Pharmacotherapy • Foundational medical therapy • Additional medical therapy • Guideline directed interventional therapy • Cardiac resynchronization therapy • Implantable cardioverter-defibrillator • Aetiology • Diagnosis • Comorbidities • Cardiac amyloidosis

Table of contents

1. Preamble	7		
2. Introduction	9		
2.1. What is new	11		
3. Definition, epidemiology, and classifications	15		
3.1. Definition of heart failure	15		
3.2. Epidemiology of heart failure	15		
3.2.1. Epidemiology of heart failure phenotypes	16		
3.2.2. Natural history and prognosis	16		
3.3. Classifications	16		
3.3.1. Classification based on left ventricular ejection fraction	16		
3.3.2. Classification based on heart failure stages	17		
3.3.3. Other classifications of heart failure	17		
3.3.4. Classifications of treatments in heart failure	17		
4. Prevention of heart failure	19		
4.1. Patients at risk of heart failure (stage A heart failure) ..	19		
4.1.1. Cardiometabolic risk factors	19		
4.1.2. Risk scores for individuals without heart failure	19		
4.1.3. Lifestyle-related factors	19		
4.1.3.1. Diet and physical activity	19		
4.1.3.2. Smoking, alcohol, and substance abuse	19		
4.1.4. Specific populations at risk	20		
4.1.4.1. Arrhythmias	20		
4.1.4.2. Myocardial infarction	20		
4.1.4.3. Chronic kidney disease	20		
4.1.4.4. Cancer survivors	20		
4.1.4.5. Familial and genetic predisposition but no overt clinical disease	20		
4.1.4.6. Pulmonary disorders and sleep-disordered breathing	20		
4.1.4.7. Endocrine disorders	20		
4.1.4.8. Congenital heart disease	20		
4.2. Patients with stage B heart failure	21		
4.2.1. Asymptomatic left ventricular dysfunction	21		
4.2.2. Valvular heart disease	21		
4.3. Risk prediction in patients with established heart failure	21		
5. Diagnosis of chronic heart failure	21		
5.1. Key steps in the diagnosis of chronic heart failure	21		
5.1.1. Natriuretic peptides	22		
5.1.2. Other laboratory tests	24		
5.2. Heart failure phenotypes based on left ventricular ejection fraction	24		
5.2.1. Heart failure with reduced ejection fraction	24		
5.2.2. Heart failure with preserved ejection fraction	25		
5.3. Aetiology and subtypes of heart failure	25		
5.3.1. Cardiac imaging in heart failure: a multimodality approach	28		
5.3.2. Investigations for coronary artery disease	29		
5.3.3. Heart failure caused by arrhythmia or conduction disease	29		
6. Management of chronic heart failure	31		
6.1. Guideline-directed medical therapy for heart failure	31		
6.1.1. Goals of pharmacotherapy for patients with heart failure	31		
6.1.2. Foundational medical therapy in all patients with heart failure, independent of left ventricular ejection fraction	32		
6.1.2.1. Sodium–glucose co-transporter 2 inhibitors	32		
6.1.2.2. Mineralocorticoid receptor antagonists	32		
6.1.3. Additional medical therapy in all patients with heart failure, independent of left ventricular ejection fraction	32		
6.1.3.1. Loop diuretics	32		
6.1.3.2. Potassium binders	32		
6.1.4. Foundational medical therapy for heart failure with reduced ejection fraction	33		
6.1.4.1. Angiotensin-converting enzyme inhibitors and angiotensin receptor–neprilysin inhibitor	33		
6.1.4.2. Angiotensin II type 1 receptor blockers	33		
6.1.4.3. Beta-blockers	34		
6.1.5. Additional medical therapy for heart failure with reduced ejection fraction	34		
6.1.5.1. I _f -channel inhibitor (ivabradine)	34		
6.1.5.2. Vericiguat	34		
6.1.5.3. Hydralazine and isosorbide dinitrate	34		
6.1.5.4. Cardiac glycosides	34		
6.1.5.5. Cardiac myosin activator	35		
6.1.6. The importance of uptitrating foundational medical therapy and maintaining adherence in heart failure with reduced ejection fraction	35		
6.1.7. Pharmacological therapy for heart failure with preserved ejection fraction	35		
6.1.7.1. Angiotensin receptor–neprilysin inhibitors	35		
6.1.8. Pharmacological treatment in heart failure with improved ejection fraction	36		
6.2. Guideline-directed interventional therapies for chronic heart failure	38		
6.2.1. Implantable cardioverter-defibrillators	38		
6.2.1.1. Secondary prevention of sudden cardiac death	38		
6.2.1.2. Primary prevention of sudden cardiac death in heart failure	38		
6.2.1.3. Patient selection for implantable cardioverter-defibrillator therapy	38		
6.2.1.4. Timing of implantable cardioverter-defibrillator therapy	39		
6.2.1.5. Implantable cardioverter-defibrillator generator replacement	39		
6.2.1.6. Non-transvenous implantable cardioverter-defibrillator and wearable cardioverter-defibrillator	39		
6.2.2. Cardiac resynchronization therapy	40		
6.2.2.1. Cardiac resynchronization therapy for heart failure caused by abnormal cardiac conduction	40		
6.2.2.2. Right ventricular pacing-induced heart failure ..	40		
6.2.2.3. Timing of cardiac resynchronization therapy implantation	40		
6.2.3. Conduction system pacing	41		
6.2.4. Cardiac implantable electronic device programming and follow-up	41		
6.2.5. Other cardiac implantable electronic devices	42		
6.2.6. Other implantable devices	42		

7. Decompensated heart failure	42	9.3.2. Aortic regurgitation	62
7.1. Definition and epidemiology	42	9.3.3. Mitral regurgitation	62
7.2. Diagnosis	42	9.3.3.1. Primary mitral regurgitation	62
7.3. Clinical presentation	42	9.3.3.2. Secondary mitral regurgitation	62
7.3.1. Decompensated left-sided heart failure	42	9.3.4. Tricuspid regurgitation	64
7.3.2. Decompensated right-sided heart failure	43	9.4. Hypertension	64
7.3.3. Acute pulmonary oedema	44	9.5. Stroke	64
7.3.4. Cardiogenic shock	44	10. Non-cardiovascular comorbidities	65
7.4. General management	44	10.1. Obesity	65
7.4.1. Phase 1 (initial management)	45	10.2. Diabetes	65
7.4.2. Phase 2 (stabilization)	45	10.3. Chronic kidney disease	66
7.4.3. Phase 3 (pre-discharge and early post-discharge)	46	10.4. Iron deficiency and anaemia	66
7.5. Treatment	48	10.5. Cancer	67
7.5.1. Oxygen therapy	48	10.6. Lung disease and sleep-disordered breathing	67
7.5.2. Ventilation support	48	10.7. Anxiety, depression, and cognitive impairment	68
7.5.3. Diuretics (decongestion management)	48	10.8. Frailty	68
7.5.4. Decongestion management in the ambulatory setting	48	10.9. Other non-cardiovascular comorbidities	69
7.5.5. Sodium–glucose co-transporter 2 inhibitors	50	11. Multidisciplinary team management, long-term follow-up, and patient care	69
7.5.6. Ultrafiltration	50	11.1. Multidisciplinary management of heart failure	69
7.5.7. Vasodilators	50	11.2. Patient education, self-care, and lifestyle advice	71
7.5.8. Inotropes/inodilators	50	11.3. Implementation and adherence to therapy	71
7.5.9. Vasopressors	50	11.3.1. Implementation and optimization	71
7.5.10. Opiates	50	11.3.2. Long-term adherence	71
7.5.11. Temporary mechanical circulatory support	51	11.4. Exercise training and cardiac rehabilitation	71
7.5.11.1. Microaxial flow pumps	51	11.4.1. Benefits of exercise training according to heart failure stage and phenotype	71
7.5.11.2. Venoarterial extracorporeal life support	51	11.4.2. Safety and contraindications	71
7.5.11.3. Intra-aortic balloon pump	51	11.4.3. Exercise prescription	71
7.5.12. Thromboembolism prophylaxis	52	11.5. Telemonitoring	72
8. Advanced heart failure	52	11.6. Long-term follow-up	72
8.1. Epidemiology, definition, prognosis, and referral	52	11.6.1. Follow-up	72
8.2. Management	54	11.6.2. Advance care planning and palliative care	73
8.2.1. Pharmacological therapy and kidney replacement therapy	54	12. Specific conditions	74
8.2.2. Mechanical circulatory support	54	12.1. Pregnancy and heart failure	74
8.2.2.1. Temporary mechanical circulatory support	54	12.2. Cardiomyopathies	74
8.2.2.2. Durable mechanical circulatory support	55	12.2.1. Hypertrophic cardiomyopathy	74
8.2.3. Heart transplantation	57	12.3. Amyloidosis	74
8.2.4. Symptom control and end-of-life care	58	12.3.1. Epidemiology and diagnosis	74
9. Cardiovascular comorbidities	58	12.3.2. Disease-specific treatments	75
9.1. Arrhythmias and conduction disturbances	58	12.3.2.1. Immunoglobulin light chain cardiac amyloidosis	75
9.1.1. Atrial fibrillation	58	12.3.2.2. Transthyretin cardiac amyloidosis	75
9.1.1.1. Identification of triggers and risk factor management	58	12.3.3. Treatment of heart failure and cardiovascular comorbidities	75
9.1.1.2. Prevention of embolic events	58	12.4. Myocarditis	77
9.1.1.3. Management of heart failure and atrial fibrillation	59	12.4.1. Epidemiology and diagnosis	77
9.1.1.4. Rate control	59	12.4.2. Treatment	77
9.1.1.5. Rhythm control	59	12.5. Adult congenital heart disease	77
9.1.2. Ventricular arrhythmias	60	13. Key messages	77
9.1.3. Bradyarrhythmias	60	14. Gaps in evidence	78
9.2. Chronic coronary syndromes	60	15. Evidence tables	80
9.2.1. Medical therapy	60	16. Data availability	80
9.2.2. Myocardial revascularization	60	17. Author information	80
9.3. Valvular heart disease	62	18. Appendix	80
9.3.1. Aortic stenosis	62	19. References	81

Tables of Recommendations

Recommendation Table 1 – Recommendations for prevention of heart failure (see <i>Evidence Tables 1–15</i>)	19
Recommendation Table 2 – Recommendations for stage B heart failure and left ventricular dysfunction (see <i>Evidence Table 16</i>)	21
Recommendation Table 3 – Recommendations for diagnostic investigations in all patients with suspected heart failure (see <i>Evidence Tables 17–19</i>)	24
Recommendation Table 4 – Recommendations for specialized diagnostic investigations in patients with established heart failure to detect reversible/treatable causes of heart failure (see <i>Evidence Tables 20–28</i>)	30
Recommendation Table 5 – Recommendations for pharmacological management of chronic heart failure (see <i>Evidence Tables 29–41</i>)	37
Recommendation Table 6 – Recommendations for implantable cardioverter-defibrillator implantation (see <i>Evidence Tables 42–48</i>)	39
Recommendation Table 7 – Recommendations for cardiac resynchronization therapy implantation (see <i>Evidence Tables 49–58</i>)	41
Recommendation Table 8 – Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for decompensated heart failure (see <i>Evidence Tables 59–67</i>)	47
Recommendation Table 9 – Recommendations for the immediate and intermediate treatment of decompensated heart failure (see <i>Evidence Tables 59–67</i>)	50
Recommendation Table 10 – Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see <i>Evidence Tables 68 and 69</i>)	52
Recommendation Table 11 – Recommendations for diagnosis and evaluation of advanced heart failure (see <i>Evidence Tables 70 and 71</i>)	53
Recommendation Table 12 – Recommendations for medical management of advanced heart failure (see <i>Evidence Tables 72 and 73</i>)	54
Recommendation Table 13 – Recommendations for durable mechanical circulatory support in advanced heart failure (see <i>Evidence Table 74</i>)	57
Recommendation Table 14 – Recommendations for heart transplantation (see <i>Evidence Tables 75 and 76</i>)	58
Recommendation Table 15 – Recommendations for management of atrial fibrillation in patients with heart failure (see <i>Evidence Tables 77–81</i>)	59
Recommendation Table 16 – Recommendations for revascularization in chronic coronary syndrome in patients with heart failure (see <i>Evidence Table 82</i>)	62
Recommendation Table 17 – Recommendations for valvular heart disease in patients with heart failure (see <i>Evidence Tables 83 and 84</i>)	64
Recommendation Table 18 – Recommendations for obesity in patients with heart failure (see <i>Evidence Tables 85 and 86</i>)	65
Recommendation Table 19 – Recommendations for iron deficiency in patients with heart failure (see <i>Evidence Tables 87 and 88</i>)	67

Recommendation Table 20 – Recommendations for lung disease and sleep-disordered breathing (see <i>Evidence Table 89</i>)	68
Recommendation Table 21 – Recommendations for anxiety, depression, and frailty (see <i>Evidence Tables 90 and 91</i>)	68
Recommendation Table 22 – Recommendations for other non-cardiovascular comorbidities (see <i>Evidence Tables 92 and 93</i>)	69
Recommendation Table 23 – Recommendations for the multidisciplinary management of heart failure (see <i>Evidence Tables 94–96</i>)	69
Recommendation Table 24 – Recommendations for exercise training and cardiac rehabilitation (see <i>Evidence Tables 97–99</i>)	72
Recommendation Table 25 – Recommendations for invasive and non-invasive telemonitoring (see <i>Evidence Table 100</i>)	72
Recommendation Table 26 – Recommendations for long-term follow-up (see <i>Evidence Tables 101 and 102</i>)	74
Recommendation Table 27 – Recommendations for heart failure and pregnancy (see <i>Evidence Tables 103–107</i>)	74
Recommendation Table 28 – Recommendations for cardiac amyloidosis (see <i>Evidence Tables 108–111</i>)	77

List of tables

Table 1 Classes of recommendations	8
Table 2 Levels of evidence—therapy and prevention	9
Table 3 Levels of evidence—diagnostic tests and prediction models	9
Table 4 New concepts	11
Table 5 New recommendations	11
Table 6 Revised recommendations	13
Table 7 Symptoms and signs of heart failure	22
Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity	22
Table 9 Causes for increase or decrease in natriuretic peptide levels	24
Table 10 Simplified echocardiographic criteria for supporting objective evidence of heart failure with preserved ejection fraction	25
Table 11 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure	36
Table 12 Signs, symptoms, and altered laboratory tests in congestion and hypoperfusion profiles	44
Table 13 SCAI classification for cardiogenic shock	44
Table 14 Criteria for definition of advanced heart failure	52
Table 15 Criteria for high risk of advanced heart failure	53
Table 16 Indications and contraindications for implantation of a left ventricular assist device	57
Table 17 Indications and contraindications for heart transplantation	58
Table 18 Updated definitions for the CHA ₂ DS ₂ -VA score	59
Table 19 Selection criteria for mitral transcatheter edge-to-edge repair in heart failure with reduced ejection fraction	63
Table 20 'Red flags' for most common forms of cardiac amyloidosis	75

List of figures

Figure 1 Central illustration	10
Figure 2 Heart failure stages and classifications	17
Figure 3 New nomenclature for heart failure therapies	18
Figure 4 Diagnostic algorithm for chronic heart failure presenting in the outpatient or community setting	23
Figure 5 Major contributing causes of heart failure with reduced ejection fraction	26
Figure 6 Major risk factors of heart failure with preserved ejection fraction	27
Figure 7 Multiparametric approach to aetiology assessment in heart failure	28
Figure 8 Diagnosis of heart failure due to ischaemic aetiology	29
Figure 9 Diagnosing arrhythmia-associated heart failure and heart failure with abnormal cardiac conduction	31
Figure 10 Indications for cardiac resynchronization therapy in heart failure	40
Figure 11 Diagnosing decompensated heart failure	43
Figure 12 Phases and goals for in-hospital management of decompensated heart failure	45
Figure 13 Initial management of decompensated heart failure	46
Figure 14 Tools used for assessment of decongestion during the pre-discharge phase	47
Figure 15 Management of decongestion	49
Figure 16 Triage and timely referral of patients with advanced heart failure	53
Figure 17 INTERMACS classification	55
Figure 18 Treatment for advanced heart failure	56
Figure 19 Management of coronary artery disease in patients with heart failure	61
Figure 20 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction	63
Figure 21 Core members of the heart failure team with expanded team members depending on patient needs and local availability	70
Figure 22 Long-term follow-up of patients with stable heart failure—what—when—who	73
Figure 23 Diagnosis and treatment of cardiac amyloidosis in heart failure patients	76

Abbreviations and acronyms

18F-FDG-PET	18F-fluorodeoxyglucose-positron emission tomography
ACC	American College of Cardiology
ACE-I	Angiotensin-converting enzyme inhibitor
ACHD	Adult congenital heart disease
AF	Atrial fibrillation
AHA	American Heart Association
AL-CA	Immunoglobulin light chain cardiac amyloidosis
AMT	Additional medical therapy
APO	Acute pulmonary oedema
ARB	Angiotensin II receptor blocker
ARNI	Angiotensin receptor–neprilysin inhibitor
ARVC	Arrhythmogenic right ventricular cardiomyopathy

ASCVD	Atherosclerotic cardiovascular disease
ASV	Adaptive servo-ventilation
ATTR	Transthyretin amyloidosis
ATTR-CA	Transthyretin cardiac amyloidosis
BMI	Body mass index
BNP	B-type natriuretic peptide
CA	Cardiac amyloidosis
CABG	Coronary artery bypass grafting
CAD	Coronary artery disease
CI	Confidence interval
CIED	Cardiac implantable electronic device
CKD	Chronic kidney disease
CMR	Cardiac magnetic resonance
COPD	Chronic obstructive pulmonary disease
CPAP	Continuous positive airway pressure
CPET	Cardiopulmonary exercise testing
CRT	Cardiac resynchronization therapy
CRT-D	Cardiac resynchronization therapy with defibrillator
CRT-P	Cardiac resynchronization therapy with pacemaker
CS	Cardiogenic shock
CSA	Central sleep apnoea
CSP	Conduction system pacing
CT	Computed tomography
CTCA	Computed tomography coronary angiography
CV	Cardiovascular
CVD	Cardiovascular disease
DCM	Dilated cardiomyopathy
DHF	Decompensated heart failure
DPD	3,3-Diphosphono-1,2-propanodicarboxylic acid
ECG	Electrocardiogram
ECLS	Extracorporeal life support
ECV	Extracellular volume
eGFR	Estimated glomerular filtration rate
ESC	European Society of Cardiology
FITT	Frequency, intensity, time, type
FMT	Foundational medical therapy
GDIT	Guideline-directed interventional therapy
GDMT	Guideline-directed medical therapy
GFR	Glomerular filtration rate
GIP	Glucose-dependent insulintropic peptide
GLP-1 RA	Glucagon-like peptide-1 receptor agonist
HCM	Hypertrophic cardiomyopathy
HF	Heart failure
HFA	Heart Failure Association
HFH	Heart failure hospitalization
HF-MDT	Heart failure multidisciplinary team
HFmrEF	Heart failure with mildly reduced ejection fraction
HFpEF	Heart failure with preserved ejection fraction
HFREF	Heart failure with reduced ejection fraction
HR	Hazard ratio

i.v.	Intravenous
IABP	Intra-aortic balloon pump
ICA	Invasive coronary angiography
ICD	Implantable cardioverter-defibrillator
ID	Iron deficiency
INTERMACS	Interagency Registry for Mechanically Assisted Circulatory Support
KCCQ	Kansas City Cardiomyopathy Questionnaire
KDIGO	Kidney Disease: Improving Global Outcomes
LBBS	Left bundle branch block
LGE	Late gadolinium enhancement
LV	Left ventricular
LVAD	Left ventricular assist device
LVEF	Left ventricular ejection fraction
MCS	Mechanical circulatory support
MI	Myocardial infarction
MR	Mitral regurgitation
MRA	Mineralocorticoid receptor antagonist
MR-proANP	Mid-regional pro-atrial natriuretic peptide
NT-proBNP	N-terminal pro-B-type natriuretic peptide
NYHA	New York Heart Association
OSA	Obstructive sleep apnoea
PaO ₂	Partial pressure of oxygen
PCI	Percutaneous coronary intervention
PVC	Premature ventricular contraction
QoL	Quality of life
RCT	Randomized controlled trial
RHC	Right heart catheterization
RV	Right ventricular
SCAI	Society for Cardiovascular Angiography and Interventions
SCD	Sudden cardiac death
SDB	Sleep-disordered breathing
SGLT2	Sodium-glucose co-transporter 2
SGLT2-I	Sodium-glucose co-transporter 2 inhibitor
SHARC	Shock Academic Research Consortium
S-ICD	Subcutaneous implantable cardioverter-defibrillator
SpO ₂	Oxygen saturation
T2DM	Type 2 diabetes mellitus
TAVI	Transcatheter aortic valve implantation
TEER	Transcatheter edge-to-edge repair
TR	Tricuspid regurgitation
TSAT	Transferrin saturation
TTR	Transthyretin
UACR	Urine albumin-to-creatinine ratio
uNa ⁺	Urinary sodium
WHF	Worsening heart failure
WHO	World Health Organization

For acronyms of studies and trials, see [Supplementary data online, Table S1](#).

1. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. ESC Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with the patient or the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website (<https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines>).

This guideline updates and replaces the previous version from 2021. This Task Force was selected by the ESC to include professionals involved with the medical care of patients with this pathology and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the entire ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion.

Guidelines Task Forces perform a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk-benefit ratio. Recommendations are based on major randomized trials and relevant systematic reviews and meta-analyses, when available. Systematic literature searches are conducted in cases of controversy or uncertainty to ensure that all key studies are considered. For recommendations related to diagnosis and prognosis, additional types of evidence are included, such as diagnostic accuracy studies and studies focused on the development and validation of prognostic models. The strength of each recommendation and the level of evidence supporting it are weighed and scored according to predefined criteria. The criteria for grading the strength of recommendations are described in [Table 1](#). A new system for grading levels of evidence for ESC Guidelines has been published^{1,2} and utilized for the first time in 2026 ESC Guidelines. For therapy and prevention, the framework includes consideration of study type and the number of studies supporting a recommendation, as well as whether a study is adequately powered, shows substantial evidence against the play of chance, and is free of major sources of bias. This is described in [Table 2](#). A separate grading system has also been developed for diagnostic tests and prediction models, which is described in [Table 3](#).

Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) are also evaluated when available as the basis for recommendations and/or discussion in these guidelines.

Evidence tables summarizing key information from relevant studies are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

After an iterative process of deliberations, a first Task Force vote on all recommendations is conducted prior to the initiation of rounds of review. A second Task Force vote on all recommendations is conducted after the final round of review and revision. For each vote, the Task Force follows ESC voting procedures: to achieve quorum, at least two-thirds of the Task Force must vote agree or disagree, and to be approved all recommendations require at least 75% of votes in favour, excluding abstentions. Restrictions on voting and on participation in task force deliberations are applied as needed based on declarations of interest.

The writing and reviewing panels provide declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can be found on the ESC website (<http://www.escardio.org/doi>) and are compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived

entirely from the ESC with no involvement of the healthcare industry.

The CPG Committee supervises and coordinates the preparation of new guidelines and approves their publication. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review on a dedicated online review platform. The review is conducted by a panel of 70 or more topic experts including members from ESC National Cardiac Societies and from relevant ESC Subspecialty Communities. Reviewers critically assess and comment on the content of the Guidelines and grade their comments as major and minor. Guideline Task Forces consider all review comments and are required to respond on the online platform to all those classified as major. The review comments inform revisions after each round. After the final review round and the second Task Force vote on all recommendations, the Task Force and the CPG Committee members approve the final document for publication in the *European Heart Journal*.

Unless otherwise stated, ESC Guidelines content refers to sex, understood as the biological condition of being male or female, defined by genes, hormones, and sexual organs. Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, decisions on off-label use must be made by the responsible health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and country-specific health regulation.

Table 1 Classes of recommendations

Class of recommendation	Definition	Wording to use
I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	<i>“is recommended”</i> or <i>“is indicated”</i>
II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.	
IIa	Weight of evidence/opinion is in favour of usefulness/efficacy.	<i>“should be considered”</i>
IIb	Usefulness/efficacy is less well established by evidence/opinion.	<i>“may be considered”</i>
III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	<i>“is not recommended”</i>

Table 2 Levels of evidence—therapy and prevention

Level of evidence	Definition
A	Conclusive evidence, usually from at least two adequately powered randomized controlled trials ^a free of major bias, with substantial evidence against the play of chance when combined in a meta-analysis (e.g., $P < 0.005$ for superiority). ^b
B1	Suggestive evidence from at least one adequately powered randomized controlled trial free of major bias, or a meta-analysis of such randomized controlled trials, with some evidence against the play of chance (e.g., $P < 0.05$ for superiority). ^c
B2	Limited evidence from at least two adequately powered non-randomized studies with careful control of major sources of bias and substantial evidence against the play of chance (e.g., $P < 0.005$ for superiority), ^b or from a meta-analysis of small, underpowered randomized controlled trials with some evidence against the play of chance (e.g., $P < 0.05$ for superiority). ^c
C	Preliminary evidence from non-randomized studies without careful control of major sources of bias, a single small, underpowered randomized controlled trial, or expert consensus.

©ESC 2026

^aExceptionally, level of evidence A can be considered if (1) there is a single very large randomized controlled trial that provides convincing evidence across a wide range of patients that is already widely accepted by most practitioners, or (2) the effects of the intervention are clinically obvious; in either case, over 90% of voting guideline task force members need to agree with level of evidence A.

^bStudies do not need to individually show substantial evidence against the play of chance (e.g. a P -value of < 0.005 for superiority) if a meta-analysis of these studies provides such evidence.

^cStudies do not need to individually show some evidence against the play of chance (e.g. a P -value of < 0.05 for superiority) if a meta-analysis of these studies provides such evidence.

Table 3 Levels of evidence—diagnostic tests and prediction models

Level of evidence	Diagnostic test	Prediction model (including diagnostic and prognostic models)
A	Conclusive evidence of adequate diagnostic ability from at least two high-quality studies	Conclusive evidence of adequate predictive ability from at least one high-quality derivation study, and two or more external validation studies of at least moderate quality.
B	Suggestive evidence of adequate diagnostic ability from a single high-quality or at least two moderate-quality studies.	Suggestive evidence of adequate predictive ability from one or more derivation and one or more external validation studies of at least moderate quality.
C	Preliminary evidence of adequate diagnostic ability from a single moderate-quality study, any number of low-quality studies, or expert consensus.	Preliminary evidence of adequate predictive ability from a derivation study of at least moderate quality, but with external validation absent or in a low-quality study, or a derivation study of low quality (irrespective of external validation).

©ESC 2026

2. Introduction

In these guidelines, we have redefined the classification of heart failure (HF) compared with the definition used in the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,³ and provided a simple definition that we believe will translate into everyday clinical practice. As early detection of HF is increasingly important, we have, in alignment with the

2022 AHA/ACC/HFSA Guideline for the management of heart failure,⁴ also included risk factors and early signs of HF into the staging of HF. An updated classification for the treatment of HF has also been added, which emphasizes foundational and additional medical therapies, as well as interventional therapies. [Figure 1](#) provides an overview of current management recommendations for HF. Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and




Figure 1 Central illustration. Management of heart failure. ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; AS, aortic stenosis; AV, atrioventricular; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; ISDN, isosorbide dinitrate; IV, intravenous; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; TEER, transcatheter edge-to-edge repair; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; SGLT2-I, sodium-glucose co-transporter 2 inhibitor; SR, sinus rhythm; TAVI, transcatheter aortic valve implantation. Green colour refers to Class I recommendation. Yellow colour refers to Class IIa recommendation. Orange colour refers to Class IIb recommendation. ^aAn ARB is recommended in patients with symptomatic HFrEF if they are unable to tolerate an ACE-I or ARNI. ^bNo large prospective randomized controlled trial has been performed on the use of beta-blockers, ACE-I/ARNI/ARB exclusively in patients with LVEF 41%–49%. ^cClass of recommendation for ICD differs according to ischaemic vs non-ischaemic aetiology. ^dClass of recommendation for CRT differs according to QRS duration and morphology (see [Figure 10](#) and [Recommendation Table 7](#)). ^eCriteria for advanced HF are listed in [Table 14](#). ^fIndications and contraindications for heart transplantation are listed in [Table 17](#). ^gIndications and contraindications for LVAD implantation are listed in [Table 16](#). ^hPredominantly obstructive sleep apnoea.

chronic heart failure³ and the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,⁵ new guidance for interpretation of evidence has been published by the ESC.^{1,2} Consequently, all recommendations, new and old, have been regraded to comply with the revised ESC evidence grading system. For recommendations with more than one outcome, e.g. cardiovascular (CV) death and HF hospitalization (HFH), the wording reflects

whether both outcomes were individually significant ('AND') or the outcome was a composite ('OR').

For each topic, we have considered age and sex differences and included these in the recommendations, if deemed clinically relevant.

Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,³ several relevant guidelines on specific topics, such as cardio-oncology,⁶

pregnancy,⁷ myocarditis,⁸ valvular heart disease,⁹ and chronic coronary syndrome,¹⁰ have been published. In the current guidelines, these topics are not addressed in detail, and we refer to the specific guidelines for each topic.

2.1. What is new

In the 2026 ESC Guidelines for the management of heart failure, some new concepts compared with the 2021 version are introduced in addition to the recommendations listed below. These changes will have impact on some recommendations, specifically concerning guideline-recommended treatment of HF because we have changed the classification of HF based on left ventricular ejection fraction (LVEF). For details of the new concepts, see Sections 3, 6, and 7. Table 4 provides an overview of new concepts. Table 5 highlights the new recommendations and Table 6 the revised recommendations, included in this document.

Table 4 New concepts

New concepts
HFrEF has been expanded to include LVEF up to 50%
HFmrEF has been removed
HFpEF includes LVEF from 50% and above
Decompensated HF replaces acute HF
Stages of HF (A–D) ranging from risk factors to advanced HF have been adopted
New classifications for medical and interventional therapy have been introduced

HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.

© ESC 2026

Table 5 New recommendations

Recommendations	Class ^a	Level ^b
Prevention of heart failure—Section 4		
Counselling on healthy lifestyle choices including maintaining a healthy weight, consuming a well-balanced diet, avoiding sedentary behaviour, abstaining from smoking and heavy alcohol consumption, as well as counselling against the use of drugs such as cocaine, amphetamines, and anabolic steroids, is recommended for all patients with stage A or B HF to reduce the risk of HF progression.	I	C
A GLP-1 RA should be considered in patients with T2DM and at least one other additional CV risk factor to reduce the risk of HF or CV death.	IIa	A
An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and death.	I	A
A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death.	I	B1
Eplerenone is recommended in patients after myocardial infarction with LVEF ≤40% with signs of HF or diabetes to reduce the risk of HFH or death.	I	B1
Diagnosis of chronic heart failure—Section 5		
Initial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.	I	B
Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.	I	C
18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.	IIa	C
Review of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.	IIa	C
Electrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.	IIb	C
Management of chronic heart failure—Section 6		
Uptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death.	I	C
Continuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death.	I	C
Gradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.	IIb	C
ACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.	IIb	C
Initiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35% to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be conducted prior to CRT implantation.	IIb	C

Continued

Decompensated heart failure—Section 7		
Urinary Na ⁺ -guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.	IIb	B1
In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH.	I	B1
A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics.	I	C
Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with LV systolic dysfunction and no risk of hypoxic brain injury in order to reduce the risk of death.	IIa	B1
Temporary MCS should be considered in patients with mechanical complications related to MI as a bridge to definitive treatment.	IIa	C
Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm.	III	B1
Advanced heart failure—Section 8		
Early consultation with an advanced HF centre is recommended in patients with advanced HF or at risk of advanced HF, who are motivated and do not have absolute contraindications for heart transplantation or durable MCS, in order to evaluate candidacy.	I	A
Downtitration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms.	IIa	C
Histopathological examination of explanted heart tissue from LVAD or heart transplantation surgery should be considered in patients with non-ischaemic HF to identify an aetiological diagnosis that may be treatable or facilitate family screening.	IIa	C
Cardiovascular comorbidities—Section 9		
Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical limitations, recurrent HFH and death.	IIa	B1
Intravenous amiodarone or digoxin may be considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart rate.	IIb	C
Non-cardiovascular comorbidities—Section 10		
Semaglutide or tirzepatide should be considered for patients with symptomatic HF, LVEF $\geq 45\%$, and BMI ≥ 30 kg/m ² , regardless of diabetes status, to reduce body weight, and improve exercise capacity and QoL.	IIa	B1
Bariatric surgery may be considered in obese patients with HF and a BMI ≥ 35 kg/m ² to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss.	IIb	C
Adaptive servo-ventilation may be considered in patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep apnoea to improve sleep quality, health-related QoL, and symptoms.	IIb	C
Assessment of anxiety, depression and frailty should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes.	IIa	C
Multidisciplinary management of heart failure—Section 11		
Personalized exercise training, in the context of multidisciplinary exercise-based cardiac rehabilitation, is recommended for all stable patients, unless there are specific contraindications, in order to improve exercise capacity, and QoL, and reduce the risk of all-cause hospitalization.	I	B1
Personalized exercise training outside exercise-based cardiac rehabilitation is recommended for all stable patients on a long-term basis, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization.	I	B2
Cardiac rehabilitation is recommended in patients with an LVAD to improve functional capacity and QoL.	I	B1
Cardiac rehabilitation should be considered in patients with DHF, as soon as safely possible, to improve functional capacity and QoL.	IIa	B1
Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to facilitate communication on end of life and QoL.	I	B1
Access to an integrated HF palliative care multidisciplinary team is recommended for patients in an advanced HF stage to improve QoL and reduce symptom burden.	I	B2

Continued

Specific conditions—Section 12		
Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive therapies.	I	C
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta ₁ -selective blockers (metoprolol, bisoprolol) with close mother and foetus monitoring to reduce the risk of adverse foetal events and a lower birth weight.	I	C
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2-Is are not recommended during pregnancy due to the risk of foetotoxicity or teratogenicity.	III	C

© ESC 2026

18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CV, cardiovascular; DHF, decompensated heart failure; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; FMT, foundational medical therapy; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; LBBB, left bundle branch block; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; PYP, pyrophosphate; QoL, quality of life; RCT, randomized controlled trial; RV, right ventricular; SGLT2-I, sodium-glucose co-transporter 2 inhibitor; T2DM, type 2 diabetes mellitus.

^aClass of recommendation.

^bLevel of evidence.

Table 6 Revised recommendations

Recommendations in 2021 version	Class ^a	Level ^b	Recommendations in 2026 version	Class ^a	Level ^b
Prevention of heart failure—Section 4					
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.	I	A	Strict blood pressure control (systolic blood pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF.	I	A
Diagnosis of chronic heart failure—Section 5					
CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiographic acoustic windows.	I	C	Contrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.	I	C
CMR is recommended for the characterization of myocardial tissue in suspected infiltrative disease, Fabry disease, inflammatory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis.	I	C			
CMR with LGE should be considered in DCM to distinguish between ischaemic and non-ischaemic myocardial damage.	IIa	C			
Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.	I	B	Invasive coronary angiography is recommended in patients with HF, angina, and high probability of obstructive CAD who are potential candidates for revascularization.	I	C
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests.	IIb	B	Invasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihood of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.	IIa	C
Management of chronic heart failure—Section 6					
An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A	An MRA (sMRA for HFrEF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.	I	A
An MRA may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.	IIb	C			

Continued

Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF hospitalizations).	IIb	B	A cardiac glycoside (digoxin or digitoxin) should be considered in patients with symptomatic HFrEF with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH.	IIa	B1
Vericiguat may be considered in patients in NYHA classes II–IV who have had worsening HF despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of CV mortality and HF hospitalization. [In patients with HFrEF according to the 2021 classification.]	IIb	B	Vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite treatment with optimal FMT to reduce the risk of HFH and CV death.	IIb	B1
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF.	I	A	CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and death.	IIa	B1
Decompensated heart failure—Section 7					
Combination of a loop diuretic with thiazide-type diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.	IIa	B	The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.	IIa	B1
IABP is not routinely recommended in post-MI cardiogenic shock.	III	B	IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.	III	B1
Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of the cause of cardiogenic shock or long-term MCS or transplantation	IIa	C	Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.	IIa	C
Advanced heart failure—Section 8					
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.	IIb	C	Continuous inotropes should be considered in patients with advanced HFrEF, low cardiac output, and evidence of hypoperfusion or end-organ dysfunction, as BTD, BTT, or as bridge to durable MCS, to increase cardiac output and improve symptoms.	IIa	C
Long-term MCS should be considered in patients with advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.	IIa	A	Durable MCS (LVAD) is recommended in selected patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy to improve symptoms and reduce the risk of death.	I	C
Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of premature death.	IIa	B			
Cardiovascular comorbidities—Section 9					
Beta-blockers should be considered for short- and long-term rate control in patients with HF and AF.	IIa	B	Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.	I	C

Continued

In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.	Ila	B	Catheter ablation for AF should be considered in selected patients with symptomatic AF and HFrEF to improve QoL and reduce the risk of HFH or death.	Ila	C
Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, despite OMT including antianginal drugs.	Ila	C	Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and antianginal drugs, to relieve symptoms.	I	C
Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.	I	B	Aortic valve intervention, SAVR or TAVI, is recommended in patients with severe aortic stenosis and HF to improve symptoms and reduce the risk of death.	I	B1
Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite OMT and who fulfil criteria for achieving a reduction in HF hospitalizations.	Ila	B	Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable, symptomatic patients with HFrEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil specific clinical and echocardiographic criteria, in order to reduce the risk of HFH and improve QoL.	I	B1
Multidisciplinary management—Section 11					
Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes.	IIb	B	Remote haemodynamic monitoring of PA pressure should be considered in symptomatic patients with HF, NYHA class III and an HFH in the past 12 months in order to reduce the risk of HFH.	Ila	B1
Specific conditions—Section 12					
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.	I	B	Treatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with variant or wild-type transthyretin cardiac amyloidosis and NYHA class I–III is recommended to reduce progression of symptoms and the risk of CV hospitalization and all-cause death.	I	A
Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.	I	B			

ACE-I angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARNI, angiotensin receptor–neprilysin inhibitor; AV, atrioventricular; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CAD, coronary artery disease; CCS, chronic coronary syndrome; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CV, cardiovascular; DCM, dilated cardiomyopathy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hTTR-CA, hereditary transthyretin cardiac amyloidosis; IABP, intra-aortic balloon pump; LGE, late gadolinium enhancement; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MT, medical therapy; nsMRA, non-steroidal mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OMT, optimal medical therapy; PA, pulmonary artery; QoL, quality of life; RV, right ventricular; SAVR, surgical aortic valve replacement; sMRA, steroidal mineralocorticoid receptor antagonist; TAVI, transcatheter aortic valve implantation; TTR, transthyretin; wtTTR-CA, wild-type transthyretin cardiac amyloidosis.

^aClass of recommendation.

^bLevel of evidence.

3. Definition, epidemiology, and classifications

3.1. Definition of heart failure

Heart failure is a clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.¹¹ In addition to the subjective symptoms of HF, clinically assessed objective evidence of cardiogenic pulmonary and/or systemic congestion and diagnostic supportive tests are needed to reach the diagnosis (see Section 5).¹¹

People who are in asymptomatic stages are not included under the above definition as having HF. They are defined as being at risk for HF (stage A) or having pre-HF (stage B) (see Section 3.3).

Identification of the aetiology of the underlying cardiac dysfunction is not included in the definition of HF, although determining aetiology is clinically important as the specific pathology can determine subsequent treatment and prognosis. Specific investigations needed to identify underlying aetiologies are described in Section 5.

3.2. Epidemiology of heart failure

The prevalence of HF is estimated to be 1%–3% in the general adult population, with significant geographical, age- and sex-related

variations.^{12,13} Both the incidence and prevalence of HF are increasing with age and risk-factor burden, with wide variation depending on the population and setting studied and the diagnostic criteria used.¹⁴ In addition, several factors, such as level of education, income, neighbourhood deprivation, climate, and air pollution, influence the risk of HF, contributing to varying epidemiology worldwide.¹³

In European countries, current prevalence-estimates range from 12–58 cases per 1000 people.¹⁵

As a result of the growing cohort of older people in Western populations, the crude incidence of HF has been increasing and is currently 2–13 per 1000 person-years in Europe (ranging from <1 per 1000 person-years for people aged 45–54 years to >12 per 1000 person-years for people aged >74 years).^{16,17} However, age-adjusted HF incidence rates have been declining over the past three decades, probably because of better risk-factor control and treatment of CV conditions.^{15,17,18} Among younger adults, incidence rates of HF appear to be either increasing or stagnating. There are several possible explanations for this, including (i) a greater burden of CV risk factors, (ii) increasing numbers of patients with congenital heart disease reaching adulthood, and (iii) a change in surveillance patterns.^{16,19,20} Furthermore, the mortality of HF has improved, which has led to a higher prevalence of HF.¹³

3.2.1. Epidemiology of heart failure phenotypes

In population-based samples, nearly half of all HF cases have HF with preserved ejection fraction (HFpEF), and this proportion may be increasing due to better treatment of coronary artery disease (CAD) and the rising burden of hypertension, obesity, and other HFpEF risk factors.²¹ Patients with HFpEF are older and are more often female. The Swedish HF registry reported an average age at HFpEF onset of 77 years with 55% female.²² In patients with heart failure with reduced ejection fraction (HFrEF), 71% were male and the mean age at onset was 72 years.²² Several subtypes of HFpEF have been suggested, with up to 50% of patients having a predominantly metabolic/obesity subtype [younger, higher body mass index (BMI)] in some regions, and up to 50% with a predominantly ageing, vascular subtype [older, stiff arteries, high prevalence of chronic kidney disease (CKD)] in other regions.^{23,24}

Heart failure with reduced ejection fraction is often subdivided into ischaemic vs non-ischaemic aetiologies, with approximately half of all cases being considered ischaemic.

3.2.2. Natural history and prognosis

Although the mortality rates after HF onset have improved considerably over the past three decades, the 5-year overall survival rates are still <60%.^{25,26} For younger patients, data from Denmark suggest survival has improved with contemporary management, with a current 5-year mortality rate of 15% for patients <65 years and 39% for patients aged 65–79 years.²⁵ In patients ≥80 years, improvements in mortality have also been observed, although these improvements are not as pronounced as those observed in younger patients, partly due to a greater burden of comorbidity and a greater proportion of non-CV mortality in the elderly.^{17,25,27} Mortality may be lower in HFpEF than HFrEF, but overall differences are small as patients with HFpEF are considerably older, and the risk of hospitalization is similar.^{28,29} Patients diagnosed with HF in an outpatient setting have better

prognosis than patients diagnosed during a HFH, and patients with repeated HFH have a particularly high risk of mortality.^{30,31}

The overall burden of HF as well as HFH can be expected to rise over the next few decades due to greater survival, an ageing population, and greater prevalence of risk factors and obesity in the younger population.

3.3. Classifications

3.3.1. Classification based on left ventricular ejection fraction

Traditionally, HF has been divided into distinct phenotypes based on the measurement of LVEF. In the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, three different HF phenotypes were identified: HFrEF (LVEF ≤40%); HF with mildly reduced ejection fraction (HFmrEF, LVEF 41%–49%); and HFpEF (LVEF ≥50%).³ The rationale behind this classification relates to the inclusion criteria of the trials of therapies that improved outcomes in patients with HF and LVEF ≤40%. The HFmrEF phenotype was introduced to focus on patients usually not included in HFrEF trials. The nomenclature was changed from ‘mid-range’ to ‘mildly reduced’ to highlight that patients with HFmrEF are similar to patients with HFrEF in terms of both clinical characteristics, outcomes, and response to treatments.^{32,33} Patients with HFmrEF have similar underlying aetiology of HF to patients with HFrEF, and the pathophysiology of HFmrEF is more similar to HFrEF (reduced contractility and systolic dysfunction) than HFpEF (increased stiffness and diastolic dysfunction).³⁴ In addition, the efficacy of medical treatment of HFmrEF is more similar to HFrEF than HFpEF.^{35–45} Finally, it is important to consider LVEF trajectories, as many patients with LVEF 41%–49% may experience a deterioration in LVEF.⁴⁶ The Task Force for the 2026 ESC Guidelines for the management of heart failure has eliminated the phenotype of HFmrEF and reclassified HF based on a pathophysiological classification of HF, including two distinct phenotypes:

- (i) HFrEF: characterized by LVEF <50% and symptoms and/or signs of HF.
- (ii) HFpEF: characterized by LVEF ≥50% and symptoms and/or signs of HF and objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular (LV) diastolic dysfunction/raised LV filling pressures, supported by raised natriuretic peptides.

Using a single LVEF value as cut-point for distinguishing HFpEF and HFrEF is somewhat arbitrary and has to be evaluated in the clinical situation, as there is variability in measurement depending both on the modality and the interpreter. Furthermore, LVEF may be falsely high in certain situations, e.g. mitral regurgitation (MR). Natriuretic peptides may be used as supportive evidence for the diagnosis of HF. Importantly, drug and device therapies can lead to positive LV reverse remodelling in patients with HFrEF and, thus, improvement of LVEF. Patients with HFrEF and improved LVEF have a more favourable prognosis. However, it is important to ensure that these patients are still managed with optimal medical therapy except for selected patients. The current definition of improved LVEF requires an increase of at least 10% in LVEF (absolute) and must be at least above 40% (often normal).⁴⁷

3.3.2. Classification based on heart failure stages

An additional classification based on HF stages has been proposed previously.⁴ The Task Force has included this classification as we focus more on prevention of HF and early diagnosis (Figure 2).

3.3.3. Other classifications of heart failure

Heart failure can also be classified according to clinical presentation: *de novo* (patients without a previous diagnosis of HF) vs pre-existing (patients with a diagnosis of HF), and chronic HF vs decompensated HF (DHF). Chronic HF may deteriorate to DHF. Details on the definitions and subtypes of DHF are provided in Section 7.

Finally, an additional classification in isolated left-sided HF vs isolated right-sided HF vs combined left- and right-sided HF can be used. The main aetiology of chronic right-sided HF is LV dysfunction-induced pulmonary hypertension [World Health

Organization (WHO) group 2] leading to combined left- and right-sided HF. However, there are a number of causes of isolated right-sided HF, e.g. right ventricular (RV) myocardial infarction (MI); arrhythmogenic RV cardiomyopathy (ARVC); pulmonary hypertension WHO groups 1, 3, 4, and 5; and tricuspid or pulmonary valve regurgitation. Diagnosis and management of chronic right-sided HF is covered comprehensively in a recent Heart Failure Association (HFA) position paper.⁴⁸

3.3.4. Classifications of treatments in heart failure

The term guideline-directed medical therapy (GDMT) was introduced in the 2013 ACCF/AHA Guideline for the management of heart failure and is the cornerstone of pharmacological treatment for patients with HF.⁴⁹ The term was meant to represent optimal medical therapy primarily with a Class I recommendation, which at that time included treatment with angiotensin-




Figure 2 Heart failure stages and classifications. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. ^aSee section 4.1. Not all will develop HF, but risk factor intervention may be warranted. ^bFor example, left ventricular hypertrophy, cardiac chamber enlargement, ventricular wall motion abnormality, myocardial tissue abnormality (e.g. evidence of myocardial oedema, scar/fibrosis abnormality by T2-weighted cardiac magnetic resonance imaging or late gadolinium enhancement imaging), valvular heart disease. ^cFor example, reduced left or right ventricular systolic function, evidence of increased filling pressures (by invasive or non-invasive measures), abnormal diastolic function. ^dEspecially in the setting of exposure to cardiotoxins. ^eFor details see Table 14.

converting enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) for HFrEF. Since 2013, there have been further advances in the management of patients with HF. Class I recommendations have now been presented for the use of angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose co-transporter 2 inhibitors (SGLT2-Is) in HFrEF. Furthermore, there are now data to support Class I recommendations for the use of SGLT2-Is and MRAs in HFpEF. Although these foundational therapies are crucial to improving the prognosis in HF, many other pharmacotherapies have guideline recommendations, e.g. ivabradine, vericiguat, cardiac glycosides, and, more recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs). All of these therapies could be viewed as GDMT but are currently not included in the definition of GDMT. Furthermore, the use of the term GDMT ignores the crucial role of devices that work in synergy with medical therapy and new procedural therapies with effect on patient-reported outcomes, morbidity and mortality. The current Task Force has decided to introduce new classifications to describe medical, device, and procedural therapies in HF (Figure 3). These classifications are designed to be dynamic, so the terms can remain contemporary over time as new therapies may be easily incorporated into the terms.

Foundational medical therapy (FMT) constitutes the foundation of any HF management. Foundational medical therapy is defined as medical therapy with a guideline Class I recommendation for the treatment of the general HF population, with convincing evidence of an improvement in morbidity and/or mortality. In this guideline, FMT will include beta-blocker, ACE-I/ARNI/ARB, MRA, and SGLT2-I for HFrEF, and MRA and SGLT2-I for HFpEF. The term ‘optimal FMT’ may be used for FMT at the highest tolerated doses according to the guideline-recommended target doses (see Section 6.1). Medical therapies with a Class I recommendation only for specific subsets of patients with HF are *not* included in the definition of FMT.

Additional medical therapy (AMT) is defined as all other medical therapies that receive a Class IIa/IIb recommendation OR a Class I recommendation with proven effect only on symptoms and/or quality of life (QoL) OR a Class I recommendation in specific subsets of patients/HF phenotypes.

Guideline-directed medical therapy therefore covers both FMT and AMT.

Guideline-directed interventional therapy (GDIT) includes all cardiac implantable electronic devices (CIED) and interventional therapies that have a recommendation in the guidelines.




Figure 3 New nomenclature for heart failure therapies. Guideline-directed medical therapy (GDMT) includes foundational medical therapy (FMT) and additional medical therapy (AMT). Guideline directed interventional therapy is abbreviated as GDIT.

4. Prevention of heart failure

4.1. Patients at risk of heart failure (stage A heart failure)

4.1.1. Cardiometabolic risk factors

Diabetes, hypertension, obesity, and smoking account for approximately 50% of all HF events on a population-based level, ranging from 30%–40% among the oldest individuals (over 75 years) to 75%–80% among individuals aged <55 years, and are similar for HFpEF and HFrEF.^{50–52} These risk factors often cluster within the same individuals and tend to be stable over the life course unless intervened upon.^{53–56} Unhealthy lifestyle changes have led to a rising incidence and prevalence of obesity, hypertension, and type 2 diabetes over the past decades in many regions across Europe, particularly among young to middle-aged adults.^{57–59} Concomitantly, increases have been observed in the incidence rates of HF among young adults, underscoring the need for earlier and better prevention strategies on a population-based level.^{16,19,20} As the risk of HF is related to both risk-factor burden (intensity) and risk-factor duration (exposure time), early risk-factor management should be considered for younger people with longer anticipated exposure time. Personalized HF risk estimations (see Section 4.1.2) may aid clinicians and patients in discussions, management, and treatment decisions.

Specific recommendations on the management of obesity, hypertension, and diabetes are outlined in the ESC guidelines on prevention of CV disease (CVD), hypertension, and diabetes, respectively.^{60–62} For hypertension, most evidence supports targeting a blood pressure <130 mmHg to reduce HF risk, although there are likely additional benefits of achieving lower treatment targets if tolerated.^{63–69} For diabetes, glucose-lowering drugs without proven HF safety should be avoided,⁷⁰ and among those at particular risk of HF [especially in the presence of atherosclerotic CVD (ASCVD)], SGLT2-Is and GLP-1 RAs have been shown to lower risk of HF and CV death.^{71–73} For obesity, declines in fat mass and waist circumference, but not lean mass, lowers HF risk and should be targeted.⁷⁴ High cholesterol levels increase the risk of HF mainly through CAD, and the use of statins has shown to modestly lower HF events in people at high risk of ASCVD and HF.^{75,76}

4.1.2. Risk scores for individuals without heart failure

To assist in more individualized HF risk estimation, the use of risk scores may be considered. In addition to risk scores to predict HF and mortality among ambulatory patients with established HF^{77–80} several risk scores for primary HF prevention have been developed^{81–83}. The American Heart Association (AHA) PREVENT-HF risk score⁸¹ and the ESC SCORE2-HF⁸² were both derived to estimate risk in people without pre-existing HF over a 10- and 30-year horizon. The ESC risk scores have been calibrated for low-, moderate-, high-, and very high-risk countries to fit the European population. The ESC SMART2-HF risk score⁸³ was derived to estimate 10-year risk of HF in people

with pre-existing ASCVD. These risk scores are described in [Supplementary data online, Section S1](#) and [Figure S1](#).

4.1.3. Lifestyle-related factors

4.1.3.1. Diet and physical activity

Epidemiological studies have shown that diets high in sugars, saturated fats, refined grains, and processed food are associated with increased HF risk (especially HFpEF).^{84–90} In contrast, adherence to a diet rich in vegetables, nuts, whole grains, fish, and unsaturated fats have been associated with lowered HF risk.^{84,87} However, a secondary analysis of the PREDIMED trial comparing a Mediterranean diet (with olive oil vs nuts) to a low-fat diet in individuals at high risk of CVD did not show a significant difference in HF incidence between the groups over a median follow-up of 4.8 years.⁸⁹ Similarly, sedentary behaviour and physical inactivity are strong risk factors for especially HFpEF development^{60,91}, but no randomized controlled trials (RCTs) have investigated the role of physical activity for the prevention of HF.^{91–93} Recommendations on exercise type and intensity to promote general CV health are outlined in the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.⁹⁴

4.1.3.2. Smoking, alcohol, and substance abuse

Smoking cessation has been shown to reduce HF risk over time in epidemiological studies and should be encouraged in all individuals.^{95–97} Similarly, heavy alcohol use is associated with increased risk of HF and is discouraged, whereas light-to-moderate intake has shown more mixed data with regard to HF risk.⁹⁸ Any form of substance abuse, recreational or continuous, with drugs such as cocaine, amphetamine, and anabolic steroids is associated with increased risk of cardiomyopathy and HF.^{99–101} If use is suspected, this should be addressed with the patient and advised against.

Recommendation Table 1 — Recommendations for prevention of heart failure (see [Evidence Tables 1–15](#))

Recommendations	Class ^a	Level ^b
Strict blood pressure control (systolic blood pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF. ^{63–69,102}	I	A
An SGLT2-I is recommended in patients with T2DM at risk of HF (multiple ASCVD risk factors or established ASCVD) to reduce the risk of HF and CV death. ¹⁰³	I	A
An SGLT2-I is recommended in patients with T2DM and CKD ^c to reduce the risk of HF or CV death. ¹⁰⁴	I	A
Finerenone is recommended in patients with T2DM and CKD ^d to reduce the risk of HF. ^{105–108}	I	A

Continued

Counselling on healthy lifestyle choices including maintaining a healthy weight, consuming a well-balanced diet, avoiding sedentary behaviour, abstaining from smoking and heavy alcohol consumption as well as counselling against the use of drugs such as cocaine, amphetamines, and anabolic steroids is recommended for all patients with stage A or B HF to reduce the risk of HF progression. ^{74,84,85,87,91,95–100,109–112}	I	C
Treatment with a statin should be considered in people at high risk of, or with established ASCVD, to reduce the risk of HF. ⁷⁵	IIa	A
A GLP-1 RA should be considered in patients with T2DM and at least one other additional CV risk factor to reduce the risk of HF or CV death. ^{71,113,114}	IIa	A

© ESC 2026

ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; SGLT2-I, sodium-glucose co-transporter 2 inhibitor; T2DM, type 2 diabetes mellitus.

^aClass of recommendation.

^bLevel of evidence.

^cCKD was defined as follows: an eGFR 25–75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio ≥200–5000 mg/g in DAPA-CKD; an eGFR 20–45 mL/min/1.73 m² or an eGFR 45–90 mL/min/1.73 m² with a urinary albumin-to-creatinine ratio ≥200 mg/g in EMPA-KIDNEY; and eGFR 30–<90 mL/min/1.73 m² with a urinary albumin-to-creatinine ratio >300 to ≤5000 mg/g in CRENDENCE.^{115–117}

^dCKD was defined as follows: an eGFR 25–60 mL/min/1.73 m², a urinary albumin-to-creatinine ratio 30–300 mg/g, and diabetic retinopathy, or an eGFR 25–75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio 300–5000 mg/g, in FIDELIO-DKD¹⁰⁶; and an eGFR 25–90 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio 30 to <300 mg/g, or an eGFR >60 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio 300–5000 mg/g, in FIGARO-DKD¹⁰⁷.

4.1.4. Specific populations at risk

4.1.4.1. Arrhythmias

Atrial fibrillation (AF) and other supraventricular tachyarrhythmias, as well as frequent ventricular ectopy and conduction disease, can all lead to HF. Prevention of HF in these conditions mainly relates to treatment of the underlying condition, which is covered in the 2024 ESC Guidelines for the management of atrial fibrillation¹¹⁸ and the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.¹¹⁹

Investigation of LV systolic dysfunction and for underlying causes driving the arrhythmia should be considered based on clinical presentation (e.g. genetic, infiltrative, or inflammatory cardiomyopathy). In some patients, AF may be a marker of especially subclinical HFpEF, and evaluation and treatment of common cardiometabolic and lifestyle-related risk factors is warranted in such patients.

4.1.4.2. Myocardial infarction

Patients with MI are at high risk of HF even in absence of wall motion abnormalities or structural dysfunction. Treatment of cardiometabolic risk factors should be optimized. In post-MI patients with preserved LVEF (>50%), no difference in the risk of HF was shown for beta-blocker therapy vs placebo in the REDUCE-AMI trial, arguing against routine use of beta-blockers in this setting.¹²⁰

A meta-analysis of BETAMI–DANBLOCK and the REBOOT–CNIC trials showed no difference in major CV outcomes.¹²¹

4.1.4.3. Chronic kidney disease

Chronic kidney disease is a strong risk marker for future HF risk, and efforts should be undertaken to optimize the control of concomitant risk factors (diabetes, hypertension, ASCVD) to prevent or delay HF onset.⁷⁶ There is strong evidence that both SGLT2-Is and finerenone lower HF risk in patients with type 2 diabetes mellitus (T2DM) and CKD.^{104–108} Recommendations on specific preventive treatments for patients with CKD and CVD are outlined in the 2026 ESC Guidelines on cardiovascular disease and chronic kidney disease.¹²²

4.1.4.4. Cancer survivors

Cancer survivors, especially those with prior radiation or exposure to cardiotoxic agents (anthracycline, cyclophosphamide, immune checkpoint inhibitors, trastuzumab) are at higher risk of asymptomatic LV systolic dysfunction and HF. The prevention of HF in these patients, as well as surveillance and risk modification strategies among those undergoing active cancer treatment, are outlined in the 2022 ESC Guidelines on cardio-oncology.⁶

4.1.4.5. Familial and genetic predisposition but no overt clinical disease

Because modifiable risk factors are likely to be significant contributors to disease onset in many genetically predisposed individuals, optimal risk-factor control is recommended in individuals with familial or genetic predisposition to HF, but without clinical disease.¹²³ In carriers of dilated cardiomyopathy (DCM), non-dilated LV cardiomyopathy, or ARVC-related variants, regular follow-up and cardiac screening is suggested, according to the specific recommendations provided in the 2023 ESC Guidelines for the management of cardiomyopathies.¹²⁴

4.1.4.6. Pulmonary disorders and sleep-disordered breathing

Poor sleep quality, sleep-disordered breathing (SDB), sleep apnoea, and chronic obstructive pulmonary disease (COPD) are all associated with a higher incidence of HF.^{125–127} Recommendations for screening and treatment of these conditions are outlined in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.⁶¹

4.1.4.7. Endocrine disorders

Thyroid disorders, acromegaly, and pheochromocytoma are all associated with increased risk of HF.^{61,128} Prevention of HF is primarily related to correction of the underlying hormonal dysfunction and should otherwise follow the general principles outlined in this section.

4.1.4.8. Congenital heart disease

Advances in surgical repair and life expectancy for patients with congenital heart disease have led to an increasing burden of HF in this population.^{129,130} Patients with congenital heart disease have an eight-fold overall increased relative risk of developing HF and are on average 20–25 years younger at the time of HF onset, compared with age- and sex-matched controls.¹³¹ The risk is greatest in complex lesions such as conotruncal defects

(e.g. tetralogy of Fallot, transposition of the great arteries, truncus arteriosus, double-outlet right or left ventricle, with up to 42-fold risk), and severe non-conotruncal defects (e.g. atrioventricular septal defects, single ventricle and hypoplastic left heart syndrome, with up to 21-fold increased risk).¹³¹ Conventional HF risk factors (e.g. CAD, hypertension, diabetes, and obesity) are common in patients with congenital heart disease and contribute significantly to HF risk.^{132–134} Careful attention to risk-factor modification is warranted as they are likely to contribute to the risk of developing HF.

4.2. Patients with stage B heart failure

4.2.1. Asymptomatic left ventricular dysfunction

Based on normal reference values of LVEF in adult population-based samples, LV systolic dysfunction should be considered present if patients are asymptomatic and have an LVEF <50% in the absence of alternative explanations (e.g. athlete’s heart) for both men and women and regardless of age. Treatment with an ACE-I (or ARB if intolerant) if LVEF ≤40% and a beta-blocker if LVEF <50% are recommended to reduce the risk of HF and mortality. The evidence behind these recommendations are derived from the SOLVD-Prevention trial,^{135,136} which randomized patients with asymptomatic LV systolic dysfunction (LVEF ≤35%) to enalapril or placebo, and the TRACE¹³⁷ and SAVE¹³⁸ trials, which randomized patients post-MI with LVEF ≤35%–40% to trandolapril or placebo (TRACE) and captopril vs placebo (SAVE). These studies were conducted in the 1990s and contemporary management of multiple comorbidities (MI, diabetes, CKD) has since changed. One RCT, CAPRICORN, published in 2001, investigated beta-blockers post-MI in patients with LV systolic dysfunction, where patients were randomized to carvedilol or placebo.¹³⁹ It should be noted that this trial allowed patients to receive intravenous (i.v.) diuretics for acute HF, but excluded those with continuous need for i.v. diuretics, meaning not all had truly asymptomatic LV systolic dysfunction. The hazard ratio (HR) for all-cause mortality was 0.77 [95% confidence interval (CI) 0.60–0.98] in the group receiving carvedilol vs placebo. Additional observational data from SOLVD and SAVE suggested similar improved outcomes with a beta-blocker.^{140–142} Further, the REVERT trial, which randomized asymptomatic patients with LVEF <40% to metoprolol extended release or placebo, showed that metoprolol reversed LV remodelling.¹⁴² The role of these drugs for asymptomatic individuals with mildly reduced LVEF (41%–49%) is not well studied, but their use is reasonable also in this range of LVEF given the shared pathophysiology with more depressed LV systolic function. A meta-analysis of BETAMI–DANBLOCK and REBOOT–CNIC showed a significant reduction in the combined endpoint of mortality, MI and HF with beta-blockers vs placebo in post-MI patients with stage B HF and mildly reduced LVEF.¹²¹ Careful follow-up to assess for progressive decline in LVEF is otherwise warranted for patients without treatment. Based on the results of the EPHEBUS trial, eplerenone is recommended in patients after MI with LVEF ≤40% and diabetes to reduce the risk of HFH or death.¹⁴³

4.2.2. Valvular heart disease

Prevention of HF in patients with valvular disease should follow the recommendations outlined in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.⁹

Recommendation Table 2 — Recommendations for stage B heart failure and left ventricular dysfunction (see Evidence Table 16)

Recommendations	Class ^a	Level ^b
An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and death. ^{135–138,144}	I	A
A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death. ^{35,139,140}	I	B1
Eplerenone is recommended in patients with LVEF ≤40% after myocardial infarction with signs of HF or diabetes to reduce the risk of HFH and death. ¹⁴³	I	B1

© ESC 2026

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction.
^aClass of recommendation.
^bLevel of evidence.

4.3. Risk prediction in patients with established heart failure

Several risk scores have been developed to predict HFH and mortality among ambulatory patients with established HF, including e.g. the MAGGIC risk score,⁷⁷ the Seattle Heart Failure Model,⁷⁸ and the more recent ESC initiated LIFE-HF⁷⁹ (HFrEF) and LIFE-Preserved (HFpEF).⁸⁰ It should be noted that LIFE-HF included patients with LVEF ≤40% and LIFE-Preserved patients with LVEF ≥50%. The ESC scores therefore need to be validated for HFrEF patients in the upper range of LVEF (>40%–49%) and, ideally, in external samples across the entire LVEF spectrum before widespread implementation (see Supplementary data online, Section S1 and Figure S1). Although pharmacological treatments are indicated in patients with established HF regardless of estimated risks (as outlined in Section 6), these risk scores may be helpful in identifying high-risk patients that may benefit from closer follow-up and to facilitate discussions around patient goals of care.

5. Diagnosis of chronic heart failure

5.1. Key steps in the diagnosis of chronic heart failure

The failing heart causes a clinical syndrome with a wide array of signs and symptoms, which vary in sensitivity and specificity (Table 7), and none of which are entirely characteristic. The severity of HF symptoms can be classified according to the New York Heart Association (NYHA) functional class (Table 8). Specialist assessment relies on clinical evaluation, the examination of individual risk factors, and previous medical history as well as 12-lead ECG and chest X-ray evaluation. Clinical suspicion should be followed by testing of natriuretic peptides and echocardiography (Figure 4). In the very elderly patients, suspicion should be raised even with an atypical presentation. A recent HFA consensus paper provides a diagnostic framework for general practice and non-cardiology-based physicians.¹⁴⁵

Table 7 Symptoms and signs of heart failure

Symptoms	Signs
<i>Typical</i>	<i>More specific</i>
Dyspnoea	Elevated jugular venous pressure
Orthopnoea	Hepatojugular reflux
Paroxysmal nocturnal dyspnoea	Third heart sound (gallop rhythm)
Reduced exercise tolerance	Laterally displaced apical impulse
Fatigue, tiredness, increased time to recover after exercise	
Ankle oedema	
<i>Less typical</i>	<i>Less specific</i>
Nocturnal cough	Weight gain (>2 kg/week)
Wheezing	Weight loss (in advanced HF)
Bloated feeling	Tissue wasting (cachexia)
Loss of appetite	Cardiac murmur
Confusion (especially in the elderly ^a)	Peripheral oedema (ankle, sacral, scrotal)
Depression	Pulmonary crepitations
Palpitations	Pleural effusion
Dizziness	Tachycardia
Syncope	Irregular pulse
Bendopnoea ^b	Tachypnoea
	Cheyne–Stokes respiration
	Hepatomegaly
	Ascites
	Cold extremities
	Oliguria
	Narrow pulse pressure

HF, heart failure.

^aElderly patients may present with more atypical symptoms of HF.

^bBreathlessness on bending forward/flexing the body.

5.1.1. Natriuretic peptides

Adverse clinical events often occur soon after a new presentation of HF in the community; therefore, timely diagnosis and initiation of treatment are essential. Natriuretic peptide testing is recommended to support the diagnosis of HF and improves efficiency by avoiding unnecessary echocardiography and/or specialist assessment.^{146–150} N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most widely used natriuretic peptide in the management of HF in Europe and has two key advantages: better stability at room temperature, enabling reliable testing in both hospital and community settings; and unaltered results despite treatment with ARNIs, which affect B-type natriuretic peptide (BNP) degradation.^{149,150}

However, testing for NT-proBNP is not universally available, and some regions employ BNP or mid-regional pro-atrial natriuretic peptide (MR-proANP) testing.

The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommended a single natriuretic

Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity

NYHA class	Severity of symptoms and physical activity
Class I	No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Class II	Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Class III	Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue, or palpitations.
Class IV	Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased.

NYHA, New York Heart Association.

peptide threshold to 'rule out' HF (<125 pg/mL for NT-proBNP, <35 pg/mL; for BNP, <40 pg/mL; for MR-proANP). Single natriuretic peptide rule-out thresholds have the advantage of simplicity; however, natriuretic peptide levels are strongly related to age and lack specificity in older people.¹⁵¹ More than 75% of a healthy population >80 years were found to exceed the 125 pg/mL NT-proBNP threshold.^{152–156} The HFA-ESC consensus statement on NT-proBNP testing recommends introducing age-related thresholds determined from the 95th percentile of the Generation Scotland cohort to improve specificity and reduce unnecessary demand on echocardiography and HF services.¹⁵⁷ The suggested age-adjusted NT-proBNP levels, above which HF is 'likely' in the outpatient setting, were ≥125 pg/mL for those aged <50 years, ≥250 pg/mL between 50 and 75 years, and ≥500 pg/mL over 75 years.^{151,157} Currently there are insufficient data for determining age-specific BNP cut-offs. For the diagnosis of HFpEF, natriuretic peptide interpretation may be challenging as a variety of conditions associated with HFpEF affect natriuretic peptide levels (Table 9).¹⁵⁸ Especially obesity is associated with lower cut-off values for natriuretic peptides, and caution is advised when interpreting natriuretic peptide levels in obese patients.^{158–160} Reduced kidney function has been shown to be associated with higher NT-proBNP levels, although NT-proBNP measurements should not be disregarded in the setting of kidney dysfunction.^{161,162} Furthermore, many other factors can elevate natriuretic peptide levels (Table 9). Clinicians must consider these factors in conjunction with clinical assessment and investigation findings when interpreting natriuretic peptide measurements; however, the higher the natriuretic peptide level the greater the likelihood of HF as the diagnosis.

Natriuretic peptides also provide important prognostic information, enabling rapid triage of high-risk patients. Primary care data from England demonstrate that patients with HF and NT-proBNP levels exceeding 2000 pg/mL exhibit a two-fold increased risk of early HFH. Accordingly, expedited specialist assessment of this high-risk cohort is warranted.¹⁶³




Figure 4 Diagnostic algorithm for chronic heart failure presenting in the outpatient or community setting. BNP, B-type natriuretic peptide; CXR, chest X-ray; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; POCUS, point-of-care ultrasound; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. ^aFull blood count, kidney function, electrolytes, UACR, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin). ^bExamination by POCUS may aid in diagnosis although echocardiography is recommended. ^cNatriuretic peptides may be false low in certain settings (Table 9). ^dPreferable performed within 2 weeks if NT-proBNP >2000 pg/mL.

Table 9 Causes for increase or decrease in natriuretic peptide levels

Causes for increased natriuretic peptide levels
Acute coronary syndrome
Advanced age ^a
Atrial fibrillation
Cardiac contusion
COPD
Critical illness
Female sex
Kidney dysfunction
LV hypertrophy
Myocarditis
Obstructive sleep apnoea
Paraneoplastic syndrome
Pulmonary embolism
Pulmonary hypertension
RV pacing
Severe anaemia
Severe endocrine dysfunction
Severe infections (including pneumonia and sepsis)
Severe liver disease
Severe metabolic acidosis and diabetic ketoacidosis
Subarachnoid haemorrhage
Systemic hypertension
Valvular heart disease
Causes for decreased natriuretic peptide levels
African ancestry
ARNI ^b /ACE-I/ARB
Beta-blockers
Constrictive pericarditis
MRA
Obesity
SGLT2-I

© ESC 2026

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor.

^aSee Figure 4.

^bARNI may raise BNP levels.

required in the assessment of kidney function.¹⁶⁴ UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥ 90 mL/min/1.73 m². UACR has strong independent prognostic value for patients with HF.^{165,166} Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.¹⁶⁷

Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)

Recommendations	Class ^a	Level ^b
In patients with suspected HF, the following laboratory tests are recommended when screening for comorbidities: full blood count, kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin). ¹⁶⁸	I	C
Natriuretic peptide measurement is recommended in patients with suspected HF (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic peptide level ^c). ^{146–148,151–153,169}	I	C
A 12-lead ECG is recommended in patients with suspected HF.	I	C
Chest radiography (X-ray) is recommended in patients with suspected HF.	I	C
Transthoracic echocardiogram is recommended in patients with suspected HF to confirm the diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of HF.	I	C

© ESC 2026

ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio.

^aClass of recommendation.

^bLevel of evidence.

^cSee Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.

5.2. Heart failure phenotypes based on left ventricular ejection fraction

Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.

5.2.1. Heart failure with reduced ejection fraction

The diagnosis of HFrEF requires the following criteria:

- Presence of current or prior symptoms and/or signs of HF (Table 7)
- LVEF <50%.

Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the

5.1.2. Other laboratory tests

Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy.

Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are

diagnostic pathway, especially if echocardiography is not readily available. However, many factors may cause false positive or false negative results, which should be considered when evaluating natriuretic peptide (Table 9). LVEF is a continuous measure and may differ between methods used as well as sex. For this reason, a precise value is only given as guidance.

Aetiology assessment is important, as it may result in finding potential treatable and/or reversible causes. The major aetiologies of HFrEF are illustrated in Figure 5.

5.2.2. Heart failure with preserved ejection fraction

The diagnosis of HFpEF is more challenging and should start with the assessment of pre-test probability.¹⁷⁰ Several clinical factors may contribute to or be associated with HFpEF, as illustrated in Figure 6. The more factors present the higher the likelihood of HFpEF.

The following criteria must all be present for the diagnosis of HFpEF:

- (i) Presence of current or prior symptoms and/or signs of HF (Table 7)
- (ii) LVEF $\geq 50\%$ (requires that LVEF has not previously been $< 50\%$)
- (iii) Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures (Table 10), supported by raised natriuretic peptides (Figure 4).

Testing for elevated levels of natriuretic peptides may in most patients support the diagnosis of HFpEF. However, diagnostic thresholds for HFpEF should be critically evaluated based on patient characteristics, especially in the presence of obesity and other factors that may cause reduced natriuretic peptide levels (Table 9).¹⁵⁸

A pragmatic approach to the diagnosis of HFpEF is advised to facilitate access to diagnosis for the large population of elderly patients potentially affected. More complicated scoring systems^{171,172} have shown conflicting results in the community setting, but a meta-analysis indicates acceptable specificity and sensitivity for detection of HFpEF.^{173–175} If employed, diagnostic scoring systems should be interpreted with caution and used primarily to raise clinical suspicion of HFpEF rather than to establish a definitive diagnosis. In cases of diagnostic uncertainty, further investigations—such as cardiopulmonary exercise testing (CPET) [including measurement of peak oxygen consumption (VO_2) to confirm reduced exercise capacity and elucidate the underlying cause of dyspnoea], exercise stress echocardiography, or invasive haemodynamic assessment—may be considered.¹⁷⁶

The gold standard, confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing. An invasively measured pulmonary capillary wedge pressure of ≥ 15 mmHg (at rest), or ≥ 25 mmHg (with exercise), or an LV end-diastolic pressure ≥ 16 mmHg (at rest) is generally considered diagnostic. In recognition that invasive haemodynamic exercise testing is expensive and is not available in many centres worldwide, its main use should be limited to research settings or to patients with diagnostic uncertainty despite non-invasive testing. In most patients, the diagnosis of HFpEF can be made based on clinical history and echocardiographic signs (Table 10). Thus, invasive testing is indicated in

Table 10 Simplified echocardiographic criteria for supporting objective evidence of heart failure with preserved ejection fraction

Criteria	Echocardiographic threshold
LV hypertrophy	LV mass index ≥ 95 g/m ² (female) ≥ 115 g/m ² (male) OR Relative wall thickness > 0.42
LA dilatation (volume indexed by BSA)	> 34 mL/m ² (sinus rhythm) > 40 mL/m ² (AF)
Increased likelihood of elevated LV filling pressure	$E/e' > 9$ at rest ^a
Raised estimated systolic PA pressure	> 35 mmHg OR TR velocity at rest > 2.8 m/s

The probability for an HFpEF diagnosis increases with the number of parameters in the pathological range.

AF, atrial fibrillation; BSA, body surface area; HFpEF, heart failure with preserved ejection fraction; LA, left atrial; LV, left ventricular; PA, pulmonary artery; TR, tricuspid regurgitation.

^a $E/e' \geq 15$ is more specific, but less sensitive, for the diagnosis of HFpEF.

© ESC 2026

only a minority of patients where the diagnosis is uncertain and where establishing the diagnosis or an alternative cause of signs or symptoms is likely to affect patient management. Therefore, current guidelines do not mandate invasive haemodynamic testing in every patient with suspected HFpEF to make the diagnosis.

5.3. Aetiology and subtypes of heart failure

Assessment of aetiology is fundamental for the management of HF, as treatment should, if possible, address the underlying cause. Some treatments may be aetiology dependent, and some causes of HF are potentially reversible. Disease-modifying therapies are increasingly available, and early identification and treatment can improve survival. Targeted therapies for specific cardiomyopathies are under investigation, and precise aetiological assessment will become increasingly important in the future. Aetiology assessment also determines prognosis,¹⁷⁷ is relevant to the patient, and imperative for care planning.

Common causes of HF include ischaemic heart disease, hypertension, and valvular heart disease, although a multitude of other causes and contributing factors exist (Figures 5 and 6) and often more than one possible cause may be present.

Determining the aetiology often involves a multiparametric evaluation beginning with obtaining a medical history from the patient, continuing through patient examination and clinical tests (Figure 7). Often non-invasive testing accompanied by medical history will be sufficient to determine aetiology. Characteristic findings indicating the underlying




Figure 5 Major contributing causes of heart failure with reduced ejection fraction. HFrEF, heart failure with reduced ejection fraction.

^aToxic may include both drug-related and chemotherapy-related causes.

aetiology are noted in many patients at the time of echocardiography. Patients with ischaemic aetiology may have regions of akinesis/dyskinesis and thinning/aneurysm formation in the myocardial areas affected by coronary disease. Valvular disease is detected, often also with characteristic valvular findings dependent on cause (e.g. rheumatic or ischaemic), and the long-term sequelae of untreated hypertension may be observed (LV hypertrophy, aortic dilatation

with or without central aortic regurgitation). Findings consistent with other cardiomyopathies, cardiac amyloidosis (CA), or ventricular dyssynchrony in left bundle branch block (LBBB) may also be noted.

When considering further investigation for CAD, non-invasive assessment is often sufficient, and before proceeding to invasive assessment the risks and benefits should be considered.^{178–180}




Figure 6 Major risk factors of heart failure with preserved ejection fraction. CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction.

If an underlying cardiomyopathy is suspected or the aetiology is unclear, further imaging with cardiac magnetic resonance (CMR) imaging is recommended. We refer to the 2023 ESC Guidelines for the management of cardiomyopathies regarding specific recommendations and approaches for investigations into specific cardiomyopathies.¹²⁴ An approach with laboratory and imaging tests chosen according to the five subtypes [hypertrophic cardiomyopathy (HCM), DCM, restrictive

cardiomyopathy, ARVC, and non-dilated LV cardiomyopathy] has been recommended.¹²⁴

In patients with unexplained dyspnoea, CPET may be used to identify the cause of unexplained dyspnoea and/or exercise intolerance.

When a specific aetiology is suspected, further investigations may be required, such as 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) for suspected

cardiac sarcoidosis (see [Supplementary data online, Table S2](#)).^{181,182} Genetic testing may be appropriate when a genetic cause is suspected and the results may provide management and prognostic guidance, result in cascade family screening or reproductive management. For more specific guidance on genetic testing in specific cardiomyopathies, we refer to the 2023 ESC Guidelines for the management of cardiomyopathies.^{48,124}

5.3.1. Cardiac imaging in heart failure: a multimodality approach

Multimodal cardiac imaging plays a pivotal role in the diagnosis, management, and prognostic assessment of HF, enabling precise subtyping to aid in disease-specific therapy selection and is supported by a growing body of evidence ([Figure 7](#)).

Echocardiography is considered the first-line imaging modality in HF and remains the cornerstone of assessment. Echocardiography has widespread availability, is non-invasive, and provides the ability for real-time dynamic evaluation of cardiac structures, dimensions, volumes, filling patterns, haemodynamics, and function. Tissue Doppler imaging and speckle-tracking echocardiography have allowed clinicians to quantify myocardial global longitudinal strain, offering more sensitive measures of early systolic dysfunction even before LVEF declines, which is of particular value in patients undergoing chemotherapy, or specific strain patterns that may be suggestive of amyloidosis or HCM.^{183–185} In patients with HFpEF, diastolic stress testing is emerging as an important tool to unmask diastolic dysfunction that may not be apparent at rest. Depending on echocardiography findings, additional imaging modalities or




Figure 7 Multiparametric approach to aetiology assessment in heart failure. 18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; EMB, endomyocardial biopsy; HMPD, hydroxymethylene diphosphonate; ICA, invasive coronary angiography; PYP, pyrophosphate; RHC, right heart catheterization.

testing may be needed (see [Supplementary data online, Table S2](#)).

Advances in multimodal imaging, including CMR, stress testing, and computed tomography (CT), have significantly enhanced our capacity to comprehensively assess HF, offering complementary information that is crucial in complex cases.^{183–185} CMR is considered the gold standard for assessing LV volumes and mass, owing to its high spatial resolution and reproducibility. Late gadolinium enhancement (LGE) provides detailed insights into fibrosis and scarring and is useful in distinguishing ischaemic from non-ischaemic aetiology as well as certain cardiomyopathies.¹²⁴ CMR myocardial tissue characterization with parametric mapping [T1, T2, T2* (longitudinal, transverse, and observed transverse relaxation times), LGE and extracellular volume (ECV) expansion] enables classification of cardiomyopathies^{124,186–193} and of cardiac amyloid.¹⁹⁴ An overview of typical CMR findings in cardiomyopathies can be found in the *2023 ESC Guidelines for the management of cardiomyopathies*.¹²⁴ Description of other specific imaging modalities is provided in the Sections on specific comorbidities.

5.3.2. Investigations for coronary artery disease

Coronary artery disease is highly prevalent in HF and the most common cause of HFrEF.^{13,33,195} Even though assessment of aetiology is essential in HF, investigations for CAD should be tailored to the individual patient's risks and benefits

([Figure 8](#)). For frail patients, a typical medical history of angina accompanied by echocardiography showing coronary territory scarring or regional wall motion abnormalities may suffice. In patients with potential for revascularization, further examinations may be needed, considering individual risks and benefits.

Computed tomography coronary angiography (CTCA) has a high negative predictive value and should be considered in patients with HF when the likelihood of CAD is low to moderate.¹⁹⁶ If patients are possible candidates for revascularization, invasive coronary angiography (ICA) is indicated in patients with HFrEF with a high likelihood of CAD and in patients with angina, regardless of LVEF.

Computed tomography coronary angiography and ICA should be used with caution in patients with eGFR <30 mL/min/1.73 m² and/or contraindication for contrast medium administration. Evidence supporting the efficacy of viability testing to identify suitable patients for revascularization is lacking.^{178,179}

5.3.3. Heart failure caused by arrhythmia or conduction disease

Arrhythmia-associated HF is a broad term that encompasses HF caused by tachyarrhythmias, including AF, atrial flutter, other supraventricular tachycardias, ventricular tachycardia, and premature ventricular contraction (PVC).^{197,198} The identification




Figure 8 Diagnosis of heart failure due to ischaemic aetiology. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; CV, cardiovascular; HF, heart failure; LV, left ventricular. ^aStress tests include stress echocardiography, stress CMR, or nuclear imaging. Electrocardiographic exercise test has not been shown to properly assess coronary stress.

of arrhythmia-associated HF is important in patients with HFrEF, in whom a rhythm strategy for AF may potentially be beneficial. The diagnostic work-up may include an ECG and ambulatory ECG to characterize the electrical subtype, and CMR imaging to characterize the morphological/functional subtype. Arrhythmias may be the sole cause of HFrEF or merely a bystander in the context of other causes of HF.

Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to abnormal electrical conduction and should be suspected in patients with LV dysfunction and a QRS duration ≥ 130 ms, without evidence of other causes for HF.¹⁹⁹ It should also be considered in patients with implanted pacemakers or implantable cardioverter-defibrillators (ICDs) delivering RV pacing (see Section 6.2.2.2).^{200–203}

The diagnosis is a diagnosis of elimination, and it may only be reached retrospectively, if LV function improves following cardiac resynchronization therapy (CRT) implantation.²⁰⁴

In terms of likelihood of response, there is a spectrum. At one end, abnormal cardiac conduction may be the sole culprit, whereas at the other, it may be a bystander in the context of HF due to other causes (Figure 9). CMR may be useful in identifying myocardial scar and morphological abnormalities pointing to other aetiologies of HF. Abnormal cardiac conduction, as the sole cause of HFrEF, is most likely in patients with HFrEF, LBBB, wide QRS duration, with no myocardial scarring on CMR and in patients with RV pacing-induced HF.¹⁹⁹

Recommendation Table 4 – Recommendations for specialized diagnostic investigations in patients with established heart failure to detect reversible/treatable causes of heart failure (see Evidence Tables 20–28)

Recommendations	Class ^a	Level ^b
Investigations for underlying aetiology in patients with HFpEF or HFrEF		
Contrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care. ^{205–215}	I	C
Initial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis. ^{216–222}	I	B
Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance. ^{223–227}	I	C
Invasive coronary angiography is recommended in patients with HF, angina, and high probability ^c of obstructive CAD who are potential candidates for revascularization ^d .	I	C
18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected. ^{181,182}	IIa	C
Endomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means. ²²⁸	IIa	C
Right heart catheterization ^e should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease. ²²⁹	IIa	C
Right heart catheterization ^f may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state. ^{230,231}	IIb	C
Investigations for patients with HFrEF		
Invasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihood ^c of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies. ^{178–180}	IIa	C
CTCA should be considered in patients with HFrEF and low-moderate pre-test likelihood ^c of obstructive CAD. ^{196,232–234}	IIa	C
Review of the proportion of RV pacing should be considered in all patients with CIED and <i>de novo</i> or worsening HFrEF. ^{202,235–239}	IIa	C
Electrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function. ²⁴⁰	IIb	C

18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; AF, atrial fibrillation; CAD, coronary artery disease; CIED, cardiac implantable electronic device; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; RV, right ventricular.

^aClass of recommendation.

^bLevel of evidence.

^cBased on cardiovascular risk factors and clinical history.

^dExclude frailty, multiple severe comorbidities, limited life expectancy.

^eRight and left heart catheterization needed for the differential diagnosis of constrictive pericarditis and restrictive cardiomyopathy.

^fPotentially including exercise right heart catheterization.




Figure 9 Diagnosing arrhythmia-associated heart failure and heart failure with abnormal cardiac conduction. AF, atrial fibrillation; CIED, cardiac implantable electronic device; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle branch block; PET, positron emission tomography; PMT, pacemaker tachycardia; PVC, premature ventricular contraction; RBBB, right bundle branch block; RV, right ventricular; SVT, supraventricular tachycardia; VT, ventricular tachycardia; WHF, worsening heart failure.

6. Management of chronic heart failure

6.1. Guideline-directed medical therapy for heart failure

The Task Force have decided to introduce the terms FMT and AMT, as described in *Section 3* (Figure 3). Together FMT and AMT cover GDMT. For HFrEF, FMT currently includes beta-blockers, ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is, whereas for HFpEF it includes SGLT2-Is and MRAs.

Importantly, AMT and GDIT based on the underlying cause of HF, phenotypical characteristics, and comorbidities are discussed in other sections.

6.1.1. Goals of pharmacotherapy for patients with heart failure

Pharmacotherapy remains the cornerstone of treatment for stage C HF and should be implemented at doses used in RCTs in patients with HF before considering device therapy, and alongside non-pharmacological interventions (Figure 1 and Table 11).

There are three major goals of treatment for patients with HF: (i) reduction in mortality; (ii) prevention of recurrent

hospitalizations due to worsening HF (WHF); and (iii) improvements in clinical status, functional capacity and QoL. The recommendations for each treatment depending on LVEF are summarized below. Overall, there are no sex differences in recommendations for HF pharmacotherapy.

In this section, we address the management of predominantly left-sided HF. Management of right-sided HF is covered comprehensively in a recent HFA consensus paper.⁴⁸

6.1.2. Foundational medical therapy in all patients with heart failure, independent of left ventricular ejection fraction

Mineralocorticoid receptor antagonists and SGLT2-Is are recommended for all symptomatic patients with HF, regardless of LVEF, as these drugs reduce mortality and the risk of HFH. The recommended doses of these drugs are given in [Table 11](#). Other agents can be used in selected patients.

6.1.2.1. Sodium–glucose co-transporter 2 inhibitors

The SGLT2-Is dapagliflozin and empagliflozin have been shown to reduce the composite endpoint of HFH or CV mortality in symptomatic ambulatory patients with HF.^{241–245} Although there were consistent reductions in the primary endpoint across the LVEF ranges studied, the individual endpoint of CV mortality was only reduced in HFrEF.^{44,241,246} Thus, it is recognized that in HFpEF the reduction in the primary endpoint is driven by a reduction in HFH. The guideline Task Force has decided to base recommendations on the primary endpoints. SGLT2-Is also improve QoL.^{247,248} Common side effects include genital and urinary infections. A mild initial decline in eGFR is expected, but long-term kidney function is improved.^{249–253}

Practical guidance in the use and initiation of SGLT2-Is are provided in [Supplementary material online, Table S9](#).

The use of SGLT2-Is in DHF is discussed in [Section 7](#).

6.1.2.2. Mineralocorticoid receptor antagonists

Mineralocorticoid receptor antagonists have been shown to reduce the composite endpoint of HFH or death in patients with HF.^{43,254–257} The guideline Task Force decided to base recommendations on the primary endpoints. Although there were consistent reductions in the primary endpoint across the LVEF ranges studied, the individual endpoint of mortality was only reduced in HFrEF.^{43,254,256} There were differences in the mortality endpoints used in HFrEF and HFpEF trials, with all-cause mortality used in HFrEF trials and CV mortality used in HFpEF trials. Furthermore, different RCTs have included patients with different LVEF ranges not entirely consistent with the distinction between HFrEF and HFpEF. Whereas spironolactone was studied across LVEF ranges, eplerenone was only studied in HFrEF (LVEF up to 35%) and finerenone in patients with LVEF >40%. Although finerenone reduced the composite endpoint of HFH and CV mortality in the FINEARTS-HF trial, spironolactone did not in the overall results of the TOPCAT trial.^{255,257} However, a meta-analysis demonstrated a significant effect of the MRAs used in FINEARTS-HF and TOPCAT on the primary endpoint of HFH and CV mortality in patients with LVEF >40%.⁴³

Mineralocorticoid receptor antagonists are chemically and structurally different; they block the receptors that bind aldosterone with different affinity and distribution in the heart and

kidneys and also block other steroid hormones with different degrees of affinity (e.g. corticosterone blockade) (see [Supplementary data online, Table S3](#)).²⁵⁸ Eplerenone and the non-steroidal MRA finerenone are more mineralocorticoid receptor-specific and therefore induce less gynaecomastia. Caution should be exercised when MRAs are started in patients with impaired kidney function (MRAs have not been tested in patients with eGFR <25 mL/min/1.73 m²) and in those with potassium levels ≥5.0 mmol/L.²⁵⁹ In patients taking MRAs whose serum potassium is >5.5 mEq/L, there might be an indication for dose reduction of the MRA or temporary discontinuation of the MRA to avoid life-threatening hyperkalaemia. The first step would be to recheck potassium levels. If the MRA dose is reduced or temporarily discontinued, the drug should be restarted if hyperkalaemia resolves. Practical guidance in the use and uptitration of MRAs are provided in [Supplementary material online, Table S8](#).

6.1.3. Additional medical therapy in all patients with heart failure, independent of left ventricular ejection fraction

6.1.3.1. Loop diuretics

Loop diuretics are recommended to reduce signs and/or symptoms of congestion in patients with HF and volume overload. Their effects on morbidity and mortality have not been studied in adequately powered RCTs. However, the major disease-modifying treatment trials for HF were always conducted with a high background use of loop diuretic therapy. One meta-analysis has shown that in patients with HF, diuretics appear to reduce the risk of death and WHF compared with a placebo, and compared with an active control, diuretics improved exercise capacity.²⁶⁰

Several observational studies have linked loop diuretic use to higher mortality, even after adjustment or propensity matching.²⁶¹ However, several biases remain as sicker patients are generally prescribed higher doses of loop diuretics. Clearly, patients benefit from maintenance therapy with a loop diuretic to prevent or control congestion. However, the use of loop diuretics may result in electrolyte disturbances, further neurohormonal activation, accelerated kidney function decline, and symptomatic hypotension. The latter may be especially relevant as it could result in treatment with lower doses of FMT. It is generally advised to use the lowest possible dose of diuretics to maintain euvoaemia. Importantly, the individual diuretic dose may change significantly over time.²⁶² Therefore, dynamic and individualized dosing of loop diuretic is recommended.^{263,264} The use of a multiparameter-based evaluation to assess congestion, using clinical assessment at rest and during dynamic manoeuvres, as well as biomarkers (eGFR, electrolytes, natriuretic peptides), supplemented with imaging assessment according to local expertise, is probably the best contemporary strategy to optimize diuretic dosing.²⁶⁵ Optimal FMT and GDIT often results in less need for diuretic treatment.^{266,267} The chronic use of thiazide diuretics in stable patients should be avoided, as this often induces severe electrolyte disturbances that could go undetected in the ambulatory setting.

Treatment of DHF and approach to diuretic treatment in this setting is covered in [Section 7](#).

6.1.3.2. Potassium binders

Hyperkalaemia is common in HF, often as a result of comorbidities (e.g., diabetes, CKD), concomitant use of renin–angiotensin–aldosterone system inhibitors (ACE-Is/ARNIs/ARBs and MRAs),

and because of HF itself. Hyperkalaemia may increase the risk for arrhythmias and death.²⁶⁸ Hyperkalaemia, and the fear of inducing it, often results in under-utilization, dose reductions, or discontinuation of ACE-Is/ARNIs/ARBs and MRAs compromising their cardio-kidney benefit in HF. The gastrointestinal potassium binders patiomer and sodium zirconium cyclosilicate remove potassium by exchanging cations, leading to increased faecal excretion. Both agents have shown favourable results to treat and/or prevent hyperkalaemia in patients receiving ACE-Is/ARNIs/ARBs and MRAs, therefore facilitating the continuation or up-titration of ACE-Is/ARNIs/ARBs and MRAs.^{269–272} Whether potassium binders improve clinical outcomes is still unclear. In the REALIZE-K trial, there was a signal towards more HF deterioration with sodium zirconium cyclosilicate as compared with placebo, although the trial was not powered to detect clinical outcomes.²⁷² Potential adverse effects for the potassium binders include gastrointestinal symptoms (nausea, constipation, diarrhoea), hypomagnesaemia (for patiomer), and oedema (for sodium zirconium cyclosilicate).

No specific recommendations for the use of potassium binders are included in the guideline at current time, due to insufficient evidence for clinical benefit.

6.1.4. Foundational medical therapy for heart failure with reduced ejection fraction

Modulation of the renin–angiotensin–aldosterone system, sympathetic nervous systems, and sodium–glucose co-transporter (SGLT2) inhibition has been shown to improve survival, reduce the risk of HFH, and reduce symptoms in patients with HFrEF. Treatment with optimal FMT, including ACE-Is/ARNIs/ARBs, beta-blockers, MRAs, and SGLT2-Is, is recommended as the foundation of treatment for all patients with HFrEF. There is no evidence favouring any particular sequencing during initiation and up-titration. Therefore, the consensus is that FMT can be commenced together with individual variations based on clinical assessment as soon as the diagnosis of HFrEF is established. Drugs should be up-titrated and continued at the doses used in the RCTs (or to the highest tolerated doses). Misinterpretation of changes in kidney function is a leading cause of insufficient dosing or inappropriate discontinuation of FMT and should be avoided (Section 6.1.6).²⁷³

Additional medical therapy may be used in selected patients with HFrEF (see Section 6.1.5).

No large prospective RCT has been performed exclusively in patients with LVEF 41%–49%. Patients with LVEF 41%–49% appear to respond to FMT, similar to patients with LVEF <40%.^{36,38–41} Many patients with LVEF 41%–49% may already be on ACE-Is or ARBs and beta-blockers for other CV indications such as CAD, hypertension, or post-MI LV systolic dysfunction.

Sodium–glucose co-transporter 2 inhibitors and MRAs are recommended for all ranges of LVEF, as covered in Section 6.1.2. The recommended doses of FMT and AMT are provided in Table 11. Practical guidance in the use and up-titration of FMT are provided in Supplementary material online, Tables S4–S9.

6.1.4.1. Angiotensin-converting enzyme inhibitors and angiotensin receptor–neprilysin inhibitor

Angiotensin-converting enzyme inhibitors were the first class of drugs shown to reduce mortality and morbidity and to improve symptoms in patients with HFrEF.^{137,138,274–277} They are

recommended in all patients with HFrEF unless contraindicated or not tolerated and should be up-titrated to the highest recommended doses. If these doses are not tolerated, intermediate doses should be tried. In the higher end of LVEF, evidence is limited. The PEP-CHF trial (perindopril) was conducted in patients with an LVEF >40%, but it did not report outcomes according to LVEF.³⁹ The PEACE trial reported a subgroup analysis showing a reduction in mortality with trandolapril in patients with LVEF from 40% to 50%.³⁸

An ARNI is composed of an ARB and an inhibitor of neprilysin, an enzyme that degrades natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides. In the PARADIGM-HF trial, the ARNI, sacubitril–valsartan, was compared with enalapril in symptomatic patients with HFrEF who already tolerated an adequate dose of either an ACE-I or an ARB.²⁷⁸ ARNI significantly reduced the composite endpoint of CV death or HFH by 20% as compared with enalapril.²⁷⁸ Additional benefits included improvement in QoL, reduction in decline of eGFR, a reduction in loop diuretic dose, and lower risk of hyperkalaemia.^{279,280} If patients continue to have chronic symptomatic HFrEF and they tolerate an ACE-I or an ARB, it is recommended that they be switched to an ARNI to reduce morbidity and mortality. Pre- and post-discharge initiation of ARNIs in HFrEF patients have shown similar efficacy and safety, and larger NT-proBNP reductions compared with ACE-I treatment in ACE-I/ARB naïve patients.^{281–283} As such, the use of an ARNI may be efficacious as *de novo* treatment in patients with symptomatic chronic HFrEF to simplify management and maintain eGFR and QoL.

Use of an ARNI is more frequently associated with symptomatic hypotension, and a washout period of at least 36 h after ACE-I therapy is required to minimize the risk of angio-oedema. Treatment with ACE-Is or ARNIs is indicated, but should be given with caution, to patients with low blood pressures (systolic blood pressure <100 mmHg), kidney insufficiency (eGFR <30 mL/min/1.73 m²), or elevated serum potassium (>5.2 mEq/L). Abrupt withdrawal of ACE-Is or ARNIs can lead to clinical deterioration and should be avoided, and in those patients for whom treatment with an ARNI is not possible, continued use of an ACE-I remains strongly advised.

6.1.4.2. Angiotensin II type 1 receptor blockers

Angiotensin II receptor blockers are recommended for HFrEF patients who cannot tolerate ACE-Is or ARNIs due to side effects. Unlike ACE-Is, ARBs do not inhibit kininases and are associated with a much lower incidence of cough and angio-oedema. In the CHARM-Alternative study, candesartan reduced CV death and HFH in patients who were not receiving an ACE-I due to previous intolerance.²⁸⁴ In the HEAAL study, high-dose losartan reduced HFH compared with low-dose losartan in ACE-I intolerant patients.²⁸⁵ Valsartan, in addition to usual therapy, including ACE-Is, reduced HFH in the Val-HeFT trial.²⁸⁶ However, no ARB has reduced all-cause mortality in any trial, and combination with an ACE-I increases adverse effects. Also, in patients with higher LVEF, evidence is limited. The CHARM-Preserved trial did not show a reduction in its primary endpoint of CV death or HFH, but a retrospective analysis showed that candesartan reduced the number of patients hospitalized for HF among those with LVEF 40%–49%.^{40,41}

6.1.4.3. Beta-blockers

Beta-blockers have been shown to reduce morbidity and mortality in patients with HFrEF in addition to treatment with an ACE-I and diuretics.^{36,287–292} Bisoprolol, sustained-release metoprolol (succinate), and carvedilol have been shown to reduce the risk of death in patients with HFrEF, whereas nebivolol only reduced the combined endpoint of all-cause mortality and CV hospitalization. An individual patient meta-analysis of RCTs of beta-blockers suggested similar reductions in CV and all-cause mortality for patients in sinus rhythm with HFrEF who had LVEF <40% and LVEF 40%–50%.³⁶ Beta-blockers should be initiated early in clinically stable patients, at low doses and gradually uptitrated to the highest tolerated dose. In patients admitted with DHF, beta-blockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized. Every effort should be made to achieve the target doses of the beta-blockers shown to be effective in major clinical trials (Table 11). Even if symptoms do not improve, long-term treatment should be maintained to reduce the risk of major CV events.

The effect of beta-blockers in patients with HFrEF and AF remains uncertain. A retrospective subgroup individual-patient data meta-analysis of all major beta-blocker trials in HFrEF showed no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF.^{36,293} However, to date no RCT has ever been conducted investigating the effect of beta-blockers specifically in patients with AF and HFrEF, despite beta-blockers being potentially useful for rate control of AF.

6.1.5. Additional medical therapy for heart failure with reduced ejection fraction

6.1.5.1. *I_f*-channel inhibitor (ivabradine)

Ivabradine should be considered in patients with symptomatic HFrEF who at rest are in sinus rhythm with heart rate ≥ 70 b.p.m., LVEF $\leq 35\%$, and recent HFH, despite stable FMT including optimized beta-blocker therapy.²⁹⁴ Ivabradine slows heart rate by inhibition of the *I_f* current. In the SHIFT trial, the primary composite endpoint of CV death or HFH was reduced, mainly driven by a reduction in HFH.²⁹⁴ Importantly, only 25% of patients studied in the trial were on optimal doses of beta-blockers.²⁹⁴ As beta-blockers have well-proven morbidity and mortality benefits, they should be initiated and uptitrated to target doses first, before assessing the resting heart rate for consideration of adding ivabradine.

6.1.5.2. Vericiguat

The oral soluble guanylate cyclase stimulator vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite optimal FMT.

The VICTORIA study assessed the efficacy and safety of vericiguat in patients with LVEF <45% and with recent episodes of WHF, who were already on the highest tolerated FMT. The incidence of the primary endpoint of CV death or HFH was lower among those who received vericiguat than among those who received placebo.²⁹⁵ There was no reduction in either all-cause or CV death. The much higher event rate in VICTORIA compared with other RCTs in patients with HFrEF was associated with a shorter median follow-up to acquire the total number of events needed, which may explain why HFH were reduced, but CV

mortality was not significantly reduced.²⁹⁶ There was also heterogeneity in a subgroup analysis, with less benefit in patients with the highest NT-proBNP levels. The VICTOR study evaluated vericiguat in ambulatory patients with HFrEF (LVEF $\leq 40\%$) who did not have a recent WHF event and who were on contemporary FMT. VICTOR was neutral for the primary composite endpoint of time to CV death or HFH (HR 0.93; 95% CI 0.83–1.04; $P = .22$).²⁹⁷ Over a median follow-up of ~ 18.5 months, CV death was numerically lower with vericiguat (9.6% vs 11.3%; HR 0.83; 95% CI 0.71–0.97), whereas HFH was similar between groups (11.4% vs 11.9%; HR 0.95; 95% CI 0.82–1.10). The trial therefore did not confirm a primary composite benefit in a stable, well-treated ambulatory HFrEF population, although pooled analyses combining VICTOR and VICTORIA suggest benefit across the broader HFrEF spectrum. Also, there was a reduction in all-cause mortality, a secondary endpoint in the trials.^{298,299}

6.1.5.3. Hydralazine and isosorbide dinitrate

There is no clear evidence to recommend the use of hydralazine and isosorbide dinitrate in all patients with HFrEF. In a small RCT conducted in self-identified black patients the addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy at that time (an ACE-I, a beta-blocker, and an MRA) reduced mortality and HFH, and improved QoL in patients with symptomatic HFrEF.³⁰⁰ It is unclear if a benefit of hydralazine and isosorbide dinitrate exists for non-black patients with HFrEF. Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, an ARNI, or an ARB (or if they are contraindicated) to potentially reduce HFH and mortality. This recommendation is based on the results of the Veterans Administration Cooperative Study, which included only male patients with symptomatic HFrEF who were treated with only digoxin and diuretics.³⁰¹

6.1.5.4. Cardiac glycosides

Cardiac glycosides, digoxin or digitoxin, should be considered in patients with HFrEF to reduce the risk of HFH.^{302–304} In the DIG trial, the overall effect on mortality with digoxin was neutral but there was a reduction in HFH.³⁰³ Moreover, the effects of digoxin in patients with HFrEF and AF have not been studied in RCTs, but digoxin may be useful for the treatment of AF with rapid ventricular rate when other therapies cannot be used.^{305–307}

A serum digoxin concentration <1.2 ng/mL should be used as a target during ongoing therapy.³⁰⁸ The DIGIT-HF trial examined whether low-dose digitoxin added to contemporary FMT improves outcomes in patients with chronic symptomatic HFrEF (LVEF $\leq 40\%$ and NYHA class III/IV or LVEF $\leq 30\%$ and NYHA class II).³⁰⁴ The trial included most patients in NYHA class III and, contrary to the DIG trial, also included patients with AF. They were randomized to digitoxin [starting 0.07 mg daily, then titrated to target serum concentrations (10.5–23.6 nmol/L)] vs placebo. Over a median follow-up of 36 months, the primary composite endpoint—death from any cause or HFH—occurred in 39.5% of the digitoxin group vs 44.1% of the placebo group (HR 0.82; 95% CI 0.69–0.98; $P = .03$). There was no significant reduction in all-cause mortality alone (27.2% vs 29.5%; HR 0.86; 95% CI 0.69–1.07) or in HFH alone (28.1% vs 30.4%;

HR 0.85; 95% CI 0.69–1.05).³⁰⁴ Taken together, available evidence suggests that cardiac glycosides (digoxin or digitoxin), when added to FMT, can reduce the risk of HFH in patients with chronic symptomatic HFrEF. Both agents share a narrow therapeutic window and require careful monitoring but differ in their metabolic elimination: digoxin is primarily eliminated through the kidneys, whereas digitoxin undergoes hepatic elimination.

6.1.5.5. Cardiac myosin activator

Omecamtiv mecarbil, a cardiac myosin activator, reduced the risk of HF events modestly in the GALACTIC-HF trial, but without a significant mortality benefit. The drug is not currently approved for clinical use in HF.³⁰⁹

6.1.6. The importance of uptitrating foundational medical therapy and maintaining adherence in heart failure with reduced ejection fraction

Foundational medical therapy is essential in HFrEF and must be initiated and uptitrated to target (Table 11) or highest tolerated doses.^{306,307} A practical guidance for the use of medical therapies is available in [Supplementary data online, Tables S4–S9](#).

Randomized controlled trials of medical therapy in HF initiated therapy at low doses, with protocol-driven uptitration, irrespective of symptomatic improvement, unless limited by intolerance. The target doses used in these trials established the efficacy and safety of these therapies and therefore form the basis of guideline recommendations. When target doses are not achievable or tolerated, the maximal tolerated dose is recommended.

Registry and real-life data have shown significant under-implementation of FMT in HFrEF, both with regard to number of drugs and doses used. Importantly, misinterpretation of changes in kidney function, leading to inappropriate discontinuation or down-regulation of doses of FMT, is a leading cause of insufficient FMT and should be avoided, both in decompensated and chronic HF.^{273,310}

Many classes of FMT can safely be initiated in patients with lower eGFR ([Supplementary data online, Tables S4–S9](#) and *2026 ESC Guidelines on cardiovascular disease and chronic kidney disease*).^{122,259} No statistically significant interaction has been found between the presence of CKD and the treatment effect of the components of FMT on the primary endpoint of their respective trials.²⁵⁹ Therefore, in terms of relative risk reduction, these agents are equally effective in patients with CKD. Because patients with CKD are at the highest baseline risk for CV death or HFH, the absolute risk reduction effect is even more pronounced in patients with HF and CKD. Therefore, it is crucial that FMT is initiated, uptitrated, and maintained in patients with CKD.²⁵⁹

In trials that have evaluated dose responses for outcomes, composite event rates were lower with target doses compared with lower doses.^{274,311}

Maintenance of FMT in patients with HFrEF is crucial for reducing the risk of HFH and improving survival and QoL. Even if symptoms and/or LVEF improve, it is recommended that optimal FMT is continued as lifelong treatment. Only in very selected cases of HFrEF with complete normalization of LV volumes and LVEF, including natriuretic peptides and in the

context of a clear treatable reversible cause of HF, gradual discontinuation may be considered.

Non-adherence to FMT can be multifactorial. Patient-related factors such as side-effects, drug interactions, economic difficulties, psychosocial issues, or poor health literacy may be contributing factors. However, healthcare-related inappropriate discontinuation of FMT should not be neglected. In general, incur-rent illness or infections without haemodynamic compromise should not lead to down-titration or discontinuation of FMT. Asymptomatic or tolerable hypotension should not lead to down-titration or discontinuation of FMT but may require re-evaluation of diuretic use. It is recommended that patients with HFrEF and CKD maintain FMT, as several trials have shown beneficial effects on kidney endpoints as well as CV endpoints.³¹² However, temporary discontinuation of MRAs/ARNIs/ACE-Is/ARBs and SGLT2-Is may be needed in cases with acute kidney injury and eGFR <15 mL/min/1.73 m². Severe hyperkalaemia (potassium >5.5 or >6 mmol/L) should lead to temporary down-titration or discontinuation of MRAs and/or ARNIs/ACE-Is/ARBs (see [Supplementary data online, Tables S4, S5 and S9](#)). Temporary discontinuation of beta-blockers and ARNIs/ACE-Is/ARBs is advised in patients with severe haemodynamic instability. If FMT has been temporarily discontinued for less than 14 days, it should, in most cases, be safe to initiate FMT directly at the previously tolerated doses in stable patients. Euvolaemia is important prior to initiating beta-blockers.

6.1.7. Pharmacological therapy for heart failure with preserved ejection fraction

Foundational medical therapy for HFpEF includes SGLT2-Is and MRAs, as covered in [Section 6.1.2](#).

Heart failure with preserved ejection fraction differs from HFrEF as patients tend to be older, and more often female with a high burden of comorbidities including AF, CKD, obesity, diabetes, and non-CV comorbidities.^{313,314}

There are numerous potential causes of HFpEF and, as the pathophysiology of various HFpEF syndromes differ, they also require distinct individualized therapies. Furthermore, it is important to exclude other conditions that might mimic the HFpEF syndrome (e.g. HCM, amyloidosis) or realize that certain diseases have similar symptoms but may coexist with HFpEF (pulmonary disease, anaemia, obesity, and deconditioning). There are Class I recommendations for SGLT2-Is and MRAs to be used in all symptomatic patients with HF, and diuretics to be used to treat signs and symptoms of congestion. Other pharmacological agents, such as ACE-Is, ARBs, and beta-blockers, may be used particularly for comorbidities, as there is uncertainty of the effect on morbidity and mortality. Recently, in RCTs, treatment with the GLP-1 RA semaglutide or the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA tirzepatide improved QoL in addition to weight reduction in patients with HFpEF and obesity, independently of diabetes status (see [Section 10](#)).^{315–317}

6.1.7.1. Angiotensin receptor–neprilysin inhibitors

In the PARAGON-HF trial, sacubitril–valsartan compared with valsartan did not achieve a significant reduction in the primary composite endpoint of CV death or total HFH in patients with symptomatic HF and LVEF ≥45%.⁴² There was a reduction in

total HFH (rate ratio 0.85; 95% CI 0.72–1.00; $P = .056$) that also did not meet statistical significance. A meta-analysis of the PARADIGM-HF and PARAGON-HF trials showed a benefit of sacubitril–valsartan compared with valsartan in patients with an LVEF below 60–65%.^{318,319} ARNIs therefore may be considered in HFpEF, especially in those with lower LVEF ranges.

Although renin–angiotensin system inhibition strategies with ACE-Is and/or ARBs have been successful in the treatment of HFrEF, clinical trials have not shown a clear benefit in HFpEF patients. In a meta-analysis of four trials evaluating ARBs in patients with HFpEF, there was no signal for benefit on CV death (HR 1.02), all-cause death (HR 1.01; 95% CI 0.92–1.11), or HFH (HR 0.92; 95% CI 0.83–1.02).³²⁰ Candesartan was associated with a reduction in recurrent HFH until LVEF was over 60%.⁴⁰ Although no strong recommendation is given to start these agents in patients with HFpEF, many have coexisting indications for ACE-I/ARB therapy (hypertension/diabetes/CKD).

6.1.8. Pharmacological treatment in heart failure with improved ejection fraction

In patients with HFrEF, FMT and GDIT can result in improvement in symptoms, functional capacity, NT-proBNP levels and LVEF (i.e. reverse remodelling). However, in most patients, LV function and structural abnormalities do not fully normalize, and symptoms and biomarker abnormalities may persist or reoccur. Many patients deemed to have recovered from HFrEF with resolution of symptoms and improvement of LVEF and natriuretic peptide levels will relapse after withdrawal of FMT. TRED-HF was a small open-label trial in which phased withdrawal of FMT was conducted in patients with HFrEF and DCM whose LVEF had improved (but not necessarily normalized—from LVEF <40% to LVEF at least 50%) after treatment with FMT, their LV volume

had normalized, and the NT-proBNP concentrations were reduced to <250 ng/L. Withdrawal of FMT resulted in relapse of HFrEF in 40% of the patients within 6 months, warranting reinitiation of therapy.^{321,322} In contrast, the CATHEDRAL-HF trial—a single-centre, open-label pilot study—randomized 60 patients with similar characteristics to those in the TRED-HF trial to either phased withdrawal of FMT (excluding carvedilol) or continued FMT. Phased withdrawal did not result in a higher rate of HFrEF relapse.^{323,324} Taken together, there is no solid evidence at this time to suggest that resolution of symptoms and improvement in cardiac function and biomarkers after treatment reflects actual recovery but, rather, remission, which requires FMT to be maintained.

Some causes of HF might be reversible (e.g. Takotsubo syndrome, arrhythmia-associated HF, myocarditis, HF caused by abnormal cardiac conduction). In these patients, where a completely reversible cause of HF is suspected and where complete normalization of LV function and volume has occurred after treatment of the reversible cause, including normalization of natriuretic peptides, a gradual trial of FMT withdrawal might be considered. However, this may be considered with caution and only in exceptional cases upon the request of the patient. The open-label, single-centre STOP-CRT trial indicated that gradual neurohumoral blocker withdrawal (and thus a CRT-only strategy) was feasible and safe in a small number of very selected patients with normalized LVEF after CRT.³²⁵ Such withdrawal should only be done under frequent clinical, laboratory, and imaging control to rule out relapse of HF. One should take into consideration that often coexisting comorbidities warrant continuation of FMT. However, more and larger RCTs in this domain are needed to assess the clinical effect of withdrawal of each component of FMT in patients with HFrEF and improved LVEF.

Table 11 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure

Drug	Starting dose	Target dose
ACE-Is		
Captopril ^a	6.25 mg t.i.d.	50 mg t.i.d.
Enalapril	2.5 mg b.i.d.	10–20 mg b.i.d.
Lisinopril ^b	2.5–5 mg o.d.	20–35 mg o.d.
Ramipril	1.25–2.5 mg b.i.d.	5 mg b.i.d.
Trandolapril ^a	0.5 mg o.d.	4 mg o.d.
ARNIs		
Sacubitril–valsartan	49/51 mg b.i.d. ^c	97/103 mg b.i.d.
ARBs		
Candesartan	4 mg o.d.	32 mg o.d.
Losartan	(12.5) 25–50 mg o.d.	150 mg o.d.
Valsartan	40 mg b.i.d.	160 mg b.i.d.
Beta-blockers		
Bisoprolol	1.25 mg o.d.	10 mg o.d.
Carvedilol	3.125 mg b.i.d.	25 mg b.i.d. ^d
Metoprolol succinate (CR/XL)	12.5–25 mg o.d.	200 mg o.d.
Nebivolol ^e	1.25 mg o.d.	10 mg o.d.

Continued

MRAs		
<i>Steroidal</i>		
Eplerenone	25 mg o.d.	50 mg o.d.
Spironolactone	12.5–25 mg o.d. ^f	50 mg o.d.
<i>Non-steroidal</i>		
Finerenone	10–20 mg o.d. ^g	20–40 mg o.d. ^g
SGLT2-Is		
Dapagliflozin	10 mg o.d.	10 mg o.d.
Empagliflozin	10 mg o.d.	10 mg o.d.
Other agents		
Digoxin ^h	62.5 µg o.d.	250 µg o.d.
Digitoxin ^h	0.07 mg o.d.	0.1 mg o.d.
Ivabradine	5 mg b.i.d.	7.5 mg b.i.d.
Vericiguat	2.5 mg o.d.	10 mg o.d.
Hydralazine/isosorbide dinitrate	37.5 mg t.i.d./20 mg t.i.d.	75 mg t.i.d./40 mg t.i.d.

© ESC 2026

The table provides initiation and target doses of FMT and AMT. For practical guidance in use of the different drugs, see [Supplementary data online, Tables S4–S9](#).

ACE-I, angiotensin-converting enzyme inhibitor; AMT, additional medical therapy; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; b.i.d., bis in die (twice daily); CR, controlled release; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FMT, foundational medical therapy; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; o.d., omne in die (once daily); SGLT2-I, sodium–glucose co-transporter 2 inhibitor; t.i.d., ter in die (three times a day); XL, extended release.

^aIndicates an ACE-I where the dosing target is derived from post-MI trials.

^bIndicates drugs where a higher dose has been shown to reduce morbidity/mortality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimal dose is uncertain.

^cSacubitril–valsartan may have an optional lower starting dose of 24/26 mg twice daily for those with a history of symptomatic hypotension, ACE-I naïve patients and patients with eGFR 30–60 mL/min/1.73 m².

^dA maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg.

^eIndicates a treatment not shown to reduce CV or all-cause death in patients with heart failure (or shown to be non-inferior to a treatment that does).

^fSpironolactone has an optional starting dose of 12.5 mg in patients where kidney status or hyperkalaemia warrant caution.

^gFinerenone has a different starting and target dose according to eGFR (10–20 mg, if eGFR ≤60 mL/min/1.73 m²; 20–40 mg, if eGFR >60 mL/min/1.73 m²).

^hDigoxin/digitoxin should be titrated according to plasma levels.

Recommendation Table 5 – Recommendations for pharmacological management of chronic heart failure (see [Evidence Tables 29–41](#))

Recommendations	Class ^a	Level ^b
All patients with HF, independent of LVEF		
An SGLT2-I (dapagliflozin or empagliflozin) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death. ^{241–245,326}	I	A
An MRA (sMRA for HFREF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death. ^{c43,254–257}	I	A
Dynamic individualized dosing of loop diuretics according to volume status is recommended in patients with HF and signs and/or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce the risk of HFH. ^{d 327–329}	I	A
Uptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death. ^{274,311}	I	C
Continuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death. ³²¹	I	C
HFREF		
A beta-blocker is recommended in stable patients with symptomatic HFREF to reduce the risk of HFH and death. ^{e 36,287–293,330}	I	A
An ACE-I or ARNI is recommended in patients with symptomatic HFREF to reduce the risk of HFH and death. ^{e 274–278}	I	A
Switching from an ACE-I or ARB to an ARNI is recommended in patients with symptomatic HFREF to reduce the risk of HFH and death. ^{e 278}	I	B1
An ARB is recommended in patients with symptomatic HFREF to reduce the risk of HFH and CV death if they are unable to tolerate an ACE-I or ARNI. ^{e 284–286,331}	I	A
A cardiac glycoside (digoxin or digitoxin) should be considered in patients with symptomatic HFREF with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH. ^{303,304}	IIa	B1

Continued

Ivabradine should be considered for patients with symptomatic HFrEF, LVEF $\leq 35\%$, in sinus rhythm, resting heart rate >70 b.p.m., on the highest tolerated ACE-I/ARNI, MRA, SGLT2-I, and beta-blockers to reduce the risk of HFH or CV death. ²⁹⁴	Ila	B1
Ivabradine should be considered in patients with symptomatic HFrEF, LVEF $\leq 35\%$, in sinus rhythm, who are unable to tolerate a beta-blocker, on the highest tolerated ACE-I/ARNI and MRA to reduce the risk of HFH or CV death. ²⁹⁴	Ila	C
Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with symptomatic HFrEF with LVEF $\leq 40\%$ on top of optimal FMT to reduce the risk of HFH and death. ³⁰⁰	Ila	B2
Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF with LVEF $\leq 40\%$ who cannot tolerate ARNI, ACE-I, or ARB to reduce the risk of HFH and death. ³⁰¹	Ilb	C
Vericiguat may be considered in patients with symptomatic HFrEF and LVEF $<45\%$ despite treatment with optimal FMT to reduce the risk of HFH and CV death. ^{295,297,298}	Ilb	B1
Gradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference. ³²⁵	Ilb	C
HFpEF		
ACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH. ^{39,40,42,319,332–337}	Ilb	C

© ESC 2026

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; nsMRA, non-steroidal mineralocorticoid receptor antagonist; RCT, randomized clinical trial; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; sMRA, steroidal mineralocorticoid receptor antagonist.

^aClass of recommendation.

^bLevel of evidence.

^cThe evidence for using MRAs in patients with HFrEF is based on RCTs conducted with sMRAs (spironolactone and eplerenone), whereas the evidence for patients with HFpEF originates from a meta-analysis of RCTs using both steroidal (spironolactone) and non-steroidal MRAs (finerenone).

^dThis recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness. Dynamic dosing of loop diuretics has been widely accepted as effective and therefore no adequately powered RCTs have ever been conducted or are likely to be conducted for ethical reasons.

^eNo large prospective RCT has been performed on the use of beta-blockers, ACE-I/ARNI/ARB exclusively in patients with LVEF 41%–49%.

6.2. Guideline-directed interventional therapies for chronic heart failure

The term GDIT includes all guideline-directed interventional therapies for HF (see *Section 3*). In this section, we provide recommendations for ICDs and CRT. Other implantable devices, for which recommendations have not been made, will be discussed at the end of this section. *Section 7* provides recommendations for interventional therapies in the setting of DHF, and *Section 8* provides recommendations for interventional therapies in the setting of advanced HF. *Section 9* covers comorbidity-specific interventional therapies.

6.2.1. Implantable cardioverter-defibrillators

The recognition that arrhythmic sudden cardiac death (SCD) accounted for ~30%–60% of all deaths in the early HF trials³³⁸ paved the way for the use of ICDs in patients with HFrEF. Antiarrhythmic drugs, such as amiodarone and dronedarone, are effective in reducing ventricular arrhythmias, but they do not prolong survival and may shorten it.^{339,340} In contrast, ICDs are effective in preventing SCD and prolonging survival in patients with HFrEF who are at high risk of SCD.^{340–344}

6.2.1.1. Secondary prevention of sudden cardiac death

Unlike antiarrhythmic drugs such as amiodarone, ICDs reduce mortality in cardiac arrest survivors and those with sustained ventricular arrhythmias, regardless of LVEF or presence of HF.^{345–348} Recommendations for secondary prevention ICD implantation are provided in the 2022 *ESC Guidelines for the management of patients with ventricular arrhythmias and the*

prevention of sudden cardiac death.¹¹⁹ Cardiomyopathy-specific recommendations for secondary prevention ICD implantation are provided in the 2023 *ESC Guidelines for the management of cardiomyopathies*.¹²⁴

6.2.1.2. Primary prevention of sudden cardiac death in heart failure

In the SCD-HeFT trial, compared to amiodarone, ICD reduced all-cause death by 23% in patients with HFrEF.³⁴⁰ In MADIT-II, 1232 patients were randomized to an ICD or control, and ICD therapy reduced all-cause death by 31%.³⁴² Although the risk of SCD has declined over time, the residual risk of SCD is still high (annual rate of 3.3 per 100 patient-years in PARADIGM-HF), warranting primary prevention ICD implantation in patients with HFrEF deemed at high risk of SCD.³⁴⁹ For details, see [Supplementary data online, Section S3.1.1.1](#).^{340,342,349–352}

6.2.1.3. Patient selection for implantable cardioverter-defibrillator therapy

Selection of patients with HFrEF for ICD implantation should be based on LVEF thresholds established in RCTs and underlying aetiology, as individuals with non-ischaemic HF may derive less benefit than those with ischaemic heart disease.^{341,343,353,354} However, a meta-analysis of RCTs demonstrated an overall survival benefit, even in patients with non-ischaemic HF.³⁴⁴ The effect of ICD treatment depends on the competing risk of non-sudden death, both CV and non-CV. Thus, in patients with many comorbidities and older age, the benefit of ICD therapy may be substantially lower.³⁵⁵ Shared decision-making is essential when considering ICD implantation in patients with HF.

Both patient preferences and clinical factors should be carefully considered. Individualized patient information on the potential risks and benefits should be provided to support an informed decision.

The presence and the extent of myocardial fibrosis, genotypes, and additional factors may help arrhythmic risk stratification in patients with cardiomyopathies.^{124,356,357}

6.2.1.4. Timing of implantable cardioverter-defibrillator therapy

Two studies have shown that primary prevention ICD implantation within 40 days of an MI does not improve outcomes.^{358,359}

A 3-month period after uptitration of FMT before considering ICD implantation is reasonable. Delaying ICD implantation carries a risk of SCD at 2%–4% by 6 months and ~7% by 1 year.³⁶⁰

6.2.1.5. Implantable cardioverter-defibrillator generator replacement

As with FMT, the commitment to GDIT is in most cases lifelong. Implantation of an ICD commits the patient to lifelong monitoring and the need for generator replacements. The lifelong risk of complications should be considered in the decision to implant. A further question is whether ICD generators should be replaced in patients who have not had appropriate ICD therapies. ICD shocks occur in more than 15% of patients after generator replacement in those who have not had an appropriate ICD shock during the lifetime of their first ICD generator.³⁶¹ Even in patients with LVEF improvement after FMT and CRT, a considerable residual risk of SCD remains.^{362,363} As HFrEF and comorbidities progress, the benefit of ICD therapy may diminish. The need for ICD and the risk of SCD should be reconsidered over time and prior to every generator replacement, taking risk of SCD, remaining lifespan of the patient, risk of complications, competing risks of death due to comorbidities, frailty, and patient choice into account.^{364–367}

6.2.1.6. Non-transvenous implantable cardioverter-defibrillator and wearable cardioverter-defibrillator

In a subcutaneous ICD (S-ICD), the lead is extravascular and, therefore, not prone to intravascular infection. It is particularly attractive in patients with difficult venous access or those who are at risk of infection. The S-ICD is comparable to transvenous ICDs in terms of efficacy, complication rates, and inappropriate shock rates.^{368,369} Importantly, the S-ICD cannot treat bradyarrhythmia (other than post-shock pacing) and does not provide anti-tachycardia pacing.

The extravascular ICD consists of a generator implanted in a subfascial or submuscular pocket and a subinternally deployed lead.³⁷⁰ A notable advantage over the S-ICD is that the generator is similar in size to a transvenous ICD. Long-term data on efficacy and safety are required.

A wearable defibrillator may be considered in patients deemed at especially high risk of SCD or as a bridge to decision for ICD implantation, although no mortality benefit has been shown in RCTs^{371,372} (see [Supplementary data online, Section S3.1.1.2](#)).

Recommendation Table 6 — Recommendations for implantable cardioverter-defibrillator implantation (see [Evidence Tables 42–48](#))

Recommendations	Class ^a	Level ^b
An ICD is recommended in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability (secondary prevention), and who are expected to survive for >1 year with good functional status, in the absence of reversible causes, or unless the ventricular arrhythmia has occurred <48 h after an MI, to reduce the risk of sudden death and all-cause death. ³⁴⁶	I	A
An ICD is recommended in patients with symptomatic HFrEF (NYHA class II/III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death. ^{340,342,373,374}	I	B1
An ICD should be considered in patients with symptomatic HFrEF (NYHA class II/III) of a non-ischaemic aetiology, and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death. ^{340,341,344,375}	IIa	B1
Prior to generator replacement for CIEDs, a shared decision-making process between the patient and a cardiologist experienced in CIEDs and HF should be considered to ensure that the balance between risks and benefits still favour a CIED. ^{376–380}	IIa	C
A wearable cardioverter-defibrillator may be considered in patients with HF who are at risk of sudden cardiac death for a limited period in order to increase survival as a bridge to decision for permanent ICD implantation or while listed for heart transplantation. ^{381–384}	IIb	C
ICD implantation for primary prevention is not recommended within 40 days of an MI as implantation during this period does not improve prognosis. ^{358,359}	III	B1
ICD implantation is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or heart transplantation. ^{374,385–387}	III	C

CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.

^aClass of recommendation.

^bLevel of evidence.

6.2.2. Cardiac resynchronization therapy

In carefully selected patients with HFrEF, CRT improves cardiac function, QoL, and reduces hospitalizations and death. Landmark RCTs support CRT use across a range of HF severity.^{388–398}

The first RCT to address the effects of CRT on morbidity and mortality was COMPANION³⁸⁸ in which CRT with pacemaker (CRT-P) and CRT with defibrillator (CRT-D) reduced the composite endpoint of all-cause death and hospitalizations for any cause by 20%. A reduction in all-cause death was shown with CRT-D, but not with CRT-P. In contrast, in the CARE-HF trial,³⁹² which randomized participants to medical therapy with or without CRT-P, CRT-P reduced all-cause death and HFH. In the MADIT-CRT trial, in which 1820 patients in NYHA classes I and II were randomized to CRT-D or ICD, CRT-D reduced all-cause death or HF events by 34%.³⁹⁷ In the REVERSE trial,³⁹⁶ which also involved patients in NYHA classes I and II with primary prevention ICD indications, CRT improved LVEF and reduced HFH. Importantly, in the 5-year follow-up of REVERSE, annualized death was low at 2.9% in patients randomized to 'CRT-on'.³⁹⁹ Together, these findings have provided compelling evidence for using CRT across the spectrum of severity of HFrEF. For landmark trials of CRT, see [Supplementary data online, Table S10](#).^{388,389,392,396–398,400–412} [Figure 10](#) provides an overview of factors to consider when evaluating patients for CRT.

6.2.2.1. Cardiac resynchronization therapy for heart failure caused by abnormal cardiac conduction

Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to conduction abnormalities ([Figure 9](#) and [Section 5.3.3](#)). In patients with HF, where no other cause of HF other than abnormal cardiac conduction can be found, and there is a low likelihood of LVEF improvement, planning for CRT implantation may be considered early—even before full FMT uptitration.

6.2.2.2. Right ventricular pacing-induced heart failure

As expected from the effects of ectopic cardiac stimulation, RV pacing leads to HFrEF in some patients.^{202,413} The incidence of pacemaker- or RV pacing-induced HF varies between 5.9% and 39%, depending on the definition.^{202,236–239} In the recent BUDAPEST-CRT Upgrade trial, upgrading to CRT-D significantly reduced death and HFH in patients with $\geq 20\%$ RV pacing burden and QRS ≥ 150 ms (HR 0.27; $P < .001$). The BUDAPEST-CRT Upgrade trial is the first RCT and included only 360 patients in total. Therefore, CRT-D upgrade should be considered in such patients.^{202,237,238,412,414}

6.2.2.3. Timing of cardiac resynchronization therapy implantation

The timing of CRT in relation to hospitalizations has not been addressed by RCTs. In an observational study of 64 968




Figure 10 Indications for cardiac resynchronization therapy in heart failure. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HFrEF, heart failure with reduced ejection fraction; ICD, Implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction. In the decision on device implantation consider the following: patient preference, likely benefit of ICD/CRT at the patient's age, frailty and comorbidities, risk of complications, venous access issues. ^aUptitration to the highest tolerated doses of HFrEF FMT (see [Table 11](#)). ^bInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥ 150 ms, and LVEF $\leq 35\%$, to improve symptoms and reduce morbidity and mortality, although reassessment of LVEF should be conducted prior to CRT implantation. (Class IIb).

patients undergoing CRT, the combined endpoint of all-cause death and HFH was lowest in patients with no HFH prior to implantation (9.7 per 100 person-years) and those who had CRT during the first HFH (11.1 per 100 person-years) compared with patients who had a CRT implantation within a year of their first HFH (17.3 per 100 patient-years).⁴¹⁵ In a study of 15 619 CRT-eligible patients with HF in the Get With The Guidelines-HF registry, all-cause death was lower in those who received CRT implantation during HFH (adjusted HR 0.63; $P < .0001$) compared with patients who did not have CRT.⁴¹⁶ A lower rate HF rehospitalization was observed in patients with CRT implanted during the first hospitalization (adjusted HR 0.64; $P < .0001$), but not in those prescribed CRT at discharge. As HFH is a critical step in the progression of HF, it may be beneficial to implant CRT at an early stage in patients who are most likely to benefit (LVEF $\leq 35\%$, LBBB with QRS ≥ 150 ms), ideally before an HFH has occurred.

Recommendation Table 7 — Recommendations for cardiac resynchronization therapy implantation (see [Evidence Tables 49–58](#))

Recommendations	Class ^a	Level ^b
CRT is recommended in patients with symptomatic HFrEF, LVEF $\leq 35\%$, despite optimal FMT, in SR with LBBB and QRS duration ≥ 150 ms in order to improve symptoms and reduce the risk of hospitalizations and death. ^{388–398}	I	A
An upgrade to CRT should be considered in patients with an LVEF $\leq 35\%$ who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite optimal FMT and who have a significant proportion of RV pacing in order to reduce the risk of HFH or death. ⁴¹²	IIa	B1
CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and death. ⁴⁰⁹	IIa	B1
CRT should be considered in patients with symptomatic HFrEF, LVEF $\leq 35\%$, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration ≥ 150 ms in order to improve symptoms and reduce morbidity and death. ^{388–398}	IIa	C
CRT should be considered in patients with symptomatic HFrEF, LVEF $\leq 35\%$, despite optimal FMT, who are in SR with LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death. ^{390,417}	IIa	C

Continued

CRT may be considered in patients with symptomatic HFrEF, LVEF $\leq 35\%$, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death. ^{391,397}	IIb	C
Initiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥ 150 ms, and LVEF $\leq 35\%$, to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be conducted prior to CRT implantation. ^{418–423}	IIb	C
CRT is not recommended in patients with a QRS duration < 130 ms who do not have an indication for pacing due to high-degree AV block. ^{410,424,425}	III	A

© ESC 2026

AV, atrioventricular; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricular; SR, sinus rhythm.

^aClass of recommendation.

^bLevel of evidence.

6.2.3. Conduction system pacing

Conduction system pacing (CSP), including His bundle and left bundle branch area pacing, aims to engage the Purkinje network for rapid and synchronous LV activation.⁴²⁶ Left bundle branch area pacing may prove to be a feasible alternative to CRT when implantation is challenging. However, no RCT with patient-centred outcomes has evaluated the efficacy or long-term safety of CSP in HFrEF. Therefore, no recommendations can currently be made. See [Evidence Table 22](#) and [Supplementary data online, Section S3.1.3](#) for further details.^{427–433}

6.2.4. Cardiac implantable electronic device programming and follow-up

In the same way that FMT implies lifelong adherence to drugs, a CIED requires a lifelong commitment to device follow-up. For the clinician, skills in interpretation of device-derived electrograms, device-related problem solving, and programming are essential.^{434,435}

For ICDs, routine defibrillation testing of shock efficacy does not reduce arrhythmic death and is therefore no longer recommended.⁴³⁶ Programming a high-rate cut-off and long detection intervals between detection of ventricular tachycardia and anti-tachycardia pacing or shocks dramatically reduce inappropriate shocks and unnecessary ICD therapy.^{436,437} At follow-up, the RV pacing burden as well as the intrinsic QRS duration are an important focus for deciding whether to upgrade from an ICD to a CRT-D device.

In patients with a CRT device, regular follow-up and optimization should be implemented, as CRT programming and FMT may require further optimization after implantation.⁴³⁵ Appropriate programming of atrioventricular intervals and optimal LV lead vectors are required to optimize CRT response. In patients

with AF, the percentage of effective biventricular pacing (with-out fusion or pseudofusion) is an important focus. Further details on CRT follow-up and optimization are outlined in an HFA position paper.⁴³⁵

6.2.5. Other cardiac implantable electronic devices

In a small unblinded RCT, cardiac contractility modulation marginally improved peak oxygen uptake and QoL in patients with advanced HFrEF and a QRS <130 ms.⁴³⁸ In a small pilot study, cardiac contractility modulation improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) score by 18 points in patients with HFpEF.⁴³⁹ No clinical outcome studies have emerged. Similarly, baroreceptor activation therapy led to improvements in 6-min walk distance and QoL in an unblinded RCT, but long-term clinical outcome data were neutral.^{440,441}

Current evidence for these CIEDs is insufficient to support guideline recommendations. Although promising, these findings require confirmation in large, well-designed trials.⁴³⁹

6.2.6. Other implantable devices

It has been hypothesized that an interatrial shunt could improve HF symptoms and outcomes by decompressing the left atrium. In the RELIEVE-HF study, 508 patients with HF and predominantly NYHA class III symptoms and any LVEF were randomized to transcatheter shunt implantation vs a sham procedure.⁴⁴² After 2 years, no difference emerged in the primary effectiveness outcome [hierarchical composite ranking of all-cause death, cardiac transplantation or LV assist device (LVAD) implantation, HFH, outpatient WHF events, and change in QoL]. Importantly, patients with reduced LVEF had fewer adverse CV events with shunt treatment, whereas patients with HFpEF had more CV events. In the REDUCE LAP-HF II study in patients with LVEF ≥40%, the atrial shunt device was no better than the sham procedure in terms of the hierarchical composite of CV death or non-fatal ischaemic stroke at 12 months, rate of total HF events up to 24 months, and change in QoL at 12 months.⁴⁴³

7. Decompensated heart failure

7.1. Definition and epidemiology

Decompensated HF is defined as acute or gradual onset of symptoms and/or signs of HF, severe enough to require urgent medical attention and treatment initiation or intensification. DHF can lead to an unplanned hospital admission, an emergency department visit, or an unplanned ambulatory visit requiring treatment for HF. DHF may present as either worsening of pre-existing HF or as the initial manifestation of the disease (*de novo* HF). In the setting of patients with pre-existing HF, WHF is characterized by a deterioration in the symptoms and/or signs of HF and represents an event in HF progression, whereas DHF is specifically characterized by the requirement for treatment modification.⁴⁴⁴

Decompensated HF is associated with a high risk of death: 3%–10% during HF admission; 20%–30% at 1 year, >50% after 5 years.^{445–450} Compared to DHF occurring in patients with pre-existing HF, *de novo* DHF may be associated with higher in-hospital death, but lower post-discharge death and rehospitalization rates.^{451–453} Following a hospitalization for DHF, 1-year rehospitalization rates range between 35% and 44%.^{447,448,453–455} In addition, up to 50% of patients with HF

require intensification of treatment in the emergency service or in outpatient settings.^{456–462}

7.2. Diagnosis

Decompensated HF requires prompt diagnosis to ensure early treatment.⁴⁶³ If DHF is suspected, assessment of signs and symptoms of congestion and hypoperfusion must be done at the first medical contact. Non-invasive blood pressure, respiratory rate, pulse oximetry monitoring, body temperature measurement, and ECG should be performed early.⁴⁶⁴ In haemodynamically unstable patients with suspected hypoperfusion, assessment of serum lactate levels should be performed promptly.⁴⁶⁵

The currently recommended, non-age-adjusted, natriuretic peptide 'rule-out' thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL.^{157,466–469} However, if clinical suspicion of HF remains despite values below 'rule-out' thresholds, specialist assessment and echocardiogram should be sought. Age-related thresholds for NT-proBNP, above which DHF is considered 'likely', are given in the footnote of [Figure 11](#). In the older population, using the age-related NT-proBNP threshold may aid appropriate triage and help reduce unnecessary exams. NT-pro-BNP >5000 pg/mL indicates very high risk, and admission is generally recommended. For other laboratory tests and investigations for patients with suspected DHF, see [Supplementary data online, Table S11](#). Initial investigations are carried out to diagnose DHF and rapidly detect any possible triggers.

Transthoracic echocardiography should be performed in patients with high levels of NT-proBNP and in those for whom there is a high clinical suspicion of DHF.

Where trained personnel are available, lung ultrasound identifies patients with pulmonary congestion and has utility in serial assessments.^{470–473}

7.3. Clinical presentation

Congestion and hypoperfusion are two major clinical manifestations of DHF.^{447,453} Congestion may stem from fluid overload, fluid redistribution, increased vascular permeability, and increased intracardiac pressures. Different clinical, laboratory, and imaging utilities should be used to assess congestion and its dynamic changes (see [Supplementary data online, Table S12](#)). Hypoperfusion is not a synonym for hypotension,^{474,475} although patients with DHF and hypotension also experience inadequate perfusion. An objective marker, serum lactate, may help identify patients with peripheral hypoperfusion and monitor therapy.⁴⁶⁵ Signs and symptoms associated with congestion and hypoperfusion are reported in [Table 12](#).

Four categories of DHF can be recognized based on clinical presentation: decompensated left-sided HF, decompensated right-sided HF, acute pulmonary oedema (APO), and cardiogenic shock (CS).

Pathophysiology, timing of onset, and speed of deterioration differ between the four categories, but possible overlaps exist.

7.3.1. Decompensated left-sided heart failure

Decompensated left-sided HF, in its classical clinical presentation, is characterized by a gradual onset of signs and symptoms with accumulating congestion as the primary pathophysiological process.⁴⁷⁶ It may occur in patients across the spectrum of LVEF and, in advanced stages, can lead to RV dysfunction and




Figure 11 Diagnosing decompensated heart failure. APO, acute pulmonary oedema; BNP, B-type natriuretic peptide; CS, cardiogenic shock; DHF, decompensated heart failure; ECG, electrocardiogram; LUS, lung ultrasound; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ^aSee [Supplementary data online, Table S11](#) for more details on admission investigations in DHF. ^bIn case of APO or CS, early treatment is recommended. ^cThe currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL. Combination with age-related ‘likely’ rule-in thresholds may reduce unnecessary exams: NT-proBNP >450 pg/mL (<50 years), NT-proBNP >900 pg/mL (50–74 years), NT-proBNP >1800 pg/mL (>74 years). ^dIn case of DHF unlikely, look for other causes of symptoms.

decompensated right-sided heart failure. Thus, both pulmonary and peripheral congestion may be present. Hypoperfusion can occur.^{447,465,476} Treatment is mainly based on decongestion by means of diuretic therapy. Site of care can be outpatient clinic or hospital.

7.3.2. Decompensated right-sided heart failure

Decompensated isolated right-sided HF is characterized by elevated RV and right atrial pressures, leading to systemic congestion and, in more advanced stages, hypoperfusion. It is often

associated with tricuspid regurgitation (TR) and can also impair LV filling and reduce systemic cardiac output through ventricular interdependence. Pulmonary embolism and acute MI involving the right ventricle are possible causes of decompensated right HF that need to be excluded during initial evaluation and treated. Fluid overload, elevated central venous pressures, and multiorgan dysfunction are the most frequent elements of the clinical picture of the disease. In the most severe cases, it can manifest as a refractory shock. The RV function and its effect on other organs (kidney, liver) usually determine the clinical

Table 12 Signs, symptoms, and altered laboratory tests in congestion and hypoperfusion profiles

Left-sided congestion	Right-sided congestion	Hypoperfusion
Dyspnoea	Peripheral oedema	Cold, sweaty extremities
Orthopnoea	Abdominal distension	Pale skin
Cough	Hepatomegaly	Dizziness
Tachypnoea	Jugular vein distension	Mental confusion
Rales	Hepatojugular reflux	Oliguria
S3	Pleural effusion	Narrow pulse pressure
Pleural effusion	Elevated serum creatinine	Elevated serum lactate
Elevated natriuretic peptides	Elevated bilirubin, ALP, GGT	Elevated serum creatinine
	Slightly elevated natriuretic peptides	Elevated aminotransferase

© ESC 2026

ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase.

trajectory, thus a close monitoring of kidney and hepatic function is needed. Onset can be gradual or rapid depending on causes, triggers, and precipitating factors. Optimal care requires a multifaceted approach, including diuretics, judicious fluid management, appropriate use of inotropes and vasopressors, and mechanical circulatory support (MCS) when indicated.

7.3.3. Acute pulmonary oedema

Acute pulmonary oedema is a life-threatening condition that needs prompt, optimally targeted rescue therapy.^{477,478} Clinical criteria for the diagnosis of APO include signs and symptoms of respiratory distress [dyspnoea with orthopnoea, respiratory failure (hypoxaemia with or without hypercapnia), tachypnoea (>25 breaths/min), and increased work of breathing], caused by massive pulmonary congestion, which typically develops over a short period of time.⁴⁷⁷ The major objectives of the treatment are relieving pulmonary congestion, treating respiratory insufficiency, and ensuring peripheral perfusion. The mechanism of development of congestion is complex, with a predominant fluid redistribution that implies pulmonary congestion without total volume overload, primarily due to blood shift into the pulmonary circulation. Such patients usually do not need high doses of diuretics, but they may need vasodilators. The cause of decompensation should be investigated in every patient, and causal treatment, if possible, is imperative.

7.3.4. Cardiogenic shock

Cardiogenic shock is defined as a state of critical end-organ hypoperfusion caused by primary cardiac dysfunction.^{479–481}

The Shock Academic Research Consortium (SHARC) consensus defines CS as a cardiac disorder that results in both clinical

Table 13 SCAI classification for cardiogenic shock

STAGE A 'At risk'	A patient who is not currently experiencing signs or symptoms of CS but is at risk for development of CS.
STAGE B 'Beginning/pre-shock' cardiogenic shock	A patient who has clinical evidence of hemodynamic instability (including relative hypotension or tachycardia) without hypoperfusion.
STAGE C 'Classic' cardiogenic shock	A patient that manifests with hypoperfusion requiring intervention (inotrope, vasopressor, or mechanical support).
STAGE D 'Deteriorating'	A patient that is similar to stage C but deteriorating with failure to respond to initial interventions.
STAGE E 'Extremis'	A patient with refractory shock or cardiac arrest requiring multiple simultaneous acute interventions, including CPR.

© ESC 2026

CPR, cardiopulmonary resuscitation; CS, cardiogenic shock; MI, myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions.

and biochemical evidence of sustained tissue hypoperfusion.⁴⁸² Generally, CS is characterized by hypoperfusion and hypotension; however, no specific blood pressure cut-off is defined, as CS is a complex clinical condition, involving many parameters and nuances. Thus, any arbitrary blood pressure threshold will have inherent limitations. CS may also present as hypoperfusion with normotension, which has better prognosis than hypotensive CS.^{483,484}

Importantly, septic and hypovolaemic shock also manifests with hypotension and end-organ hypoperfusion, and mixed forms of shock often exist simultaneously.^{480,485} Clinical features of hypoperfusion are reported in [Table 12](#). Biochemical manifestation of inadequate tissue perfusion is best measured by arterial lactate, where a value of >2 mmol/L is required.^{479,480} Additional markers used in assessment of hypoperfusion are acute kidney injury and/or acute hepatic injury.⁴⁸⁰

The Society for Cardiovascular Angiography and Interventions introduced a staging scheme—SCAI classification—to address the severity of CS.⁴⁷⁹ Based on this, there are five categories of CS: (A) at risk, (B) pre-shock, (C) classic, (D) deteriorating, and (E) extremis ([Table 13](#)).

7.4. General management

In-hospital management of DHF can be divided into three general phases ([Figure 12](#)). Importantly, each clinical category of DHF has different trajectories through these phases. For instance, CS patients usually remain in phase 1 for several days and may never reach phase 2.⁴⁷⁴ On the other hand, patients with uncomplicated decompensated left-sided or right-sided HF or APO can experience quick transition through all phases of treatment.




Figure 12 Phases and goals for in-hospital management of decompensated heart failure. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure. ^aSee [Figure 14](#).

7.4.1. Phase 1 (initial management)

The primary objectives in phase 1 are reported in [Figure 12](#). In many cases, this phase starts in pre-hospital settings. Pre-hospital management should not delay the rapid transfer of the patient to the most appropriate medical setting, where further work-up is undertaken.

Patients should be triaged based on their haemodynamic and clinical status to determine the appropriate level of care and monitoring requirements. For patient risk stratification, specific scores have been proposed, but they need further validation (see [Supplementary data online, Section S4.2.1](#)).^{486,487}

In patients with suspicion of CS and with a potential indication for temporary MCS, consultation with the Shock Team is recommended (see [Section 7.5.11](#)).⁴⁸⁸ In these patients, as well as in those with other life-threatening conditions, the diagnostic

work-up and appropriate rescue pharmacological and non-pharmacological treatment should be initiated promptly and simultaneously ([Figure 13](#)). Identification and possible treatment of acute causes is crucial.^{118,119,489–491} Combination and timing of different treatments depend on clinical presentation ([Figure 13](#)). In patients already receiving FMT, continuation and/or rapid reintroduction as soon as possible is recommended. Discontinuation of FMT is not recommended unless there are clear signs of hypoperfusion or specific clinical indications. Monitoring during and after initial stabilization is mandatory (see [Supplementary data online, Table S12](#)).

7.4.2. Phase 2 (stabilization)

The primary objective of this phase is to maintain and enhance the patient's haemodynamic status and, once the patient is




Figure 13 Initial management of decompensated heart failure. HF, heart failure; MCS, mechanical circulatory support. ^aOverlap between different clinical phenotypes can exist. ^bConsultation with the Shock Team is recommended. ^cConsider in case of hypoxaemia. ^dConsider when systolic blood pressure is >110 mmHg.

stabilized, to start/optimize long-term FMT to alter the course of the disease and improve patient outcomes. Decongestion is crucial and must be started and continued in phase 2 (Figure 13). Data from recent RCTs have demonstrated that initiating MRAs, SGLT2-Is, or ARNIs is feasible and safe in this phase of DHF.^{281,492,493} Much debate is ongoing on the optimal FMT initiation/optimization. It is clear that the traditional sequential approach is suboptimal and time-consuming. There is growing evidence that simultaneous implementation of FMT is more effective, safe, and associated with clinical benefit, thus this approach should be preferred. As no prospective RCT has been conducted comparing the different approaches to implementing FMT, no specific recommendation can be made regarding the number of drug classes to be introduced simultaneously or sequencing of the drugs. A more conservative approach may be reserved for specific (high-risk) groups of patients, such as patients with low eGFR, hypotension, and history of hyperkalaemia.

7.4.3. Phase 3 (pre-discharge and early post-discharge)

This transition phase covers the last days of hospitalization and the first days/weeks after discharge.⁴⁹⁴ During this period, efforts should focus on reducing the risk of subsequent DHF/WHF

episodes, further optimizing FMT, and determining any indications for AMT and GDIT. The STRONG-HF trial demonstrated the safety and efficacy of an approach based on a rapid and intensive initiation and uptitration of FMT followed by close outpatient visits.³¹¹ This study has been criticized due to several limitations, including a highly selected population (based on NT-proBNP values and changes), the suboptimal medical treatment in the control arm and the lack of SGLT2-I use (lack of evidence and recommendations at the time when the study was conducted). Nevertheless, the trial showed that a strategy of fast uptitration after HFH is safe and feasible and therefore this approach is recommended. Safety indicators, including vital signs (blood pressure and heart rate) and laboratory tests (creatinine, potassium, and NT-proBNP) are helpful to guide uptitration.⁴⁹⁵

Residual congestion is associated with poor outcomes and a high risk of rehospitalization. Thus, pre-discharge assessment of residual congestion using clinical, laboratory, and imaging techniques is recommended (Figure 14).⁴⁹⁴ If not done earlier, the pre-discharge phase may also be used for iron supplementation in patients with iron deficiency (ID), based on the results of the AFFIRM-AHF trial (see Section 10.4).⁴⁹⁶ Finally, patients should be enrolled in disease management and rehabilitation programmes, educated, and guided in appropriate lifestyle adjustments.




Figure 14 Tools used for assessment of decongestion during the pre-discharge phase. All these tools are intended to be optional as no evidence from randomized controlled trials exists. BNP, B-type natriuretic peptide; CSI, congestion score index; EDT, E-wave deceleration time; IVC, inferior vena cava; LUS, lung ultrasound; LV, left ventricular; NP, natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TRV, tricuspid regurgitation velocity. ^aCongestion score = 0 denotes the absence of clinical congestion (absence of dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).⁴⁹⁷ Congestion score = 1–2 denotes mild congestion (slight or moderate dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).⁴⁹⁷ ^bThe CSI is a six-zone evaluation of a chest X-ray, with individual scores ranging from 0 to 3. A total score of 0 indicates all zones are clear (i.e. no congestion). ^cThe IVC is an optional tool to assess decongestion, although CAVA-ADHF showed no added benefit.⁴⁹⁸

Recommendation Table 8 – Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for decompensated heart failure (see [Evidence Tables 59–67](#))

Recommendations	Class ^a	Level ^b
Careful evaluation ^c before discharge is recommended in patients hospitalized for DHF to exclude persistent signs of congestion.	I	C
An intensive strategy of rapid initiation and uptitration of FMT before discharge and during frequent follow-up visits in the first 6 weeks following an HFH is recommended to reduce the risk of HF rehospitalization or death. ³¹¹	I	B2

DHF, decompensated heart failure; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization.

^aClass of recommendation.

^bLevel of evidence.

^cClinical evaluation, natriuretic peptide levels ([Table 9](#)), kidney function and electrolytes, imaging (see [Figure 14](#)).

7.5. Treatment

7.5.1. Oxygen therapy

Oxygen therapy is recommended in patients with hypoxaemia [oxygen saturation (SpO₂) <90% or partial pressure of oxygen (PaO₂) <60 mmHg]. Studies, including RCTs, have demonstrated that indiscriminate oxygen administration in non-hypoxaemic patients may be harmful.^{499–501}

7.5.2. Ventilation support

Non-invasive ventilation is recommended in patients with APO or CS and respiratory failure to improve oxygenation and reduce the need for intubation as shown by multiple trials and meta analyses.^{502,503} However, the increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and blood pressure and should therefore be used with caution in patients with reduced preload reserve and hypotension (i.e. decompensated right-sided HF). Endotracheal intubation is reserved for selected cases (see [Recommendation Table 9](#)).⁴⁷⁷

7.5.3. Diuretics (decongestion management)

Intravenous loop diuretics remain the cornerstone of decongestion in DHF. In the DOSE-AHF trial, no difference in the primary efficacy outcome of patients' symptom global assessment was shown with a high-dose regimen compared with a low-dose regimen of furosemide. There is no evidence indicating differential outcomes with i.v. bolus administration compared to continuous infusion or that one loop diuretic is superior to another.^{327,504} Patients naïve to diuretics usually respond well to 40 mg of i.v. furosemide or equivalent, whereas i.v. doses of two times the patient's usual oral diuretic dose should be considered for patients who have been on loop diuretics as outpatients.⁵⁰⁵

Possible worsening kidney function should be evaluated in the context of diuretic response, because small and transient rises in serum creatinine during diuretic therapy are not associated with poor outcome if decongestion is achieved.^{506,507}

Subsequent doses of loop diuretics during the initial days of hospitalization may be adjusted based on urinary sodium (uNa⁺) assessments, diuretic response, and the patient's clinical status. A satisfactory diuretic response can be defined as a uNa⁺ content ≥70 mEq/L at 2 h or by a urine output ≥100 mL/h during the first 6 h ([Figure 15](#)). The PUSH-AHF trial showed that a strategy based on frequent clinical assessment, and uNa⁺-guided diuretic therapy led to higher natriuresis at 24 h vs standard of care.⁵⁰⁸ In the ENACT-HF open-label study, the uNa⁺-based approach also resulted in higher natriuresis and diuresis, as well as shorter hospital stay.⁵⁰⁹ No clinical trial has thus far showed benefit of uNa⁺-guided diuretic therapy on death or recurrent HFH.

Intravenous diuretics should be continued until optimal decongestion is achieved; then, a switch to oral diuretics, if needed to maintain the volume status, is recommended.

If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled and/or a non-loop diuretic added. ([Figure 15](#)).

Two recent RCTs examined the role of non-loop diuretics for enhanced decongestion in DHF. In the ADVOR trial, patients

were randomized to i.v. acetazolamide (500 mg) or placebo added to i.v. loop diuretics. Treatment with acetazolamide resulted in a greater incidence of successful decongestion, defined as the absence of signs of volume overload within 3 days.⁵¹⁰ In the CLOROTIC trial, oral hydrochlorothiazide (dose adjusted for eGFR) was compared with placebo in patients receiving i.v. furosemide.⁵¹¹ The treatment with hydrochlorothiazide resulted in more pronounced weight loss at 72 h but did not impact patient-reported dyspnoea. Treatment with hydrochlorothiazide was associated with greater 24 h diuresis but also more likely worsened kidney function and hypokalaemia, warranting caution. Importantly, the study was prematurely halted due to slow recruitment. Both ADVOR and CLOROTIC did not show benefit of non-loop diuretics on hard endpoints. The pharmacotherapy of different diuretics and a practical guidance for their use in DHF is reported in [Supplementary data online, Table S13](#). In patients with DHF, fluid intake should be less than urine output and fluid restriction may be appropriate in patients with hyponatraemia, based on individual assessment. Similarly, sodium intake should remain less than natriuresis.

Implementing SGLT2-I and neurohormonal blockade, including MRA, can contribute to more effective and sustainable decongestion.^{512–514} Thus, it is imperative to consider early implementation and optimization of FMT in parallel to decongestion ([Figure 15](#)).

7.5.4. Decongestion management in the ambulatory setting

In ambulatory patients with chronic HF showing signs of worsening, both i.v. diuretic administration and intensification of oral diuretic therapy can be considered.

A practical guide for the outpatient management of WHF has been published, covering both ambulatory i.v. diuretics administered in a day-hospital setting and 'hospital-at-home' care models, including telehealth-enabled approaches.^{515–517} Diuretic sessions usually consist of a 3–6 h i.v. diuretic infusion with dosing based on the patient's existing oral diuretic regimen. Close monitoring of kidney function, electrolyte levels, and treatment response, including measurements of urine output, uNa⁺, signs of clinical decongestion, biomarkers, and/or ultrasound findings, is essential.^{444,515,518}

The new formulations of diuretics (e.g. subcutaneous) might be particularly useful for home treatment.^{519–521}

Intensification of oral diuretic therapy may include: (i) initiating a loop diuretic in previously untreated individuals; (ii) increasing the total daily dose of a loop diuretic; or (iii) temporarily adding a diuretic with a different mechanism of action. Thiazide-like diuretics—particularly oral metolazone (2.5–5 mg)—can be used in patients with advanced HF who exhibit diuretic resistance, as part of a sequential nephron blockade approach, or in those with an eGFR <30 mL/min/1.73 m². This strategy requires careful monitoring of eGFR and electrolytes.

Patients with WHF that progresses to advanced HF are a key population for either outpatient i.v. diuretic treatment, whether in a day hospital or 'hospital-at-home' setting, or oral thiazide-like diuretics. Indeed, these patients often experience frequent hospitalizations and spend a substantial amount of time in hospital ('frequent flyers'). Such patients require prompt evaluation for advanced HF treatments (see [Section 8](#)).




Figure 15 Management of decongestion. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FMT, foundational medical therapy; i.v., intravenous; K⁺, potassium; MRA, mineralocorticoid receptor antagonist; uNa⁺, urinary sodium. ^aHigher initial i.v. dose in case of CKD. ^bAfter 24 h of treatment, total diuresis should be taken into consideration. If diuresis remains <3 l and congestion persists, further diuretic escalation should be considered during the second day of treatment. ^cAcetazolamide (500 mg i.v. once daily) or hydrochlorothiazide (if eGFR >50 mL/min/1.73 m²: 25 mg daily; eGFR 20–50 mL/min/1.73 m²: 50 mg daily; and eGFR <20 mL/min/1.73 m²: 100 mg daily). Acetazolamide might be preferable in more advanced CKD. ^dThe highest daily dose for i.v. loop diuretics is generally considered furosemide 600 mg, although up to 1000 mg may be considered in patients with severely impaired kidney function. ^eConsider MRA and K⁺ supplements in case of hypokalaemia.

7.5.5. Sodium–glucose co-transporter 2 inhibitors

Several trials and meta-analyses have confirmed the safety and clinical benefit of in-hospital initiation of an SGLT2-I.^{492,522–525} The EMPULSE trial demonstrated that in-hospital initiation of 10 mg empagliflozin resulted in significantly higher chances of clinical benefit, at 90 days.⁴⁹² In the SOLOIST-WHF trial, initiation of sotagliflozin in hospital or within 3 days of discharge was safe and effective in patients with HF and diabetes.³²⁶ Initiation of SGLT2-Is in HF has been shown to be associated with lower diuretic demand and facilitated decongestion even though the long-term ‘diuretic effect’ of SGLT2-Is is unknown.^{514,522–524,526} Thus, early initiation of SGLT2-Is in DHF is recommended both as part of FMT (i.e. prognostic implications) and as a tool to enable optimal decongestion (Figure 15).

7.5.6. Ultrafiltration

Given the available data, the role of ultrafiltration in managing DHF remains uncertain, but it may be considered in selected patients who are responding insufficiently to diuretic escalation.^{527,528}

7.5.7. Vasodilators

Intravenous vasodilators (i.v. nitroglycerine or nitroprusside) may be effective in patients with DHF, particularly in those with predominant vasoconstriction and volume redistribution. For example, in APO, where increased cardiac filling pressures and elevated systemic blood pressures occur in the absence of, or with minimal, systemic fluid accumulation, vasodilators can reduce pulmonary congestion (Supplementary data online, Section S4.3 and Table S14).⁵²⁹ Importantly, close monitoring of blood pressure is recommended during drug administration, as hypotension related to vasodilatation may be harmful.^{529,530} None of the large-scale RCTs have shown a clear clinical benefit of vasodilatation on hard endpoints.^{531–533} A meta-analysis of available RCTs has demonstrated that using vasodilators was associated with a lower risk of tracheal intubation in DHF with no effect on death or length of hospital stay.⁵³⁴

7.5.8. Inotropes/inodilators

Inotropic agents may be considered in patients with DHF, systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Due to risks of arrhythmias and myocardial ischaemia, their use is not routinely recommended in patients with DHF and should be cautious.⁵³⁵ A Cochrane analysis found insufficient evidence to establish mortality benefits of any inotrope in patients with CS or low cardiac output.⁵³⁶ An RCT found no difference between milrinone and dobutamine.⁵³⁷ For levosimendan, no relevant RCTs in CS are available. Based on the mode of action, levosimendan or phosphodiesterase-III inhibitors may be preferred over dobutamine for patients on beta-blockers. For more details on the specific inotropic agents, see Supplementary data online, Tables S15 and S16.

7.5.9. Vasopressors

Vasopressors may be considered in patients with hypotension and DHF. Some studies, although with limitations, support the

use of norepinephrine as first choice, compared with dopamine or epinephrine. Dopamine vs norepinephrine was associated with significantly higher rate of arrhythmic events in an RCT including patients with unspecified shock.⁵³⁸ In the CS subgroup, a mortality benefit was observed with norepinephrine, although without a significant *P*-value for interaction. Comparing epinephrine and norepinephrine showed similar effects on cardiac index in a small trial of infarct-related CS.⁵³⁹ However, this trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Vasopressin has not been studied in CS so far. The target mean blood pressure is not well defined in CS. For more details, see Supplementary data online, Table S16.

7.5.10. Opiates

Routine use of opiates is not recommended in patients with DHF; Their use should be limited to carefully selected patients with severe anxiety or distress refractory to other treatments and must be approached with caution due to the risk of respiratory failure.

Recommendation Table 9 – Recommendations for the immediate and intermediate treatment of decompensated heart failure (see Evidence Tables 59–67)

Recommendations	Class ^a	Level ^b
Oxygen and ventilatory support		
Oxygen is recommended in patients with SpO ₂ <90% or PaO ₂ <60 mmHg to correct hypoxaemia.	I	C
Intubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemia ^c .	I	C
Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO ₂ <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation. ⁵⁴⁰	IIa	B2
Diuretics		
Intravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptoms ^d .	I	A
The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion. ^{510,511}	IIa	B1
Urinary Na ⁺ -guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis. ⁵⁰⁸	IIb	B1

Continued

SGLT2-I		
In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH. ^{492,522,525,541}	I	B1
Vasodilators		
Intravenous vasodilators may be considered as initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve symptoms and reduce congestion. ⁵³⁴	IIb	C
Inotropic agents		
Inotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion.	IIb	C
Vasopressors		
Vasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.	IIb	C
Opiates		
Routine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm. ⁵⁴²	III	C

© ESC 2026

DHF, decompensated heart failure; HFH, heart failure hospitalization; NIV, non-invasive ventilation; PaCO₂, partial pressure of carbon dioxide; PaO₂, partial pressure of oxygen; QoL, quality of life; SGLT2-I, sodium-glucose co-transporter 2 inhibitor; SpO₂, oxygen saturation.

^aClass of recommendation.

^bLevel of evidence.

^cCriteria for endotracheal intubation in DHF: cardiac or respiratory arrest, progressive worsening of altered mental status, progressive worsening of respiratory failure with hypoxaemia (PaO₂ <60 mmHg, PaCO₂ >50 mmHg and pH <7.35) despite NIV or intolerance to NIV, persistent haemodynamic instability, need for airway protection.⁴⁷⁷

^dThis recommendation is considered by the Task Force to have level of evidence A due to clear clinical benefit. Treatment of DHF with loop diuretics has been widely accepted as effective and therefore no adequately powered randomized clinical trial has ever been conducted or is likely to be conducted for ethical reasons.

7.5.11. Temporary mechanical circulatory support

Temporary MCS should be considered as an option for stabilizing haemodynamics and enhancing end-organ perfusion in highly selected patients.^{434,474,543,544}

Different percutaneous devices operate through distinct mechanisms, delivering diverse haemodynamic support levels, each associated with specific potential benefits but also possible complications. In addition to single use, multiple combinations are feasible, addressing specific needs for LV unloading or combined left and right ventricular support. Decisions on the modality and type of temporary MCS should be guided by a multidisciplinary Shock Team including a cardiologist specialized in HF, a cardiothoracic surgeon, an interventional cardiologist, and an intensive care specialist, working at an experienced advanced HF centre (i.e. high-volume for temporary MCS).^{488,545} A recent meta-analysis

suggests that temporary MCS are beneficial in highly selected patients with ST-elevation MI complicated by CS who do not have hypoxic brain injury, although rates of severe complications remain high.⁵⁴⁶

7.5.11.1. Microaxial flow pumps

Microaxial percutaneous flow pumps provide support of up to 4 l/min. Newer devices with 5.5 l/min requiring surgical insertion offer complete LV support.

Until recently, the percutaneous device had been investigated in a few RCTs on infarct-related CS and in large-scale propensity-matched studies encompassing more than 100 000 patients and consistently showed no survival benefit with higher complication rates such as major bleeding and limb ischaemia.^{547,548} In the DanGer Shock trial, including 360 highly selected patients with ST-elevation MI and CS, treatment with microaxial flow pump vs standard of care was associated with lower 180-day death (HR 0.74; 95% CI 0.55–0.99; *P* = .04), which persisted up to 10-year follow-up.^{549,550} This trial also showed an increased incidence of bleeding and limb ischaemia compared with controls. Despite the mortality benefit observed in this trial, multiple open questions remain.^{548,551}

Utilization of microaxial flow pumps should be considered in highly selected patients with CS caused by ST-elevation MI, who do not have risk of hypoxic brain injury. Routine use of microaxial flow pumps in CS is not recommended. RCTs on the efficacy of microaxial flow pumps in non-infarct-related CS have yet to be conducted.⁵⁴⁶

7.5.11.2. Venoarterial extracorporeal life support

Extracorporeal life support (ECLS) can deliver support of up to 6 l/min and provide full respiratory and circulatory support. In the ECLS-SHOCK trial involving patients with severe infarct-related CS, early routine ECLS use showed no significant difference in 30-day all-cause death (relative risk 0.98; 95% CI 0.80–1.19).⁵⁵² These data are in line with an individual patient data meta-analysis of ECLS RCTs in patients with infarct-related CS in which no mortality benefit was observed but more complications with ECLS were seen.⁵⁵³

Importantly, ECLS may harm the heart itself owing to the after-load increase by generation of retrograde blood flow. Active unloading with microaxial flow pumps or intra-aortic balloon pump (IABP) aims to mitigate these adverse effects. A recent RCT comparing routine LV unloading by a transseptal left atrial cannula vs ECLS alone showed no effect on death.⁵⁵⁴ RCTs investigating the efficacy of ECLS in non-ischaemic CS have yet to be performed.

7.5.11.3. Intra-aortic balloon pump

Routine use of IABP is not recommended in unselected patients with CS. In the IABP shock trial, 40 patients with post-MI CS were randomised to IABP treatment or standard of care. Treatment with IABP did not significantly augment cardiac output or any other haemodynamic variable as compared to control.⁵⁵⁵ In a large-scale RCT in infarct-related CS, routine use of IABP did not show a survival benefit compared with medical therapy at 30-day and longer follow-up.^{556–558} Also, in advanced HF CS, IABP had no survival benefit as compared to standard of care.^{559,560} The decision to use an IABP should therefore be highly individualized, based on patient-specific factors and the availability of alternative therapies.^{559,561–563}

Recommendation Table 10 – Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see [Evidence Tables 68 and 69](#))

Recommendations	Class ^a	Level ^b
A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics. ^{564,565}	I	C
Cardiogenic shock caused by acute MI		
Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no risk of hypoxic brain injury ^c in order to reduce the risk of death. ^{546,549,550}	IIa	B1
Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm. ^{546,552,553}	III	B1
IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect. ^{557,560}	III	B1
MI-related mechanical complications		
Temporary MCS ^d should be considered in patients with mechanical complications related to MI ^e as a bridge to definitive treatment.	IIa	C
Advanced HF cardiogenic shock		
Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.	IIa	C

© ESC 2026

BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; HF, heart failure; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; MI, myocardial infarction; VA-ECLS, venoarterial extracorporeal life support.

^aClass of recommendation.

^bLevel of evidence.

^cNo risk of hypoxic brain injury was defined as: (i) no out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation⁵⁴⁹; and (ii) no resuscitation or resuscitation lasting <10 min.⁵⁴⁶

^dThe choice of passive IABP or active percutaneous MCS should be based on the severity of cardiogenic shock as assessed by the Shock Team.

^eIn case of large ventricular septal defect, temporary MCS should be used with caution due to the potential increase of left-to-right interventricular shunt (VA-ECLS) or shunt inversion (microaxial flow pump). In case of ventricular free-wall rupture, temporary MCS should be avoided; however, VA-ECLS can be considered to allow emergent cardiac surgery in patients presenting with profound cardiogenic shock and/or cardiac arrest if no sign of irreversible brain injury is present.

7.5.12. Thromboembolism prophylaxis

Although patients with DHF are recognized as being at increased thromboembolic risk, no RCT has compared anticoagulation vs placebo in a DHF population, thus no definitive recommendation can be made.^{566–570} However, in case of immobilization or other risk factors, thromboembolic prophylaxis is generally indicated.

8. Advanced heart failure

8.1. Epidemiology, definition, prognosis, and referral

Many patients with HF progress into a phase of advanced HF (stage D), characterized by persistent severe symptoms and objective measures of cardiogenic impairment despite optimal therapy. In the Framingham population, 5.1%–7.7% of patients with HF had advanced HF.⁵⁷¹ Prognosis in medically treated patients with advanced HF remains poor with 1-year mortality >40%.^{572,573} Criteria for definition are reported in [Table 14](#).⁵⁷²

Table 14 Criteria for definition of advanced heart failure

All the following criteria must be present despite FMT, AMT, and GDIT:

1. Severe and persistent symptoms of HF (NYHA class III or IV).
2. Severe cardiac dysfunction defined by at least one of the following:
 - LVEF ≤30%
 - Isolated RV failure (e.g. ARVC)
 - Non-operable severe valve abnormalities
 - Non-operable severe congenital abnormalities
 - Persistently high (or increasing) BNP or NT-proBNP values and severe LV diastolic dysfunction or structural abnormalities (i.e. HFPeF,^a hypertrophic or restrictive cardiomyopathies).
3. Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics (or diuretic combinations) or malignant arrhythmias causing ≥2 unplanned visits or hospitalizations in the last 12 months, or ≥1 episode of low output requiring inotropes or vasoactive drugs.
4. Severe impairment of exercise capacity with inability to exercise, or low 6-min walk test distance (<300 m), or pVO₂ <12–14 mL/kg/min,^b or <50% predicted value, estimated to be of cardiac origin.

© ESC 2026

AMT, additional medical therapy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B-type natriuretic peptide; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFPeF, heart failure with preserved ejection fraction; i.v., intravenous; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pVO₂, peak oxygen consumption; RV, right ventricular.

^aSee [Table 10](#).

^bThe cut-off 12 mL/kg/min refers to patients on beta-blocker.

A severely reduced LVEF is common but not required for a diagnosis of advanced HF, as it may develop in patients with HFPeF or other structural abnormalities.

Early risk stratification and timely referral to an advanced HF centre are crucial to improve outcomes ([Figure 16](#)).^{574,575}

Systematic assessment for advanced HF using the ‘Rule of three’ or ‘I NEED HELP’ criteria is essential for timely referral to an advanced HF centre^{576–578} ([Figure 16](#) and [Table 15](#)).

Cardiopulmonary exercise testing and right heart catheterization (RHC) are key tools for risk stratification and eligibility assessment.^{579–582}

Women and sociocultural minority groups are less likely to receive MCS and heart transplantation for reasons not explained by medical factors or social determinants of health and deserve extra attention for timely referral and patient communication.^{583–585}




Figure 16 Triage and timely referral of patients with advanced heart failure. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; LVAD, left ventricular assist device; NYHA, New York Heart Association; QoL, quality of life. ^aLimited life expectancy may be due to major comorbidities, such as cancer, dementia, end-stage irreversible organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cognitive dysfunction, psychiatric disorder, or psychosocial issues. ^bRefer to [Table 15](#) for ‘Rule of three’ or ‘I NEED HELP’ criteria. ^cA centre performing LVAD implantation and/or heart transplantation.

Table 15 Criteria for high risk of advanced heart failure

Rule of three criteria (at least 1):
• HFH (≥2 or ≥1 requiring inotropes within the last year)
• Diuretic resistance
• Intolerance to neurohormonal drugs with onset of cardiorenal syndrome
I NEED HELP criteria (at least 1):
• Inotropes
• NYHA class III/IV or persistently high natriuretic peptides
• End-organ dysfunction (liver, kidney)
• EF <20% or poor RV function
• Defibrillator shocks
• HFH >1
• Escalating diuretics
• Low blood pressure, high heart rate
• Prognostic medication intolerance or the need to downtitrate

EF, ejection fraction; HFH, heart failure hospitalization; NYHA, New York Heart Association; RV, right ventricular.

An organizational model between centres with different levels of care complexity, based on a ‘Hub and Spoke’ network, is key to good patient management. A recent consensus document focuses on identifying and overcoming barriers to early referral to an advanced HF centre.⁵⁷⁴

Patients with contraindications to MCS or heart transplantation should receive palliative care (see [Section 11.6.2](#)).

Advance care planning should be discussed in all patients with advanced HF regardless of treatment strategy (see [Section 11](#)). Frailty, malnutrition, cardiac cachexia, and sarcopenia are highly prevalent in patients with advanced HF and are associated with a greater risk of death (see [Supplementary data online, Table S17](#) for detailed definitions).^{586–589} When evaluating frailty in patients with advanced HF, it is important to assess whether frailty is primarily due to the cardiac condition or other factors.⁵⁹⁰

Recommendation Table 11 – Recommendations for diagnosis and evaluation of advanced heart failure (see [Evidence Tables 70 and 71](#))

Recommendations	Class ^a	Level ^b
Early consultation with an advanced HF centre ^c is recommended in patients with advanced HF or at risk of advanced HF, who are motivated and do not have absolute contraindications for heart transplantation or durable MCS ^d , in order to evaluate candidacy. ^e 573,591	I	A
Cardiopulmonary exercise testing is recommended in patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS. 579,580,582	I	C

Continued

Right heart catheterization is recommended in patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.^{580–582}

I

C

© ESC 2026

HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support.

^aClass of recommendation.

^bLevel of evidence.

^cA centre performing LVAD implantation and/or heart transplantation.

^dEligibility criteria are reported in [Tables 16 and 17](#).

^eThis recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness.

8.2. Management

The indication and timing of advanced HF treatments are guided by patient goals, comorbidities, and clinical status. Pharmacological therapy and temporary MCS may be indicated until implantation of durable MCS or heart transplantation becomes available.⁵⁴³

The SCAI classification may be useful in identifying patients for temporary MCS as a possible bridge to advanced therapies ([Table 13](#)). The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles⁵⁹² describe clinical parameters and characteristics consistent with a need for advanced therapies ([Figures 17 and 18](#)).

8.2.1. Pharmacological therapy and kidney replacement therapy

Every effort should be made to reach target doses of FMT in all patients with HF. However, patients with advanced HF are under-represented in RCTs. Most patients with advanced HF reach a stage where dose reduction or cessation of neurohormonal therapy is necessary due to progressive intolerance. Although evidence is lacking, it is reasonable to perform individualized changes in FMT, and AMT if needed, on a patient-tailored basis. For example, in a patient with hypotension and high arrhythmic burden, the ACE-I dose can be reduced so that treatment with beta-blockers can be prioritized. However, in a patient with hypoperfusion and persistently low stroke volume despite therapy, reduction or cessation of beta-blockers may be the first step to maintaining cardiac output. In these cases, amiodarone may be better tolerated than beta-blockers when arrhythmias occur. Most importantly, any of these down-titrations should prompt contact with, or referral to, an advanced HF centre if there are no absolute contraindications for MCS or heart transplantation. AMT implementation should not delay early referral to advanced HF therapies.

In patients with signs of hypoperfusion, inotropes may improve haemodynamic parameters, augmenting cardiac output and aiding peripheral perfusion. They may also reduce congestion when the response to diuretic therapy is insufficient. Inotropic therapy is often used to assess reversibility of end-organ dysfunction in the screening phase for durable MCS or heart transplantation, or to maintain cardiac output until such therapies become available (see [Supplementary data online, Table S18](#)). Inotropes can be used as palliative therapy for the relief of symptoms in patients without other treatment options (see [Supplementary data online, Figure S2](#)).⁵⁹⁴

However, because inotropic therapy may exacerbate or induce myocardial ischaemia and/or tachyarrhythmias, it should

only be used in the lowest required dose and for as short a period as possible.^{595,596}

Kidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling the loop diuretic dose or concomitant administration of non-loop diuretics is indicated.²⁶⁵ However, in patients who fail to respond to diuretic-based strategies, kidney replacement therapies should be considered. Ultrafiltration and peritoneal dialysis are the most common approaches. It may be considered in those with diuretic resistance to treat volume overload, even if data about its effects on clinical outcomes are inconclusive.^{527,597}

Recommendation Table 12 – Recommendations for medical management of advanced heart failure (see [Evidence Tables 72 and 73](#))

Recommendations	Class ^a	Level ^b
Down-titration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms.	Ila	C
Continuous inotropes should be considered in patients with advanced HFrEF, low cardiac output, and evidence of hypoperfusion or end-organ dysfunction, as BTd, BTT or as bridge to durable MCS, to increase cardiac output and improve symptoms. ^{598,599}	Ila	C
Kidney replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure to improve symptoms. ⁶⁰⁰	Ila	C
Ultrafiltration may be considered in patients with refractory volume overload unresponsive to escalation of diuretic therapy to reduce the risk of rehospitalization. ⁶⁰¹	IIb	C

© ESC 2026

BTd, bridge to decision; BTT, bridge to transplantation; HFrEF, heart failure with reduced ejection fraction; MCS, mechanical circulatory support.

^aClass of recommendation.

^bLevel of evidence.

8.2.2. Mechanical circulatory support

Mechanical circulatory support can improve survival and symptoms of patients with advanced HF. The use of MCS should be considered for the different scenarios listed in [Supplementary data online, Table S19](#). Indications for temporary and durable MCS should be based on the SCAI classification ([Table 13, Section 7](#)) and INTERMACS profiles ([Figures 17 and 18](#)).

8.2.2.1. Temporary mechanical circulatory support

Temporary MCS devices are indicated in selected patients to reverse critical end-organ hypoperfusion and hypoxia in the setting of CS (see [Section 7](#)). The aim is to support cerebral and end-organ perfusion, reverse acidosis and multiorgan failure,




Figure 17 INTERMACS classification. ADLs, activities of daily living; CPET, cardiopulmonary exercise testing; HF, heart failure; i.v., intravenous; MCS, mechanical circulatory support; NYHA, New York Heart Association. The INTERMACS classification supports risk stratification and guides the timing of durable MCS or heart transplantation in patients with advanced HF.⁵⁹³ [Supplementary data online, Table S18](#) provides a definition for inotrope dependence.

and provide support until the patient's trajectory clarifies, whether towards myocardial recovery, transition to durable MCS or heart transplantation, or a palliative pathway. The care of patients on temporary MCS is complex and requires specialized expertise, including predefined strategies for withdrawal of support when there is no meaningful neurological and cardiac recovery. Temporary MCS should be considered in patients with INTERMACS profiles 1 or 2 as a bridge to decision, bridge to recovery, or bridge to either durable MCS or urgent heart transplantation ([Figure 18](#)).

8.2.2.2. Durable mechanical circulatory support

Durable MCS is indicated to prolong life and improve QoL in selected patients when FMT, and GDIT are insufficient or when temporary MCS has not led to cardiac recovery or clinical improvement ([Table 16](#)).^{602,603} Left ventricular assist device is by far the most common and reliable type of durable MCS; however, in cases with biventricular failure or special anatomical situations, a total artificial heart or implantable biventricular assist device is occasionally used.⁵⁸² Management of patients who are possible candidates for LVAD or heart transplantation is outlined in [Figure 18](#).




Figure 18 Treatment for advanced heart failure. ARVC, arrhythmogenic right ventricular cardiomyopathy; BTC, bridge to candidacy; BTR, bridge to recovery; BTT, bridge to transplantation; CA, cardiac amyloidosis; CMP, cardiomyopathy; DT, destination therapy; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFA, Heart Failure Association; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; MCS, mechanical circulatory support. The figure depicts a guidance for advanced HF treatment based on clinical profile. Colour code for classes of recommendation: green for Class of recommendation I and yellow for Class of recommendation IIa. This algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria, with exception of arrhythmic storm, and refractory angina. HCM, CA, other restrictive CMP, ARVC, and adult congenital heart disease are other exceptions. ^aTo be discussed with the Shock Team. ^bRecurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption <12–14 mL/kg/min or <50% of expected value (see [Table 16](#)).

Current 2-year survival rates in patients receiving the latest LVAD types are comparable to those after heart transplantation. Among patients with fully magnetically levitated continuous-flow LVADs, 2-year and 5-year survival rates were 79% and 58.4%, respectively, in the MOMENTUM 3 trial with a previous LVAD type as the control group.^{604,605} These rates are considerably higher than could be expected from medical treatment in this population with >85% of patients in INTERMACS 1–3 at the time of LVAD implantation.^{604,605} Comparable outcomes were described in European and North American real-world populations.^{606–608}

Adverse events may negatively affect QoL in patients receiving LVAD. Although pump thrombosis has become extremely rare, driveline infections remain similar to that with older devices.⁶⁰⁹ Right HF and arrhythmias may cause readmissions. Bleeding events can be minimized by avoiding antiplatelet therapy in addition to anticoagulation.⁶¹⁰ A guidance document is available to support non-LVAD specialist healthcare providers outside of the implanting centre.⁶⁰⁹

Although now dated, the REMATCH trial is the only RCT comparing an LVAD as destination therapy with optimal medical

Table 16 Indications and contraindications for implantation of a left ventricular assist device

Indications ^a
HF with severely reduced LVEF and one of the following:
INTERMACS 1–2 with neurological and other end-organ recovery but no cardiac recovery on temporary MCS OR
INTERMACS 2–4 OR
- Severe symptoms and signs (NYHA class III/IV; INTERMACS >4) despite optimal FMT and GDIT, and at least one of the following: - Unable to exercise due to HF or, if able to perform CPET, with pVO₂ <12–14 mL/kg/min and/or <50% predicted value. - End-organ dysfunction (worsening kidney and/or hepatic function, group 2 pulmonary hypertension, cardiac cachexia) due to reduced perfusion as indicated by cardiac index ≤2 L/min/m² despite euvolaemic or therapy-resistant hypervolaemic status. - Repeated HFH within the previous 12 months without an obvious precipitating cause.
Contraindications
Absolute:
- Severe right ventricular dysfunction despite euvolaemic status - Severe irreversible end-organ (kidney and/or liver) disease - Severe irreversible neurological disease - Severe pulmonary disease - Contraindication to long-term oral anticoagulation - Medical non-adherence and/or other psychosocial limitations - Insufficient social supports to achieve compliant care in the outpatient setting - Psychological instability that jeopardizes proper follow-up and intensive therapeutic regime after implantation
Relative:
- Obesity or malnutrition - Musculoskeletal disease that impairs rehabilitation - Malignancy (depending on type and prognosis) - Severe peripheral arterial disease - Systemic infection - Alcohol or substance abuse within the past 6 months, or active smoking - Impaired cognitive function - Frailty

CPET, cardiopulmonary exercise testing; HF, heart failure; HFH, heart failure hospitalization; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NYHA, New York Heart Association; pVO₂, peak oxygen consumption; RHC, right heart catheterization.
^aIndication by transplantation centre includes assessment of HF severity by RHC and/or CPET.

therapy in patients with advanced HF. REMATCH showed lower all-cause death with a previous type of LVAD therapy (HeartMate XVE) compared with medical treatment. However, mortality rates at 2 years were high in both arms.⁶¹¹ Other studies have not been randomized or compared different devices or post-implant strategies.^{604,606,607,610,612,613} Prospective RCTs have been initiated

to study strategies of early LVAD implantation vs prolonged medical treatment: Early-VAD (NCT02387112),⁶¹⁴ SweVAD,⁶¹⁵ AMBU-VAD (NCT04768322), and TEAM-HF (NCT06526195).

Histological examination of heart tissue after LVAD implantation or transplantation can identify potentially treatable or genetic causes of HF and is valuable for family screening and determining potential for myocardial recovery in LVAD patients.^{616–619}

Recommendation Table 13 – Recommendations for durable mechanical circulatory support in advanced heart failure (see [Evidence Table 74](#))

Recommendations	Class ^a	Level ^b
Durable MCS (LVAD) is recommended in selected ^c patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy to improve symptoms and reduce the risk of death. ^{604,611,613,620,621}	I	C
Histopathological examination of explanted heart tissue from LVAD or heart transplantation surgery should be considered in patients with non-ischaemic HF to identify an aetiological diagnosis that may be treatable or facilitate family screening. ^{616,618}	IIa	C

BTC, bridge to candidacy; BTR, bridge to recovery; BTT, bridge to transplantation; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; MCS, mechanical circulatory support.

^aClass of recommendation.
^bLevel of evidence.
^cEligibility criteria are reported in [Table 16](#).

8.2.3. Heart transplantation

Heart transplantation, although never evaluated in RCTs, remains the gold-standard treatment for advanced HF in the absence of contraindications. Post-transplant 1-year survival is 80%–90% and median survival is around 12.5 years.^{622,623} Transplantation significantly improves QoL and functional status. The main challenge after heart transplantation is the balance between efficacy and side effects of immunosuppression. Organ donor shortage remains the main limitation. Several countries have now started donation after circulatory death programmes, besides donation after brain death, with comparable mid-term results^{624,625} and, as a result, the numbers of heart transplantations have increased. Nevertheless, careful recipient selection remains essential, based on pre-transplant and post-transplant life expectancy (both influenced by pre-operative status and comorbidities). The main indications and contraindications for heart transplantation are listed in [Table 17](#).⁵⁸⁰

Although patients younger than 65 years of age might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age, and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered. The decision pathway to transplantation or LVAD is rarely straightforward and is unique to each patient.

Table 17 Indications and contraindications for heart transplantation

Indications ^a
Advanced HF and no other therapeutic option (except for durable MCS as BTT)
Absolute contraindications
Inability to comply with the therapeutic regimen (e.g. dementia)
Serious comorbidities with poor prognosis, not reversible with heart transplantation
Other contraindications
Active infection ^b
Severe peripheral arterial or cerebrovascular disease
Elevated pulmonary vascular resistance (if pharmacologically irreversible) ^c
Cancer ^d
Irreversible liver dysfunction (cirrhosis) or irreversible kidney dysfunction ^e
Systemic disease with multiorgan involvement
BMI >35 kg/m ² or severe cachexia
Alcohol or substance abuse or active smoking within the past 6 months
Psychological instability
Insufficient social support to achieve compliant care in the outpatient setting

© ESC 2026

BMI, body mass index; BTT, bridge to transplantation; CPET, cardiopulmonary exercise testing; HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support; RHC, right heart catheterization.

^aIndication by heart transplantation centre includes assessment of HF severity by RHC and/or CPET.

^bActive infection is a relative contraindication to transplantation, but infected LVAD may be an indication.

^cLVAD as bridge to candidacy should be considered.

^dHighly selected cases may be eligible, to be discussed with an oncologist.

^eCombined heart–liver or heart–kidney transplantation may be considered.

Eligibility for each option may change according to the specific conditions of each patient, which may also change over time. Some younger patients prefer to remain on LVAD for a prolonged period, rather than proceeding to transplantation immediately, to increase the potential number of life years gained. Other factors not related to the patient, such as average time on the heart transplantation waiting list, the centre's surgical experience, and resources, can also influence decision-making.

Recommendation Table 14 – Recommendations for heart transplantation (see [Evidence Tables 75 and 76](#))

Recommendation	Class ^a	Level ^b
Heart transplantation is recommended in selected ^c patients with advanced HF refractory to FMT and GDIT, and without contraindications, to improve QoL and survival. ^{622,626}	I	C

© ESC 2026

FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

^cEligibility criteria are reported in [Table 17](#).

8.2.4. Symptom control and end-of-life care

Advance care planning is recommended in parallel to advanced HF treatments to determine goals of care and improve QoL along the disease trajectory.⁶²⁷ For indications and the core components of end-of-life care, see [Supplementary data online, Table S20](#).

End-of-life care in advanced HF focuses on symptom management (including breathlessness, pain, and anxiety and depression), patient comfort, and maintaining QoL ensuring personalized, compassionate care. It involves clear communication, shared decision-making, and integrating palliative or hospice care to support both the patient and their family. For further details on symptom management, see [Supplementary data online, Section S5.2.3](#).

Patients on durable MCS may request withdrawal of life-sustaining treatments because these are no longer consistent with their goals of care, because of poor QoL or newly developed serious comorbidities such as cancer. The MCS may be deactivated after careful evaluation of the patient's wish and by, or under the supervision of, a specialized team. This decision has to take national laws into account. For details regarding follow-up in patients with advanced HF see [section 11.6.2](#) and [Recommendation Table 26](#).

9. Cardiovascular comorbidities

9.1. Arrhythmias and conduction disturbances

9.1.1. Atrial fibrillation

Heart failure and AF frequently coexist, with AF occurring in more than half of patients with HF, and HF occurring in more than one-third of patients with AF. The prevalence of AF is slightly higher in patients with HFpEF compared with HFrEF.^{195,628–631} The two conditions are deeply interrelated with shared risk factors and pathophysiological mechanisms. The coexistence of HF and AF is associated with a high risk of death, HFH, and stroke regardless of LVEF.^{195,628–631} HF induced by AF appears to have a more favourable outcome than HF causing AF.^{13,632}

The management of patients with HF and AF include identification of triggers, prevention of embolic events, management of HF, and rate or rhythm control of AF.

9.1.1.1. Identification of triggers and risk factor management

Precipitating factors for AF – e.g. hyperthyroidism, toxic agents (e.g. including alcohol), valvular heart diseases, infection, diabetes, uncontrolled hypertension, obesity, sleep disorders, and volume overload – should be routinely identified and appropriately managed. Diuretic therapy is indicated to relieve congestion and may increase the chances of restoring sinus rhythm by reducing filling pressures and ventricular rate.

9.1.1.2. Prevention of embolic events

Oral anticoagulation is recommended in patients with HF and AF to reduce the risk of thromboembolism, according to the CHA₂DS₂-VA score ([Table 18](#)).^{118,633–635} However, patients with HCM and CA are at higher risk of thromboembolism irrespective of CHA₂DS₂-VA score, and anticoagulation is recommended for all these patients with AF.^{636–642} In the absence of mechanical prosthetic heart valves and/or moderate

Table 18 Updated definitions for the CHA₂DS₂-VA score

	Description	Point
C	Chronic HF stage B, C, D	1
H	Hypertension	1
A	Age ≥75 years	2
D	Diabetes mellitus	1
S	Stroke/transient ischaemic attack/arterial thromboembolism	2
V	Vascular disease (CAD and/or PAD)	1
A	Age 65–74 years	1

© ESC 2026

CAD, coronary artery disease; CHA₂DS₂-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; PAD, peripheral artery disease.

A CHA₂DS₂-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation.

A CHA₂DS₂-VA score of 1 should be considered an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation.

or severe mitral stenosis, direct-acting oral anticoagulants are recommended as the anticoagulant of choice.^{643–646} Left atrial appendage closure can be an option for selected patients as described in the 2024 ESC Guidelines for the management of atrial fibrillation.^{118,647–651}

9.1.1.3. Management of heart failure and atrial fibrillation

All patients with coexisting HF and AF should be optimally treated with FMT, AMT, and GDIT regardless of AF (Section 6.2.4).⁴³⁵

In patients with AF and HFrEF, where there may be a high likelihood of LVEF recovery following rhythm control, evidence remains limited. However, given the well-established prognostic benefit of FMT on long-term prognosis in the general HFrEF population, initiation of FMT upfront seems reasonable.

There is ongoing debate regarding the optimal management of AF in patients with HF. Currently, there is insufficient evidence to support a rhythm-control strategy over a rate-control strategy.^{337,652–658} Decisions with regard to choice of strategy must be made taking into account the cause–effect relationship between AF and HF, along with clinical presentation, symptom burden, stage of disease, comorbidities, and patient preference.

9.1.1.4. Rate control

Data to support strict vs lenient rate control in patients with HF and AF are inconclusive. Analyses from a large observational registry showed a significant association between heart rate in AF and long-term death only in patients with HFrEF and heart rate >100 b.p.m.^{659,660} The RACE II trial demonstrated that lenient rate control (target heart rate <110 b.p.m.) was non-inferior to strict rate control (<80 b.p.m. at rest; <110 b.p.m. during exercise) in patients with permanent AF with a primary endpoint of death from CV causes, HFH, stroke, systemic embolism, bleeding, and life-threatening arrhythmic events.³⁰⁷ A post-hoc combined analysis from the AFFIRM and the RACE trials showed similar results.⁶⁶¹ However, these trials were not focused on HF and only a minority of patients included had HF.

A large observational study showed that a lenient rate-control strategy and poor rate control are associated with a higher risk

of death as compared with strict rate control in patients with AF and HF regardless of LVEF.⁶⁶² Lenient rate control, with resting heart rate <110 b.p.m., should be considered as initial target in both patients with and without HF, with re-evaluation based on symptoms.¹¹⁸

Beta-blockers have proven safety and efficacy in patients with AF and HFrEF and are recommended as the first-line approach.^{663,664} If the ventricular rate control is suboptimal with beta-blockers, or if beta-blockers are not tolerated, digoxin or diltiazem should be considered.^{665–667} In patients with HFrEF who are haemodynamically unstable, i.v. amiodarone or digoxin may be used to achieve acute control of heart rate and improve haemodynamics, although acute electrical cardioversion to restore sinus rhythm should be first choice.^{668–671} There is no evidence on pharmacological strategies for rate control in patients with AF and HFpEF.

Atrioventricular node ablation combined with CRT was found to be superior to pharmacological therapy in reducing death and HFH and improving QoL in patients with severely symptomatic permanent AF and HF, regardless of LVEF.^{672,673}

9.1.1.5. Rhythm control

The results of RCTs comparing catheter ablation vs pharmacological rhythm control in patients with HFrEF cannot be considered conclusive for hard outcomes on HFH and death, although catheter ablation has proven superior to antiarrhythmic treatment for AF recurrence.^{674–682} Data on the role of catheter ablation in HFpEF are limited.^{683,684} For a detailed description, see [Supplementary data online, Section S6.1.1](#).^{674–681,683–686} Based on current evidence, catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. This Task Force suggests that these criteria should be used to guide the selection of patients for catheter ablation: high burden AF,⁶⁸⁷ less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF.

In patients presenting with DHF, AF with rapid ventricular rates, and haemodynamic instability, urgent cardioversion is recommended. Pharmacological and electrical cardioversion seem to have similar outcomes, although specific studies in HF populations are lacking.^{688,689} Amiodarone is recommended in patients with HFrEF requiring pharmacological cardioversion. Other antiarrhythmic drugs, i.e. propafenone, flecainide, and dronedarone, are associated with poorer outcomes in HFrEF and should be avoided.^{690–694} There are no data on pharmacological cardioversion in HFpEF.

Recommendation Table 15 – Recommendations for management of atrial fibrillation in patients with heart failure (see [Evidence Tables 77–81](#))

Recommendations	Class ^a	Level ^b
Recommendations for anticoagulation		
Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk, as determined by CHA ₂ DS ₂ -VA score ^c , to prevent ischaemic stroke and thromboembolism. ⁶³⁵	I	A

Continued

DOACs are recommended in preference to VKAs in patients with HF ^d to prevent stroke and thromboembolism. ^{643–646}	I	B1
Rate control		
Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control. ^{663,665}	I	C
Digoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not tolerated, in order to obtain short- and long-term rate control. ^{665–667}	IIa	C
Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical limitations, recurrent HFH, and death. ^{672,673}	IIa	B1
Intravenous amiodarone or digoxin may be considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart rate. ^{668–671}	IIb	C
Cardioversion		
Urgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm. ^{669,671,692,695}	I	C
Atrial fibrillation catheter ablation		
Catheter ablation for AF should be considered in selected ^e patients with symptomatic AF and HFrEF to improve QoL and reduce the risk of HFH or death. ^{674–676,678,681,682,684,696}	IIa	C

© ESC 2026

AF, atrial fibrillation; CHA₂DS₂-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; CRT, cardiac resynchronization therapy; DHF, decompensated heart failure; DOAC, direct-acting oral anticoagulant; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life; VKA, vitamin K antagonist.

^aClass of recommendation.

^bLevel of evidence.

^cSee Table 18.

^dExcept for patients with moderate or severe mitral stenosis and in patients with mechanical prosthetic heart valves where VKAs are recommended.

^eAll the following criteria are required: high burden AF, less than 1-year duration for continuous persistent AF, clear cause–effect relationship between AF and HF.

9.1.2. Ventricular arrhythmias

Ventricular arrhythmias may cause HF or be a consequence thereof. In sustained ventricular tachycardia, initial management should include stabilization (electrical cardioversion), followed by identification and correction of precipitating factors, and optimization of FMT. Although amiodarone reduces ventricular arrhythmias, it does not reduce SCD or death.⁶⁹⁷ Patients with HF and resuscitated cardiac arrest or life-threatening ventricular arrhythmias have an indication for a secondary prevention ICD.¹¹⁹

Heart failure can occur because of frequent PVCs.⁶⁹⁸ A burden of PVCs of about 10% precipitates an increased risk of HF and the risk increases with higher burden.^{119,699–701} Thus, regular assessment of LVEF in this setting is indicated. Amiodarone may be considered to reduce recurrent arrhythmias and improve LV function,⁶⁹⁷ with regular follow-up to assess possible side effects. Catheter ablation of PVCs may improve LV function and, possibly, outcomes in patients with PVCs.^{702–705} For further details, please refer to the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.¹¹⁹

9.1.3. Bradyarrhythmias

Pacing indications in patients with HF do not differ from those without HF. However, long-term RV pacing can adversely impact LV function.⁷⁰⁶ In patients with HFrEF, where there is an expectation of high pacing requirements, i.e. complete heart block or AF with slow ventricular response, CRT implantation should be considered to improve outcomes (see Recommendation Table 7).⁴⁰⁹

9.2. Chronic coronary syndromes

Obstructive CAD is a frequent cause of HF.³³ Coronary microvascular dysfunction affects up to 80% of patients with HFpEF and seems to be associated with poor prognosis.^{707–709} Diagnostic work-up of chronic coronary syndromes in patients with HF is described in Section 5. Treatment of chronic coronary syndromes in patients with established HF is described below.

9.2.1. Medical therapy

Beta-blockers are recommended as first-line therapy in patients with HFrEF and CAD due to their prognostic effects, closely followed by other FMT drugs.^{288,290,291,710–712} Ivabradine should be considered in patients with HFrEF in sinus rhythm with heart rate >70 b.p.m. despite beta-blockers at the highest tolerated dose or if beta-blockers are contraindicated.^{294,713} Other medications such as amlodipine,⁷¹⁴ felodipine,⁷¹⁵ nicorandil,⁷¹⁶ and ranolazine⁷¹⁷ do not have effects on death but may improve symptoms. Trimetazidine may improve LV function and exercise capacity in patients with HFrEF and chronic coronary syndrome already on beta-blockers.^{718–720} Importantly, initiation and/or uptitration of antianginal therapy should not lead to reduction in FMT. Short-acting nitrates can cause hypotension and should be used with caution. Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) are not recommended in patients with HFrEF due to their negative inotropic effects which may precipitate the risk of HF events.⁷²¹ The use of beta-blockers or calcium channel blockers do not appear to be associated with worse outcomes in HFpEF.^{722,723} Treatment of patients with HFpEF should be similar to that of patients without HF (see the 2024 ESC Guidelines for the management of chronic coronary syndromes).¹⁰

9.2.2. Myocardial revascularization

Data to support the prognostic benefit of myocardial revascularization in patients with stable obstructive CAD and HF are limited. Two RCTs compared revascularization vs medical therapy in patients with LVEF ≤35% and multivessel coronary disease.^{178–180} The STICH trial compared coronary artery bypass grafting (CABG) to medical therapy and showed survival benefit

for CABG at long-term follow-up.^{179,180} The REVIVED-BCIS2 study compared percutaneous coronary intervention (PCI) and optimal medical therapy to optimal medical therapy alone and was neutral.¹⁷⁸ The patient populations differed between the two trials and patients in REVIVED-BCIS2 were 10 years older, making comparison between them difficult. For details of these results and other studies, see [Supplementary data online, Section S6.2.1](#).^{178,180,724–735}

Patients with HF and chronic coronary syndrome due to obstructive CAD must receive FMT before revascularization. A multidisciplinary Heart Team discussion including an HF specialist is recommended to decide whether conservative treatment or an invasive treatment strategy should be adopted. If

revascularization is planned, the multidisciplinary Heart Team should provide an individualized recommendation on the revascularization strategy—CABG or PCI—depending on patient characteristics. In case of persistent angina despite FMT for HF and antianginal drugs, revascularization is recommended regardless of LVEF. If the Heart Team agrees that revascularization is the best treatment option, in patients with HFrEF, LVEF $\leq 35\%$ and multivessel disease, CABG should be the first choice ([Figure 19](#)).

The Task Force recognizes an apparent discrepancy between the latter recommendation (class of recommendation IIa, level of evidence B1) and other recommendations in this context across other guidelines (e.g. *2024 ESC Guidelines for the management of chronic coronary syndromes*, class of recommendation I, level




Figure 19 Management of coronary artery disease in patients with heart failure. BB, beta-blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Colours refer to class of recommendation. ^aExclusion of frailty, severe and multiple comorbidities and limited life expectancy making the risk of revascularization higher than the expected benefit. ^bPCI or continued medical therapy are alternative treatments if the patient is not eligible for CABG.

of evidence B). However, the patient populations that were considered are slightly different in the chronic coronary syndrome guidelines (often patients with chronic coronary syndrome presenting with reduced LVEF) as compared to these guidelines (often patients with HFrEF presenting with CAD). In addition, according to the most recent system for level of evidence grading, proposed by the ESC, the Task Force considered STICHES, with all its limitations (mean age 60 years, limited number of events at 10 years, limited use of modern FMT), as the only possible study available to support the recommendation.¹⁸⁰

Recommendation Table 16 – Recommendations for revascularization in chronic coronary syndrome in patients with heart failure (see *Evidence Table 82*)

Recommendations	Class ^a	Level ^b
Revascularization for symptom improvement (HFpEF and HFrEF)		
Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and antianginal drugs, to relieve symptoms. ^{734,735}	I	C
Revascularization for outcome improvement (HFrEF)		
If revascularization is planned after assessment by a Heart Team, CABG should be considered as the preferred revascularization strategy, in patients with LVEF ≤35% and multivessel CAD suitable for surgery, to improve long-term survival. ¹⁸⁰	IIa	B1

CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.

^aClass of recommendation.

^bLevel of evidence.

9.3. Valvular heart disease

9.3.1. Aortic stenosis

Aortic stenosis can contribute to or cause HF by increasing LV afterload.⁷³⁶ Prevalence of aortic stenosis ranges between 3% and 7% in patients with chronic HF and is higher in patients with HFpEF as compared with those with HFrEF.⁷³⁷ About 50% of patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) have HF.⁷³⁸ Once HF symptoms develop, prognosis is poor and timely valve intervention is mandatory. HF therapies may be used cautiously and should not delay valve intervention. After valve intervention, a clinical and echocardiographic reassessment is important to detect residual HF or risk of HF readmission. In this regard, further optimization of FMT as well as treatment of comorbidities and management of procedure-related factors is appropriate.⁷³⁹ In the recent open-label DapaTAVI trial, 1222 patients with history of HF and at least one risk factor (diabetes, CKD, LV dysfunction) were randomly assigned to receive either dapagliflozin or standard of care. At 1-year follow-up, the risk of the primary endpoint (death from any cause or WHF events) was reduced by 28% in the treatment arm as compared with the

control arm, mainly driven by WHF events.⁷⁴⁰ Therefore, treatment with a SGLT2-I is reasonable in these patients.

Aortic valve intervention is recommended in all patients with HF and a life expectancy >1 year with high-gradient severe aortic stenosis, irrespective of LVEF, as well as in patients with severe low-flow low-gradient aortic stenosis and HFrEF. In patients with severe low-flow low-gradient aortic stenosis and HFpEF, aortic valve intervention should be considered. Details on diagnostic work-up, specific indications and the modality of intervention (TAVI vs surgery) are reported in the *2025 ESC/EACTS Guidelines for the management of valvular heart disease*.⁹

9.3.2. Aortic regurgitation

Severe aortic regurgitation can lead to LV dilatation and dysfunction which may progress to HF. Treatment with ACE-Is/ARNIs/ARBs/MRAs while awaiting aortic valve intervention can be beneficial.⁷⁴¹ Beta-blockers can prolong diastole and should be used only after careful consideration of risks and benefits.

Specific recommendations for intervention are reported in the *2025 ESC/EACTS Guidelines for the management of valvular heart disease*.⁹

9.3.3. Mitral regurgitation

9.3.3.1. Primary mitral regurgitation

Primary MR is caused by abnormalities of the valve apparatus and can lead to HF. In severe primary MR with HF symptoms, surgical repair is preferred over replacement whenever feasible.^{739,742,743} Mitral transcatheter edge-to-edge repair (TEER) should be considered in patients at high surgical risk.^{9,744,745}

9.3.3.2. Secondary mitral regurgitation

Secondary or functional MR is primarily a disease of the left cardiac chambers rather than the valvular apparatus. It is common in patients with HF, especially those with HFrEF in whom the disease has a prevalence of 25%.^{746,747} In order to adequately assess the severity of MR, the patient should be euvoelaemic or as close to euvoelaemia as possible. The underlying aetiology and severity of MR needs to be assessed by cardiologists specialized in echocardiography and structural heart diseases.⁷⁴⁸

A new classification, differentiating between atrial secondary MR and ventricular secondary MR has been recently proposed.⁹ Atrial secondary MR can be associated with HFpEF.⁷⁴⁹ Indications for mitral valve treatment in atrial secondary MR are reported in the *2025 ESC/EACTS Guidelines for the management of valvular heart disease*.⁹

In patients with severe ventricular secondary MR and HFrEF, optimization of FMT and GDIT with CRT implantation (if indicated) is mandatory before considering any mitral valve intervention (*Figure 20*). In case of concomitant CAD requiring revascularization, specific recommendations on management are reported in the *2025 ESC/EACTS Guidelines for the management of valvular heart disease*.⁹ In selected patients without need for coronary revascularization, TEER is recommended. *Table 19* provides the clinical and echocardiographic criteria for patient selection, which are based on inclusion criteria from RCTs. For the results of these studies, see *Supplementary data online, Section S6.3.1*.^{750–754} If the criteria reported in *Table 19* are not fulfilled, other options can be considered. Specifically, in




Figure 20 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; LVAD, left ventricular assist device; MR, mitral regurgitation; TEER, transcatheter edge-to-edge repair. Colours refer to class of recommendation. ^aSee Table 19. ^bSee Figure 10.

Table 19 Selection criteria for mitral transcatheter edge-to-edge repair in heart failure with reduced ejection fraction

Clinical and echocardiographic criteria
Optimized FMT and other GDIT (i.e. CRT) if needed
NYHA class $\geq$ II
At least one HFH within the last year
OR
Increased natriuretic peptide levels (BNP $\geq$ 300 pg/mL or NT-proBNP $\geq$ 1000 pg/mL)
No stage D (advanced) HF
No CAD requiring revascularization
No hypertrophic, restrictive, or infiltrative cardiomyopathies
LVEF 20%–50%
LVESD $\leq$ 70 mm
Anatomy deemed suitable for mitral TEER
sPAP $\leq$ 70 mmHg
No severe RV dysfunction
No severe aortic and/or tricuspid valve disease

BNP, B-type natriuretic peptide; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; TEER, transcatheter edge-to-edge repair; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; sPAP, systolic pulmonary artery pressure.

patients with advanced HF, LVAD or heart transplantation is recommended as first choice and TEER may be considered for symptom improvement in patients not suitable or waiting for these therapies (see Section 8) (Figure 20). Notably, patients with ventricular secondary MR experience a higher residual risk of death or HFH despite TEER.^{755,756} Thus, close follow-up in HF clinics is warranted.⁷⁵⁷

Recommendation Table 17 – Recommendations for valvular heart disease in patients with heart failure (see Evidence Tables 83 and 84)

Recommendations	Class ^a	Level ^b
Aortic stenosis		
Aortic valve intervention, SAVR or TAVI, is recommended in patients with severe aortic stenosis and HF ^c to improve symptoms and reduce the risk of death. ^{758–765}	I	B1
Secondary mitral regurgitation		
Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable, symptomatic patients with HFrEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil specific clinical and echocardiographic criteria, ^d in order to reduce the risk of HFH and improve QoL. ^{750–753}	I	B1
Mitral transcatheter edge-to-edge repair may be considered in selected symptomatic patients with HFpEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated (after excluding the option of LVAD or heart transplantation) who do not fulfil the clinical and echocardiographic criteria for outcome improvement, ^d in order to improve symptoms. ^{766–769}	IIb	C

CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; QoL, quality of life; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

^aClass of recommendation.

^bLevel of evidence.

^cThis recommendation refers to patients with severe high gradient aortic stenosis regardless of LVEF and to patients with low-flow low-gradient aortic stenosis and HFpEF. For details regarding low-flow low-gradient aortic stenosis in HFpEF, we refer to the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.⁹

^dFor clinical and echocardiographic criteria, see Table 19.

9.3.4. Tricuspid regurgitation

Severe TR has a high prevalence (9%–20%) in both patients with HFpEF and HFrEF.^{747,770}

Tricuspid regurgitation is currently classified as primary TR, CIED-related TR, and secondary TR. Secondary TR is most common.^{747,770} Medical therapy to target TR is limited.^{747,771} The development of transcatheter devices to treat TR provides an alternative to surgery in selected patients. Three RCTs are

currently available that investigated the role of transcatheter treatments in patients with severe symptomatic TR. They showed a significant benefit in terms of QoL in patients receiving device therapy as compared with those treated conservatively, but without reduction of death or HFH at 1-year follow-up.^{772–774} Recently, a possible benefit in terms of HFH was reported in patients treated with tricuspid TEER, but with a high rate of crossover after 1-year follow-up.^{775,776} It should be noted that all these studies were unblinded and did not focus on HFpEF or HFrEF populations.

Indications for TR treatment are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.⁹

9.4. Hypertension

Hypertension is common in patients with HF, especially those with HFpEF.^{454,777,778} In hypertensive heart disease, LV remodelling and LV hypertrophy lead to both diastolic and systolic impairment. Specific blood pressure targets for patients with hypertension and HF have not been evaluated in RCTs.

In patients presenting with HF due to refractory hypertension, secondary causes [i.e. primary aldosteronism, renovascular hypertension, and obstructive sleep apnoea (OSA)] should be ruled out and treated.⁶²

Indications for the treatment of hypertension in HF are reported in the 2024 ESC Guidelines for the management of elevated blood pressure and hypertension.⁶²

Lifestyle interventions, such as increasing physical activity, optimizing weight, reducing salt and alcohol intake, and smoking cessation, are beneficial in all cases.⁶²

The optimal treatment strategy for hypertension in patients with HFpEF is uncertain. FMT with effect on blood pressure (i.e. MRA) should be started, continued, or uptitrated. Loop diuretics reduce congestion and decrease blood pressure. In addition, ACE-Is, ARBs, and calcium channel blockers cause LV regression and therefore may be beneficial in both controlling blood pressure and improving HFpEF symptoms.⁶² Patients with HFpEF have limited preload reserve; therefore, normotension should be maintained and hypotension avoided.

In patients with HFrEF, treatment strategies are similar to those for normotensive patients, as FMT also lowers blood pressure. Once FMT has been initiated and uptitrated, suboptimal blood pressure control is rare in HFrEF. If additional agents are required, amlodipine or felodipine may be considered provided the patient is euvoelaemic.^{714,715} Alpha-blockers may be continued for the treatment of prostatic hyperplasia in the absence of hypotension but are not recommended for the treatment of hypertension in HFrEF. Non-dihydropyridine calcium channel blockers, e.g. verapamil and diltiazem, and central sympathetic agonists, e.g. moxonidine, are contraindicated due to poor outcomes in patients with HFrEF.⁷⁷⁹ In patients with HFrEF, asymptomatic hypotension should be accepted in order to maintain target doses of FMT.⁷⁸⁰

9.5. Stroke

Heart failure and stroke share common risk factors. Approximately 10%–24% of patients with ischaemic stroke have concomitant HF either *de novo* or pre-existing.^{781–784} Conversely, patients with HF have an increased risk of stroke compared with those without.⁷⁸⁵ A history of stroke is reported

in 8%–11% patients with HF^{785–789} with similar^{790–794} or increased^{795,796} prevalence in patients with HFpEF compared with HFrEF.

Poorer outcomes after stroke are observed in patients with HF with a 2.2–4.5 times higher rate of death compared with people without HF,^{782,783,797} as well as an increased rate of recurrent stroke.⁷⁹⁸

The risk of stroke in patients with HF seems independent of rhythm, with an annualized stroke risk of 2.0 per 100 patient-years in patients in sinus rhythm and 2.87 per 100 patient-years in patients with AF.^{799–802} However, RCTs failed to demonstrate a possible benefit of oral anticoagulation in patients with HFrEF in sinus rhythm.^{803–806} Thus, in the absence of AF, there is no evidence to recommend routine anticoagulation for stroke prevention in patients with HFrEF.

Optimization of blood pressure, heart rate, and cardiac output immediately after a stroke is key to reducing the risk of DHF and improving outcomes. In patients already established on FMT, treatment with FMT should be maintained if possible and attention should be paid to dose modification in order to avoid both hypo- and hypertension as well as rebound tachycardia in patients in whom beta-blockers have been withdrawn.⁸⁰⁷ Following the acute phase, treatment of HF in patients with stroke does not differ from treatment in patients without stroke.

10. Non-cardiovascular comorbidities

10.1. Obesity

Obesity contributes to the development of well-known CV and HF risk factors like hypertension, diabetes, and dyslipidaemia. Obesity has direct adverse effects on cardiac structure and function, and is associated with the development of CVD, including HF.⁸⁰⁸ Patients with HF and obesity may have lower natriuretic peptide concentrations due to increased expression of clearance receptors, augmented peptide degradation by the adipose tissue,¹⁵⁵ and underestimation of circulatory congestion.⁸⁰⁹ Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients, and an adjustment for lean body mass should be used for risk stratification pro-inflammatory.⁸¹⁰

A stronger association between obesity and HFpEF rather than HFrEF has been described.^{778,811} Among patients with HFpEF, the obesity-related phenotype has a high prevalence (30%–40% in Europe and 60%–70% in North America).^{314,812} These patients display several pathophysiological mechanisms that differ from non-obese patients with HFpEF.⁸¹³ An increase in adipocyte mass induces a state of systemic inflammation and a proinflammatory transformation of epicardial adipose tissue that may lead to fibrosis. The capacity of the left ventricle to dilate in response to an increase in blood volume is impaired, and thus, even modest degrees of volume overload may lead to cardiac overfilling and disproportionate increase in cardiac filling pressures.⁸¹⁴ On average, patients with HFpEF and obesity are younger, experience worse HF signs and symptoms, poorer QoL, and worse functional capacity, than those without obesity.^{815,816}

Weight-loss interventions in patients with HFpEF and obesity alleviate symptoms and may improve outcomes. Lifestyle interventions, such as caloric restriction, exercise, and patient education, have a significant impact on body weight and are recommended in all patients with HF.^{817,818} Recent RCTs

demonstrated favourable effects of the GLP-1 RA semaglutide and the dual GIP/GLP-1 RA tirzepatide in patients with HFpEF and obesity regardless of diabetes status, namely reduction of body weight, improvement of QoL, symptoms, and functional capacity (see [Supplementary data online, Section S7.1](#)).^{315–317} Pooled and secondary analyses of RCTs, and the recent SUMMIT trial, have also suggested a potential benefit of these drugs on HF events.^{317,819,820}

Dedicated RCTs are needed to evaluate safety and efficacy of these drugs in patients with HFpEF and to assess long-term follow-up.^{821,822}

In propensity score-matched cohort studies, bariatric surgery was associated with weight loss and a lower risk of all-cause and CV death, HFH, and AF as compared to medical therapy in patients with HF and a BMI ≥ 35 kg/m², with consistent benefits observed among patients with HFrEF and HFpEF.^{823,824}

Studies comparing bariatric surgery vs new anti-obesity medications are lacking, and the indications for bariatric surgery may change in the future.

Recommendation Table 18 – Recommendations for obesity in patients with heart failure (see Evidence Tables 85 and 86)

Recommendations	Class ^a	Level ^b
Semaglutide or tirzepatide should be considered for patients with symptomatic HF, LVEF $\geq 45\%$, and BMI ≥ 30 kg/m ² , regardless of diabetes status, to reduce body weight, and improve exercise capacity and QoL. ^{315–317,819,820,825}	Ila	B1
Bariatric surgery may be considered in obese patients with HF and a BMI ≥ 35 kg/m ² to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss. ^{823,824}	Ilb	C

BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

© ESC 2026

10.2. Diabetes

Patients with HF who have T2DM have a poorer prognosis than patients who do not have T2DM.^{826–828}

The diagnostic process and therapeutic approach to HF in patients with T2DM is the same as the population without T2DM. There is no evidence that the efficacy of FMT is altered by the presence of T2DM.^{241,829–833} ⁶⁰ The 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes dedicated a specific section to the treatment of diabetes in patients with HF.⁶⁰

Sodium–glucose co-transporter 2 inhibitors have been investigated in different populations with diabetes, ranging from patients with ASCVD or multiple ASCVD risk factors to patients with established HF across the entire range of LVEF or recently hospitalized for WHF, with greater absolute risk reduction of clinical events in patients at higher risk.⁸³⁴ Thus, the use of

SGLT2-Is is recommended in all patients with HF and T2DM, independently of glycated haemoglobin levels or other concomitant glucose-lowering agents. SGLT2-Is are generally well tolerated, although they may cause urinary infections and genital fungal infections as vulvovaginitis and balanitis with a prevalence of up to 6.9% in women and 4.8% in men. They are not indicated in patients with type 1 diabetes mellitus due to the risk of diabetic ketoacidosis (reported incidence of 2%–3%).^{835,836} Semaglutide or tirzepatide should be added if not contraindicated in patients with HFpEF and T2DM, especially if they are also obese.^{316,317}

Metformin, despite its long history as first-line treatment of T2DM, has no dedicated CV outcome trials to assess its safety or efficacy; observational studies reported a lower risk of death or HFH in patients with HF when compared with insulin and sulfonylureas.^{837–839} Metformin is not recommended in patients with an eGFR <30 mL/min/1.73 m² or hepatic impairment because of the risk of lactic acidosis.

In the context of T2DM, insulin glargine and insulin degludec have been evaluated in specific CV outcome trials, demonstrating a neutral effect on incident HF in patients with diabetes.^{840–842} In post-hoc analyses of RCTs and retrospective registries, use of insulin was associated with poorer outcomes among patients with HF. Thus, if insulin is needed in a patient with HF, patients should be monitored for WHF after initiation of treatment.^{843,844}

The dipeptidyl peptidase-4 inhibitor saxagliptin and thiazolidinediones (glitazones) have been associated with an approximately 30% increased risk of HFH and, thus, are contraindicated in patients with HF.^{845,846} No consistent data are available for the use of sulphonylureas in patients with HF.⁶⁰

10.3. Chronic kidney disease

Chronic kidney disease and HF frequently coexist.⁸⁴⁷ They share common risk factors and may develop simultaneously. CKD may lead to worsening of cardiac function and vice versa. The incidence of CKD is five-fold higher in patients with HF as compared with those without.⁸⁴⁸ About 30%–40% of individuals with chronic HF have CKD, with the highest proportions, up to 50%, in HFpEF.^{778,849,850} CKD is a major independent determinant of increased mortality and morbidity in HF.⁸⁵⁰ Albuminuria and low GFR are independently associated with an increased risk of major ASCVD, HF events, and CV death.^{61,851–854} The presence of CKD might have an impact on FMT optimization, and it is often cited as a reason for FMT under-utilization in clinical practice.⁸⁵⁵ Even in most patients with CKD the initiation of beta-blockers, ACE-Is/ARNIs/ARBs, SGLT2-Is, and MRAs is recommended.¹⁶⁴

Several RCTs have shown that patients with HF and concomitant CKD are at higher risk of events as compared to those without CKD. However, no interaction between drug effects and kidney function was noted in subgroup analyses of these trials.^{242–245,309} Furthermore, the beneficial effects of FMT are similar, or even higher, irrespective of CKD.^{251,252,847,856–858}

An evidence gap remains for the treatment of HF in patients with severe CKD as these patients were generally excluded from RCTs.

Worsening kidney function in patients with chronic HF is not necessarily associated with worse outcomes. For example, after initiation of ACE-Is/ARNIs/ARBs, MRAs or SGLT2-Is, an initial decrease in the glomerular filtration pressure may decrease GFR and increase serum creatinine. These changes are generally transient and occur despite improvement in patient outcomes and may delay long term deterioration of kidney function.^{243,250–253} Sacubitril-valsartan, compared with enalapril, led to a slower decline in kidney function, despite a slight increase in the UACR, and improved CV outcomes to a similar extent in patients with CKD vs other patients in the PARADIGM-HF trial.²⁷⁹ In a participant-level pooled analysis of the DAPA-HF and DELIVER trials, patients experiencing worsening of eGFR to <25 mL/min/1.73 m² were at heightened risk for development of subsequent CV events. Continuation of dapagliflozin was associated with lower rates of the primary composite outcome.⁸⁵⁹

A prespecified secondary analysis of the FINEARTS-HF trial, in patients with HF and LVEF ≥40%, reported an acute decline in eGFR of −2.9 mL/min/1.73 m² (95% CI −3.4 to −2.4) during the first 3 months on finerenone vs placebo.⁸⁶⁰ However, finerenone still reduced the risk of new-onset micro- and macroalbuminuria by 24% and 38%, respectively.⁸⁶⁰

Thus, a transient decrease in kidney function after the initiation of ACE-Is/ARNIs/ARBs and MRAs or SGLT2-Is should not prompt their interruption. An increase in serum creatinine of <50% above baseline, as long as eGFR remains >15 mL/min/1.73 m², is considered acceptable.

Notably, in patients with HFpEF, semaglutide and tirzepatide may acutely reduce eGFR; however, they exhibit a long-term protective effect on kidney function.^{861,862}

Chronic kidney disease is highly prevalent in patients with DHF. Worsening or improvement of kidney function occurs commonly, affecting about 30%–50% of patients admitted with HF.²⁷³ Adverse CV outcomes are observed in patients with worsening kidney function and poor diuretic response, but not in patients with good diuretic response.^{506,863}

Data from the STRONG-HF trial showed that a decrease in eGFR within 1 week after discharge was associated with more evidence of congestion and with an increased incidence of HF readmissions.⁸⁶⁴ Conversely, worsening kidney function is not associated with poor outcomes in the context of successful decongestion.^{506,863} For further details refer to the 2026 ESC Guidelines on cardiovascular disease and chronic kidney disease.¹²²

10.4. Iron deficiency and anaemia

Iron deficiency and anaemia are common in patients with HF and are associated with reduced functional capacity, and worse QoL and prognosis independently of each other.^{778,865–868} Iron deficiency is slightly more prevalent in patients with HFpEF than in patients with HFrEF.^{865,869}

In patients with HF, ID has been defined as either ferritin <100 ng/mL, or ferritin 100–299 ng/mL with TSAT <20%. This definition has been adopted by the 2021 *ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure*³ and the 2023 *Focused Update of the 2021 ESC Guidelines for the*

diagnosis and treatment of acute and chronic heart failure,⁵ and has been used in almost all recent trials assessing the effects of i.v. iron supplementation in patients with HF and ID. However, it has recently been recognized that in patients with HF this definition does not reliably identify patients with absolute or functional ID. The current definition of ID may include patients with TSATs ($\geq 20\%$) and serum ferritin levels (20–100 mg/L) in the normal range, who are probably not iron deficient, exhibit a better prognosis, and might not respond to i.v. iron therapy.⁸⁷⁰ Moreover, serum ferritin levels are highly sensitive to inflammation and oxidative stress. Thus, an alternative definition of ID—TSAT $< 20\%$ —has been proposed, mainly based on evidence from explorative analyses and meta-analyses of RCTs. A TSAT $< 20\%$ has higher sensitivity and specificity compared with the previous definition of ID and is associated with higher mortality rates, independently of HF phenotype.^{869–871} Moreover, some meta-analyses of large RCTs reported that lower TSAT values better identify patients that will respond favourably to i.v. iron supplementation.^{872–874} The Task Force supports the use of this most recent definition of ID in patients with HF and recognizes the need for new trials investigating the efficacy of i.v. iron supplementation in patients with HF and ID as defined by TSAT $< 20\%$.

Several trials, including AFFIRM-AHF,⁴⁹⁶ CONFIRM-HF,⁸⁷⁵ FAIR-HF,^{876,877} EFFECT-HF,⁸⁷⁸ and IRONMAN⁸⁷⁹ (where ID was defined as either ferritin < 100 ng/mL, or ferritin 100–299 ng/mL with TSAT $< 20\%$), have demonstrated that iron supplementation with i.v. ferric carboxymaltose is safe and effective in improving symptoms and QoL in patients with HF and LVEF $< 40\%$ – 45% .

Thus, i.v. iron supplementation is recommended in patients with symptomatic HFrEF and ID to alleviate HF symptoms and improve QoL. Data in patients with HFpEF are scarce.⁸⁸⁰

The prognostic benefit of i.v. iron supplementation in patients with HF has been investigated in several RCTs and meta-analyses (see [Supplementary data online, Section S7.2](#)).^{496,872,873,879,881–886} Given the conflicting results of major RCTs, the position of the Task Force is that evidence regarding the benefits of i.v. iron supplementation on strong endpoints is not conclusive. This is primarily due to the use of the old definition of ID as an enrolment criterion in almost all trials, the heterogeneity of RCTs in terms of enrolled populations as well as of i.v. iron doses and timing of administration and that some major RCTs were affected by the coronavirus disease 2019 pandemic. Thus, i.v. iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in patients with symptomatic HFrEF and ID to reduce the risk of HFH, taking into account that patients with TSAT $< 20\%$ might benefit most. Further trials using TSAT $< 20\%$, or other criteria that do not rely on ferritin levels as inclusion criteria, are warranted.

In patients with HFrEF and mild to moderate anaemia enrolled in the RED-HF trial,⁸⁸⁷ darbepoetin-alpha failed to reduce all-cause death or HFH and showed an increased risk of thromboembolic events. Thus, erythropoietin-stimulating agents should be avoided for the treatment of anaemia related to HF.

Recommendation Table 19 – Recommendations for iron deficiency in patients with heart failure (see [Evidence Tables 87 and 88](#))

Recommendations	Class ^a	Level ^b
Intravenous iron supplementation is recommended in patients with symptomatic HFrEF and iron deficiency to alleviate HF symptoms and improve QoL. ^{875–879}	I	B1
Intravenous iron supplementation should be considered in patients with symptomatic HFrEF and iron deficiency to reduce the risk of HFH. ^{872–874,879,881,885,886,888}	IIa	B1

© ESC 2026

HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

10.5. Cancer

In patients with cancer, HF may occur as a result of the interactions between cancer therapy, cancer itself, and/or patients' CV backgrounds (risk factors and coexisting CVD). Current cancer treatments may cause HF through direct cardiotoxic effects, or indirectly, favouring the occurrence of pathological conditions predisposing to HF, such as volume overload from i.v. infusions and corticosteroids, myocarditis, myocardial ischaemia, systemic or pulmonary hypertension, thromboembolism, arrhythmias, or valve disease.^{6,889,890}

The definition of symptomatic and asymptomatic cancer therapy-related cardiac dysfunction is reported in [Supplementary data online, Table S21](#). Cancer drugs causing HF are reported in [Supplementary data online, Table S22](#).

In patients who develop symptomatic HF during cancer therapy, FMT is recommended, regardless of LVEF.⁶ Discontinuation vs continuation of cardiotoxic drugs should be discussed by a multi-disciplinary team. Severity of cancer therapy-related cardiac dysfunction guides the decision.^{6,891} Initiation of FMT for HFrEF is recommended in patients with asymptomatic moderate-to-severe cancer therapy-related cardiac dysfunction and should be considered in asymptomatic patients with mild presentations.

For details regarding CV toxicity risk assessment process, diagnostic work-up, follow-up procedures, and therapeutic management of cardiotoxicity, we refer to the 2022 ESC Guidelines on cardio-oncology.⁶

10.6. Lung disease and sleep-disordered breathing

Chronic obstructive pulmonary disease is common among patients with HF.^{892–894} Due to the overlap in symptoms and signs, the differentiation between HF and COPD may be difficult.⁸⁹⁵

Chronic obstructive pulmonary disease significantly impacts on symptoms and QoL, has been associated with HF undertreatment, and negatively influences prognosis of HF.^{893,896}

Treatment of HF is generally well tolerated in COPD. The use of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or nebivolol) should be preferred. In patients with asthma,

these medications require more caution and should be started at low doses after consideration of the risks and benefits, with close monitoring for signs of airway obstruction, and appropriate supervision.⁸⁹⁷ Chronic obstructive pulmonary disease exacerbations should not be a cause of beta-blocker discontinuation.⁸⁹⁸ Inhaled corticosteroids and beta-adrenergic agonists have not been specifically studied in patients with HF; however, they do not seem to increase CV risk.^{899,900} In addition, appropriate management of COPD can improve cardiac function.⁹⁰¹

Sleep-disordered breathing is found in over one-third of patients with HF and is even more prevalent in DHF. Sleep-disordered breathing includes OSA, central sleep apnoea (CSA), and mixed disease. SDB negatively impacts disease progression and prognosis.^{902,903} Patients with a suspicion of SDB should be referred for overnight polysomnography to definitively diagnose SDB, and to document the predominant type of sleep apnoea (central vs obstructive).⁹⁰² The therapeutic approach to SDB includes the correction of underlying causes, when identified.

The use of adaptive servo-ventilation (ASV) in patients with HFrEF and predominantly CSA is not recommended, based on the results of the SERVE-HF trial,⁹⁰⁴ which showed an increase in both all-cause and CV death in patients with chronic HF, LVEF ≤45%, and SDB with predominant CSA.⁹⁰⁴

The ADVENT-HF trial randomized 731 patients with HF, LVEF ≤45%, and coexisting SDB, mostly OSA (73%) to standard optimal treatment alone or standard optimal treatment and ASV (1:1). Over a mean follow-up period of 3.6 years, ASV had a neutral effect on the primary composite outcome (the cumulative incidence of all-cause death, first CV hospitalization, new-onset AF/flutter, and delivery of an appropriate ICD shock).⁹⁰⁵ However, ASV improved sleep quality and structure, health-related QoL, and symptoms of patients with SDB.⁹⁰⁵

Thus, in patients with SDB and predominant OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure (CPAP), bilevel positive airway pressure, and ASV.

When SDB is caused by CSA, implantable phrenic nerve stimulation was found to be safe and effective in reducing the apnoea-hypopnoea index in a small RCT.^{906–908}

Recommendation Table 20 – Recommendations for lung disease and sleep-disordered breathing (see [Evidence Table 89](#))

Recommendations	Class ^a	Level ^b
Adaptive servo-ventilation may be considered in patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep apnoea to improve sleep quality, health-related QoL and symptoms. ⁹⁰⁵	IIb	C
Adaptive servo-ventilation is not recommended in patients with HFrEF and sleep-disordered breathing with predominant central sleep apnoea because of an increased risk of CV and all-cause death. ⁹⁰⁴	III	A

CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

10.7. Anxiety, depression, and cognitive impairment

Anxiety and depression are common findings in patients affected by chronic and disabling conditions, such as HF, and need to be promptly identified to minimize psychological distress and its negative consequences.⁹⁰⁹ Depression affects 20% of patients with HF, and it may affect adherence to FMT. Its prevalence is higher in women, and it is associated with worse clinical status and poorer prognosis.^{910–912}

The diagnosis of depression typically relies on standardized questionnaires and clinical interviews. Symptom overlap between HF and depression can complicate diagnosis, as both conditions may present with cognitive issues (e.g. difficulty concentrating) and physical symptoms (e.g. fatigue). Several validated questionnaires are available for screening clinically significant depressive symptoms⁹¹¹ (see [Supplementary data online, Section S7.4, Table S23](#)).

Cognitive impairment in these patients has been reported.^{911,913} However, there is still no consensus on the best therapy for patients with HF and depression.

Cognitive behavioural therapy has demonstrated significant favourable long-term (4–9 months) reduction of anxiety and depression and improvement in QoL compared with non-treated patients.^{914,915} The safety of sertraline and escitalopram has been demonstrated, although without a significant reduction in depression compared with placebo.^{916,917} Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, WHF, and arrhythmias.^{911,912}

10.8. Frailty

Frailty is defined as a multidimensional, dynamic, and potentially reversible state, related to, but independent of, age, that makes individuals more vulnerable to the effects of stressors and at increased risk of poor outcomes. A score assessing frailty including four domains (clinical, functional, psychocognitive, and social) has recently been proposed.⁹¹⁸

The presence of frailty might have an impact on disease management and is associated with higher rates of death and hospitalizations, and reduced health-related QoL, regardless of which tool was used to assess frailty.^{919–923} In patients with HF, frailty is particularly prevalent in older adults. When frailty is suspected or identified, a multidisciplinary approach to facilitate an individualized management is warranted.^{918,922,924}

Recommendation Table 21 – Recommendations for anxiety, depression, and frailty (see [Evidence Tables 90 and 91](#))

Recommendation	Class ^a	Level ^b
Assessment of anxiety, depression and frailty should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes. ^{909,914,915,920,923}	IIa	C

HF, heart failure.

^aClass of recommendation.

^bLevel of evidence.

10.9. Other non-cardiovascular comorbidities

Infections may cause WHF and can precipitate HFH.^{925,926} Infections should ideally be prevented or, if present, promptly recognized and treated to avoid disease progression.^{927–930}

Influenza vaccination is associated with a reduced risk of pneumonia and all-cause death in patients with HF.^{931–936} Thus, influenza and pneumococcal vaccination should be considered in all patients with HF in order to reduce the risk of infection-related complications.⁹³⁵

Thyroid dysfunction can cause changes in cardiac function and structure and may precipitate DHF.^{937,938} Assessment of thyroid function is recommended in patients with *de novo* HF or DHF and should be regularly assessed during follow-up of patients with HF. Treatment of thyroid dysfunction should be guided by endocrine guidelines.^{939–942}

Hyperuricaemia and consequent gout attacks can be frequent in patients with HF, mainly caused or precipitated by diuretic treatment.^{943,944} Allopurinol is recommended as the first choice to chronically reduce uric acid levels in patients with HF,⁹⁴⁵ whereas colchicine can be used for acute gout attacks. Non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors are not recommended in patients with HF because they may precipitate decompensation and worsen kidney function.^{942,946–948}

Heart failure and erectile dysfunction frequently coexist.^{949,950} Cardiosselective beta-blockers should be preferred in patients with HF and erectile dysfunction, mainly bisoprolol and nebivolol, started at the lowest doses.⁸⁹⁷ In the presence of erectile dysfunction symptoms, phosphodiesterase-V inhibitors are generally safe and can be considered in patients who are compensated,⁹⁵¹ avoiding their concomitant use with nitrates.⁹⁵²

Recommendation Table 22 – Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93)

Recommendations	Class ^a	Level ^b
Influenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications, hospitalization, and death. ^{931–934,936,953,954}	IIa	C
NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and HFH. ^{942,946–948}	III	B2

COX-2, cyclooxygenase-2; HF, heart failure; HFH, heart failure hospitalization; NSAID, non-steroidal anti-inflammatory drug.

^aClass of recommendation.

^bLevel of evidence.

11. Multidisciplinary team management, long-term follow-up, and patient care

11.1. Multidisciplinary management of heart failure

Multidisciplinary care for HF combines the expertise of various professionals to provide integrated, patient-centred care that

improves both clinical outcomes and QoL for patients (Figure 21).

Access to healthcare professionals with awareness of HF and expertise in its diagnosis and management is essential for early detection and better outcomes. Multidisciplinary HF care involves generalist and specialist healthcare professionals,⁹⁵⁵ including cardiologists, cardiothoracic surgeons, specialist nurses, pharmacists, and physiologists (Figure 21) (see Supplementary data online, Section S8.1).^{17,956–963}

Management by an HF multidisciplinary team (HF-MDT) across outpatient and inpatient settings improves outcomes for people with HF.^{962,964–967}

The literature evaluates various methods of delivering HF management programmes enabling local HF services to design services tailored to their HF-MDT and the structure of their healthcare system. A meta-analysis of 16 RCTs with 3999 eligible patients evaluating the benefits of multidisciplinary HF clinics compared with usual care demonstrated a reduction in HFH.⁹⁶⁷ A meta-analysis of eight RCTs with 1764 patients indicated that multidisciplinary teams may have the potential to reduce death, although a definitive RCT is needed.⁹⁶⁴ The benefits were more evident in patients with a recent emergency department presentation or HFH.⁹⁶⁶ Other methods of delivery, including home visits and transitional care models, are given in Supplementary data online, Section S8.1.^{145,962,965,968–972}

Healthcare professionals involved in the management of HF, whether specialist or generalist, should be equipped with the knowledge required to effectively assess and manage HF through appropriate education and training.^{958,973,974} Malnutrition has been associated with worse prognosis in patients with HF.⁷³⁸ Thus, nutritional assessment and dietary interventions can be useful.^{588,589} No evidence supports fluid restriction in chronic HF.^{975,976}

Recommendation Table 23 – Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96)

Recommendations	Class ^a	Level ^b
A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and death. ^{964–967}	I	B1
HF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death. ⁹⁷⁷	I	A
Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death. ^{978–981}	I	B2

HF, heart failure; HFH, heart failure hospitalization.

^aClass of recommendation.

^bLevel of evidence.




Figure 21 Core members of the heart failure team with expanded team members depending on patient needs and local availability. AP, allied professional; EP, electrophysiology; HF, heart failure.

11.2. Patient education, self-care, and lifestyle advice

Education, self-care, and lifestyle advice empower patients and their caregivers in managing HF and engage in shared decision-making. Self-care incorporates education and strategies to support maintenance, monitoring, and management of HF.⁹⁷³ The aim is to ensure people with HF and their caregivers are equipped with knowledge and skills and be partners in their care and not simply recipients of information and treatments. The benefits of self-care are described in a meta-analysis of 20 RCTs including 5624 patients.⁹⁷⁷ Self-management interventions on the background of usual HF care improved QoL and reduced time to HFH or all-cause death. There may be some barriers to self-care, but these can be overcome by careful design of programmes^{982,983} (see [Supplementary data online, Section S8.2](#)).

Effective self-care enhances QoL, reduces symptom severity, and lowers the risk of hospitalization. It is essential that HF professionals collaborate with patients and caregivers, using shared decision-making to develop personalized self-care plans ([Supplementary data online, Table S24](#)).

11.3. Implementation and adherence to therapy

11.3.1. Implementation and optimization

Implementation of HF therapies should be individualized, based on available evidence, and involve the HF-MDT and patients and caregivers. Yet, there remain delays to implementation and optimization of treatments.^{984–986} Multivariable adjusted large observational studies suggest that among the strongest factors associated with improved FMT, AMT, and GDIT use is access to cardiologist specialists.^{987–990} For barriers and facilitators to improved implementation of HF therapies, including clinical inertia, impact of race, ethnicity, gender, and health literacy, see [Supplementary data online, Table S25](#).

Evidence supports the role of HF nurses and pharmacists in the implementation and optimization of HF therapies and avoidance of unnecessary side effects of polypharmacy.^{991–994}

Pharmacists play a key role in ensuring safe and effective use of medicines, including medication reconciliation and the optimization of therapies for comorbidities. Development of the HF-MDT to support the implementation and optimization of HF and to address the barriers that exist is key to improving outcomes for patients.

11.3.2. Long-term adherence

Adherence to self-care strategies and therapies is essential to control symptoms, limit disease progression, and reduce hospitalization and death.⁹⁸¹ Factors that impact adherence and affect clinical outcomes include health literacy, polypharmacy, and managing multiple health conditions.^{978,979,995} Strategies to improve adherence in the context of HF have been described elsewhere and provide guidance on the use of education tailored to the individual, communication skills, polypharmacy review, and co-ordinated care.^{980,996} Central to these is the importance of the HF-MDT recognizing the barriers to adherence, assessing those barriers, and utilizing other members of the health and social care team to address them.

11.4. Exercise training and cardiac rehabilitation

11.4.1. Benefits of exercise training according to heart failure stage and phenotype

There is consistent evidence that exercise training improves exercise tolerance and health-related QoL in patients with HF.⁹⁴ HF-ACTION was the largest RCT on exercise training in HF including 2331 patients with LVEF $\leq 35\%$ (NYHA classes II–IV). Compared with usual care, supervised exercise training plus usual care showed modest, non-significant reductions in all-cause death and hospitalizations. However, prespecified adjustments revealed significant reductions in CV death and HFH.⁹⁹⁷ A systematic review of 60 trials with 8728 patients (mean age 63 years, mean LVEF 32%) confirmed improvements in functional capacity, QoL, and reductions in HFH with exercise training but found no reduction in death.⁹⁹⁸ Similar findings were reported by another systematic review focusing on HFrEF (LVEF $< 40\%$).^{94,999}

In HFpEF, exercise training is safe and significantly enhances exercise capacity and QoL, with no significant impact on diastolic function, arterial stiffness, or vascular function, and insufficient data exist to assess its impact on clinical events, such as death and hospital admissions, due to small sample sizes and short follow-up times.^{1000,1001}

Most trials in HF, except for HF-ACTION, are too small to reliably evaluate the effects of exercise rehabilitation across subgroups (see [Supplementary data online, Section S8.4](#)).^{1002,1003}

In patients with long-term mechanical support, the benefit of exercise training on functional capacity has been demonstrated.^{1004,1005} The Rehab-VAD trial showed that moderate intensity aerobic training was safe in patients with continuous-flow LVADs and yielded significantly improved health status, treadmill time, and leg strength, without significant improvements in peak oxygen consumption.¹⁰⁰⁶ If a patient with advanced HF can tolerate physical activity, exercise training can improve QoL.¹⁰⁰⁷ Exercise training before and after heart transplantation should follow recommendations according to the consensus document.¹⁰⁰⁸

11.4.2. Safety and contraindications

No major adverse effects of exercise training were reported in the included studies of above systematic reviews and meta-analyses.^{1001,1009} However, exercise interventions should only be initiated in stable individuals after initiation of FMT.

Exercise training is contraindicated in patients with refractory/unstable angina and other high-risk CV conditions (e.g. high-grade arrhythmias, DHF, active thromboembolic disease) and in any other unstable non-cardiac condition (e.g. active infection, uncontrolled diabetes, end-stage cancer, COPD exacerbation).⁹⁴

11.4.3. Exercise prescription

A personalized training programme, with the mode of delivery, type, and intensity tailored to the patient's preferences, risk level, and comorbidities, is recommended to improve uptake of exercise-based cardiac rehabilitation. Exercise training should be started as part of cardiac rehabilitation and be individually prescribed according to the FITT model (frequency, intensity,

time, type) for aerobic training, resistance training, and inspiratory muscle training^{1010,1011} (see [Supplementary data online, Section S8.4](#)).^{998,1012–1016}

Adherence to the prescribed exercise regimen is crucial (see [Supplementary data online, Section S8.4](#)).^{1017–1020}

Recommendation Table 24 – Recommendations for exercise training and cardiac rehabilitation (see [Evidence Tables 97–99](#))

Recommendations	Class ^a	Level ^b
Personalized exercise training, in the context of multidisciplinary exercise-based cardiac rehabilitation, is recommended for all stable patients, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization. ¹⁰²¹	I	B1
Personalized exercise training outside exercise-based cardiac rehabilitation is recommended for all stable patients on a long-term basis, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization. ¹⁰²²	I	B2
Cardiac rehabilitation ^c is recommended in patients with an LVAD to improve functional capacity and QoL. ^{1005,1023}	I	B1
Cardiac rehabilitation ^c should be considered in patients with DHF, as soon as safely possible, to improve functional capacity and QoL. ^{1002,1024–1026}	IIa	B1

© ESC 2026

DHF, decompensated heart failure; LVAD, left ventricular assist device; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

^cEither comprehensive or exercise-based.

11.5. Telemonitoring

Advances in digital technology and telemonitoring have, in recent years, contributed substantially to the transformation of (remote) care delivery, from a hospital-centred approach to a patient-oriented approach. Telemonitoring can involve non-invasive and invasive monitoring modalities. Non-invasive telemonitoring relies on traditional vital parameters measured remotely (e.g. weight, heart rate, and blood pressure), which can be used to guide patients remotely to adjust therapy or seek advice either through telephone consultations or eHealth-based environments. Recent systematic reviews and meta-analyses report significant reductions in all-cause death and HFH with non-invasive telemonitoring.^{1027–1029} However, despite a growing body of evidence, results from individual trials are inconsistent and limited mainly by considerable heterogeneity in terms of patient population, modality, and intervention (see [Supplementary data online, Section S8.5](#)).^{1027–1031} At present, non-invasive telemonitoring may be considered for patients with HF in order to reduce the risk of HFH.

Device-based monitoring modalities (pacemaker/ICD/CRT) based upon thoracic impedance, heart sounds, and breathing patterns, aim to assist in the selection between stable patients and those that need rapid access to care.^{1032,1033} Many implanted devices can provide remote information either on the device itself (generator and lead function), arrhythmias, or on patient physiology (heart rate, heart sounds, bio-impedance). There is evidence that monitoring can detect device malfunction/integrity and that it may be useful for detecting arrhythmias. However, there is currently little evidence that device monitoring improves clinical outcomes, although ongoing RCTs are awaited.^{1029,1033–1039}

Invasive monitoring modalities consist of several specifically designed telemonitoring sensor technologies measuring remote haemodynamic parameters. Currently, only pulmonary artery sensor-guided therapy has been studied in multiple RCTs and has shown a benefit in reducing HFH in patients in NYHA class III and a HFH within the past 12 months.^{1029,1040–1047} Additionally, several prospective studies have confirmed the safety and efficacy of pulmonary artery-guided therapy in reducing HFH in multiple settings.^{1037,1048–1052} Remote haemodynamic monitoring by pulmonary artery-guided therapy should be considered in selected patients with moderate-to-severe HF with NYHA class III and a HFH within the past 12 months in order to reduce the risk of HFH.

Recommendation Table 25 – Recommendations for invasive and non-invasive telemonitoring (see [Evidence Table 100](#))

Recommendations	Class ^a	Level ^b
Remote haemodynamic monitoring of PA pressure should be considered in symptomatic patients with HF, NYHA class III, and an HFH in the past 12 months in order to reduce the risk of HFH. ^{1029,1043,1045}	IIa	B1
Non-invasive telemonitoring modalities may be considered for patients with HF in order to reduce the risk of HFH. ^{1027,1029,1053}	IIb	B1

© ESC 2026

HF, heart failure; HFH, heart failure hospitalization; NYHA, New York Heart Association; PA, pulmonary artery.

^aClass of recommendation.

^bLevel of evidence.

11.6. Long-term follow-up

11.6.1. Follow-up

Patients with HF, even when symptoms are stable and well controlled, require regular in-person follow-up to ensure ongoing optimization of therapy, detect asymptomatic disease progression or comorbidities, and discuss new advances in care. For follow-up intervals of patients with a recent episode of DHF undergoing optimization or uptitration of FMT, see [Section 7](#).

For symptomatic patients with HF with no recent DHF, these guidelines recommend assessment of symptom severity, pharmacological adherence, arrhythmias, changes in the ECG and, if deemed relevant, echocardiography and laboratory parameters (including full blood count, electrolytes, iron




Figure 22 Long-term follow-up of patients with stable heart failure—what—when—who. CIED, cardiac implantable electronic device; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HF, heart failure; HF-MDT, heart failure multidisciplinary team; RHC, right heart catheterization. ^aIf deemed clinically relevant. ^bCheck 'I NEED HELP' criteria, [Figure 16](#); [Table 15](#) (Section 8). ^cIntervals may be shorter.

status, liver, kidney, and thyroid function). What is needed, at which interval and who has to perform the follow-up assessment depend on HF stage ([Figure 22](#)). The necessity of cardiologist-led follow-up for these patients remains uncertain, with some studies suggesting that primary care follow-up may be appropriate.¹⁰⁵⁴ However, evidence-based intervention uptake is low in many settings, and studies indicate that follow-up by an HF clinic, alongside quality improvement registries, may lead to better therapy optimization and improved outcomes.^{990,994,1054–1057}

An ECG is recommended to detect QRS prolongation, which may qualify patients for CRT, as well as to identify conduction disturbances, AF, and other arrhythmias. Echocardiography should be performed if there is clinical deterioration or if otherwise deemed relevant. Trials investigating the use of biomarkers, such as BNP and NT-proBNP, to guide therapy in HFrEF have yielded inconsistent results.^{1058–1060} Although these biomarkers are strong prognostic indicators, it remains unclear what additional value a biomarker-guided strategy offers beyond strict adherence to FMT. As such, routine biomarker measurement for guidance on diuretic therapy is not currently supported by the evidence.

11.6.2. Advance care planning and palliative care

While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading to death. Communication about disease trajectory and advance care planning should be incorporated by all healthcare professionals throughout the course of the disease.^{1061,1062}

Advance care planning is a structured process that facilitates the exploration and communication of the patient's personal values, life goals, and preferences regarding future medical care, and may include preferences for place of death and resuscitation (which may include deactivating devices, such as ICD or durable MCS). Advance care planning should be documented, regularly reviewed, and routinely communicated to all those involved in the patient's care. Evidence shows that proactive advance care planning can reduce hospitalizations and improve QoL and end-of-life care, yet many patients with HF lack formalized plans, highlighting the need for better implementation.⁶²⁷

Palliative care, defined as patient- and family-centred care aimed at optimizing health-related QoL by anticipating, preventing, and alleviating suffering, should be integrated into the management of patients with HF in an advanced stage of the

disease. The role of palliative and supportive care spans the entire course of HF, beginning early in the disease, intensifying as the condition progresses, and extending into caregiver bereavement. Evidence supports the use of multidisciplinary palliative care in people with advanced HF to improve patient-reported outcomes (symptom burden, depression, functional status, QoL), but trials do not identify who would benefit most from specialist palliative referral.^{1063–1065} There are no sufficiently robust multicentre evaluation phase trials to provide generalizable findings.

Recommendation Table 26 – Recommendations for long-term follow-up (see [Evidence Tables 101 and 102](#))

Recommendations	Class ^a	Level ^b
Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to facilitate communication on end of life and QoL. ⁶²⁷	I	B1
Access to an integrated HF palliative care multidisciplinary team is recommended for patients in an advanced HF stage to improve QoL and reduce symptom burden. ^{1066–1068}	I	B2

© ESC 2026

HF, heart failure; QoL, quality of life.

^aClass of recommendation.

^bLevel of evidence.

12. Specific conditions

12.1. Pregnancy and heart failure

Heart failure in pregnancy requires careful multidisciplinary management.^{1069–1071} The core components of HF care in pregnancy involves multiple aspects from pre-conception to postpartum (see [Supplementary data online, Table S26](#)).

Specific recommendations for pre-conception care and management of HF during pregnancy can be found in [Recommendation Table 27](#). For an overview of managing HF in pregnancy, see [Supplementary data online, Section S9.1](#). For a comprehensive and detailed guidance, we refer to the 2025 *ESC Guidelines for the management of cardiovascular disease and pregnancy*.⁷

Recommendation Table 27 – Recommendations for heart failure and pregnancy (see [Evidence Tables 103–107](#))

Recommendations	Class ^a	Level ^b
Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive therapies.	I	C

Continued

In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta ₁ -selective blockers (metoprolol, bisoprolol) with close mother and foetus monitoring to reduce the risk of adverse foetal events and a lower birth weight. ^{1072,1073}	I	C
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2-Is are not recommended during pregnancy due to the risk of foetotoxicity or teratogenicity. ^{1074–1076}	III	C

© ESC 2026

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2-I, sodium–glucose co-transporter 2 inhibitor.

^aClass of recommendation.

^bLevel of evidence.

12.2. Cardiomyopathies

Cardiomyopathies are a common and specific cause of HF.¹²⁴

The 2023 *ESC Guidelines for the management of cardiomyopathies* described cardiomyopathy phenotypes based on structural (e.g. ventricular hypertrophy, dilatation, or scar) and functional (e.g. systolic or diastolic dysfunction) features.¹²⁴ Detailed recommendations and algorithms for the diagnosis and management of cardiomyopathies are provided in the 2023 *ESC Guidelines for the management of cardiomyopathies*.¹²⁴

12.2.1. Hypertrophic cardiomyopathy

Patients with HCM may develop HFrEF; in such cases, they should in general be treated as other patients with HFrEF. However, many patients develop symptoms of HF without having HFrEF, and these should be treated according to the cardiomyopathy guidelines (see [Supplementary data online, Section S9.2](#)).¹²⁴

12.3. Amyloidosis

12.3.1. Epidemiology and diagnosis

Cardiac amyloidosis is an infiltrative cardiomyopathy caused by amyloid fibril deposition in the extracellular space, resulting in increased myocardial thickness and stiffness, leading to a restrictive physiology.^{1077,1078} The two most prevalent forms of CA are immunoglobulin light chain CA (AL-CA) and transthyretin amyloidosis (ATTR). Transthyretin amyloidosis includes the wild-type (>90% of cases), and the hereditary or variant forms.¹⁰⁷⁷ Greater awareness of CA, streamlined diagnostic processes, and the emergence of new treatments has led to an increase in the prevalence of CA.^{1079,1080} The prevalence of CA is higher in males.¹⁰⁸¹

Cardiac amyloidosis should be suspected in patients with HF and increased LV wall thickness in the presence of specific red flags ([Table 20](#)), particularly in patients aged >65 years.

A timely, definitive diagnosis should be obtained as patient outcomes depend largely on early initiation of therapy (particularly in AL-CA). Cardiac amyloidosis can be diagnosed using both invasive and non-invasive diagnostic criteria. Invasive diagnostic criteria apply to all forms of CA, whereas non-invasive criteria are accepted only for transthyretin CA (ATTR-CA).¹⁰⁷⁷ [Figure 23](#) displays the diagnostic work-up and treatment options. For more diagnostic details, the Task Force refers to the 2021 ESC position statement on CA.¹⁰⁷⁷

Table 20 'Red flags' for most common forms of cardiac amyloidosis

Category	Red flag	TTR	AL
Extracardiac	Polyneuropathy	X	X
	Dysautonomia	X	X
	Skin bruising	–	X
	Macroglossia	–	X
	Deafness	X	–
	Bilateral carpal tunnel syndrome	X	–
	Ruptured biceps tendon	X	–
	Lumbar spinal stenosis	X	–
	Vitreous deposits	X ^a	–
	Family history	X ^a	–
	Kidney insufficiency	X	X
	Proteinuria	X	X
Cardiac clinical	Hypotension or normotension if previously hypertensive	X	X
ECG	Pseudo-infarct ECG pattern	X	X
	Low/decreased QRS voltage relative to LV thickness	X	X
	AV conduction disease	X	X
Laboratory	Disproportionally elevated NT-proBNP relative to HF severity	X	X
	Persistently elevated cardiac troponin levels	X	X
Echocardiography	Granular sparkling of myocardium	X	X
	Increased right ventricular wall thickness	X	X
	Increased valve thickness	X	X
	Increased interatrial septum thickness	X	X
	Pericardial effusion	X	X
	Reduced longitudinal strain with apical sparing pattern	X	X
CMR ^b	Global subendocardial or transmural LGE	X	X
	Elevated native T1 values	X	X
	Increased extracellular volume	X	X
	Abnormal gadolinium kinetics	X	X

© ESC 2026

AL, immunoglobulin light chain; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HF, heart failure; LGE, late gadolinium enhancement; LV, left ventricular; NT-proBNP, N-terminal-pro-B-type natriuretic peptide; TTR, transthyretin.

^aHereditary TTR-CA.

^bCMR can be diagnostic for CA.

12.3.2. Disease-specific treatments

12.3.2.1. Immunoglobulin light chain cardiac amyloidosis

Treatment of AL-CA includes chemotherapy or autologous stem cell transplantation with careful monitoring of haematological response, cardiac and organ function. Management of AL-CA should be undertaken by a multidisciplinary team involving

oncohaematology specialists and cardiologists, and whenever possible, patients should be referred to specialized centres.

12.3.2.2. Transthyretin cardiac amyloidosis

Therapeutic agents for ATTR-CA include drugs that inhibit hepatic synthesis of transthyretin (TTR), stabilize the tetramer, or disrupt the amyloid fibrils. Based on the results of large RCTs, the Task Force recommends treatment with a TTR stabilizer or a TTR silencer with proven safety and efficacy on morbidity and mortality, in patients with either wild-type or hereditary ATTR-CA and a clinical history of HF with NYHA classes I–III. These drugs include the TTR stabilizers tafamidis and acoramidis and the TTR silencer vutrisiran.^{1082–1084}

In the ATTR-ACT trial, tafamidis reduced all-cause death and CV hospitalizations over 30 months in both hereditary and wild-type ATTR-CA.¹⁰⁸² Benefits on functional capacity occurred within 6 months, whereas reduction in all-cause death was observed from 18 months onwards. It showed limited impact in advanced cases (NYHA class III).

In the ATTRIBUTE-CM trial, after 30 months of treatment, acoramidis was superior to placebo in a hierarchical analysis (all-cause death, CV hospitalization, change from baseline in NT-proBNP, and change from baseline in 6-min walk test).¹⁰⁸³ Although it did not independently lower death at 30 months, it did reduce the combined endpoint of all-cause death or CV hospitalizations. Notably, survival rates in the placebo arm were higher than in the treatment group of ATTR-ACT, possibly reflecting earlier disease stage and the improvements in earlier diagnosis and access to specialist care. Furthermore, in the open-label extension study, early initiation and continuous use of acoramidis significantly reduced death at 42 months, as compared with the later initiation of acoramidis.¹⁰⁸⁵

In the APOLLO-B trial, patisiran (i.v.) reduced functional decline over 12 months.¹⁰⁸⁶ However, no data are available regarding morbidity and mortality. In the HELIOS-B trial, vutrisiran (subcutaneous) reduced the risk of the combined endpoint of all-cause death and recurrent CV events vs placebo.¹⁰⁸⁴ Also, the risk of all-cause death through 42 months was lowered with vutrisiran. These benefits persisted regardless of background tafamidis use at baseline (~40% of the trial population).¹⁰⁸⁴

None of the studies provided a head-to-head comparison of TTR silencers vs stabilizers nor a head-to-head comparison of monotherapy vs combination therapies. Several studies are ongoing with further therapeutic options acting on gene editing, RNA silencing, or the repletion of amyloid deposits, and might change the management of ATTR-CA in the future.

12.3.3. Treatment of heart failure and cardiovascular comorbidities

Evidence for the use of FMT in patients with CA is still scarce and limited to post-hoc analyses of RCTs or retrospective studies.^{1087–1092} Patients with CA may poorly tolerate standard HF therapies due to restrictive physiology, autonomic dysfunction, atrioventricular conduction disturbance, and kidney impairment. Diuretics remain central for congestion management but must be used cautiously within a narrow euvolaemic window.^{1089,1090}

Increasing diuretic dose is a signal of disease progression with worse outcomes.^{1093,1094} Evidence supports the safety and benefit of SGLT2-Is.^{73,1089–1092} MRA might also be useful.¹⁰⁹²




Figure 23 Diagnosis and treatment of cardiac amyloidosis in heart failure patients. ^{99m}Tc, technetium-99m; AL, immunoglobulin light chain; AL-CA, immunoglobulin light chain cardiac amyloidosis; ATTR-CA, transthyretin cardiac amyloidosis; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HMDP, hydroxymethylene diphosphonate; LVH, left ventricular hypertrophy; PYP, pyrophosphate; SPECT, single-photon emission computed tomography; TTR, transthyretin. ^aSee Table 20. ^bUsually an extracardiac biopsy is performed first. ^cPerform TTR genetic testing. ^dDiagnosis will be based on the results from the individualized approach.

Beta-blockers and ACE-I/ARNI/ARB use requires caution, individualized decisions, and close monitoring.

In patients with CA and AF, anticoagulation is indicated regardless of CHA₂DS₂-VA score, due to high thromboembolic risk.^{1077,1095–1097} Transoesophageal echocardiography is necessary before cardioversion to exclude intracardiac thrombus, regardless of the duration of anticoagulation before the procedure.¹⁰⁹⁸ The use of digoxin is generally discouraged due to high risk of toxicity. Few patients with CA and advanced symptoms may be eligible for heart transplantation in line with international criteria.⁵⁸⁰

Recommendation Table 28 — Recommendations for cardiac amyloidosis (see Evidence Tables 108–111)

Recommendation	Class ^a	Level ^b
Treatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with variant or wild-type transthyretin cardiac amyloidosis and NYHA classes I–III is recommended to reduce progression of symptoms and the risk of CV hospitalization and all-cause death. ^{1082–1084}	I	A

CV, cardiovascular; NYHA, New York Heart Association; TTR, transthyretin.
^aClass of recommendation.
^bLevel of evidence.

12.4. Myocarditis

12.4.1. Epidemiology and diagnosis

The contribution of myocarditis as a cause of HF is estimated to be less than 5%.¹⁰⁹⁹ When patients with myocarditis present with DHF, LVEF <40%, life-threatening arrhythmias (ventricular tachycardia/fibrillation, third-degree atrioventricular block), and/or extensive LGE on CMR, they should be viewed as high risk.^{1100,1101} High-risk patients may require an endomyocardial biopsy in order to tailor treatment,⁸ whereas lower-risk patients may be examined with CMR imaging. The clinical presentation ranges from impaired LV function to refractory HF, CS (fulminant myocarditis), or sudden cardiac arrest. Some patients present primarily with arrhythmias. Prognosis depends on initial presentation.^{1100,1101} Patients with fulminant myocarditis should be transferred or discussed with a center that has the possibility to perform endomyocardial biopsy and provide MCS support. High-risk patients have a high mortality and may need temporary MCS and/or in the long term heart transplantation or durable MCS.^{1102–1104}

12.4.2. Treatment

The treatment algorithm is reported in the 2025 ESC Guidelines for the management of myocarditis and pericarditis.⁸ Patients with myocarditis and HFrEF should be empirically treated with FMT for HFrEF (see Section 7). Routine immunosuppression is not recommended in patients with preserved LVEF and should be

reserved for fulminant, non-infectious forms of myocarditis to stabilize the patients.⁸

12.5. Adult congenital heart disease

Adult congenital heart disease is a heterogeneous group of structural heart abnormalities varying in complexity. There has been an improvement in survival with contemporary care.¹¹⁰⁵ Consequently, HF in ACHD is increasingly common,^{1106,1107} and represents a major contributor to morbidity and mortality, accounting for 26%–46% of deaths, with higher rates seen in more complex lesions.^{1108–1110}

Managing HF in ACHD poses specific challenges related to original anatomy, presence of haemodynamic lesions, previous interventions, and extracardiac complications such as kidney and liver dysfunction.^{1111,1112}

Specific indications on the management of these patients are reported in the 2020 ESC Guidelines for the management of adult congenital heart disease¹¹¹¹ and in a recent ESC clinical consensus statement.¹¹¹³

13. Key messages

New classifications

- Heart failure has been redefined with two distinct phenotypes:
 - HFrEF: LVEF <50% + symptoms and/or signs of HF.
 - HFpEF: LVEF ≥50% + symptoms and/or signs of HF + objective evidence of cardiac structural and/or functional abnormalities.
- Stages of HF (A–D) have been adopted:
 - Stage A: individuals at risk for HF but without signs, symptoms, and cardiac abnormalities.
 - Stage B: pre-HF, defined as the presence of cardiac abnormalities without signs and symptoms of HF.
 - Stage C: symptomatic HF, defined as the presence of cardiac abnormalities and current or prior signs and/or symptoms of HF.
 - Stage D: advanced HF.
- New classifications for medical and interventional HF therapies have been introduced. The terms are designed to be dynamic and may therefore remain contemporary over time:
 - FMT—Foundational medical therapy: medical therapies for unselected patients with HF with Class I recommendation for reducing HFH and/or death.
 - AMT—Additional medical therapy: medical therapies with Class IIa/IIb recommendations or Class I recommendations for improving symptoms/QoL or reducing morbidity or mortality in specific subsets of patients with HF.
 - GDIT—Guideline-directed interventional therapy: all guideline-recommended implantable devices or interventional therapies.

Prevention of heart failure

- A strict control of HF risk factors is recommended to prevent HF.

Diagnosis of heart failure

- Measurement of natriuretic peptides and echocardiography have key roles in the diagnosis of HF. Additional testing is useful for aetiologies and phenotypes.
- Multimodality aetiology assessment should be sought to find potential treatable causes of HF.

Guideline-recommended therapies

- ARNIs or ACE-Is (ARB in case of intolerance) beta-blockers, MRAs, and SGLT2-Is are recommended as FMT for patients with HFrEF, whereas MRAs and SGLT2-Is are recommended as FMT for patients with HFpEF.
- ICDs are recommended in selected patients with HFrEF, LVEF $\leq 35\%$, and an ischaemic aetiology, and should be considered in those with a non-ischaemic aetiology.
- CRT-P or CRT-D is recommended in patients with HFrEF, LVEF $\leq 35\%$, in sinus rhythm, with an LBBB ≥ 150 ms and should be considered in those with an LBBB ≥ 130 – 149 ms or non-LBBB ≥ 150 ms.

Decompensated heart failure

- Decompensated heart failure refers to acute or gradual onset of symptoms and/or signs of HF, severe enough to deserve urgent medical attention, leading to an unplanned hospital admission or an emergency department visit or an ambulatory visit, and requiring subsequent initiation or intensification of treatment.
- Treatment of DHF is based on addressing any associated triggers urgently, diuretics for congestion with the addition of vasodilators for high blood pressure, inotropes, and/or temporary MCS for hypoperfusion.
- Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. FMT must be started or optimized before discharge and close visits in the early post-discharge period must be planned.

Advanced heart failure

- Patients with advanced HF refractory to FMT and GDIT who do not have absolute contraindications must have timely referral for consideration of heart transplantation or MCS.

Cardiovascular comorbidities

- Catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. Selection criteria include high-burden AF, less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF.
- Patients with obstructive CAD and HF need to be treated conservatively or invasively (CABG or PCI) according to clinical and anatomical suitability for revascularization, HF phenotype and history, presence of angina, comorbidities, frailty, and patient preference.
- Surgical aortic valve replacement or TAVI, as assessed by the Heart Team, is recommended in patient with severe low-flow

low-gradient aortic stenosis and HF regardless of LVEF and in patients with severe low-flow low-gradient aortic stenosis and HFrEF.

- Mitral TEER is recommended in selected patients with severe ventricular secondary MR and HFrEF after optimization of FMT and CRT implantation (if needed).

Non-cardiovascular comorbidities

- Patients should be routinely screened and treated for non-CV comorbidities (e.g. diabetes, CKD, obesity, ID, anxiety and depression) and frailty.
- Lifestyle interventions, exercise, diet, and patient education are fundamental steps for body-weight management in patients with HF and obesity, followed by pharmacological and surgical interventions.
- It is recommended to switch glucose-lowering treatment from agents without proven CV efficacy or safety to agents with proven CV benefit in patients with HF and diabetes.

Multidisciplinary management

- A multidisciplinary HF management programme is recommended.
- Cardiac rehabilitation, with exercise training, is a key tool to reduce hospitalizations and improve functional capacity and QoL in patients with HF.
- Remote haemodynamic monitoring of PA pressure should be considered in selected patients; non-invasive telemonitoring modalities may be considered.

Specific conditions

- Pre-conception care and counselling is recommended for patients with stage B or C HF to facilitate decision-making surrounding pregnancy.
- Specific disease-modifying therapies are recommended in patients with CA.

14. Gaps in evidence

Despite advances in the management of HF, multiple areas of uncertainty remain. Future research should address the following gaps.

(1) Definitions and prevention

- Consensus regarding normal values/ranges of ejection fraction.
- More information on the incidence, prevalence and prognostic importance of HF with improved LVEF, and a need to validate and evaluate the clinical importance of the new definition proposed by the Second Universal Definition of HF.⁴⁷
- The benefits and risks of various weight-loss methods for HF risk reduction in obesity need further studies.
- More research is needed to understand if SGLT2-Is and MRAs prevent HF in patients without diabetes but with comorbidities like obesity, hypertension, and/or CKD.
- Studies are needed to better understand if CPAP therapy lowers risk of HF in patients with sleep apnoea.

(2) Diagnosis and phenotyping

- Further research into the underlying characteristics, pathophysiology, diagnosis, and phenotyping of HFpEF.
- Role of artificial intelligence in the diagnostic pathway for HF as well as for patient inclusion in RCTs.
- Validated diagnostic protocols including deeper phenotyping for the diagnosis of HFpEF.
- Validation of the historic exercise-induced pulmonary capillary wedge pressure cut-offs used in the diagnosis of HFpEF.
- Prospective validation of age-related natriuretic peptide cut-offs in chronic HF.
- Degree of influence of BMI on natriuretic peptides to allow for individual adjustment of expected ranges.
- Prospective studies to test the diagnostic yield for endomyocardial biopsy, and whether a biopsy would affect treatment decisions and outcomes in patients with unexplained cardiomyopathy and evidence of inflammation/infiltration/storage on CMR or CT-positron emission tomography.

(3) Medical treatment and devices

- Contemporary reproducibility of old trials on medical and device therapies.
- Future trials on medical/device therapy for HF should adhere to contemporary FMT.
- Randomized clinical trials comparing different MRAs in both HFrEF and HFpEF.
- Randomized clinical trials investigating the optimal medical therapy for HFpEF.
- Randomized clinical trials comparing different GLP-1 RAs.
- Randomized clinical trials on the optimal sequencing when initiating FMT both in HFrEF and HFpEF.
- More data on the role of potassium binders, both in patients with and without CKD.
- Management strategies and therapies for HF with improved LVEF.
- Indications for ICDs in specific subgroups of patients, and optimal selection of ICD candidates in HFrEF, including patients with ischaemic and non-ischaemic HF.
- Efficacy of CRT in AF.
- Randomized controlled trials with morbidity and mortality endpoints and long-term follow-up, comparing CSP and trans-coronary vein CRT in patients with HFrEF.
- Randomized controlled trials with morbidity and mortality and long-term follow-up on interatrial shunt devices in patients with HFrEF and HFpEF.

(4) Decompensated heart failure

- Evidence on medical therapy with prognostic benefit in DHF.
- Evidence for best decongestion protocols in patients with and without CKD and in the setting of continued/initiation of FMT.
- Evidence-based use of imaging techniques and biomarkers that have an impact on patients' clinical course in DHF.
- Definition of evidence-based treatment options and therapeutic algorithms for patients with CS.
- Better definition of the role of MCS in CS.

- Better definition of the role of inotropes, vasopressors and vasodilators in DHF.
- Studies on the best early post-discharge risk-based management protocols to reduce early readmission to hospital.

(5) Advanced heart failure

- Benefit of FMT, AMT, and GDIT in advanced HFrEF needs further investigation.
- Which medication to down-titrate/stop first in patients with advanced HF who no longer tolerate all FMT.
- Durable MCS (LVADs) vs medical treatment in INTERMACS >4 without high-risk features.
- Optimal lifetime management strategies in very young adults with advanced HF.
- Advances in durable MCS, including strategies to reduce the risk of infection.
- Advances in medical treatment for the many patients who cannot undergo MCS or heart transplantation, including development of treatment strategies, and novel inotropes or myotropes for patients with advanced HF.

(6) Cardiovascular comorbidities

- Adequately powered RCTs showing the best strategy for management of AF in patients with HF.
- Selection of patients with HFrEF and HFpEF that may benefit from AF ablation.
- Better characterization of patients with arrhythmia-associated HF, especially patients with AF-associated HF.
- Randomized controlled trials investigating best management options for patients with AF-associated HF, both in terms of HF management and management of AF.
- Randomized controlled trials to assess the role of coronary revascularization and different revascularization strategies in patients with HFrEF and HFpEF on current FMT.
- Longer-term follow-up results for mitral TEER interventions in HFrEF.
- Role of mitral TEER in patients with HFrEF who do not fulfil specific echocardiographic and clinical criteria.
- Treatment of atrial secondary MR in patients with HFpEF.
- Further RCTs to assess the role of transcatheter valve intervention in patients with HF and TR.

(7) Non-cardiovascular comorbidities

- More clinically appropriate definition of ID in HF.
- Further RCTs, using the novel definition of ID as an inclusion criterion, to assess the prognostic role of i.v. iron supplementation.
- The prognostic role of HF treatment in patients with severe kidney dysfunction (i.e. eGFR <30 mL/min/1.73 m²), excluded from RCTs.
- The effects of GLP-1 RAs and tirzepatide on morbidity and mortality in patients with HFpEF and HFrEF.
- Treatment of SDB, both central and obstructive, needs further investigation to clarify benefit and safety concerns.

(8) Multidisciplinary management

- Studies on optimal models for follow-up of patients with stable HF.

- Long-term trials on exercise in patients with HF.
- Studies to determine personalized approach for palliative care to improve patient-centred outcomes.
- Models of care that incorporate contemporary patients with HF and the wider multidisciplinary team including cardio-kidney-metabolic professionals in HF care.
- Patient selection for telemonitoring.

(9) Specific conditions

- Randomized clinical trials for the treatment of peripartum cardiomyopathy.
- Head-to-head comparison between different disease-modifying drugs in ATTR-CA.
- Evidence for the combined use of disease-modifying drugs in ATTR-CA.
- Evidence for gene editing and antibodies for the removal of amyloid deposits.
- Efficacy of traditional HF therapies in patients with CA.
- Identification of patients with ATTR-CA who could benefit from device therapy (e.g. ICD/CRT).
- Data collection to support advice on screening for *TTR* gene carriers—when to initiate and follow-up interval.

15. Evidence tables

Evidence tables are available at [European Heart Journal](#) online.

16. Data availability

No new data were generated or analysed in support of this research.

17. Author information

Author/Task Force Member Affiliations: **Anne-Christine Ruwald**, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; **Daniela Tomasoni**, Cardiology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, and Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; **Lisa J. Anderson**, Cardiology Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, and Cardiovascular and Genomic Research Institute, City St George's University of London, London, United Kingdom; **Charlotte Andersson**, Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, MA, United States of America; **Jasper J. Brugts**, Cardiology Department, Erasmus MC University Medical Center, Cardiovascular Institute, Rotterdam, Netherlands; **Ovidiu Chioncel**, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania and University of Medicine Carol Davila, Bucharest, Romania; **Erwan Donal**, Cardiology Department-LTSI-Inserm 1099, CHU Rennes—Université Rennes, Rennes, France; **Peter Ferdinandy**, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, and Pharmahungary Group, Szeged, Hungary; **Pardeep S. Jhund**, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; **Francisco Leyva**, Aston Medical School, Aston University, Birmingham, United Kingdom, and Department of Cardiology,

University Hospitals Birmingham, Queen Elizabeth, Birmingham, United Kingdom; **Roberto Lorusso**, Cardio-Thoracic Surgery, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands, and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands; **Michael Madigan** (Ireland), ESC Patient Forum, Sophia Antipolis, France; **Wilfried Mullens**, Cardiology Department, Ziekenhuis Oost Limburg, Genk, Belgium, and Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium; **Stefania Paolillo**, Department of Advanced Biomedical Sciences, Section of Cardiology, Federico II University of Naples, Naples, Italy; **Nicola Ryan**, Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; **Maggie Simpson**, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom; **Holger Thiele**, Cardiology Department, Heart Center Leipzig at Leipzig University, Leipzig, Germany, and Leipzig Heart Science, Leipzig, Germany; **Jens Jakob Thune**, Department of Cardiology, Copenhagen University Hospital—Bispebjerg and Frederiksberg, Copenhagen, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; **Emeline M. Van Craenenbroeck**, Cardiology Department, Antwerp University Hospital, Edegem, Belgium, and Cardiovascular Diseases, GENCOR, University of Antwerp, Belgium; **Linda W. Van Laake**, Cardiology Department, University Medical Center Utrecht, Utrecht, Netherlands, and Utrecht University, Utrecht, Netherlands, and Transplantation Center, University Medical Center Utrecht, Utrecht, Netherlands; **Mariette Verbakel** (Netherlands), ESC Patient Forum, Sophia Antipolis, France.

18. Appendix

ESC Guidelines Advisory Group

Includes Document Reviewers and ESC National Cardiac Societies.

Document Reviewers: Christina Christersson (CPG Review Coordinator) (Sweden), Massimo F. Piepoli (CPG Review Coordinator) (Italy), Ana Abreu (Portugal), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Claudio Ceconi (Italy), Christina Chrysoshoou (Greece), Kevin Damman (Netherlands), Jean-Claude Deharo (France), Victoria Delgado (Spain), Fernando Dominguez (Spain), Gloria Färber (Germany), Daniel Fernandez-Berges (Spain), Marc Ferrini (France), Estelle Gandjbakhch (France), Luna Gargani (Italy), Bettina Heidecker (Germany), Borja Ibanez (Spain), Massimo Imazio (Italy), Stefan James (Sweden), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Lars H. Lund (Sweden), Sharon MacDonald (United Kingdom), John William McEvoy (Ireland), Lorenzo Menicanti (Italy), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Christian E. Mueller (Switzerland), Lis Neubeck (United Kingdom), Daniela Pini (Italy), Evgenij V. Potapov (Germany), Anne-Catherine Pouleur (Belgium), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Hatem Soliman Aboumarie (United Kingdom), Felix C. Tanner (Switzerland), Izabella Uchmanowicz (Poland), Mattias Van

Heetvelde (Belgium), Matthias Wilhelm (Switzerland), Stefanos Zafeiropoulos (Switzerland), Katja Zeppenfeld (Netherlands), Daniel Zimpfer (Austria)

ESC National Cardiac Societies actively involved in the review process of the 2026 ESC Guidelines for the management of heart failure.

Albania: Albanian Society of Cardiology, Albana Doko Banushi; **Algeria:** Algerian Society of Cardiology, Brahim Kichou; **Armenia:** Armenian Cardiologists Association, Hamayak S. Sisakian; **Austria:** Austrian Society of Cardiology, Noemi Pavo; **Azerbaijan:** Azerbaijan Society of Cardiology, Ulvi Mirzoyev; **Belgium:** Belgian Society of Cardiology, Ana Roussoulières; **Bosnia and Herzegovina:** Association of Cardiologists in Bosnia and Herzegovina, Zumreta Kusljagic; **Bulgaria:** Bulgarian Society of Cardiology, Vassil Traykov; **Croatia:** Croatian Cardiac Society, Nina Jakus; **Cyprus:** Cyprus Society of Cardiology, Constantinos Ergatoudes; **Czechia:** Czech Society of Cardiology, Anna Chaloupka; **Denmark:** Danish Society of Cardiology, Henrik Wiggers; **Egypt:** Egyptian Society of Cardiology, Azza Farrag; **Estonia:** Estonian Society of Cardiology, Pentti Pöder; **Finland:** Finnish Cardiac Society, Katariina Pitkänen; **France:** French Society of Cardiology, Damien Logeart; **Germany:** German Cardiac Society, Kristian Hellenkamp; **Greece:** Hellenic Society of Cardiology, Katerina K. Naka; **Hungary:** Hungarian Society of Cardiology, Annamaria Kosztin; **Iceland:** Icelandic Society of Cardiology, Inga J. Ingimarsdottir; **Ireland:** Irish Cardiac Society, Helen Cooney; **Israel:** Israel Heart Society, Rabea Asleh; **Italy:** Italian Federation of Cardiology, Savina Nodari; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Makhabbat Bekbossynova; **Kosovo (Republic of):** Kosovo Society of Cardiology, Pranvera Ibrahim; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Erkin Mirrakhimov; **Latvia:** Latvian Society of Cardiology, Ginta Kamzola; **Lebanon:** Lebanese Society of Cardiology, Hadi Skouri; **Lithuania:** Lithuanian Society of Cardiology, Egle Rumbinaite; **Luxembourg:** Luxembourg Society of Cardiology, Steve Huijnen; **Malta:** Maltese Cardiac Society, Alice May Moore; **Moldova (Republic of):** Moldavian Society of Cardiology, Eleonora Vataman; **Morocco:** Moroccan Society of Cardiology, Ahmed Bennis; **Netherlands:** Netherlands Society of Cardiology, Vanessa van Empel; **North Macedonia:** National Society of Cardiology of North Macedonia, Marija Vavlukis; **Norway:** Norwegian Society of Cardiology, Eva Rice; **Poland:** Polish Cardiac Society, Agnieszka Kołodzińska; **Portugal:** Portuguese Society of Cardiology, Susana Dias da Costa; **Romania:** Romanian Society of Cardiology, Elena-Laura Antohi; **San Marino:** San Marino Society of Cardiology, Marina Foscoli; **Slovakia:** Slovak Society of Cardiology, Marcela Dankova; **Slovenia:** Slovenian Society of Cardiology, Mitja Lainscak; **Spain:** Spanish Society of Cardiology, Sonia Mirabet Perez; **Sweden:** Swedish Society of Cardiology, Gabriel Arefalk; **Switzerland:** Swiss Society of Cardiology, Philippe Meyer; **Syrian Arab Republic:** Syrian Cardiovascular Association, Ahmad Alayed; **Tunisia:** Tunisian Society of Cardiology and Cardiovascular Surgery, Leila Abid; **Türkiye:** Turkish Society of Cardiology, Ozlem Yildirimturk; **Turkmenistan:** Turkmen Committee of Cardiologists, Bahram Kadyrov; **Ukraine:** Ukrainian Association of Cardiology, Leonid Voronkov; **United**

Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Andrew J. Ludman, **Uzbekistan:** Association of Cardiologists of Uzbekistan, Timur Abdullaev.

ESC Clinical Practice Guidelines (CPG) Committee: Ulf Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski (Poland), Katja Zeppenfeld (Netherlands)

Contributor either withdrew or was engaged in only a part of the development process: Jan Biegus (Poland)

Contributors either withdrew or were engaged in only a part of the review process: Barry Borlaug (United States of America), Mohamed El-Harari (Libya), Giovanna Sarno (Sweden), Anastazija D. Stojisic Milosavljevic (Serbia)

19. References

1. Juni P, Antoniou S, Arbelo E, Bucchini S, Cikes M, da Costa BR, et al. 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention. *Eur Heart J* 2025;**46**: 1885–94. <https://doi.org/10.1093/eurheartj/ehaf009>
2. Di Angelantonio E, Pennells L, Abdelhamid M, Aboyans V, Asteggiano R, Celutkiene J, et al. 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models. *Eur Heart J* 2025;**46**:1895–906. <https://doi.org/10.1093/eurheartj/ehaf016>
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–726. <https://doi.org/10.1093/eurheartj/ehab368>
4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;**145**:e895–1032. <https://doi.org/10.1161/CIR.0000000000001063>
5. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2023;**44**:3627–39. <https://doi.org/10.1093/eurheartj/ehad195>
6. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J* 2022;**43**: 4229–361. <https://doi.org/10.1093/eurheartj/ehac244>
7. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. *Eur Heart J* 2025;**43**:4462–568. <https://doi.org/10.1093/eurheartj/ehaf193>
8. Schulz-Menger J, Collini V, Groschel J, Adler Y, Brucato A, Christian V, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. *Eur Heart J* 2025;**46**:3952–4041. <https://doi.org/10.1093/eurheartj/ehaf192>
9. Praz F, Borger MA, Lanz J, Marin-Cuatas M, Abreu A, Adamo M, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2025;**44**:4635–736. <https://doi.org/10.1093/eurheartj/ehaf194>

10. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. *Eur Heart J* 2024;**45**:3415–537. <https://doi.org/10.1093/eurheartj/ehae177>
11. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail* 2021;**23**:352–80. <https://doi.org/10.1002/ehf.2115>
12. Becher PM, Lund LH, Coats AJS, Savarese G. An update on global epidemiology in heart failure. *Eur Heart J* 2022;**43**:3005–7. <https://doi.org/10.1093/eurheartj/ehac248>
13. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovasc Res* 2023;**118**:3272–87. <https://doi.org/10.1093/cvr/cvac013>
14. Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. *Heart* 2022;**108**:1351–60. <https://doi.org/10.1136/heartjnl-2021-320131>
15. Seferovic PM, Polovina M, Savarese G, Milinkovic I, Stanisavljevic D, Lund L, et al. Insights into the European heart failure epidemiology. *Eur J Heart Fail* 2025;**27**:1950–60. <https://doi.org/10.1002/ehf.3710>
16. Christiansen MN, Kober L, Weeke P, Vasan RS, Jeppesen JL, Smith JG, et al. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. *Circulation* 2017;**135**:1214–23. <https://doi.org/10.1161/CIRCULATIONAHA.116.025941>
17. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespiello AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *Lancet* 2018;**391**:572–80. [https://doi.org/10.1016/S0140-6736\(17\)32520-5](https://doi.org/10.1016/S0140-6736(17)32520-5)
18. Wei S, Miranda JJ, Mamas MA, Zuhke LJ, Kontopantelis E, Thabane L, et al. Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990–2019. *Eur Heart J Qual Care Clin Outcomes* 2023;**9**:662–72. <https://doi.org/10.1093/ehjqcco/qcac088>
19. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. *Eur Heart J* 2014;**35**:25–32. <https://doi.org/10.1093/eurheartj/ehu278>
20. Lecoq E, Domeng O, Fayol A, Jannot AS, Hulot JS. Epidemiology of heart failure in young adults: a French nationwide cohort study. *Eur Heart J* 2023;**44**:383–92. <https://doi.org/10.1093/eurheartj/ehac651>
21. Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. *JACC Cardiovasc Imaging* 2018;**11**:1–11. <https://doi.org/10.1016/j.jcmg.2017.08.007>
22. Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. *JACC Heart Fail* 2019;**7**:505–15. <https://doi.org/10.1016/j.jchf.2019.03.011>
23. Peters AE, Tromp J, Shah SJ, Lam CSP, Lewis GD, Borlaug BA, et al. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. *Cardiovasc Res* 2023;**118**:3403–15. <https://doi.org/10.1093/cvr/cvac179>
24. Yang M, Kondo T, Jhund PS, Alcocer-Gamba MA, Borleffs CJW, Chiang CE, et al. Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction. *Eur J Heart Fail* 2024;**26**:1788–803. <https://doi.org/10.1002/ehf.3352>
25. Garred CH, Malmberg M, Malik ME, Zahir D, Christensen DM, Arulmuruganthavadiel A, et al. Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study. *Lancet Healthy Longev* 2024;**5**:e326–35. [https://doi.org/10.1016/S2666-7568\(24\)00029-1](https://doi.org/10.1016/S2666-7568(24)00029-1)
26. Lindberg F, Benson L, Dahlstrom U, Lund LH, Savarese G. Trends in heart failure mortality in Sweden between 1997 and 2022. *Eur J Heart Fail* 2024;**27**:366–76. <https://doi.org/10.1002/ehf.3506>
27. Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, et al. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. *JAMA Cardiol* 2019;**4**:1102–11. <https://doi.org/10.1001/jamacardio.2019.3593>
28. Shah KS, Xu H, Matsouka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. *J Am Coll Cardiol* 2017;**70**:2476–86. <https://doi.org/10.1016/j.jacc.2017.08.074>
29. Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. *Am J Cardiol* 2015;**116**:1088–92. <https://doi.org/10.1016/j.amjcard.2015.07.018>
30. Arulmuruganthavadiel A, Holt A, Parveen S, Lamberts M, Gislason GH, Torp-Pedersen C, et al. Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. *Eur Heart J Qual Care Clin Outcomes* 2022;**8**:750–60. <https://doi.org/10.1093/ehjqcco/qcab073>
31. Lindmark K, Boman K, Stalhammar J, Olofsson M, Lahoz R, Studer R, et al. Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: a real-world study. *ESC Heart Fail* 2021;**8**:2144–53. <https://doi.org/10.1002/ehf2.13296>
32. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. *Eur J Heart Fail* 2017;**19**:1624–34. <https://doi.org/10.1002/ehf.945>
33. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, mid-range, and reduced ejection fraction: a nationwide cohort study. *Circ Heart Fail* 2017;**10**:e003875. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875>
34. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. *Nat Rev Cardiol* 2022;**19**:100–16. <https://doi.org/10.1038/s41569-021-00605-5>
35. Rossello X, Prescott EIB, Kristensen AMD, Latini R, Fuster V, Fagerland MW, et al. β Blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. *Lancet* 2025;**406**:1128–37. [https://doi.org/10.1016/S0140-6736\(25\)01592-2](https://doi.org/10.1016/S0140-6736(25)01592-2)
36. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018;**39**:26–35. <https://doi.org/10.1093/eurheartj/ehx564>
37. Sidiq SA, Truly TA, Minhas AMK, Pickett JK, Suffredini JM, Kayani W, et al. Association between oral beta blocker therapy and long-term outcomes after myocardial infarction in individuals with mildly reduced or preserved left ventricular function: a meta-analysis of contemporary randomized controlled trials. *Cardiovasc Drugs Ther* 2025. <https://doi.org/10.1007/s10557-025-07826-7>
38. Alzahrani T, Tiu J, Panjraht G, Solomon A. The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. *Ther Adv Cardiovasc Dis* 2018;**12**:351–59. <https://doi.org/10.1177/1753944718809266>
39. Cleland JG, Tendra M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J* 2006;**27**:2338–45. <https://doi.org/10.1093/eurheartj/ehl250>
40. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. *Eur J Heart Fail* 2018;**20**:1230–39. <https://doi.org/10.1002/ehf.1149>
41. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. *Lancet* 2003;**362**:777–81. [https://doi.org/10.1016/S0140-6736\(03\)14285-7](https://doi.org/10.1016/S0140-6736(03)14285-7)
42. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019;**381**:1609–20. <https://doi.org/10.1056/NEJMoa1908655>
43. Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. *Lancet* 2024;**404**:1119–31. [https://doi.org/10.1016/S0140-6736\(24\)01733-1](https://doi.org/10.1016/S0140-6736(24)01733-1)
44. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. *Nat Med* 2022;**28**:1956–64. <https://doi.org/10.1038/s41591-022-01971-4>
45. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. *Eur Heart J* 2022;**43**:416–26. <https://doi.org/10.1093/eurheartj/ehab798>

46. Miller RJH, Nabipour M, Youngson E, Kotrri G, Fine NM, Howlett JG, et al. Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. *ESC Heart Fail* 2022;**9**:1564–73. <https://doi.org/10.1002/ehf2.13869>
47. Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, et al. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure. *Eur Heart J* 2026. <https://doi.org/10.1093/eurheartj/ehag500>
48. Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD, et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. *Eur J Heart Fail* 2024;**26**:18–33. <https://doi.org/10.1002/ehf.3106>
49. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;**62**:e147–239. <https://doi.org/10.1016/j.jacc.2013.05.019>
50. Zhu F, Boersma E, Tilly M, Ikram MK, Qi H, Kavousi M. Trends in population attributable fraction of modifiable risk factors for cardiovascular diseases across three decades. *Eur J Prev Cardiol* 2024;**31**:1724–33. <https://doi.org/10.1093/eurjpc/zwae219>
51. Sinha A, Ning H, Carnethon MR, Allen NB, Wilkins JT, Lloyd-Jones DM, et al. Race- and sex-specific population attributable fractions of incident heart failure: a population-based cohort study from the Lifetime Risk Pooling Project. *Circ Heart Fail* 2021;**14**:e008113. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.008113>
52. Folsom AR, Yamagishi K, Hozawa A, Chambless LE; Atherosclerosis Risk in Communities Study Investigators. Absolute and attributable risks of heart failure incidence in relation to optimal risk factors. *Circ Heart Fail* 2009;**2**:11–17. <https://doi.org/10.1161/CIRCHEARTFAILURE.108.794933>
53. Cleland V, Tian J, Buscot MJ, Magnussen CG, Bazzano L, Burns TL, et al. Body-mass index trajectories from childhood to mid-adulthood and their sociodemographic predictors: evidence from the International Childhood Cardiovascular Cohort (i3C) Consortium. *EclinicalMedicine* 2022;**48**:101440. <https://doi.org/10.1016/j.eclim.2022.101440>
54. Holthuis EI, Visseren FLJ, Bots ML, Peters SAE; UCC-SMART Study Group. Risk factor clusters and cardiovascular disease in high-risk patients: the UCC-SMART study. *Glob Heart* 2021;**16**:85. <https://doi.org/10.5334/gh.897>
55. Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham Study over 35 years. *J Am Heart Assoc* 2019;**8**:e011433. <https://doi.org/10.1161/JAHA.118.011433>
56. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. *JAMA* 2014;**311**:490–97. <https://doi.org/10.1001/jama.2013.285122>
57. Armocida B, Monasta L, Sawyer SM, Bustreo F, Onder G, Castelpietra G, et al. The burden of type 1 and type 2 diabetes among adolescents and young adults in 24 western European countries, 1990–2019: results from the Global Burden of Disease study 2019. *Int J Public Health* 2023;**68**:1606491. <https://doi.org/10.3389/ijph.2023.1606491>
58. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet* 2021;**398**:957–80. [https://doi.org/10.1016/S0140-6736\(21\)01330-1](https://doi.org/10.1016/S0140-6736(21)01330-1)
59. GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease study 2021. *Lancet* 2025;**405**:813–38. [https://doi.org/10.1016/S0140-6736\(25\)00355-1](https://doi.org/10.1016/S0140-6736(25)00355-1)
60. Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J* 2023;**44**:4043–140. <https://doi.org/10.1093/eurheartj/ehad192>
61. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;**42**:3227–337. <https://doi.org/10.1093/eurheartj/ehab484>
62. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. *Eur Heart J* 2024;**45**:3912–4018. <https://doi.org/10.1093/eurheartj/ehae178>
63. Guo X, Ouyang N, Sun G, Zhang N, Li Z, Zhang X, et al. Multifaceted intensive blood pressure control model in older and younger individuals with hypertension: a randomized clinical trial. *JAMA Cardiol* 2024;**9**:781–90. <https://doi.org/10.1001/jamacardio.2024.1449>
64. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. *N Engl J Med* 2021;**385**:1268–79. <https://doi.org/10.1056/NEJMoa2111437>
65. Yang Q, Zheng R, Wang S, Zhu J, Li M, Wang T, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. *Hypertension* 2023;**80**:1640–53. <https://doi.org/10.1161/HYPERTENSIONAHA.123.20954>
66. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008;**358**:1887–98. <https://doi.org/10.1056/NEJMoa0801369>
67. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;**373**:2103–16. <https://doi.org/10.1056/NEJMoa1511939>
68. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. *JAMA* 1997;**278**:212–16.
69. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. *JAMA* 2016;**315**:2673–82. <https://doi.org/10.1001/jama.2016.7050>
70. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 2015;**3**:356–66. [https://doi.org/10.1016/S2213-8587\(15\)00044-3](https://doi.org/10.1016/S2213-8587(15)00044-3)
71. Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. *Clin Res Cardiol* 2024;**113**:898–909. <https://doi.org/10.1007/s00392-023-02362-6>
72. Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. *Diabetes Care* 2025;**48**:846–59. <https://doi.org/10.2337/dc25-0241>
73. Metra M, Tomasoni D, Adamo M, Amir O, Anker SD, Bayes-Genis A, et al. SGLT2 inhibitors for the prevention and treatment of heart failure: a scientific statement of the HFA and the HFAI. *ESC Heart Fail* 2025;**12**:3806–25. <https://doi.org/10.1002/ehf2.15408>
74. Patel KV, Bahnsen JL, Gaussoin SA, Johnson KC, Pi-Sunyer X, White U, et al. Association of baseline and longitudinal changes in body composition measures with risk of heart failure and myocardial infarction in type 2 diabetes: findings from the Look AHEAD trial. *Circulation* 2020;**142**:2420–30. <https://doi.org/10.1161/CIRCULATIONAHA.120.050941>
75. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *Eur Heart J* 2015;**36**:1536–46. <https://doi.org/10.1093/eurheartj/ehv072>
76. Shah S, Henry A, Roselli C, Lin H, Sveinbjornsson G, Fatemifar G, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun* 2020;**11**:163. <https://doi.org/10.1038/s41467-019-13690-5>
77. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur Heart J* 2013;**34**:1404–13. <https://doi.org/10.1093/eurheartj/ehs337>
78. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006;**113**:1424–33. <https://doi.org/10.1161/CIRCULATIONAHA.105.584102>
79. Burger PM, Savarese G, Tromp J, Adamson C, Jhund PS, Benson L, et al. Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. *Eur J Heart Fail* 2023;**25**:1962–75. <https://doi.org/10.1002/ehf.3028>
80. Reitsma TH, Savarese G, Kuzma L, Deo SV, Pennells L, Hageman SHJ, et al. Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-preserved model. *Eur Heart J* 2026. <https://doi.org/10.1093/eurheartj/ehag182>
81. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American Heart Association's

- PREVENT equations. *Circulation* 2024;**149**:430–49. <https://doi.org/10.1161/CIRCULATIONAHA.123.067626>
82. SCORE2 Writing Group; European Society of Cardiology's Cardiovascular Risk Collaboration (CRC) Unit. Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. *Eur Heart J* 2026. <https://doi.org/10.1093/eurheartj/ehag154>
 83. Reitsma TH, Lim CE, Gynnild MN, Kaptoge S, Loo L, Holtrop J, et al. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. *Eur Heart J* 2026. <https://doi.org/10.1093/eurheartj/ehag153>
 84. Zhang S, Marken I, Stubbendorff A, Ericson U, Qi L, Sonestedt E, et al. The EAT-Lancet diet index, plasma proteins, and risk of heart failure in a population-based cohort. *JACC Heart Fail* 2024;**12**:1197–208. <https://doi.org/10.1016/j.jchf.2024.02.017>
 85. Zhu Z, Li FR, Jia Y, Li Y, Guo D, Chen J, et al. Association of lifestyle with incidence of heart failure according to metabolic and genetic risk status: a population-based prospective study. *Circ Heart Fail* 2022;**15**:e009592. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.009592>
 86. Ibsen DB, Chiu YH, Gemes K, Wolk A. Hypothetical 22-year intervention with the Dietary Approaches to Stop Hypertension and risk of heart failure in a general population. *Am J Epidemiol* 2024;**193**:96–106. <https://doi.org/10.1093/aje/kwad181>
 87. Ibsen DB, Levitan EB, Akesson A, Gigante B, Wolk A. The DASH diet is associated with a lower risk of heart failure: a cohort study. *Eur J Prev Cardiol* 2022;**29**:1114–23. <https://doi.org/10.1093/eurjpc/zwac003>
 88. Strengers JG, den Ruijter HM, Boer JMA, Asselbergs FW, Verschuren WMM, van der Schouw YT, et al. The association of the Mediterranean diet with heart failure risk in a Dutch population. *Nutr Metab Cardiovasc Dis* 2021;**31**:60–66. <https://doi.org/10.1016/j.numecd.2020.08.003>
 89. Papadaki A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, Salas-Salvado J, Corella D, et al. Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. *Eur J Heart Fail* 2017;**19**:1179–85. <https://doi.org/10.1002/ehf.750>
 90. Larsson SC, Tektonidou TG, Gigante B, Akesson A, Wolk A. Healthy lifestyle and risk of heart failure: results from 2 prospective cohort studies. *Circ Heart Fail* 2016;**9**:e002855. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002855>
 91. LaMonte MJ, LaCroix AZ, Nguyen S, Evenson KR, Di C, Stefanick ML, et al. Accelerometer-measured physical activity, sedentary time, and heart failure risk in women aged 63 to 99 years. *JAMA Cardiol* 2024;**9**:336–45. <https://doi.org/10.1001/jamacardio.2023.5692>
 92. Jung I, Kwon H, Park SE, Han KD, Park YG, Rhee EJ, et al. Changes in patterns of physical activity and risk of heart failure in newly diagnosed diabetes mellitus patients. *Diabetes Metab J* 2022;**46**:327–36. <https://doi.org/10.4093/dmj.2021.0046>
 93. Rariden BS, Boltz AJ, Brawner CA, Pinkstaff SO, Richardson MR, Johnson TM, et al. Sedentary time and cumulative risk of preserved and reduced ejection fraction heart failure: from the Multi-Ethnic Study of Atherosclerosis. *J Card Fail* 2019;**25**:418–24. <https://doi.org/10.1016/j.cardfail.2019.03.017>
 94. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J* 2021;**42**:17–96. <https://doi.org/10.1093/eurheartj/ehaa605>
 95. Yoo JE, Jeong SM, Yeo Y, Jung W, Yoo J, Han K, et al. Smoking cessation reduces the risk of heart failure: a nationwide cohort study. *JACC Heart Fail* 2023;**11**:277–87. <https://doi.org/10.1016/j.jchf.2022.07.006>
 96. Ding N, Shah AM, Blaha MJ, Chang PP, Rosamond WD, Matsushita K. Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction. *J Am Coll Cardiol* 2022;**79**:2298–305. <https://doi.org/10.1016/j.jacc.2022.03.377>
 97. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: a systematic review and meta-analysis of prospective studies. *Eur J Prev Cardiol* 2019;**26**:279–88. <https://doi.org/10.1177/2047487318806658>
 98. Andersson C, Schou M, Gustafsson F, Torp-Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: consensus and controversy. *Circ Heart Fail* 2022;**15**:e009459. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.009459>
 99. Abdullah R, Bjornebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, et al. Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids. *Eur J Prev Cardiol* 2024;**31**:599–608. <https://doi.org/10.1093/eurjpc/zwad362>
 100. Arenas DJ, Beltran S, Zhou S, Goldberg LR. Cocaine, cardiomyopathy, and heart failure: a systematic review and meta-analysis. *Sci Rep* 2020;**10**:19795. <https://doi.org/10.1038/s41598-020-76273-1>
 101. Schurer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. *JACC Heart Fail* 2017;**5**:435–45. <https://doi.org/10.1016/j.jchf.2017.02.017>
 102. Group SR, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final report of a trial of intensive versus standard blood-pressure control. *N Engl J Med* 2021;**384**:1921–30. <https://doi.org/10.1056/NEJMoa1901281>
 103. Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2024;**12**:447–61. [https://doi.org/10.1016/S2213-8587\(24\)00102-5](https://doi.org/10.1016/S2213-8587(24)00102-5)
 104. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet* 2022;**400**:1788–801. [https://doi.org/10.1016/S0140-6736\(22\)02074-8](https://doi.org/10.1016/S0140-6736(22)02074-8)
 105. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J* 2022;**43**:474–84. <https://doi.org/10.1093/eurheartj/ehab777>
 106. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020;**383**:2219–29. <https://doi.org/10.1056/NEJMoa2025845>
 107. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 2021;**385**:2252–63. <https://doi.org/10.1056/NEJMoa2110956>
 108. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. *Eur J Heart Fail* 2022;**24**:996–1005. <https://doi.org/10.1002/ehf.2469>
 109. Yang R, Lv J, Yu C, Guo Y, Bian Z, Han Y, et al. Importance of healthy lifestyle factors and ideal cardiovascular health metrics for risk of heart failure in Chinese adults. *Int J Epidemiol* 2022;**51**:567–78. <https://doi.org/10.1093/ije/dyab236>
 110. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. *Circulation* 2025;**151**:828–34. <https://doi.org/10.1161/CIRCULATIONAHA.124.071117>
 111. Baggish AL, Weiner RB, Kanayama G, Hudson JL, Picard MH, Hutter AM Jr, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. *Circ Heart Fail* 2010;**3**:472–6. <https://doi.org/10.1161/CIRCHEARTFAILURE.109.931063>
 112. Richards JR, Harms BN, Kelly A, Turnipseed SD. Methamphetamine use and heart failure: prevalence, risk factors, and predictors. *Am J Emerg Med* 2018;**36**:1423–8. <https://doi.org/10.1016/j.ajem.2018.01.001>
 113. Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCLE trial. *Circulation* 2019;**140**:1613–22. <https://doi.org/10.1161/CIRCULATIONAHA.119.041659>
 114. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. *J Am Coll Cardiol* 2020;**75**:1128–41. <https://doi.org/10.1016/j.jacc.2019.12.063>
 115. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;**383**:1436–46. <https://doi.org/10.1056/NEJMoa2024816>
 116. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 2023;**388**:117–27. <https://doi.org/10.1056/NEJMoa2204233>
 117. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;**380**:2295–306. <https://doi.org/10.1056/NEJMoa1811744>
 118. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024;**45**:3314–414. <https://doi.org/10.1093/eurheartj/ehae176>
 119. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular

- arrhythmias and the prevention of sudden cardiac death. *Eur Heart J* 2022; **43**:3997–4126. <https://doi.org/10.1093/eurheartj/ehac262>
120. Yndeggen T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. *N Engl J Med* 2024;**390**:1372–81. <https://doi.org/10.1056/NEJMoa2401479>
 121. Kristensen AMD, Rossello X, Atar D, Yndeggen T, Kimura T, Latini R, et al. Beta-blockers after myocardial infarction with normal ejection fraction. *N Engl J Med* 2025;**394**:540–50. <https://doi.org/10.1056/NEJMoa2512686>
 122. Damman K, ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). *Eur Heart J* 2026. <https://doi.org/10.1093/eurheartj/ehag098>
 123. Andersson C, Schou M, Schwartz B, Vasan RS, Christiansen MN, D'Souza M, et al. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. *Int J Cardiol Heart Vasc* 2022;**41**:101065. <https://doi.org/10.1016/j.ijcha.2022.101065>
 124. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J* 2023;**44**:3503–626. <https://doi.org/10.1093/eurheartj/ehad194>
 125. Hesse K, Bourke S, Steer J. Heart failure in patients with COPD exacerbations: looking below the tip of the iceberg. *Respir Med* 2022;**196**:106800. <https://doi.org/10.1016/j.rmed.2022.106800>
 126. Mahmood A, Ray M, Dobalian A, Ward KD, Ahn S. Insomnia symptoms and incident heart failure: a population-based cohort study. *Eur Heart J* 2021; **42**:4169–76. <https://doi.org/10.1093/eurheartj/ehab500>
 127. Cowie MR, Linz D, Redline S, Somers VK, Simonds AK. Sleep disordered breathing and cardiovascular disease: JACC state-of-the-art review. *J Am Coll Cardiol* 2021;**78**:608–24. <https://doi.org/10.1016/j.jacc.2021.05.048>
 128. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: mechanisms and associations. *Curr Heart Fail Rep* 2017;**14**:48–58. <https://doi.org/10.1007/s11897-017-0312-5>
 129. Burchill LJ, Gao L, Kovacs AH, Opatowski AR, Maxwell BG, Minnier J, et al. Hospitalization trends and health resource use for adult congenital heart disease-related heart failure. *J Am Heart Assoc* 2018;**7**:e008775. <https://doi.org/10.1161/JAHA.118.008775>
 130. Dellborg M, Giang KW, Eriksson P, Liden H, Fedchenko M, Ahnfelt A, et al. Adults with congenital heart disease: trends in event-free survival past middle age. *Circulation* 2023;**147**:930–8. <https://doi.org/10.1161/CIRCULATIONAHA.122.060834>
 131. Bergh N, Skoglund K, Fedchenko M, Bollano E, Eriksson P, Dellborg M, et al. Risk of heart failure in congenital heart disease: a nationwide register-based cohort study. *Circulation* 2023;**147**:982–4. <https://doi.org/10.1161/CIRCULATIONAHA.122.061546>
 132. Papazoglou AS, Kyriakoulis KG, Barmpagiannos K, Moysidis DV, Kartas A, Chatzi M, et al. Atherosclerotic risk factor prevalence in adults with congenital heart disease: a meta-analysis. *JACC Adv* 2024;**3**:101359. <https://doi.org/10.1016/j.jaccadv.2024.101359>
 133. Brida M, De Rosa S, Legendre A, Ladouceur M, Dos Subira L, Scognamiglio G, et al. Acquired cardiovascular disease in adults with congenital heart disease. *Eur Heart J* 2023;**44**:4533–48. <https://doi.org/10.1093/eurheartj/ehad570>
 134. Landstrom AP, Spears T, D'Ottavio A, Chiswell K, Sommerhalter K, Soim A, et al. Cardiovascular disease risk factors in congenital heart disease survivors are associated with heart failure. *Pediatr Res* 2025;**97**:700–6. <https://doi.org/10.1038/s41390-024-03352-8>
 135. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. *Lancet* 2003;**361**:1843–8. [https://doi.org/10.1016/S0140-6736\(03\)13501-5](https://doi.org/10.1016/S0140-6736(03)13501-5)
 136. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992;**327**:685–91. <https://doi.org/10.1056/NEJM199209033271003>
 137. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med* 1995; **333**:1670–6. <https://doi.org/10.1056/NEJM199512213332503>
 138. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. *N Engl J Med* 1992; **327**:669–77. <https://doi.org/10.1056/NEJM199209033271001>
 139. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001;**357**:1385–90. [https://doi.org/10.1016/S0140-6736\(00\)04560-8](https://doi.org/10.1016/S0140-6736(00)04560-8)
 140. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol* 1999;**33**:916–23. [https://doi.org/10.1016/S0735-1097\(98\)00675-5](https://doi.org/10.1016/S0735-1097(98)00675-5)
 141. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. *J Am Coll Cardiol* 1997;**29**:229–36. [https://doi.org/10.1016/S0735-1097\(96\)00489-5](https://doi.org/10.1016/S0735-1097(96)00489-5)
 142. Colucci WS, Koliak TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. *Circulation* 2007;**116**:49–56. <https://doi.org/10.1161/CIRCULATIONAHA.106.666016>
 143. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003;**348**:1309–21. <https://doi.org/10.1056/NEJMoa030207>
 144. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;**349**:1893–906. <https://doi.org/10.1056/NEJMoa032292>
 145. Docherty KF, Lam CSP, Rakisheva A, Coats AJS, Greenhalgh T, Metra M, et al. Heart failure diagnosis in the general community—who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2023;**25**:1185–98. <https://doi.org/10.1002/ehfj.2946>
 146. Booth RA, Hill SA, Don-Wauchope A, Santaguida PL, Oremus M, McKelvie R, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. *Heart Fail Rev* 2014;**19**:439–51. <https://doi.org/10.1007/s10741-014-9445-8>
 147. Clerico A, Fontana M, Zyw L, Passino C, Ermdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. *Clin Chem* 2007;**53**:813–22. <https://doi.org/10.1373/clinchem.2006.075713>
 148. Roalke AK, Taylor CJ, Kelder JC, Hoes AW, Hobbs FDR. Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. *ESC Heart Fail* 2021;**8**:2193–201. <https://doi.org/10.1002/ehf2.13311>
 149. Ordóñez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. *Am J Cardiol* 2008; **101**:9–15. <https://doi.org/10.1016/j.amjcard.2007.11.013>
 150. Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. *J Am Coll Cardiol* 2019;**73**:1264–72. <https://doi.org/10.1016/j.jacc.2019.01.018>
 151. Taylor CJ, Taylor KS, Jones NR, Ordóñez-Mena JM, Bayes-Genis A, Hobbs FDR. Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: diagnostic accuracy study. *ESC Heart Fail* 2025;**12**:3552–68. <https://doi.org/10.1002/ehf2.15383>
 152. Welsh P, Campbell RT, Mooney L, Kimenai DM, Hayward C, Campbell A, et al. Reference ranges for NT-proBNP (N-terminal Pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. *Circ Heart Fail* 2022;**15**:e009427. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.009427>
 153. Shetty NS, Patel N, Gaonkar M, Li P, Arora G, Arora P. Natriuretic peptide normative levels and deficiency: the National Health and Nutrition Examination Survey. *JACC Heart Fail* 2024;**12**:50–63. <https://doi.org/10.1016/j.jchf.2023.07.018>
 154. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. *Eur Heart J* 2010;**31**:1881–9. <https://doi.org/10.1093/eurheartj/ehq163>
 155. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. *Eur J Heart Fail* 2019;**21**:715–31. <https://doi.org/10.1002/ehfj.1494>
 156. Lee KH, Kim JY, Koh SB, Lee SH, Yoon J, Han SW, et al. N-terminal pro-B-type natriuretic peptide levels in the Korean general population. *Korean Circ J* 2010;**40**:645–50. <https://doi.org/10.4070/kcj.2010.40.12.645>

157. Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. *Eur J Heart Fail* 2023;**25**:1891–8. <https://doi.org/10.1002/ehfj.3036>
158. Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory out-patient setting. *Circulation* 2025;**151**:976–89. <https://doi.org/10.1161/CIRCULATIONAHA.124.072156>
159. Kozuharov N, Martin J, Wussler D, Lopez-Ayala P, Belkin M, Strebel I, et al. Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. *Eur J Heart Fail* 2022;**24**:1545–54. <https://doi.org/10.1002/ehfj.2618>
160. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. *Am Heart J* 2006;**151**:999–1005. <https://doi.org/10.1016/j.ahj.2005.10.011>
161. Lu Y, Chen J, Chen R, Lukwaro AF, Zhou S, Luo Y, et al. Determining kidney function-specific thresholds for N-terminal pro-B-type natriuretic peptide in heart failure risk prediction among patients with chronic kidney disease: a multicentre, observational, cohort study. *Heart* 2025;**111**:828–34. <https://doi.org/10.1136/heartjnl-2024-324679>
162. Neuen BL, Vaduganathan M, Claggett BL, Beldhuis I, Myhre P, Desai AS, et al. Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction. *JACC Heart Fail* 2025;**13**:28–39. <https://doi.org/10.1016/j.jchf.2024.08.009>
163. Taylor CJ, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, Jones NR, Roalfe AK, et al. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018. *Heart* 2022;**108**:543–9. <https://doi.org/10.1136/heartjnl-2021-319196>
164. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int* 2024;**105**:S117–314. <https://doi.org/10.1016/j.kint.2023.10.018>
165. Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. *JACC Heart Fail* 2014;**2**:586–96. <https://doi.org/10.1016/j.jchf.2014.05.016>
166. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. *Lancet* 2009;**374**:543–50. [https://doi.org/10.1016/S0140-6736\(09\)61378-7](https://doi.org/10.1016/S0140-6736(09)61378-7)
167. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. *Circ Heart Fail* 2018;**11**:e005288. <https://doi.org/10.1161/CIRCHEARTFAILURE.118.005288>
168. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. *Lancet Diabetes Endocrinol* 2015;**3**:514–25. [https://doi.org/10.1016/S2213-8587\(15\)00040-6](https://doi.org/10.1016/S2213-8587(15)00040-6)
169. Chen H, Chhor M, Rayner BS, McGrath K, McClements L. Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *Arch Cardiovasc Dis* 2021;**114**:793–804. <https://doi.org/10.1016/j.acvd.2021.10.007>
170. Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, et al. An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. *Nat Med* 2024;**30**:2258–64. <https://doi.org/10.1038/s41591-024-03140-1>
171. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2020;**22**:391–412. <https://doi.org/10.1002/ehfj.1741>
172. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018;**138**:861–70. <https://doi.org/10.1161/CIRCULATIONAHA.118.034646>
173. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. *JACC Heart Fail* 2020;**8**:640–53. <https://doi.org/10.1016/j.jchf.2020.03.013>
174. Reddy YNV, Kaye DM, Handoko ML, van de Bovenkamp AA, Tedford RJ, Keck C, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. *JAMA Cardiol* 2022;**7**:891–9. <https://doi.org/10.1001/jamacardio.2022.1916>
175. Li S, Zhu X, Zhang Y, Li F, Guo S. Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis. *ESC Heart Fail* 2023;**10**:2225–35. <https://doi.org/10.1002/ehf2.14421>
176. Guazzi M, Wilhelm M, Halle M, Van Craenenbroeck E, Kemps H, de Boer RA, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy—a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. *Eur J Heart Fail* 2022;**24**:1327–45. <https://doi.org/10.1002/ehfj.2601>
177. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000;**342**:1077–84. <https://doi.org/10.1056/NEJM200004133421502>
178. Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. *N Engl J Med* 2022;**387**:1351–60. <https://doi.org/10.1056/NEJMoa2206606>
179. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011;**364**:1607–16. <https://doi.org/10.1056/NEJMoa1100356>
180. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016;**374**:1511–20. <https://doi.org/10.1056/NEJMoa1602001>
181. Shen Y, Yang Y. Comparing the diagnostic performance of [¹⁸F]FDG PET/CT and [¹⁸F]FDG PET/MRI for detecting cardiac sarcoidosis: a meta-analysis. *Clin Imaging* 2024;**113**:110248. <https://doi.org/10.1016/j.clinimag.2024.110248>
182. Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis: a systematic review and meta-analysis. *J Nucl Cardiol* 2020;**27**:2103–15. <https://doi.org/10.1007/s12350-018-01582-y>
183. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. *JAMA Cardiol* 2019;**4**:1007–18. <https://doi.org/10.1001/jamacardio.2019.2952>
184. Sun JP, Xu TY, Ni XD, Yang XS, Hu JL, Wang SC, et al. Echocardiographic strain in hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. *Echocardiography* 2019;**36**:257–65. <https://doi.org/10.1111/echo.14222>
185. Pagourelas ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. *Circ Cardiovasc Imaging* 2017;**10**:e005588. <https://doi.org/10.1161/CIRCIMAGING.116.005588>
186. Alba AC, Gaztanaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D, et al. Prognostic value of late gadolinium enhancement for the prediction of cardiovascular outcomes in dilated cardiomyopathy: an international, multi-institutional study of the MINICOR group. *Circ Cardiovasc Imaging* 2020;**13**:e010105. <https://doi.org/10.1161/CIRCIMAGING.119.010105>
187. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. *JACC Cardiovasc Imaging* 2020;**13**:69–80. <https://doi.org/10.1016/j.jcmg.2019.03.026>
188. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J* 2001;**22**:2171–9. <https://doi.org/10.1053/ehuj.2001.2822>
189. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson* 2017;**19**:75. <https://doi.org/10.1186/s12968-017-0389-8>
190. Quarta G, Husain SI, Flett AS, Sado DM, Chao CY, Tome Esteban MT, et al. Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2013;**15**:16. <https://doi.org/10.1186/1532-429X-15-16>
191. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. *Circulation* 2005;**112**:855–61. <https://doi.org/10.1161/CIRCULATIONAHA.104.507723>

192. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. *Circ Cardiovasc Imaging* 2013;6:392–8. <https://doi.org/10.1161/CIRCIMAGING.112.000070>
193. Holmstrom M, Kivisto S, Helio T, Jurkko R, Kaartinen M, Antila M, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy. *J Cardiovasc Magn Reson* 2011;13:30. <https://doi.org/10.1186/1532-429X-13-30>
194. Cai S, Haghighyan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, et al. Tissue mapping by cardiac magnetic resonance imaging for the prognostic of cardiac amyloidosis: a systematic review and meta-analysis. *Int J Cardiol* 2024;403:131892. <https://doi.org/10.1016/j.ijcard.2024.131892>
195. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;19:1574–85. <https://doi.org/10.1002/ehf.813>
196. Graversen CB, Rasmussen LD, Sundboll J, Wurtz M, Kragholm KH, Bottcher M, et al. Cardiac computed tomography for rule-out of ischaemic heart disease in patients with new-onset heart failure. *Eur Heart J Cardiovasc Imaging* 2025;26:794–801. <https://doi.org/10.1093/ehjci/jeaf090>
197. Desai D, Maheta DK, Agrawal SP, Abouarab AG, Frishman WH, Aronow WS. Understanding arrhythmia-induced cardiomyopathy: symptoms and treatments. *Cardiol Rev* 2024. <https://doi.org/10.1097/CRD.0000000000000755>
198. Shoureshi P, Tan AY, Koneru J, Ellenbogen KA, Kaszala K, Huizar JF. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol* 2024;83:2214–32. <https://doi.org/10.1016/j.jacc.2024.03.416>
199. Huizar JF, Kaszala K, Tan A, Koneru J, Mankad P, Kron J, et al. Abnormal conduction-induced cardiomyopathy: JACC review topic of the week. *J Am Coll Cardiol* 2023;81:1192–200. <https://doi.org/10.1016/j.jacc.2023.01.040>
200. Merkely B, Geller L, Zima E, Osztosheimer I, Molnar L, Foldesi C, et al. Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial. *Eur J Heart Fail* 2022;24:1652–61. <https://doi.org/10.1002/ehf.2609>
201. Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and clinical outcomes of pacing induced cardiomyopathy in patients with normal left ventricular systolic function and atrioventricular block. *Am J Cardiol* 2020;128:174–80. <https://doi.org/10.1016/j.amjcard.2020.05.017>
202. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation* 2003;107:2932–7. <https://doi.org/10.1161/01.CIR.0000072769.12795.B1>
203. Yu CM, Fang F, Luo XX, Zhang Q, Azlan H, Razali O. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. *Eur J Heart Fail* 2014;16:1016–25. <https://doi.org/10.1002/ehf.157>
204. Lu W, Lin J, Dai Y, Chen K, Zhang S. The therapeutic effects of upgrade to cardiac resynchronization therapy in pacing-induced cardiomyopathy or chronic right ventricular pacing patients: a meta-analysis. *Heart Fail Rev* 2022;27:507–16. <https://doi.org/10.1007/s10741-021-10091-z>
205. Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. *JACC Cardiovasc Imaging* 2018;11:1274–84. <https://doi.org/10.1016/j.jcmg.2018.03.006>
206. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. *Heart* 2015;101:1406–11. <https://doi.org/10.1136/heartjnl-2015-307682>
207. Duan X, Li J, Zhang Q, Zeng Z, Luo Y, Jiang J, et al. Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis. *Clin Radiol* 2015;70:999–1008. <https://doi.org/10.1016/j.crad.2015.05.007>
208. Golukhova EZ, Bulaeva NI, Alexandrova SA, Mrikaev DV, Gromova OI, Ruzina EV, et al. The extent of late gadolinium enhancement predicts mortality, sudden death and major adverse cardiovascular events in patients with nonischemic cardiomyopathy: a systematic review and meta-analysis. *Clin Radiol* 2023;78:e342–9. <https://doi.org/10.1016/j.crad.2022.12.015>
209. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. *JACC Cardiovasc Imaging* 2012;5:370–7. <https://doi.org/10.1016/j.jcmg.2011.11.021>
210. He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. *Heart Lung* 2018;47:122–6. <https://doi.org/10.1016/j.hrtlung.2017.10.008>
211. Helali J, Ramesh K, Brown J, Preciado-Ruiz C, Nguyen T, Silva LT, et al. Late gadolinium enhancement on cardiac MRI: a systematic review and meta-analysis of prognosis across cardiomyopathies. *Int J Cardiol* 2025;419:132711. <https://doi.org/10.1016/j.ijcard.2024.132711>
212. Kamp NJ, Chery G, Kosinski AS, Desai MY, Wazni O, Schmidler GS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Prog Cardiovasc Dis* 2021;66:10–6. <https://doi.org/10.1016/j.pcad.2020.11.001>
213. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. *Circ Cardiovasc Imaging* 2014;7:250–8. <https://doi.org/10.1161/CIRCIMAGING.113.001144>
214. Paterson DI, Wells G, Erthal F, Mielniczuk L, O'Meara E, White J, et al. OUTSMART HF: a randomized controlled trial of routine versus selective cardiac magnetic resonance for patients with nonischemic heart failure (IMAGE-HF 1B). *Circulation* 2020;141:818–27. <https://doi.org/10.1161/CIRCULATIONAHA.119.043964>
215. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. *JACC Cardiovasc Imaging* 2016;9:1392–402. <https://doi.org/10.1016/j.jcmg.2016.02.031>
216. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. *J Am Coll Cardiol* 2005;46:1076–84. <https://doi.org/10.1016/j.jacc.2005.05.073>
217. Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argio A, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. *Eur Heart J* 2023;44:2187–98. <https://doi.org/10.1093/eurheartj/ehad139>
218. Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. *J Nucl Cardiol* 2019;26:497–504. <https://doi.org/10.1007/s12350-017-0922-z>
219. Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. *Amyloid* 2015;22:210–20. <https://doi.org/10.3109/13506129.2015.1072089>
220. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation* 2016;133:2404–12. <https://doi.org/10.1161/CIRCULATIONAHA.116.021612>
221. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. *JACC Cardiovasc Imaging* 2014;7:531–2. <https://doi.org/10.1016/j.jcmg.2014.03.004>
222. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. *Circ Cardiovasc Imaging* 2013;6:195–201. <https://doi.org/10.1161/CIRCIMAGING.112.000132>
223. McBenedit B, Hauwanga WN, Amadi ES, Abraham AA, Sivakumar R, Okere MO, et al. Impact of genetic testing on the diagnosis, management, and prognosis of hypertrophic cardiomyopathy: a systematic review. *Cureus* 2024;16:e70993. <https://doi.org/10.7759/cureus.70993>
224. Anastasiou V, Papazoglou AS, Gossios T, Zegkos T, Daivos S, Moysidis DV, et al. Prognostic implications of genotype findings in non-ischaemic dilated cardiomyopathy: a network meta-analysis. *Eur J Heart Fail* 2024;26:2155–68. <https://doi.org/10.1002/ehf.3403>
225. Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, et al. A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. *Genet Med* 2019;21:2815–22. <https://doi.org/10.1038/s41436-019-0582-2>
226. Christian S, Cirino A, Hansen B, Harris S, Murad AM, Natoli JL, et al. Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Open Heart* 2022;9:e001815. <https://doi.org/10.1136/openhrt-2021-001815>
227. Ingles J, McGaughan J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. *Heart* 2012;98:625–30. <https://doi.org/10.1136/heartjnl-2011-300368>
228. Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M, et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. *Heart Fail Rev* 2020;25:277–94. <https://doi.org/10.1007/s10741-019-09835-9>
229. Hurrell DG, Nishimura RA, Higano ST, Appleton CP, Danielson GK, Holmes DR Jr, et al. Value of dynamic respiratory changes in left and right ventricular

- pressures for the diagnosis of constrictive pericarditis. *Circulation* 1996;**93**: 2007–13. <https://doi.org/10.1161/01.cir.93.11.2007>
230. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. *Eur Heart J* 2014;**35**:3103–12. <https://doi.org/10.1093/eurheartj/ehu315>
 231. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail* 2010;**3**:588–95. <https://doi.org/10.1161/CIRCHEARTFAILURE.109.930701>
 232. van den Boogert TPW, Claessen B, van Randen A, van Schuppen J, Boekholdt SM, Beijk MAM, et al. Implementation of CT coronary angiography as an alternative to invasive coronary angiography in the diagnostic work-up of non-coronary cardiac surgery, cardiomyopathy, heart failure and ventricular arrhythmias. *J Clin Med* 2021;**10**:2374. <https://doi.org/10.3390/jcm10112374>
 233. Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H, et al. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). *Eur Heart J Cardiovasc Imaging* 2021;**22**:1083–90. <https://doi.org/10.1093/ehjci/jeaa109>
 234. Andreini D, Pontone G, Bartorelli AL, Agostoni P, Mushtaq S, Bertella E, et al. Sixty-four-slice multidetector computed tomography: an accurate imaging modality for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. *Circ Cardiovasc Imaging* 2009;**2**:199–205. <https://doi.org/10.1161/CIRCIMAGING.108.822809>
 235. Merkely B, Hatala R, Merkely E, Szigeti M, Veres B, Fabian A, et al. Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation. *Europace* 2024;**26**:euae179. <https://doi.org/10.1093/europace/euae179>
 236. Kaye G, Ng JY, Ahmed S, Valencia D, Harrop D, Ng ACT. The prevalence of pacing-induced cardiomyopathy (PICM) in patients with long term right ventricular pacing—is it a matter of definition? *Heart Lung Circ* 2019;**28**:1027–33. <https://doi.org/10.1016/j.hlc.2018.05.196>
 237. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm* 2014;**11**:1619–25. <https://doi.org/10.1016/j.hrthm.2014.05.040>
 238. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. *Heart Rhythm* 2016;**13**:2272–8. <https://doi.org/10.1016/j.hrthm.2016.09.027>
 239. Somma V, Ha FJ, Palmer S, Mohamed U, Agarwal S. Pacing-induced cardiomyopathy: a systematic review and meta-analysis of definition, prevalence, risk factors, and management. *Heart Rhythm* 2023;**20**:282–90. <https://doi.org/10.1016/j.hrthm.2022.09.019>
 240. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. 'Asymptomatic' persistent or permanent atrial fibrillation: a misnomer in selected patients. *Int J Cardiol* 2015;**185**:112–3. <https://doi.org/10.1016/j.ijcard.2015.03.122>
 241. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet* 2022;**400**:757–67. [https://doi.org/10.1016/S0140-6736\(22\)01429-5](https://doi.org/10.1016/S0140-6736(22)01429-5)
 242. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;**381**:1995–2008. <https://doi.org/10.1056/NEJMoa1911303>
 243. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;**383**:1413–24. <https://doi.org/10.1056/NEJMoa2022190>
 244. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**:1451–61. <https://doi.org/10.1056/NEJMoa2107038>
 245. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2022;**387**:1089–98. <https://doi.org/10.1056/NEJMoa2206286>
 246. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020;**396**:819–29. [https://doi.org/10.1016/S0140-6736\(20\)31824-9](https://doi.org/10.1016/S0140-6736(20)31824-9)
 247. Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. *JAMA Netw Open* 2024;**7**:e245135. <https://doi.org/10.1001/jamanetworkopen.2024.5135>
 248. Oriecua C, Tomasoni D, Sala I, Bonfili GB, Adamo M, Gussago C, et al. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother* 2024;**10**: 147–57. <https://doi.org/10.1093/ehjcvp/pvad088>
 249. Kondo T, Jhund PS, Gasparyan SB, Yang M, Claggett BL, McCausland FR, et al. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. *Nat Med* 2024;**30**:1432–9. <https://doi.org/10.1038/s41591-024-02941-8>
 250. Sharma A, Ferreira JP, Zannad F, Pocock SJ, Filippatos G, Pfarr E, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-preserved trial. *Eur J Heart Fail* 2023;**25**:1337–48. <https://doi.org/10.1002/ehf.2857>
 251. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. *Circulation* 2021;**143**:298–309. <https://doi.org/10.1161/CIRCULATIONAHA.120.050391>
 252. McCausland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. *JAMA Cardiol* 2023;**8**:56–65. <https://doi.org/10.1001/jamacardio.2022.4210>
 253. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. *Circulation* 2021;**143**: 310–21. <https://doi.org/10.1161/CIRCULATIONAHA.120.051685>
 254. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;**341**:709–17. <https://doi.org/10.1056/NEJM199909023411001>
 255. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014;**370**:1383–92. <https://doi.org/10.1056/NEJMoa1313731>
 256. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;**364**:11–21. <https://doi.org/10.1056/NEJMoa1009492>
 257. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2024;**391**:1475–85. <https://doi.org/10.1056/NEJMoa2407107>
 258. Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, et al. Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. *JACC Heart Fail* 2025;**13**:102637. <https://doi.org/10.1016/j.jchf.2025.102637>
 259. Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2022;**24**:603–19. <https://doi.org/10.1002/ehf.2471>
 260. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. *Int J Cardiol* 2002;**82**:149–58. [https://doi.org/10.1016/S0167-5273\(01\)00600-3](https://doi.org/10.1016/S0167-5273(01)00600-3)
 261. Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. *Eur J Heart Fail* 2016;**18**:328–36. <https://doi.org/10.1002/ehf.462>
 262. Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. *JACC Heart Fail* 2016;**4**:333–44. <https://doi.org/10.1016/j.jchf.2015.11.011>
 263. Galve E, Mallol A, Catalan R, Palet J, Mendez S, Nieto E, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. *Eur J Heart Fail* 2005;**7**:892–8. <https://doi.org/10.1016/j.ejheart.2004.09.006>
 264. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. *Am J Cardiol* 1994;**73**:881–6. [https://doi.org/10.1016/0002-9149\(94\)90815-x](https://doi.org/10.1016/0002-9149(94)90815-x)
 265. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;**21**:137–55. <https://doi.org/10.1002/ehf.1369>

266. Tomasoni D, Benson L, Gatti P, Villaschi A, Ljungman C, Metra M, et al. Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure. *Eur J Heart Fail* 2025;27:1820–33. <https://doi.org/10.1002/ehj.3719>
267. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Changes in loop diuretic dose and outcome after cardiac resynchronization therapy in patients with heart failure and reduced left ventricular ejection fractions. *Am J Cardiol* 2017;120:267–73. <https://doi.org/10.1016/j.amjcard.2017.04.021>
268. Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schottker B. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. *Cardiovasc Drugs Ther* 2018;32:197–212. <https://doi.org/10.1007/s10557-018-6783-0>
269. Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *Eur J Heart Fail* 2015;17:1050–6. <https://doi.org/10.1002/ehj.300>
270. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. *Eur Heart J* 2011;32:820–8. <https://doi.org/10.1093/eurheartj/ehq502>
271. Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. *Eur Heart J* 2022;43:4362–73. <https://doi.org/10.1093/eurheartj/ehac401>
272. Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. *J Am Coll Cardiol* 2024;85:971–84. <https://doi.org/10.1016/j.jacc.2024.11.014>
273. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2020;22:584–603. <https://doi.org/10.1002/ehj.1697>
274. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation* 1999;100:2312–8. <https://doi.org/10.1161/01.cir.100.23.2312>
275. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991;325:293–302. <https://doi.org/10.1056/NEJM199108013250501>
276. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995;273:1450–6. <https://doi.org/10.1001/jama.1995.03520420066040>
277. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987;316:1429–35. <https://doi.org/10.1056/NEJM198706043162301>
278. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371:993–1004. <https://doi.org/10.1056/NEJMoa1409077>
279. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. *JACC Heart Fail* 2018;6:489–98. <https://doi.org/10.1016/j.jchf.2018.02.004>
280. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. *JAMA Cardiol* 2017;2:79–85. <https://doi.org/10.1001/jamacardio.2016.4733>
281. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-e in acute decompensated heart failure. *N Engl J Med* 2019;380:539–48. <https://doi.org/10.1056/NEJMoa1812851>
282. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. *Circulation* 2019;139:2285–8. <https://doi.org/10.1161/CIRCULATIONAHA.118.039331>
283. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. *Eur J Heart Fail* 2019;21:998–1007. <https://doi.org/10.1002/ehj.1498>
284. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;362:772–6. [https://doi.org/10.1016/S0140-6736\(03\)14284-5](https://doi.org/10.1016/S0140-6736(03)14284-5)
285. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet* 2009;374:1840–8. [https://doi.org/10.1016/S0140-6736\(09\)61913-9](https://doi.org/10.1016/S0140-6736(09)61913-9)
286. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667–75. <https://doi.org/10.1056/NEJMoa010713>
287. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;353:2001–7. [https://doi.org/10.1016/S0140-6736\(99\)04440-2](https://doi.org/10.1016/S0140-6736(99)04440-2)
288. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353:9–13. [https://doi.org/10.1016/S0140-6736\(98\)11181-9](https://doi.org/10.1016/S0140-6736(98)11181-9)
289. Beta-Blocker Evaluation of Survival Trial Investigators; Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med* 2001;344:1659–67. <https://doi.org/10.1056/NEJM200105313442202>
290. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215–25. <https://doi.org/10.1093/eurheartj/ehi115>
291. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacs P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344:1651–8. <https://doi.org/10.1056/NEJM200105313442201>
292. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003;362:7–13. [https://doi.org/10.1016/S0140-6736\(03\)13800-7](https://doi.org/10.1016/S0140-6736(03)13800-7)
293. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;384:2235–43. [https://doi.org/10.1016/S0140-6736\(14\)61373-8](https://doi.org/10.1016/S0140-6736(14)61373-8)
294. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010;376:875–85. [https://doi.org/10.1016/S0140-6736\(10\)61198-1](https://doi.org/10.1016/S0140-6736(10)61198-1)
295. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020;382:1883–93. <https://doi.org/10.1056/NEJMoa1915928>
296. Butler J, Anstrom KJ, Armstrong PW. Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. *Circulation* 2020;142:717–9. <https://doi.org/10.1161/CIRCULATIONAHA.120.047086>
297. Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet* 2025;406:1341–50. [https://doi.org/10.1016/S0140-6736\(25\)01665-4](https://doi.org/10.1016/S0140-6736(25)01665-4)
298. Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. *Lancet* 2025;406:1351–62. [https://doi.org/10.1016/S0140-6736\(25\)01682-4](https://doi.org/10.1016/S0140-6736(25)01682-4)
299. Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, et al. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. *Eur Heart J* 2026;47:683–97. <https://doi.org/10.1093/eurheartj/ehaf655>
300. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino Jr R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004;351:2049–57. <https://doi.org/10.1056/NEJMoa042934>
301. Cohn JN, Archibald DG, Ziesche S, Francis JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986;314:1547–52. <https://doi.org/10.1056/NEJM198606123142404>
302. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, et al. Effects of digoxin at low serum concentrations on mortality and

- hospitalization in heart failure: a propensity-matched study of the DIG trial. *Int J Cardiol* 2008;**123**:138–46. <https://doi.org/10.1016/j.ijcard.2006.12.001>
303. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997;**336**:525–33. <https://doi.org/10.1056/NEJM199702203360801>
 304. Bavendiek U, Grosshennig A, Schwab J, Berliner D, Rieth A, Maier LS, et al. Digitoxin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2025;**393**:1155–65. <https://doi.org/10.1056/NEJMoa2415471>
 305. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. *Eur Heart J* 2015;**36**:1831–8. <https://doi.org/10.1093/eurheartj/ehv143>
 306. Washam JB, Stevens SR, Lohknygina Y, Halperin JL, Breithardt G, Singer DE, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Lancet* 2015;**385**:2363–70. [https://doi.org/10.1016/S0140-6736\(14\)61836-5](https://doi.org/10.1016/S0140-6736(14)61836-5)
 307. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;**362**:1363–73. <https://doi.org/10.1056/NEJMoa1001337>
 308. Ahmed A, Gambassi G, Weaver MT, Young JB, Wehnmacher WH, Rich MW. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. *Am J Cardiol* 2007;**100**:280–4. <https://doi.org/10.1016/j.amjcard.2007.02.099>
 309. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. *N Engl J Med* 2021;**384**:105–16. <https://doi.org/10.1056/NEJMoa2025797>
 310. Hulot JS, Ter Maaten JM, Bayes-Genis A, Halliday BP, Metra M, Moura B, et al. Heart failure improvement, remission, and recovery: a *European Journal of Heart Failure* expert consensus document. *Eur J Heart Fail* 2025;**27**:1807–19. <https://doi.org/10.1002/ejhf.3732>
 311. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. *Lancet* 2022;**400**:1938–52. [https://doi.org/10.1016/S0140-6736\(22\)02076-1](https://doi.org/10.1016/S0140-6736(22)02076-1)
 312. Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. *Circulation* 2022;**145**:693–712. <https://doi.org/10.1161/CIRCULATIONAHA.121.052792>
 313. Cannata A, McDonagh TA. Heart failure with preserved ejection fraction. *N Engl J Med* 2025;**392**:173–84. <https://doi.org/10.1056/NEJMcp2305181>
 314. Anker SD, Usman MS, Anker MS, Butler J, Bohm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. *Eur J Heart Fail* 2023;**25**:936–55. <https://doi.org/10.1002/ejhf.2894>
 315. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023;**389**:1069–84. <https://doi.org/10.1056/NEJMoa2306963>
 316. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. *N Engl J Med* 2024;**390**:1394–407. <https://doi.org/10.1056/NEJMoa2313917>
 317. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2025;**392**:427–37. <https://doi.org/10.1056/NEJMoa2410027>
 318. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. *Circulation* 2020;**141**:338–51. <https://doi.org/10.1161/CIRCULATIONAHA.119.044491>
 319. Solomon SD, Vaduganathan M, B LC, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. *Circulation* 2020;**141**:352–61. <https://doi.org/10.1161/CIRCULATIONAHA.119.044586>
 320. Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. *Cochrane Database Syst Rev* 2018;**6**:CD012721. <https://doi.org/10.1002/14651858.CD012721.pub2>
 321. Halliday BP, Wassall R, Lota AS, Khaliq Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. *Lancet* 2019;**393**:61–73. [https://doi.org/10.1016/S0140-6736\(18\)32484-X](https://doi.org/10.1016/S0140-6736(18)32484-X)
 322. Cheng L, Hammersley D, Ragavan A, Javed S, Mukhopadhyay S, Gregson J, et al. Long-term follow-up of the TRED-HF trial: implications for therapy in patients with dilated cardiomyopathy and heart failure remission. *Eur J Heart Fail* 2025;**27**:113–23. <https://doi.org/10.1002/ejhf.3475>
 323. Belfort DSP, Bocchi EA, Cafezeiro CRF, Wanderley MRB Jr, Salemi VMC, Rocon C, et al. Carvedilol as single therapy for heart failure with improved ejection fraction: a randomized clinical trial (CATHEDRAL-HF). *JACC Heart Fail* 2025;**13**:1041–44. <https://doi.org/10.1016/j.jchf.2025.02.022>
 324. Segan L, Kistler PM, Nanayakkara S, Taylor A, Hare J, Costello B, et al. Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial. *Eur Heart J* 2025;**47**:250–62. <https://doi.org/10.1093/eurheartj/ehaf563>
 325. Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, et al. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. *J Am Coll Cardiol* 2020;**75**:1426–38. <https://doi.org/10.1016/j.jacc.2020.01.040>
 326. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 2021;**384**:117–28. <https://doi.org/10.1056/NEJMoa2030183>
 327. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. *JAMA* 2023;**329**:214–23. <https://doi.org/10.1001/jama.2022.23924>
 328. Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. *J Am Coll Cardiol* 2020;**76**:669–79. <https://doi.org/10.1016/j.jacc.2020.06.022>
 329. Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simoes MV, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. *Eur Heart J* 2019;**40**:3605–12. <https://doi.org/10.1093/eurheartj/ehz554>
 330. Lund LH, Benson L, Dahlstrom U, Edner M, Friberg L. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. *JAMA* 2014;**312**:2008–18. <https://doi.org/10.1001/jama.2014.15241>
 331. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet* 2008;**372**:1174–83. [https://doi.org/10.1016/S0140-6736\(08\)61242-8](https://doi.org/10.1016/S0140-6736(08)61242-8)
 332. Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, et al. Sacubitril/valsartan in patients hospitalized with decompensated heart failure. *J Am Coll Cardiol* 2024;**83**:1123–32. <https://doi.org/10.1016/j.jacc.2024.01.027>
 333. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. *JAMA* 2012;**308**:2108–17. <https://doi.org/10.1001/jama.2012.14785>
 334. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008;**359**:2456–67. <https://doi.org/10.1056/NEJMoa0805450>
 335. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. *J Am Coll Cardiol* 2023;**82**:1–12. <https://doi.org/10.1016/j.jacc.2023.04.019>
 336. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. *Eur J Heart Fail* 2014;**16**:33–40. <https://doi.org/10.1002/ejhf.29>
 337. Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV, et al. Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis. *JACC Heart Fail* 2024;**12**:616–27. <https://doi.org/10.1016/j.jchf.2023.07.014>
 338. Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. *Heart Fail Rev* 2002;**7**:229–42. <https://doi.org/10.1023/a:1020024122726>

339. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. *N Engl J Med* 2008;**358**:2678–87. <https://doi.org/10.1056/NEJMoa0800456>
340. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225–37. <https://doi.org/10.1056/NEJMoa043399>
341. Kober L, Thune JJ, Nielsen JC, Haarto J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. *N Engl J Med* 2016;**375**:1221–30. <https://doi.org/10.1056/NEJMoa1608029>
342. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;**346**:877–83. <https://doi.org/10.1056/NEJMoa013474>
343. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. *Heart* 2018;**104**:144–50. <https://doi.org/10.1136/heartjnl-2016-310850>
344. Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. *Eur Heart J* 2017;**38**:1738–46. <https://doi.org/10.1093/eurheartj/ehx028>
345. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000;**101**:1297–302. <https://doi.org/10.1161/01.cir.101.11.1297>
346. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J* 2000;**21**:2071–8. <https://doi.org/10.1053/ehj.2000.2476>
347. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med* 1997;**337**:1576–83. <https://doi.org/10.1056/NEJM199711273372202>
348. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). *Circulation* 2000;**102**:748–54. <https://doi.org/10.1161/01.cir.102.7.748>
349. Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Bohm M, Chioncel O, et al. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? *Eur J Heart Fail* 2022;**24**:1460–6. <https://doi.org/10.1002/ehj.2594>
350. Leyva F, Israel CW, Singh J. Declining risk of sudden cardiac death in heart failure: fact or myth? *Circulation* 2023;**147**:759–67. <https://doi.org/10.1161/CIRCULATIONAHA.122.062159>
351. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis. *JACC Heart Fail* 2020;**8**:844–55. <https://doi.org/10.1016/j.jchf.2020.06.015>
352. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. *Eur Heart J* 2015;**36**:1990–7. <https://doi.org/10.1093/eurheartj/ehv186>
353. Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, et al. Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT. *J Am Coll Cardiol* 2020;**76**:405–15. <https://doi.org/10.1016/j.jacc.2020.05.061>
354. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. *J Am Coll Cardiol* 2003;**41**:1707–12. [https://doi.org/10.1016/s0735-1097\(03\)00297-3](https://doi.org/10.1016/s0735-1097(03)00297-3)
355. Elming MB, Nielsen JC, Haarto J, Videbaek L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. *Circulation* 2017;**136**:1772–80. <https://doi.org/10.1161/CIRCULATIONAHA.117.028829>
356. Hammersley DJ, Zegard A, Androulakis E, Jones RE, Okafor O, Hatipoglu S, et al. Arrhythmic risk stratification by cardiovascular magnetic resonance imaging in patients with nonischemic cardiomyopathy. *J Am Coll Cardiol* 2024;**84**:1407–20. <https://doi.org/10.1016/j.jacc.2024.06.046>
357. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. *JACC Heart Fail* 2017;**5**:28–38. <https://doi.org/10.1016/j.jchf.2016.09.017>
358. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med* 2004;**351**:2481–8. <https://doi.org/10.1056/NEJMoa041489>
359. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. *N Engl J Med* 2009;**361**:1427–36. <https://doi.org/10.1056/NEJMoa0901889>
360. DeFilippis EM, Butler J, Vaduganathan M. Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity. *Circ Heart Fail* 2017;**10**:e004478. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004478>
361. Ruwald MH, Ruwald AC, Johansen JB, Gislason G, Nielsen JC, Philbert B, et al. Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort. *Europace* 2019;**21**:1211–9. <https://doi.org/10.1093/europace/euz121>
362. Ruwald MH, Solomon SD, Foster E, Kutyla V, Ruwald AC, Sherazi S, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. *Circulation* 2014;**130**:2278–86. <https://doi.org/10.1161/CIRCULATIONAHA.114.011283>
363. Steffel J, Milosevic G, Hurlimann A, Krasniqi N, Namdar M, Ruschitzka F, et al. Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronization therapy: 'real world' experience from a single tertiary care centre. *Heart* 2011;**97**:1668–74. <https://doi.org/10.1136/heartjnl-2011-300222>
364. Lee KS, Oh O, Miller J, Hammash M, Thompson DR, Ski CF, et al. Patients' openness to discussing implantable cardioverter defibrillator deactivation at end of life: a cross-sectional study. *Eur J Cardiovasc Nurs* 2022;**21**:687–93. <https://doi.org/10.1093/eurjcn/zvab130>
365. Trussler A, Alexander B, Campbell D, Alhammad N, Enriquez A, Chacko S, et al. Deactivation of implantable cardioverter defibrillator in patients with terminal diagnoses. *Am J Cardiol* 2019;**124**:1064–8. <https://doi.org/10.1016/j.amjcard.2019.07.007>
366. Kobza R, Erne P. End-of-life decisions in ICD patients with malignant tumors. *Pacing Clin Electrophysiol* 2007;**30**:845–9. <https://doi.org/10.1111/j.1540-8159.2007.00771.x>
367. Keene D, Nielsen JC, Burri H, Chavez-Gutierrez CA, Deharo JC, Drossart I, et al. Cardiac implantable electronic device upgrades and downgrades: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS). *Europace* 2025;**27**:euauf252. <https://doi.org/10.1093/europace/euauf252>
368. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. *N Engl J Med* 2020;**383**:526–36. <https://doi.org/10.1056/NEJMoa1915932>
369. Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS registry. *J Am Coll Cardiol* 2015;**65**:1605–15. <https://doi.org/10.1016/j.jacc.2015.02.047>
370. Friedman P, Murgatroyd F, Boersma LVA, Manlucu J, O'Donnell D, Knight BP, et al. Efficacy and safety of an extracardiac implantable cardioverter-defibrillator. *N Engl J Med* 2022;**387**:1292–302. <https://doi.org/10.1056/NEJMoa2206485>
371. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter-defibrillator after myocardial infarction. *N Engl J Med* 2018;**379**:1205–15. <https://doi.org/10.1056/NEJMoa1800781>
372. Veltmann C, Duncker D, Doering M, Gummadi S, Robertson M, Wittlinger T, et al. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. *Eur Heart J* 2024;**45**:2771–81. <https://doi.org/10.1093/eurheartj/ehae334>
373. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;**335**:1933–40. <https://doi.org/10.1056/NEJM199612263352601>
374. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled

- data from 5 clinical trials. *Circ Cardiovasc Qual Outcomes* 2015;8:179–86. <https://doi.org/10.1161/CIRCOUTCOMES.114.001306>
375. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis. *JAMA Cardiol* 2017;2: 685–8. <https://doi.org/10.1001/jamacardio.2017.0630>
 376. Merchant FM, Jones P, Wehrenberg S, Lloyd MS, Saxon LA. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. *J Am Heart Assoc* 2014;3:e001289. <https://doi.org/10.1161/JAHA.114.001289>
 377. Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J, Wegscheider K, et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INCidence free SURvival after ICD REplacement (INSURE) trial—a prospective multicentre study. *Eur Heart J* 2013;34:130–7. <https://doi.org/10.1093/eurheartj/ehs177>
 378. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? *J Am Coll Cardiol* 2014;63: 2388–94. <https://doi.org/10.1016/j.jacc.2014.03.025>
 379. Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NA, 3rd, Link MS. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. *J Cardiovasc Electrophysiol* 2008;19: 784–9. <https://doi.org/10.1111/j.1540-8167.2008.01111.x>
 380. Yap SC, Schaefer BA, Bhagwandien RE, Kuhne M, Dabiri Abkenari L, Osswald S, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. *Heart* 2014;100:1188–92. <https://doi.org/10.1136/heartjnl-2014-305535>
 381. Kutyla V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). *Circulation* 2015;132:1613–9. <https://doi.org/10.1161/CIRCULATIONAHA.115.015677>
 382. Kutyla V, Moss AJ, Klein HU, McNitt S, Zareba W, Goldenberg I. One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). *Pacing Clin Electrophysiol* 2018;41:1307–13. <https://doi.org/10.1111/pace.13448>
 383. Zishiri ET, Williams S, Cronin EM, Blackstone EH, Ellis SG, Roselli EE, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. *Circ Arrhythm Electrophysiol* 2013;6:117–28. <https://doi.org/10.1161/CIRCEP.112.973552>
 384. Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. *J Heart Lung Transplant* 2015;34:1305–9. <https://doi.org/10.1016/j.healun.2015.04.004>
 385. Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis. *Can J Cardiol* 2015;31: 792–9. <https://doi.org/10.1016/j.cjca.2014.12.031>
 386. Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, et al. The effect of duration of follow-up and presence of competing risk on lifespan gain from implantable cardioverter defibrillator therapy: who benefits the most? *Eur Heart J* 2015;36:1676–88. <https://doi.org/10.1093/eurheartj/ehv102>
 387. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. *JACC Heart Fail* 2014;2:623–9. <https://doi.org/10.1016/j.jchf.2014.06.007>
 388. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;350:2140–50. <https://doi.org/10.1056/NEJMoa032423>
 389. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001;344:873–80. <https://doi.org/10.1056/NEJM200103223441202>
 390. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *Eur Heart J* 2013;34:3547–56. <https://doi.org/10.1093/eurheartj/ehs290>
 391. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CARDiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. *Eur Heart J* 2006;27:1928–32. <https://doi.org/10.1093/eurheartj/ehl099>
 392. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005;352:1539–49. <https://doi.org/10.1056/NEJMoa050496>
 393. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, et al. Long-term mortality with cardiac resynchronization therapy in the CARDiac REsynchronization-Heart Failure (CARE-HF) trial. *Eur J Heart Fail* 2012;14:628–34. <https://doi.org/10.1093/eurjhf/hfs055>
 394. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. *J Am Coll Cardiol* 2009;54:1837–46. <https://doi.org/10.1016/j.jacc.2009.08.011>
 395. Goldenberg I, Kutyla V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with cardiac-resynchronization therapy in mild heart failure. *N Engl J Med* 2014;370:1694–701. <https://doi.org/10.1056/NEJMoa1401426>
 396. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol* 2008;52: 1834–43. <https://doi.org/10.1016/j.jacc.2008.08.027>
 397. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med* 2009;361:1329–38. <https://doi.org/10.1056/NEJMoa0906431>
 398. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010;363:2385–95. <https://doi.org/10.1056/NEJMoa1009540>
 399. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization REVERsE Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. *Eur Heart J* 2013;34:2592–9. <https://doi.org/10.1093/eurheartj/ehs160>
 400. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. *Eur Heart J* 2002; 23:1780–7. <https://doi.org/10.1053/eurh.2002.3232>
 401. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol* 2002;39:2026–33. [https://doi.org/10.1016/s0735-1097\(02\)01895-8](https://doi.org/10.1016/s0735-1097(02)01895-8)
 402. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002;346: 1845–53. <https://doi.org/10.1056/NEJMoa013168>
 403. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. *JAMA* 2003; 289:2685–94. <https://doi.org/10.1001/jama.289.20.2685>
 404. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol* 2003;42:1454–9. [https://doi.org/10.1016/s0735-1097\(03\)01042-8](https://doi.org/10.1016/s0735-1097(03)01042-8)
 405. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. *Circulation* 2004; 110:2864–8. <https://doi.org/10.1161/01.CIR.0000146336.92331.D1>
 406. Kindermann M, Hennen B, Jung J, Geisel J, Bohm M, Frohlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). *J Am Coll Cardiol* 2006;47: 1927–37. <https://doi.org/10.1016/j.jacc.2005.12.056>
 407. Beshai JF, Grimm RA, Nagueh SF, Baker JH 2nd, Beau SL, Greenberg SM, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. *N Engl J Med* 2007;357:2461–71. <https://doi.org/10.1056/NEJMoa0706695>
 408. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. *Circulation* 2008;117:2608–16. <https://doi.org/10.1161/CIRCULATIONAHA.107.743120>

409. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfese L, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med* 2013;**368**:1585–93. <https://doi.org/10.1056/NEJMoa1210356>
410. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. *N Engl J Med* 2013;**369**:1395–405. <https://doi.org/10.1056/NEJMoa1306687>
411. Thibault B, Harel F, Ducharme A, White M, Ellenbogen KA, Frasure-Smith N, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. *Circulation* 2013;**127**:873–81. <https://doi.org/10.1161/CIRCULATIONAHA.112.001239>
412. Merkely B, Hatala R, Wrancik JK, Duray G, Foldesi C, Som Z, et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial. *Eur Heart J* 2023;**44**:4259–69. <https://doi.org/10.1093/eurheartj/ehad591>
413. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. *JAMA* 2002;**288**:3115–23. <https://doi.org/10.1001/jama.288.24.3115>
414. Merkel E, Hatala R, Szigeti M, Schwertner W, Lakatos B, Behon A, et al. Upgrading right ventricular pacing to cardiac resynchronization in HFrEF patients improves symptoms and functional outcomes. *JACC Heart Fail* 2025;**13**:265–73. <https://doi.org/10.1016/j.jchf.2024.09.011>
415. Leyva F, Zegard A, Patel P, Stegemann B, Marshall H, Ludman P, et al. Timing of cardiac resynchronization therapy implantation. *Europace* 2023;**25**:eua059. <https://doi.org/10.1093/europace/eaad059>
416. Goldstein SA, Mentz RJ, Hellkamp AS, Randolph TC, Fonarow GC, Hernandez A, et al. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. *Clin Cardiol* 2019;**42**:256–63. <https://doi.org/10.1002/clc.23135>
417. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. *Heart* 2015;**101**:1800–6. <https://doi.org/10.1136/heartjnl-2015-307634>
418. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. *J Am Coll Cardiol* 2011;**57**:1468–76. <https://doi.org/10.1016/j.jacc.2010.11.030>
419. Cannon JA, Collier TJ, Shen L, Swedberg K, Krum H, Van Veldhuisen DJ, et al. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Eur J Heart Fail* 2015;**17**:707–16. <https://doi.org/10.1002/ehf.303>
420. Huang HT, Huang JL, Lin PL, Lee YH, Hsu CY, Chung FP, et al. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy. *ESC Heart Fail* 2022;**9**:3825–35. <https://doi.org/10.1002/ehf2.14107>
421. Straw S, McGinlay M, Gierula J, Lowry JE, Paton MF, Cole C, et al. Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. *J Cardiovasc Med (Hagerstown)* 2021;**22**:848–56. <https://doi.org/10.2459/JCM.0000000000001231>
422. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, et al. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. *J Am Coll Cardiol* 2018;**71**:306–17. <https://doi.org/10.1016/j.jacc.2017.11.020>
423. Wang NC, Singh M, Adelstein EC, Jain SK, Mendenhall GS, Shalaby AA, et al. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: the NEOLITH study. *Heart Rhythm* 2016;**13**:933–42. <https://doi.org/10.1016/j.hrthm.2015.12.020>
424. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. *Eur Heart J* 2015;**36**:1983–9. <https://doi.org/10.1093/eurheartj/ehv242>
425. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O'Callaghan KM, Carpenter JL, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. *JAMA Intern Med* 2014;**174**:1340–8. <https://doi.org/10.1001/jamainternmed.2014.2717>
426. Glikson M, Burri H, Abidin A, Cano O, Curila K, De Pooter J, et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. *Europace* 2025;**27**:eua050. <https://doi.org/10.1093/europace/eaaf050>
427. Vinther M, Risum N, Svendsen JH, Mogelvang R, Philbert BT. A randomized trial of His pacing versus biventricular pacing in symptomatic HF patients with left bundle branch block (His-Alternative). *JACC Clin Electrophysiol* 2021;**7**:1422–32. <https://doi.org/10.1016/j.jacep.2021.04.003>
428. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, et al. Long-term outcomes of His bundle pacing in patients with heart failure with left bundle branch block. *Heart* 2019;**105**:137–43. <https://doi.org/10.1136/heartjnl-2018-313415>
429. Abidin A, Werner C, Burri H, Merino JL, Vukadinovic D, Sawan N, et al. Outcomes of left bundle branch area pacing compared to His bundle pacing as a primary pacing strategy: systematic review and meta-analysis. *Pacing Clin Electrophysiol* 2023;**46**:1315–24. <https://doi.org/10.1111/pace.14836>
430. Frausing M, Baek AL, Kristensen J, Gerdes C, Nielsen JC, Kronborg MB. Long-term follow-up of selective and non-selective His bundle pacing leads in patients with atrioventricular block. *J Interv Card Electrophysiol* 2023;**66**:1849–57. <https://doi.org/10.1007/s10840-023-01488-x>
431. Graterol FR, Pujol-Lopez M, Borrás R, Ayala B, Uribe L, Guasch E, et al. Predictors of failed left bundle branch pacing implant in heart failure with reduced ejection fraction: importance of left ventricular diameter and QRS morphology. *Heart Rhythm* 2024;**21**:2571–8. <https://doi.org/10.1016/j.hrthm.2024.06.019>
432. Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, et al. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. *J Am Coll Cardiol* 2022;**80**:1205–16. <https://doi.org/10.1016/j.jacc.2022.07.019>
433. Vijayaraman P, Zalavadia D, Haseeb A, Dye C, Madan N, Skeete JR, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. *Heart Rhythm* 2022;**19**:1263–71. <https://doi.org/10.1016/j.hrthm.2022.04.023>
434. Mullens W, Dauw J, Gustafsson F, Mebazaa A, Steffel J, Witte KK, et al. Integration of implantable device therapy in patients with heart failure: a clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2024;**26**:483–501. <https://doi.org/10.1002/ehf.3150>
435. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. *Europace* 2021;**23**:1324–42. <https://doi.org/10.1093/europace/eaad411>
436. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. *N Engl J Med* 2012;**367**:2275–83. <https://doi.org/10.1056/NEJMoa1211107>
437. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. *JAMA* 2013;**309**:1903–11. <https://doi.org/10.1001/jama.2013.4598>
438. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. *JACC Heart Fail* 2018;**6**:874–83. <https://doi.org/10.1016/j.jchf.2018.04.010>
439. Linde C, Grabowski M, Ponikowski P, Rao I, Stagg A, Tschöpe C. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM-HFpEF). *Eur J Heart Fail* 2022;**24**:2275–84. <https://doi.org/10.1002/ehf.2619>
440. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. *JACC Heart Fail* 2015;**3**:487–96. <https://doi.org/10.1016/j.jchf.2015.02.006>
441. Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: long-term outcomes. *Eur J Heart Fail* 2024;**26**:1051–61. <https://doi.org/10.1002/ehf.3232>
442. Stone GW, Lindenfeld J, Rodes-Cabau J, Anker SD, Zile MR, Kar S, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. *Circulation* 2024;**150**:1931–43. <https://doi.org/10.1161/CIRCULATIONAHA.124.070870>
443. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. *Lancet* 2022;**399**:1130–40. [https://doi.org/10.1016/S0140-6736\(22\)00016-2](https://doi.org/10.1016/S0140-6736(22)00016-2)
444. Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart

- Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2023;**25**:776–91. <https://doi.org/10.1002/ehf.2874>
445. Antohi LE, Adamo M, Chioncel O. Long-term survival after acute heart failure hospitalization: from observation to collaborative interventions. *Eur J Heart Fail* 2022;**24**:1529–31. <https://doi.org/10.1002/ehf.2645>
 446. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozd J, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). *Eur J Heart Fail* 2010;**12**:1076–84. <https://doi.org/10.1093/eurjhf/hfq154>
 447. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. Acute heart failure congestion and perfusion status—impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail* 2019;**21**:1338–52. <https://doi.org/10.1002/ehf.1492>
 448. Tromp J, Bamadaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. *Lancet Glob Health* 2020;**8**:e411–22. [https://doi.org/10.1016/S2214-109X\(20\)30004-8](https://doi.org/10.1016/S2214-109X(20)30004-8)
 449. Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. *Eur J Heart Fail* 2013;**15**:465–76. <https://doi.org/10.1093/eurjhf/hfs189>
 450. Taylor CJ, Ordonez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. *BMJ* 2019;**364**:l223. <https://doi.org/10.1136/bmj.l223>
 451. Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. *Eur J Heart Fail* 2020;**22**:1777–85. <https://doi.org/10.1002/ehf.1800>
 452. Miro O, Garcia-Sarasola A, Fuenzalida C, Calderon S, Jacob J, Aguirre A, et al. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. *Eur J Heart Fail* 2019;**21**:1231–44. <https://doi.org/10.1002/ehf.1567>
 453. Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, et al. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. *Eur J Heart Fail* 2019;**21**:1353–65. <https://doi.org/10.1002/ehf.1502>
 454. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;**18**:613–25. <https://doi.org/10.1002/ehf.566>
 455. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;**19**:1242–54. <https://doi.org/10.1002/ehf.890>
 456. Chatur S, Vaduganathan M, Claggett BL, Cunningham JW, Docherty KF, Desai AS, et al. Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. *Circulation* 2023;**148**:1735–45. <https://doi.org/10.1161/CIRCULATIONAHA.123.066506>
 457. Ambrosy AP, Parikh RV, Sung SH, Tan TC, Narayanan A, Masson R, et al. Analysis of worsening heart failure events in an integrated health care system. *J Am Coll Cardiol* 2022;**80**:111–22. <https://doi.org/10.1016/j.jacc.2022.04.045>
 458. Madelaire C, Gustafsson F, Stevenson LW, Kristensen SL, Kober L, Andersen J, et al. One-year mortality after intensification of outpatient diuretic therapy. *J Am Heart Assoc* 2020;**9**:e016010. <https://doi.org/10.1161/JAHA.119.016010>
 459. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). *Circulation* 2016;**133**:2254–62. <https://doi.org/10.1161/CIRCULATIONAHA.115.020729>
 460. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. *Circulation* 2021;**144**:1284–94. <https://doi.org/10.1161/CIRCULATIONAHA.121.056824>
 461. Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. *Eur J Heart Fail* 2014;**16**:560–5. <https://doi.org/10.1002/ehf.71>
 462. Vaduganathan M, Cunningham JW, Claggett BL, Causland FM, Barkoudah E, Finn P, et al. Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial. *JACC Heart Fail* 2021;**9**:374–82. <https://doi.org/10.1016/j.jchf.2021.01.014>
 463. Matsue Y, Damman K, Voors AA, Kagiya N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. *J Am Coll Cardiol* 2017;**69**:3042–51. <https://doi.org/10.1016/j.jacc.2017.04.042>
 464. Harjola VP, Parissis J, Brunner-La Rocca HP, Celutkienė J, Chioncel O, Collins SP, et al. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2018;**20**:1081–99. <https://doi.org/10.1002/ehf.1204>
 465. Zymlinski R, Biegus J, Sokolski M, Siwolowski P, Nawrocka-Millward S, Todd J, et al. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. *Eur J Heart Fail* 2018;**20**:1011–8. <https://doi.org/10.1002/ehf.1156>
 466. Tsutsui H, Albert NM, Coats AJ, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. *Eur J Heart Fail* 2023;**25**:616–31. <https://doi.org/10.1002/ehf.2848>
 467. Walkley R, Allen AJ, Cowie MR, Maconachie R, Anderson L. The cost-effectiveness of NT-proBNP for assessment of suspected acute heart failure in the emergency department. *ESC Heart Fail* 2023;**10**:3276–86. <https://doi.org/10.1002/ehf2.14471>
 468. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. *N Engl J Med* 2004;**350**:647–54. <https://doi.org/10.1056/NEJMoa031681>
 469. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. *BMJ* 2015;**350**:h910. <https://doi.org/10.1136/bmj.h910>
 470. Chiu L, Jairam MP, Chow R, Chiu N, Shen M, Alhassan A, et al. Meta-analysis of point-of-care lung ultrasonography versus chest radiography in adults with symptoms of acute decompensated heart failure. *Am J Cardiol* 2022;**174**:89–95. <https://doi.org/10.1016/j.amjcard.2022.03.022>
 471. Lian R, Zhang GC, Yan ST, Sun LC, Zhang SQ, Zhang GQ. Role of ultrasound lung comets in the diagnosis of acute heart failure in emergency department: a systematic review and meta-analysis. *Biomed Environ Sci* 2018;**31**:596–607. <https://doi.org/10.3967/bes2018.081>
 472. Martindale JL, Secko M, Kilpatrick JF, deSouza IS, Paladino L, Aherne A, et al. Serial sonographic assessment of pulmonary edema in patients with hypertensive acute heart failure. *J Ultrasound Med* 2018;**37**:337–45. <https://doi.org/10.1002/jum.14336>
 473. Gargani L, Girerd N, Platz E, Pellicori P, Stankovic I, Palazzuoli A, et al. Lung ultrasound in acute and chronic heart failure: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI). *Eur Heart J Cardiovasc Imaging* 2023;**24**:1569–82. <https://doi.org/10.1093/ehjci/jead169>
 474. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock—a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2020;**22**:1315–41. <https://doi.org/10.1002/ehf.1922>
 475. Rossello X, Bueno H, Gil V, Jacob J, Martin-Sanchez FJ, Llorens P, et al. Synergistic impact of systolic blood pressure and perfusion status on mortality in acute heart failure. *Circ Heart Fail* 2021;**14**:e007347. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007347>
 476. Filippatos G, Angermann CE, Cleland JGF, Lam CSP, Dahlstrom U, Dickstein K, et al. Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. *JAMA Cardiol* 2020;**5**:401–10. <https://doi.org/10.1001/jamacardio.2019.5108>
 477. Masip J, Peacock WF, Price S, Cullen L, Martin-Sanchez FJ, Seferovic P, et al. Indications and practical approach to non-invasive ventilation in acute heart failure. *Eur Heart J* 2018;**39**:17–25. <https://doi.org/10.1093/eurheartj/ehx580>
 478. Chioncel O, Collins SP, Ambrosy AP, Gheorghiade M, Filippatos G. Pulmonary oedema—therapeutic targets. *Card Fail Rev* 2015;**1**:38–45. <https://doi.org/10.15420/CFR.2015.01.01.38>

479. Naidu SS, Baran DA, Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. *J Am Coll Cardiol* 2022;**79**:933–46. <https://doi.org/10.1016/j.jacc.2022.01.018>
480. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. *Circulation* 2017;**136**:e232–68. <https://doi.org/10.1161/CIR.0000000000000525>
481. Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care* 2020;**9**:183–97. <https://doi.org/10.1177/2048872619894254>
482. Waksman R, Pahuja M, van Diepen S, Proudfoot AG, Morrow D, Spitzer E, et al. Standardized definitions for cardiogenic shock research and mechanical circulatory support devices: scientific expert panel from the Shock Academic Research Consortium (SHARC). *Circulation* 2023;**148**:1113–26. <https://doi.org/10.1161/CIRCULATIONAHA.123.064527>
483. Patel SM, Berg DD, Bohula EA, Baird-Zars VM, Park JG, Barnett CF, et al. Continuum of preshock to classic cardiogenic shock in the Critical Care Cardiology Trials Network Registry. *JACC Heart Fail* 2024;**12**:1625–35. <https://doi.org/10.1016/j.jchf.2024.06.009>
484. Jentzer JC, Burstein B, Van Diepen S, Murphy J, Holmes DR Jr, Bell MR, et al. Defining shock and preshock for mortality risk stratification in cardiac intensive care unit patients. *Circ Heart Fail* 2021;**14**:e007678. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007678>
485. van Diepen S, Poss J, Senaratne JM, Gage A, Morrow DA. Mixed cardiogenic shock: a proposal for standardized classification, a hemodynamic definition, and framework for management. *Circulation* 2024;**150**:1459–68. <https://doi.org/10.1161/CIRCULATIONAHA.124.069508>
486. Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al. Trial of an intervention to improve acute heart failure outcomes. *N Engl J Med* 2023;**388**:22–32. <https://doi.org/10.1056/NEJMoa2211680>
487. Miro O, Rossello X, Gil V, Martin-Sanchez FJ, Llorens P, Herrero-Puente P, et al. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. *Ann Intern Med* 2017;**167**:698–705. <https://doi.org/10.7326/M16-2726>
488. Blumer V, Hanff TC, Gage A, Schrage B, Kanwar MK. Cardiogenic shock teams: past, present, and future directions. *Circ Heart Fail* 2025;**18**:e011630. <https://doi.org/10.1161/CIRCHEARTFAILURE.124.011630>
489. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. *Eur Heart J* 2023;**44**:3948–4042. <https://doi.org/10.1093/eurheartj/ehad193>
490. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020;**41**:543–603. <https://doi.org/10.1093/eurheartj/ehz405>
491. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 2023;**44**:3720–826. <https://doi.org/10.1093/eurheartj/ehad191>
492. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. *Nat Med* 2022;**28**:568–74. <https://doi.org/10.1038/s41591-021-01659-1>
493. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. *JAMA Cardiol* 2017;**2**:950–8. <https://doi.org/10.1001/jamacardio.2017.2198>
494. Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes-Genis A, Abdelhamid M, et al. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association of the ESC. *Eur J Heart Fail* 2023;**25**:1115–31. <https://doi.org/10.1002/ehf.2888>
495. Tomasoni D, Davison B, Adamo M, Pagnesi M, Mebazaa A, Edwards C, et al. Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial. *J Card Fail* 2024;**30**:525–37. <https://doi.org/10.1016/j.cardfail.2023.09.002>
496. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozd J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet* 2020;**396**:1895–904. [https://doi.org/10.1016/S0140-6736\(20\)32339-4](https://doi.org/10.1016/S0140-6736(20)32339-4)
497. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *JAMA* 2006;**296**:2217–26. <https://doi.org/10.1001/jama.296.18.2217>
498. Jobs A, Rausch TK, König IR, Vonthein R, Devendra A, Schafer J, et al. Inferior vena cava ultrasound to guide decongestion in acute decompensated heart failure: a randomized controlled trial. *JACC Heart Fail* 2025;**13**:102578. <https://doi.org/10.1016/j.jchf.2025.102578>
499. Thomas A, van Diepen S, Beekman R, Sinha SS, Brusca SB, Alviar CL, et al. Oxygen supplementation and hyperoxia in critically ill cardiac patients: from pathophysiology to clinical practice. *JACC Adv* 2022;**1**:100065. <https://doi.org/10.1016/j.jacadv.2022.100065>
500. Grensemann J, Fuhrmann V, Kluge S. Oxygen treatment in intensive care and emergency medicine. *Dtsch Arztebl Int* 2018;**115**:455–62. <https://doi.org/10.3238/arztebl.2018.0455>
501. Sepehrvand N, Ezekowitz JA. Oxygen therapy in patients with acute heart failure: friend or foe? *JACC Heart Fail* 2016;**4**:783–90. <https://doi.org/10.1016/j.jchf.2016.03.026>
502. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, et al. Meta-analysis: non-invasive ventilation in acute cardiogenic pulmonary edema. *Ann Intern Med* 2010;**152**:590–600. <https://doi.org/10.7326/0003-4819-152-9-201005040-00009>
503. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. *N Engl J Med* 2008;**359**:142–51. <https://doi.org/10.1056/NEJMoa0707992>
504. Rasoul D, Zhang J, Farnell E, Tsangarides AA, Chong SC, Fernando R, et al. Continuous infusion versus bolus injection of loop diuretics for acute heart failure. *Cochrane Database Syst Rev* 2024;**5**:CD014811. <https://doi.org/10.1002/14651858.CD014811.pub2>
505. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med* 2011;**364**:797–805. <https://doi.org/10.1056/NEJMoa1005419>
506. Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, et al. Worsening renal function in acute heart failure in the context of diuretic response. *Eur J Heart Fail* 2022;**24**:365–74. <https://doi.org/10.1002/ehf.2384>
507. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. *Circ Heart Fail* 2012;**5**:54–62. <https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413>
508. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. *Nat Med* 2023;**29**:2625–32. <https://doi.org/10.1038/s41591-023-02532-z>
509. Dauw J, Charaya K, Lelonek M, Zegri-Reiriz I, Nasr S, Paredes-Paucar CP, et al. Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study. *Circ Heart Fail* 2024;**17**:e011105. <https://doi.org/10.1161/CIRCHEARTFAILURE.123.011105>
510. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. *N Engl J Med* 2022;**387**:1185–95. <https://doi.org/10.1056/NEJMoa2203094>
511. Trullas JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sanchez-Martel M, Conde-Martel A, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. *Eur Heart J* 2023;**44**:411–21. <https://doi.org/10.1093/eurheartj/ehac689>
512. Biegus J, Cotter G, Metra M, Ponikowski P. Decongestion in acute heart failure: is it time to change diuretic-centred paradigm? *Eur J Heart Fail* 2024;**26**:2094–106. <https://doi.org/10.1002/ehf.3423>
513. Biegus J, Mebazaa A, Davison B, Cotter G, Edwards C, Celutkienė J, et al. Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF. *J Am Coll Cardiol* 2024;**84**:323–36. <https://doi.org/10.1016/j.jacc.2024.04.055>
514. Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. *Eur Heart J* 2023;**44**:41–50. <https://doi.org/10.1093/eurheartj/ehac530>
515. Girerd N, Mewton N, Tatiere JM, Guijarro D, Jourdain P, Damy T, et al. Practical outpatient management of worsening chronic heart failure. *Eur J Heart Fail* 2022;**24**:750–61. <https://doi.org/10.1002/ehf.2503>
516. Rasoul D, Chattopadhyay I, Mayer T, West J, Stollar H, Black C, et al. Economic evaluation of the Liverpool heart failure virtual ward model. *Eur*

- Heart J Qual Care Clin Outcomes* 2025;11:197–205. <https://doi.org/10.1093/ehjqcco/qcae095>
517. Sankaranarayanan R, Rasoul D, Murphy N, Kelly A, Nyjo S, Jackson C, et al. Telehealth-aided outpatient management of acute heart failure in a specialist virtual ward compared with standard care. *ESC Heart Fail* 2024;11:4172–84. <https://doi.org/10.1002/ehf2.15003>
 518. Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. *JACC Heart Fail* 2016;4:1–8. <https://doi.org/10.1016/j.jchf.2015.06.017>
 519. Keshvani N, Rizvi S, Segar MW, Miller JW, Coellar JD, Patel KV, et al. Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: a pilot randomized controlled trial. *Eur J Heart Fail* 2025;27:347–52. <https://doi.org/10.1002/ehf.3537>
 520. Konstam MA, Massaro J, Dhinra R, Walsh M, Ordway L, Pursley MS, et al. Avoiding treatment in hospital with subcutaneous furosemide for worsening heart failure: a pilot study (AT HOME-HF). *JACC Heart Fail* 2024;12:1830–41. <https://doi.org/10.1016/j.jchf.2024.07.015>
 521. Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. *JACC Heart Fail* 2018;6:65–70. <https://doi.org/10.1016/j.jchf.2017.10.001>
 522. Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. *Eur Heart J* 2023;44:2966–77. <https://doi.org/10.1093/eurheartj/ehad341>
 523. Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT, Adams K, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. *J Am Coll Cardiol* 2024;83:1295–306. <https://doi.org/10.1016/j.jacc.2024.02.009>
 524. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). *Circulation* 2022;146:289–98. <https://doi.org/10.1161/CIRCULATIONAHA.122.059038>
 525. Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium–glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. *Circulation* 2025. <https://doi.org/10.1161/CIRCULATIONAHA.125.076575>
 526. Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. *J Am Coll Cardiol* 2024;83:1386–98. <https://doi.org/10.1016/j.jacc.2024.02.020>
 527. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med* 2012;367:2296–304. <https://doi.org/10.1056/NEJMoa1210357>
 528. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. *J Am Coll Cardiol* 2007;49:675–83. <https://doi.org/10.1016/j.jacc.2006.07.073>
 529. Chioncel O, Mebazaa A, Farmakis D, Abdelhamid M, Lund LH, Harjola VP, et al. Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2025;27:1067–88. <https://doi.org/10.1002/ehf.3673>
 530. Patel PA, Heizer G, O'Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. *Circ Heart Fail* 2014;7:918–25. <https://doi.org/10.1161/CIRCHEARTFAILURE.113.000872>
 531. Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. *N Engl J Med* 2017;376:1956–64. <https://doi.org/10.1056/NEJMoa1601895>
 532. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al. Effects of serelaxin in patients with acute heart failure. *N Engl J Med* 2019;381:716–26. <https://doi.org/10.1056/NEJMoa1801291>
 533. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. *JAMA* 2019;322:2292–302. <https://doi.org/10.1001/jama.2019.18598>
 534. Lukoschewitz JD, Miger KC, Olesen ASO, Caidi NOE, Jorgensen CK, Nielsen OW, et al. Vasodilators for acute heart failure—a systematic review with meta-analysis. *NEJM Evid* 2024;3:EVIDo2300335. <https://doi.org/10.1056/EVIDo2300335>
 535. Riccardi M, Pagnesi M, Chioncel O, Mebazaa A, Cotter G, Gustafsson F, et al. Medical therapy of cardiogenic shock: contemporary use of inotropes and vasopressors. *Eur J Heart Fail* 2024;26:411–31. <https://doi.org/10.1002/ehf.3162>
 536. Uhlir K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. *Cochrane Database Syst Rev* 2020;11:CD009669. <https://doi.org/10.1002/14651858.CD009669.pub4>
 537. Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. *N Engl J Med* 2021;385:516–25. <https://doi.org/10.1056/NEJMoa2026845>
 538. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362:779–89. <https://doi.org/10.1056/NEJMoa0907118>
 539. Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol* 2018;72:173–82. <https://doi.org/10.1016/j.jacc.2018.04.051>
 540. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. *JAMA* 2005;294:3124–30. <https://doi.org/10.1001/jama.294.24.3124>
 541. Damman K, Beusekamp JC, Boersma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). *Eur J Heart Fail* 2020;22:713–22. <https://doi.org/10.1002/ehf.1713>
 542. Dominguez-Rodriguez A, Suero-Mendez C, Burillo-Putze G, Gil V, Calvo-Rodriguez R, Pinera-Salmeron P, et al. Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial. *Eur J Heart Fail* 2022;24:1953–62. <https://doi.org/10.1002/ehf.2602>
 543. Lorusso R, Salazar L, Nersesian G, Milojevic M, Schmack B, Engelman DT, et al. EACTS expert consensus document on protected cardiac surgery: pre-emptive use of temporary mechanical circulatory support in adult cardiac surgery patients at high risk for perioperative low cardiac output syndrome. *Eur J Cardiothorac Surg* 2025;68:ezaf296. <https://doi.org/10.1093/ejcts/ezaf296>
 544. Potapov EV, Whitman G, John R, Lanmuller P, Tucanova Z, Arora RC, et al. EACTS/STS/AATS Guidelines on temporary mechanical circulatory support in adult cardiac surgery. *Eur J Cardiothorac Surg* 2025. <https://doi.org/10.1093/ejcts/ezaf330>
 545. Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 concise clinical guidance: an ACC expert consensus statement on the evaluation and management of cardiogenic shock: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2025;85:1618–41. <https://doi.org/10.1016/j.jacc.2025.02.018>
 546. Thiele H, Moller JE, Henriques JPS, Bogerd M, Seyfarth M, Burkhardt D, et al. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up. *Lancet* 2024;404:1019–28. [https://doi.org/10.1016/S0140-6736\(24\)01448-X](https://doi.org/10.1016/S0140-6736(24)01448-X)
 547. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA* 2020;323:734–45. <https://doi.org/10.1001/jama.2020.0254>
 548. Thiele H, Jobs A, Ouwenel DM, Henriques JPS, Seyfarth M, Desch S, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. *Eur Heart J* 2017;38:3523–31. <https://doi.org/10.1093/eurheartj/ehx363>
 549. Moller JE, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. *N Engl J Med* 2024;390:1382–93. <https://doi.org/10.1056/NEJMoa2312572>
 550. Moller JE, Beske RP, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, et al. Long-term outcomes of the DanGer Shock trial. *N Engl J Med* 2025;393:1037–8. <https://doi.org/10.1056/NEJMc2508284>
 551. Lusebrink E, Binzenhofer L, Thiele H. The DanGer Shock trial: a new dawn but much to uncover. *Eur Heart J* 2024;45:4181–3. <https://doi.org/10.1093/eurheartj/ehae516>

552. Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal life support in infarct-related cardiogenic shock. *N Engl J Med* 2023;**389**:1286–97. <https://doi.org/10.1056/NEJMoa2307227>
553. Zeymer U, Freund A, Hochadel M, Ostadal P, Belohlavek J, Rokytka R, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. *Lancet* 2023;**402**:1338–46. [https://doi.org/10.1016/S0140-6736\(23\)01607-0](https://doi.org/10.1016/S0140-6736(23)01607-0)
554. Kim MC, Lim Y, Lee SH, Shin Y, Ahn JH, Hyun DY, et al. Early left ventricular unloading or conventional approach after venoarterial extracorporeal membrane oxygenation: the EARLY-UNLOAD randomized clinical trial. *Circulation* 2023;**148**:1570–81. <https://doi.org/10.1161/CIRCULATIONAHA.123.066179>
555. Prondzinsky R, Unverzagt S, Russ M, Lemm H, Swyter M, Wegener N, et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial. *Shock* 2012;**37**:378–84. <https://doi.org/10.1097/SHK.0b013e31824a67af>
556. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. *Lancet* 2013;**382**:1638–45. [https://doi.org/10.1016/S0140-6736\(13\)61783-3](https://doi.org/10.1016/S0140-6736(13)61783-3)
557. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 2012;**367**:1287–96. <https://doi.org/10.1056/NEJMoa1208410>
558. Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II trial. *Circulation* 2019;**139**:395–403. <https://doi.org/10.1161/CIRCULATIONAHA.118.038201>
559. den Uil CA, Van Mieghem NM, M BB, Jewbali LS, Lenzen MJ, Engstrom AE, et al. Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial. *EuroIntervention* 2019;**15**:586–93. <https://doi.org/10.4244/EIJ-D-19-00254>
560. Morici N, Sacco A, Frea S, Rota M, Villanova L, Gravinese C, et al. Early intra-aortic balloon support for heart failure-related cardiogenic shock: a randomized clinical trial. *J Am Coll Cardiol* 2025;**85**:1587–97. <https://doi.org/10.1016/j.jacc.2025.03.003>
561. Morici N, Marini C, Sacco A, Tavazzi G, Saia F, Palazzini M, et al. Intra-aortic balloon pump for acute-on-chronic heart failure complicated by cardiogenic shock. *J Card Fail* 2022;**28**:1202–16. <https://doi.org/10.1016/j.cardfail.2021.11.009>
562. Baldetti L, Pagnesi M, Gramegna M, Belletti A, Beneduce A, Pazzanese V, et al. Intra-aortic balloon pumping in acute decompensated heart failure with hypoperfusion: from pathophysiology to clinical practice. *Circ Heart Fail* 2021;**14**:e008527. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.008527>
563. Malick W, Fried JA, Masoumi A, Nair A, Zuver A, Huang A, et al. Comparison of the hemodynamic response to intra-aortic balloon counterpulsation in patients with cardiogenic shock resulting from acute myocardial infarction versus acute decompensated heart failure. *Am J Cardiol* 2019;**124**:1947–53. <https://doi.org/10.1016/j.amjcard.2019.09.016>
564. Herion FX, Beurton A, Oddos C, Nubret K, Aguerreche C, Quessard A, et al. Multidisciplinary cardiogenic shock team approach improves the long-term outcomes of patients suffering from refractory cardiogenic shock treated with short-term mechanical circulatory support. *Eur Heart J Acute Cardiovasc Care* 2023;**12**:821–30. <https://doi.org/10.1093/ehjacc/zuad108>
565. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, et al. Management and outcomes of cardiogenic shock in cardiac ICUs with versus without shock teams. *J Am Coll Cardiol* 2021;**78**:1309–17. <https://doi.org/10.1016/j.jacc.2021.07.044>
566. Mebazaa A, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. *Circulation* 2014;**130**:410–18. <https://doi.org/10.1161/CIRCULATIONAHA.113.003126>
567. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med* 2013;**368**:513–23. <https://doi.org/10.1056/NEJMoa1111096>
568. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anti-coagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med* 2007;**146**:278–88. <https://doi.org/10.7326/0003-4819-146-4-200702200-00007>
569. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J* 2003;**145**:614–21. <https://doi.org/10.1067/mhj.2003.189>
570. Tang L, Wu YY, Lip GY, Yin P, Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. *Lancet Haematol* 2016;**3**:e30–44. [https://doi.org/10.1016/S2352-3026\(15\)00228-8](https://doi.org/10.1016/S2352-3026(15)00228-8)
571. Dunlay SM, Roger VL, Killian JM, Weston SA, Schulte PJ, Subramaniam AV, et al. Advanced heart failure epidemiology and outcomes: a population-based study. *JACC Heart Fail* 2021;**9**:722–32. <https://doi.org/10.1016/j.jchf.2021.05.009>
572. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;**20**:1505–35. <https://doi.org/10.1002/ehf.1236>
573. Pagnesi M, Lombardi CM, Chiarito M, Stolfo D, Baldetti L, Loiacono F, et al. Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry. *Eur J Heart Fail* 2022;**24**:1493–503. <https://doi.org/10.1002/ehf.2561>
574. Baudry G, Crespo-Leiro MG, Delmas C, Guidetti F, Bravo MJ, Valente F, et al. Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2025;**27**:3312–25. <https://doi.org/10.1002/ehf.70003>
575. Richter I, Fried J, Clerkin K, Raikhelkar J, Lotan D, Elad B, et al. Increasing access: reducing referral delay in patients with ambulatory advanced HF. *J Card Fail* 2025;**32**:758–67. <https://doi.org/10.1016/j.cardfail.2025.03.015>
576. Mehra MR, Gustafsson F. Left ventricular assist devices at the crossroad of innovation in advanced heart failure. *J Card Fail* 2021;**27**:1291–4. <https://doi.org/10.1016/j.cardfail.2021.06.003>
577. Baumwol J. 'I need help'—a mnemonic to aid timely referral in advanced heart failure. *J Heart Lung Transplant* 2017;**36**:593–4. <https://doi.org/10.1016/j.healun.2017.02.010>
578. Pagnesi M, Ghiraldin D, Vizzardi E, Chiarito M, Stolfo D, Baldetti L, et al. Detailed assessment of the 'I need help' criteria in patients with heart failure: insights from the HELP-HF registry. *Circ Heart Fail* 2023;**16**:e011003. <https://doi.org/10.1161/CIRCHEARTFAILURE.123.011003>
579. Mancini DM, Eisen H, Kusmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation* 1991;**83**:778–86. <https://doi.org/10.1161/01.cir.83.3.778>
580. Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S, et al. International Society for Heart and Lung Transplantation Guidelines for the evaluation and care of cardiac transplant candidates—2024. *J Heart Lung Transplant* 2024;**43**:1529–628.e54. <https://doi.org/10.1016/j.healun.2024.05.010>
581. Cooper LB, Mentz RJ, Stevens SR, Felker GM, Lombardi C, Metra M, et al. Hemodynamic predictors of heart failure morbidity and mortality: fluid or flow? *J Card Fail* 2016;**22**:182–9. <https://doi.org/10.1016/j.cardfail.2015.11.012>
582. Saeed D, Feldman D, Banayasy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: a 10-year update. *J Heart Lung Transplant* 2023;**42**:e1–222. <https://doi.org/10.1016/j.healun.2022.12.004>
583. Cascino TM, Somanchi S, Colvin M, Chung GS, Brescia AA, Pienta M, et al. Racial and sex inequities in the use of and outcomes after left ventricular assist device implantation among Medicare beneficiaries. *JAMA Netw Open* 2022;**5**:e2223080. <https://doi.org/10.1001/jamanetworkopen.2022.23080>
584. Lund LH, Trochu JN, Meyns B, Caliskan K, Shaw S, Schmitt JD, et al. Screening for heart transplantation and left ventricular assist system: results from the ScREening for advanced Heart Failure treatment (SEE-HF) study. *Eur J Heart Fail* 2018;**20**:152–60. <https://doi.org/10.1002/ehf.975>
585. Radhoe SP, Jakus N, Veenis JF, Timmermans P, Pouleur AC, Rubis P, et al. Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry. *ESC Heart Fail* 2023;**10**:1054–65. <https://doi.org/10.1002/ehf2.14261>
586. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;**48**:16–31. <https://doi.org/10.1093/ageing/afy169>
587. Pagnesi M, Serafini L, Chiarito M, Stolfo D, Baldetti L, Inciardi RM, et al. Impact of malnutrition in patients with severe heart failure. *Eur J Heart Fail* 2024;**26**:1585–93. <https://doi.org/10.1002/ehf.3285>
588. Driggin E, Cohen LP, Gallagher D, Karmally W, Maddox T, Hummel SL, et al. Nutrition assessment and dietary interventions in heart failure: JACC review topic of the week. *J Am Coll Cardiol* 2022;**79**:1623–35. <https://doi.org/10.1016/j.jacc.2022.02.025>
589. Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements

- Committee. *J Card Fail* 2019;25:380–400. <https://doi.org/10.1016/j.cardfail.2019.03.007>
590. Denfeld QE, Jha SR, Fung E, Jaarsma T, Maurer MS, Reeves GR, et al. Assessing and managing frailty in advanced heart failure: an International Society for Heart and Lung Transplantation consensus statement. *J Heart Lung Transplant* 2024;43:1–27. <https://doi.org/10.1016/j.healun.2023.09.013>
 591. Baudry G, Girerd N, Cikes M, Crespo-Leiro MG, Damman K, Delmas C, et al. Knowledge and application of ESC/HFA Guidelines in the management of advanced heart failure. *Eur J Heart Fail* 2024;27:1126–35. <https://doi.org/10.1002/ehfj.3530>
 592. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al. INTERMACS profiles of advanced heart failure: the current picture. *J Heart Lung Transplant* 2009;28:535–41. <https://doi.org/10.1016/j.healun.2009.02.015>
 593. Samman-Tahhan A, Hedley JS, McCue AA, Bjork JB, Georgiopolou VV, Morris AA, et al. INTERMACS profiles and outcomes among non-inotrope-dependent outpatients with heart failure and reduced ejection fraction. *JACC Heart Fail* 2018;6:743–53. <https://doi.org/10.1016/j.jchf.2018.03.018>
 594. Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2023;25:457–68. <https://doi.org/10.1002/ehfj.2814>
 595. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. *Eur J Heart Fail* 2019;21:1064–78. <https://doi.org/10.1002/ehfj.1557>
 596. Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, et al. Treatments targeting inotropy. *Eur Heart J* 2019;40:3626–44. <https://doi.org/10.1093/eurheartj/ehy600>
 597. Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy. *JACC Heart Fail* 2021;9:518–27. <https://doi.org/10.1016/j.jchf.2021.04.005>
 598. Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock DD, et al. Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis. *JACC Heart Fail* 2018;6:757–67. <https://doi.org/10.1016/j.jchf.2018.03.019>
 599. Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. *Am Heart J* 2003;145:324–9. <https://doi.org/10.1067/mhj.2003.50>
 600. Timoteo AT, Mano TB. Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. *Heart Fail Rev* 2023;28:1053–63. <https://doi.org/10.1007/s10741-023-10297-3>
 601. Wang MJ, Zheng YM, Jin HX. Ultrafiltration for patients with acute decompensated heart failure: a systematic review and meta-analysis. *Medicine (Baltimore)* 2021;100:e28029. <https://doi.org/10.1097/MD.00000000000028029>
 602. Arabia FA, Murray CF, Cantor R, Deng L, Gopalan R, Amabile O, et al. Heart transplant outcomes after total artificial heart. *Transplant Proc* 2023;55:1664–73. <https://doi.org/10.1016/j.transproceed.2023.05.020>
 603. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan MM, et al. 2019 EACTS expert consensus on long-term mechanical circulatory support. *Eur J Cardiothorac Surg* 2019;56:230–70. <https://doi.org/10.1093/ejcts/ezz098>
 604. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA* 2022;328:1233–42. <https://doi.org/10.1001/jama.2022.16197>
 605. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device—final report. *N Engl J Med* 2019;380:1618–27. <https://doi.org/10.1056/NEJMoa1900486>
 606. Schmitto JD, Shaw S, Garbade J, Gustafsson F, Morshuis M, Zimpfer D, et al. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. *Eur Heart J* 2024;45:613–25. <https://doi.org/10.1093/eurheartj/ehad658>
 607. Numan L, Schramm R, Oerlemans M, van der Kaaij NP, Aarts E, Ramjankhan FZ, et al. Survival after HeartMate 3 left ventricular assist device implantation: real-world data from Europe. *ESC Heart Fail* 2023;10:2754–6. <https://doi.org/10.1002/ehf2.14444>
 608. Jorde UP, Saeed O, Koehl D, Morris AA, Wood KL, Meyer DM, et al. The Society of Thoracic Surgeons Intermacs 2023 annual report: focus on magnetically levitated devices. *Ann Thorac Surg* 2024;117:33–44. <https://doi.org/10.1016/j.athoracsurg.2023.11.004>
 609. Ben Gal T, Ben Avraham B, Milicic D, Crespo-Leiro MG, Coats AJS, Rosano G, et al. Guidance on the management of left ventricular assist device (LVAD)-supported patients for the non-LVAD specialist healthcare provider: executive summary. *Eur J Heart Fail* 2021;23:1597–609. <https://doi.org/10.1002/ehfj.2327>
 610. Mehra MR, Netuka I, Uriel N, Katz JN, Pagani FD, Jorde UP, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. *JAMA* 2023;330:2171–81. <https://doi.org/10.1001/jama.2023.23204>
 611. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 2001;345:1435–43. <https://doi.org/10.1056/NEJMoa012175>
 612. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, et al. A fully magnetically levitated circulatory pump for advanced heart failure. *N Engl J Med* 2017;376:440–50. <https://doi.org/10.1056/NEJMoa1610426>
 613. Estep JD, Starling RC, Horstmannshof DA, Milano CA, Selzman CH, Shah KB, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. *J Am Coll Cardiol* 2015;66:1747–61. <https://doi.org/10.1016/j.jacc.2015.07.075>
 614. Knosalla C, Farber G, Rieth AJ, Wachter R, Placzek M, Albert W, et al. Rationale and design of the randomized 'early ventricular assist device'—trial (VAD-DZHK3). *ESC Heart Fail* 2025;12:3731–40. <https://doi.org/10.1002/ehf2.15376>
 615. Karason K, Lund LH, Dalen M, Bjorklund E, Grinnemo K, Braun O, et al. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure: rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. *Eur J Heart Fail* 2020;22:739–50. <https://doi.org/10.1002/ehfj.1773>
 616. Silver E, Argiro A, Murray SS, Korthy L, Lin G, Pretorius V, et al. Genetic testing practices and pathological assessments in patients with end-stage heart failure undergoing heart transplantation and left ventricular assist device use. *J Card Fail* 2024;31:1039–47. <https://doi.org/10.1016/j.cardfail.2024.09.015>
 617. Yamasaki T, Sanders SP, Hyland RJ, Milligan C, Fynn-Thompson F, Mayer JE Jr, et al. Pathology of explanted pediatric hearts: an 11-year study. Population characteristics and implications for outcomes. *Pediatr Transplant* 2024;28:e14742. <https://doi.org/10.1111/petr.14742>
 618. Roberts WC, Salam YM. Frequency of congruence and incongruence between the clinical and morphological diagnoses in patients having orthotopic heart transplantations at the Baylor University Medical Center at Dallas from 1993 to 2020. *Am J Cardiol* 2021;156:114–22. <https://doi.org/10.1016/j.amjcard.2021.06.027>
 619. Kim Y, Gunnarsdottir OB, Viveiros A, Reichart D, Quait D, Willcox JAL, et al. Genetic contribution to end-stage cardiomyopathy requiring heart transplantation. *Circ Genom Precis Med* 2023;16:452–61. <https://doi.org/10.1161/CIRCGEN.123.004062>
 620. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol* 2014;63:1751–57. <https://doi.org/10.1016/j.jacc.2014.01.053>
 621. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. *Ann Cardiothorac Surg* 2018;7:3–11. <https://doi.org/10.21037/acs.2017.09.18>
 622. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsieh E, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report—2019; focus theme: donor and recipient size match. *J Heart Lung Transplant* 2019;38:1056–66. <https://doi.org/10.1016/j.healun.2019.08.004>
 623. Khush KK, Hsieh E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report—2021; focus on recipient characteristics. *J Heart Lung Transplant* 2021;40:1035–49. <https://doi.org/10.1016/j.healun.2021.07.015>
 624. Bakhtiyar SS, Sakowitz S, Mallick S, Curry J, Benharash P. Heart transplantation after donation after circulatory death: early United States experience. *Ann Thorac Surg* 2024;118:484–93. <https://doi.org/10.1016/j.athoracsurg.2024.05.013>

625. Schroder JN, Patel CB, DeVore AD, Bryner BS, Casalino S, Shah A, et al. Transplantation outcomes with donor hearts after circulatory death. *N Engl J Med* 2023;**388**:2121–31. <https://doi.org/10.1056/NEJMoa2212438>
626. Colvin MM, Smith JM, Ahn YS, Handarova DK, Martinez AC, Lindblad KA, et al. OPTN/SRTR 2022 annual data report: heart. *Am J Transplant* 2024;**24**:S305–93. <https://doi.org/10.1016/j.ajt.2024.01.016>
627. Schichtel M, Wee B, Perera R, Onakpoya I. The effect of advance care planning on heart failure: a systematic review and meta-analysis. *J Gen Intern Med* 2020;**35**:874–84. <https://doi.org/10.1007/s11606-019-05482-w>
628. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. *JACC Heart Fail* 2019;**7**:447–56. <https://doi.org/10.1016/j.jchf.2019.03.005>
629. Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. *JACC Heart Fail* 2017;**5**:565–74. <https://doi.org/10.1016/j.jchf.2017.05.001>
630. Mundisugih J, Franke KB, Tully PJ, Munawar DA, Kumar S, Mahajan R. Prevalence and prognostic implication of atrial fibrillation in heart failure subtypes: systematic review and meta-analysis. *Heart Lung Circ* 2023;**32**:666–77. <https://doi.org/10.1016/j.hlc.2023.02.009>
631. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. *Circulation* 2016;**133**:484–92. <https://doi.org/10.1161/CIRCULATIONAHA.115.018614>
632. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The importance of whether atrial fibrillation or heart failure develops first. *Eur J Heart Fail* 2012;**14**:1030–40. <https://doi.org/10.1093/eurjhf/hfs097>
633. Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. *Lancet Reg Health Eur* 2024;**43**:100967. <https://doi.org/10.1016/j.lanepe.2024.100967>
634. Yoshimura H, Providencia R, Finan C, Schmidt AF, Lip GYH. Refining the CHA₂DS₂-VASc risk stratification scheme: shall we drop the sex category criterion? *Europace* 2024;**26**:euae280. <https://doi.org/10.1093/europace/euae280>
635. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;**146**:857–67. <https://doi.org/10.7326/0003-4819-146-12-200706190-00007>
636. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Satri G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. *Eur J Heart Fail* 2022;**24**:1387–96. <https://doi.org/10.1002/ehf.2566>
637. Guttman OP, Rahman MS, O'Mahony C, Anastakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. *Heart* 2014;**100**:465–72. <https://doi.org/10.1136/heartjnl-2013-304276>
638. Guttman OP, Pavlou M, O'Mahony C, Monserrat L, Anastakis A, Rapezzi C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). *Eur J Heart Fail* 2015;**17**:837–45. <https://doi.org/10.1002/ehf.316>
639. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort—results from Kochi RYOMA study. *Circ J* 2019;**83**:1747–54. <https://doi.org/10.1253/circj.CJ-19-0186>
640. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. *Aging (Albany NY)* 2020;**12**:24219–27. <https://doi.org/10.18632/aging.104133>
641. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. *J Atr Fibrillation* 2019;**12**:2207. <https://doi.org/10.4022/jafib.2207>
642. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. *Heart* 2017;**103**:1496–501. <https://doi.org/10.1136/heartjnl-2016-310720>
643. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;**383**:955–62. [https://doi.org/10.1016/S0140-6736\(13\)62343-0](https://doi.org/10.1016/S0140-6736(13)62343-0)
644. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. *JACC Heart Fail* 2016;**4**:870–80. <https://doi.org/10.1016/j.jchf.2016.07.012>
645. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. *Eur J Heart Fail* 2015;**17**:1192–200. <https://doi.org/10.1002/ehf.343>
646. von Lueder TG, Atar D, Agewall S, Jensen JK, Hopper I, Kotecha D, et al. All-cause mortality and cardiovascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the Food and Drug Administration Adverse Event Reporting System. *Am J Ther* 2019;**26**:e671–8. <https://doi.org/10.1097/MJT.0000000000000883>
647. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *Eur Heart J* 2016;**37**:2465–74. <https://doi.org/10.1093/eurheartj/ehv730>
648. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol* 2013;**61**:2551–6. <https://doi.org/10.1016/j.jacc.2013.03.035>
649. Potpara T, Grygier M, Haeusler KG, Nielsen-Kudsk JE, Berti S, Genovesi S, et al. An international consensus practical guide on left atrial appendage closure for the non-implanting physician: executive summary. *Thromb Haemost* 2025;**125**:825–46. <https://doi.org/10.1055/a-2469-4896>
650. Oliva A, Ioppolo AM, Chiarito M, Cremonesi A, Azzano A, Micciche E, et al. Left atrial appendage closure compared with oral anticoagulants for patients with atrial fibrillation: a systematic review and network meta-analysis. *J Am Heart Assoc* 2024;**13**:e034815. <https://doi.org/10.1161/JAHA.124.034815>
651. Das S, Lorente-Ros M, Wu L, Mehta D, Suri R. Safety of left atrial appendage closure in heart failure patients. *J Cardiovasc Electrophysiol* 2022;**33**:2578–84. <https://doi.org/10.1111/jce.15682>
652. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med* 2020;**383**:1305–16. <https://doi.org/10.1056/NEJMoa2019422>
653. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med* 2008;**358**:2667–77. <https://doi.org/10.1056/NEJMoa0708789>
654. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med* 2002;**347**:1834–40. <https://doi.org/10.1056/NEJMoa021375>
655. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002;**347**:1825–33. <https://doi.org/10.1056/NEJMoa021328>
656. Zafeiropoulos S, Doundoulakis I, Bekiaridou A, Farmakis IT, Papadopoulos GE, Coleman KM, et al. Rhythm vs rate control strategy for atrial fibrillation: a meta-analysis of randomized controlled trials. *JACC Clin Electrophysiol* 2024;**10**:1395–405. <https://doi.org/10.1016/j.jacep.2024.03.006>
657. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *J Am Coll Cardiol* 2003;**41**:1690–6. [https://doi.org/10.1016/s0735-1097\(03\)00332-2](https://doi.org/10.1016/s0735-1097(03)00332-2)
658. Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, Cooper LB, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from Get With the Guidelines—Heart Failure. *J Am Heart Assoc* 2019;**8**:e011560. <https://doi.org/10.1161/JAHA.118.011560>
659. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2019;**21**:471–9. <https://doi.org/10.1002/ehf.1389>
660. Li SJ, Sartipy U, Lund LH, Dahlstrom U, Adiels M, Petzold M, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. *Circ Heart Fail* 2015;**8**:871–9. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002285>
661. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. *Europace* 2006;**8**:935–42. <https://doi.org/10.1093/europace/eul106>
662. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With the Guidelines—Heart Failure

- Program). *Am J Cardiol* 2020;**125**:894–900. <https://doi.org/10.1016/j.amjcard.2019.12.025>
663. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. *J Am Coll Cardiol* 2017;**69**:2885–96. <https://doi.org/10.1016/j.jacc.2017.04.001>
 664. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. *Lancet* 2016;**388**:818–28. [https://doi.org/10.1016/S0140-6736\(16\)31258-2](https://doi.org/10.1016/S0140-6736(16)31258-2)
 665. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. *JAMA* 2020;**324**:2497–508. <https://doi.org/10.1001/jama.2020.23138>
 666. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? *J Am Coll Cardiol* 2003;**42**:1944–51. <https://doi.org/10.1016/j.jacc.2003.07.020>
 667. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. *BMJ* 2015;**351**:h4451. <https://doi.org/10.1136/bmj.h4451>
 668. Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. *Eur Heart J* 1999;**20**:1833–42. <https://doi.org/10.1053/eurhj.1999.1747>
 669. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. *Eur Heart J* 1995;**16**:521–8. <https://doi.org/10.1093/oxfordjournals.eurheartj.a060945>
 670. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtnr M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. *Crit Care Med* 2001;**29**:1149–53. <https://doi.org/10.1097/00003246-200106000-00011>
 671. Hofmann R, Steinwender C, Kammler J, Kypka A, Wimmer G, Leisch F. Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. *Wien Klin Wochenschr* 2004;**116**:744–9. <https://doi.org/10.1007/s00508-004-0264-0>
 672. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. *Eur Heart J* 2018;**39**:3999–4008. <https://doi.org/10.1093/eurheartj/ehy555>
 673. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. *Eur Heart J* 2021;**42**:4731–9. <https://doi.org/10.1093/eurheartj/ehab569>
 674. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018;**378**:417–27. <https://doi.org/10.1056/NEJMoa1707855>
 675. Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. *N Engl J Med* 2023;**389**:1380–9. <https://doi.org/10.1056/NEJMoa2306037>
 676. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. *Circulation* 2022;**145**:1693–704. <https://doi.org/10.1161/CIRCULATIONAHA.121.057095>
 677. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA* 2019;**321**:1261–74. <https://doi.org/10.1001/jama.2019.0693>
 678. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. *Circulation* 2021;**143**:1377–90. <https://doi.org/10.1161/CIRCULATIONAHA.120.050991>
 679. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. *Circ Arrhythm Electrophysiol* 2019;**12**:e007731. <https://doi.org/10.1161/CIRCEP.119.007731>
 680. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. *J Am Coll Cardiol* 2017;**70**:1949–61. <https://doi.org/10.1016/j.jacc.2017.08.041>
 681. Pasqualotto E, Ternes CMP, Chavez MP, Polanczyk CA, Ferreira ROM, Nienkotter T, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: a meta-analysis. *Heart Rhythm* 2024;**21**:1604–12. <https://doi.org/10.1016/j.hrthm.2024.04.098>
 682. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation* 2016;**133**:1637–44. <https://doi.org/10.1161/CIRCULATIONAHA.115.019406>
 683. Chieng D, Sugumar H, Segan L, Tan C, Vizi D, Nanayakkara S, et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial. *JACC Heart Fail* 2023;**11**:646–58. <https://doi.org/10.1016/j.jchf.2023.01.008>
 684. Oraili A, McIntyre WF, Parkash R, Kowalik K, Razeghi G, Benz AP, et al. Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction: a systematic review and meta-analysis. *JAMA Cardiol* 2024;**9**:545–55. <https://doi.org/10.1001/jamacardio.2024.0675>
 685. Hunter J, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circ Arrhythm Electrophysiol* 2014;**7**:31–8. <https://doi.org/10.1161/CIRCEP.113.000806>
 686. Martens P, Augusto SN Jr, Erzeel J, Pison L, Mullens W, Tang WHW. Effects of atrial fibrillation ablation for heart failure with preserved ejection fraction: insights from CABANA. *JACC Heart Fail* 2025;**13**:785–94. <https://doi.org/10.1016/j.jchf.2025.01.029>
 687. Doehner W, Boriani G, Potpara T, Blomstrom-Lundqvist C, Passman R, Sposato LA, et al. Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association. *Europace* 2025;**27**:eua019. <https://doi.org/10.1093/europace/eaaf019>
 688. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomized trial. *Lancet* 2020;**395**:339–49. [https://doi.org/10.1016/S0140-6736\(19\)32994-0](https://doi.org/10.1016/S0140-6736(19)32994-0)
 689. Prasai P, Shrestha DB, Saad E, Trongtorsak A, Adhikari A, Gaire S, et al. Electric cardioversion vs. pharmacological with or without electric cardioversion for stable new-onset atrial fibrillation: a systematic review and meta-analysis. *J Clin Med* 2023;**12**:1165. <https://doi.org/10.3390/jcm12031165>
 690. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedrone in high-risk permanent atrial fibrillation. *N Engl J Med* 2011;**365**:2268–76. <https://doi.org/10.1056/NEJMoa1109867>
 691. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991;**324**:781–8. <https://doi.org/10.1056/NEJM199103213241201>
 692. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. *Circulation* 1998;**98**:2574–9. <https://doi.org/10.1161/01.cir.98.23.2574>
 693. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. *Am J Cardiol* 2012;**110**:607–13. <https://doi.org/10.1016/j.amjcard.2012.04.034>
 694. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. *Eur Heart J* 1992;**13**:1251–8. <https://doi.org/10.1093/oxfordjournals.eurheartj.a060345>
 695. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A, et al. Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. *Clin Exp Emerg Med* 2019;**6**:4–9. <https://doi.org/10.15441/ceem.17.286>
 696. Chen S, Purerfellner H, Meyer C, Acou WJ, Schratte A, Ling Z, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. *Eur Heart J* 2020;**41**:2863–73. <https://doi.org/10.1093/eurheartj/ehz443>

697. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. *N Engl J Med* 1995;333:77–82. <https://doi.org/10.1056/NEJM199507133330201>
698. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, et al. Ventricular ectopy as a predictor of heart failure and death. *J Am Coll Cardiol* 2015;66:101–9. <https://doi.org/10.1016/j.jacc.2015.04.062>
699. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. *Heart Rhythm* 2010;7:865–9. <https://doi.org/10.1016/j.hrthm.2010.03.036>
700. Hasdemir C, Ulucan C, Yavuzgil O, Yuksel A, Kartal Y, Simsek E, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. *J Cardiovasc Electrophysiol* 2011;22:663–8. <https://doi.org/10.1111/j.1540-8167.2010.01986.x>
701. Slaven S, Garg L, Sabzwari R, Barrett C, Tumolo A, Cerbin L, et al. Burden of premature ventricular complexes and risk of cardiomyopathy: a cross-sectional study. *JACC Clin Electrophysiol* 2025;11:894–903. <https://doi.org/10.1016/j.jacep.2025.01.004>
702. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. *Heart Rhythm* 2007;4:863–7. <https://doi.org/10.1016/j.hrthm.2007.03.003>
703. Berrueto A, Penela D, Jauregui B, Soto-Iglesias D, Aguinaga L, Ordonez A, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. *Europace* 2019;21:1079–87. <https://doi.org/10.1093/europace/euz027>
704. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. *Circulation* 2005;112:1092–7. <https://doi.org/10.1161/CIRCULATIONAHA.105.546432>
705. Prinzen FW, Auricchio A, Mullens W, Linde C, Huizar JF. Electrical management of heart failure: from pathophysiology to treatment. *Eur Heart J* 2022;43:1917–27. <https://doi.org/10.1093/eurheartj/ehac088>
706. Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, et al. Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. *Eur J Heart Fail* 2019;21:643–51. <https://doi.org/10.1002/ehf.1427>
707. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A, et al. Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction. *JACC Cardiovasc Imaging* 2022;15:1001–11. <https://doi.org/10.1016/j.jcmg.2021.11.022>
708. Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *JAMA Cardiol* 2021;6:1130–43. <https://doi.org/10.1001/jamacardio.2021.1825>
709. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. *Eur Heart J* 2018;39:3439–50. <https://doi.org/10.1093/eurheartj/ehy531>
710. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002;106:2194–9. <https://doi.org/10.1161/01.cir.0000035653.72855.bf>
711. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 2000;283:1295–302. <https://doi.org/10.1001/jama.283.10.1295>
712. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. *BMC Med* 2020;18:103. <https://doi.org/10.1186/s12916-020-01564-3>
713. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between intravascular treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. *Eur Heart J* 2009;30:2337–45. <https://doi.org/10.1093/eurheartj/ehp358>
714. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *N Engl J Med* 1996;335:1107–14. <https://doi.org/10.1056/NEJM199610103351504>
715. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. *Circulation* 1997;96:856–63. <https://doi.org/10.1161/01.cir.96.3.856>
716. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. *Lancet* 2002;359:1269–75. [https://doi.org/10.1016/S0140-6736\(02\)08265-X](https://doi.org/10.1016/S0140-6736(02)08265-X)
717. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 trial. *J Am Coll Cardiol* 2009;53:1510–6. <https://doi.org/10.1016/j.jacc.2009.01.037>
718. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. *Eur Heart J* 2004;25:1814–21. <https://doi.org/10.1016/j.ehj.2004.06.034>
719. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. *J Am Coll Cardiol* 2012;59:913–22. <https://doi.org/10.1016/j.jacc.2011.11.027>
720. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. *Heart* 2011;97:278–86. <https://doi.org/10.1136/hrt.2010.208751>
721. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. *Circulation* 1991;83:52–60. <https://doi.org/10.1161/01.cir.83.1.52>
722. Matsumoto S, Henderson AD, Shen L, Kondo T, Yang M, Campbell RT, et al. Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. *Eur J Heart Fail* 2025;27:124–39. <https://doi.org/10.1002/ehf.3383>
723. Matsumoto S, Kondo T, Yang M, Campbell RT, Docherty KF, de Boer RA, et al. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. *Eur J Heart Fail* 2023;25:2202–14. <https://doi.org/10.1002/ehf.3044>
724. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med* 2011;364:1617–25. <https://doi.org/10.1056/NEJMoa1100358>
725. Jolicoeur EM, Dunning A, Castelvécchio S, Dabrowski R, Wacławski MA, Petrie MC, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. *J Am Coll Cardiol* 2015;66:2092–100. <https://doi.org/10.1016/j.jacc.2015.08.882>
726. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. *J Am Coll Cardiol* 2013;61:1860–70. <https://doi.org/10.1016/j.jacc.2013.02.014>
727. Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, et al. Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 trial. *JAMA Cardiol* 2023;8:1154–61. <https://doi.org/10.1001/jamacardio.2023.3803>
728. Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, et al. Impact of anatomical and viability-guided completeness of revascularization on clinical outcomes in ischemic cardiomyopathy. *J Am Coll Cardiol* 2024;84:340–50. <https://doi.org/10.1016/j.jacc.2024.04.043>
729. Bloom JE, Vogrin S, Reid CM, Ajani AE, Clark DJ, Freeman M, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival. *Eur Heart J* 2025;46:72–80. <https://doi.org/10.1093/eurheartj/ehae672>
730. Volz S, Redfors B, Angeras O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). *Eur Heart J* 2021;42:2657–64. <https://doi.org/10.1093/eurheartj/ehab273>
731. Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. *JAMA Cardiol* 2020;5:631–41. <https://doi.org/10.1001/jamacardio.2020.0239>
732. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction:

- insights from the ISCHEMIA trial. *Circulation* 2020;**142**:1725–35. <https://doi.org/10.1161/CIRCULATIONAHA.120.050304>
733. Iaconelli A, Pellicori P, Dolce P, Busti M, Ruggio A, Aspromonte N, et al. Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials. *Eur J Heart Fail* 2023;**25**:1094–104. <https://doi.org/10.1002/ehf.2911>
 734. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. *N Engl J Med* 2023;**389**:2319–30. <https://doi.org/10.1056/NEJMoa2310610>
 735. Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, et al. Health-status outcomes with invasive or conservative care in coronary disease. *N Engl J Med* 2020;**382**:1408–19. <https://doi.org/10.1056/NEJMoa1916370>
 736. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. *Eur Heart J* 2017;**38**:3351–8. <https://doi.org/10.1093/eurheartj/ehx381>
 737. Shahim B, Shahim A, Adamo M, Chioncel O, Benson L, Crespo-Leiro MG, et al. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2023;**25**:1049–60. <https://doi.org/10.1002/ehf.2908>
 738. Krittanawong C, Kumar A, Wang Z, Johnson KW, Rastogi U, Narasimhan B, et al. Predictors of in-hospital mortality after transcatheter aortic valve implantation. *Am J Cardiol* 2020;**125**:251–7. <https://doi.org/10.1016/j.amjcard.2019.10.014>
 739. Adamo M, Pagnesi M, Chioncel O, Bayes-Genis A, Abdelhamid M, Antohi EL, et al. Management of aortic stenosis and chronic heart failure: a clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. *Eur J Heart Fail* 2025;**27**:2623–33. <https://doi.org/10.1002/ehf.70023>
 740. Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, Gonzalez Ferreiro R, Gonzalez Bermudez I, Lopez Otero D, et al. Dapagliflozin in patients undergoing transcatheter aortic-valve implantation. *N Engl J Med* 2025;**392**:1396–405. <https://doi.org/10.1056/NEJMoa2500366>
 741. Elder DH, Wei L, Szejewski BR, Libianto R, Nadir A, Pauriah M, et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. *J Am Coll Cardiol* 2011;**58**:2084–91. <https://doi.org/10.1016/j.jacc.2011.07.043>
 742. Jung JC, Jang MJ, Hwang HY. Meta-analysis comparing mitral valve repair versus replacement for degenerative mitral regurgitation across all ages. *Am J Cardiol* 2019;**123**:446–53. <https://doi.org/10.1016/j.amjcard.2018.10.024>
 743. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. *Circulation* 2017;**135**:410–22. <https://doi.org/10.1161/CIRCULATIONAHA.116.023340>
 744. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. *J Am Coll Cardiol* 2015;**66**:2844–54. <https://doi.org/10.1016/j.jacc.2015.10.018>
 745. Makkar RR, Chikwe J, Chakravarty T, Chen Q, O'Gara PT, Gillinov M, et al. Transcatheter mitral valve repair for degenerative mitral regurgitation. *JAMA* 2023;**329**:1778–88. <https://doi.org/10.1001/jama.2023.7089>
 746. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmuller S, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. *BMJ* 2021;**373**:n1421. <https://doi.org/10.1136/bmj.n1421>
 747. Adamo M, Chioncel O, Benson L, Shahim B, Crespo-Leiro MG, Anker SD, et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: an analysis from the ESC-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail* 2023;**25**:1061–71. <https://doi.org/10.1002/ehf.2929>
 748. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2013;**14**:611–44. <https://doi.org/10.1093/ehjci/jet105>
 749. Riccardi M, Cikes M, Adamo M, Pagnesi M, Lombardi CM, Solomon SD, et al. Functional mitral regurgitation and heart failure with preserved ejection fraction: clinical implications and management. *J Card Fail* 2024;**30**:929–39. <https://doi.org/10.1016/j.cardfail.2024.02.024>
 750. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 2018;**379**:2297–306. <https://doi.org/10.1056/NEJMoa1805374>
 751. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018;**379**:2307–18. <https://doi.org/10.1056/NEJMoa1806640>
 752. Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. *N Engl J Med* 2024;**391**:1799–809. <https://doi.org/10.1056/NEJMoa2314328>
 753. Anker MS, Porthun J, Bonnet G, Schulze PC, Rassaf T, Landmesser U. Percutaneous transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure: a meta-analysis of 3 randomized controlled trials. *J Am Coll Cardiol* 2024;**84**:2364–8. <https://doi.org/10.1016/j.jacc.2024.08.026>
 754. Baldus S, Doenst T, Pfister R, Gummert J, Kessler M, Boekstegers P, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. *N Engl J Med* 2024;**391**:1787–98. <https://doi.org/10.1056/NEJMoa2408739>
 755. Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. *N Engl J Med* 2023;**388**:2037–48. <https://doi.org/10.1056/NEJMoa2300213>
 756. Adamo M, Fiorelli F, Melica B, D'Ortona R, Lupi L, Giannini C, et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. *JACC Cardiovasc Interv* 2021;**14**:15–25. <https://doi.org/10.1016/j.jcin.2020.09.050>
 757. Adamo M, Pagnesi M, Ajmone Marsan N, Bauersachs J, Hausleiter J, Zieroth S, et al. Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach. *Eur Heart J* 2025;**47**:1294–303. <https://doi.org/10.1093/eurheartj/ehaf480>
 758. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;**380**:1695–705. <https://doi.org/10.1056/NEJMoa1814052>
 759. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;**363**:1597–607. <https://doi.org/10.1056/NEJMoa1008232>
 760. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;**370**:1790–8. <https://doi.org/10.1056/NEJMoa1400590>
 761. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 2019;**380**:1706–15. <https://doi.org/10.1056/NEJMoa1816885>
 762. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014;**63**:1972–81. <https://doi.org/10.1016/j.jacc.2014.02.556>
 763. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2017;**376**:1321–31. <https://doi.org/10.1056/NEJMoa1700456>
 764. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;**364**:2187–98. <https://doi.org/10.1056/NEJMoa1103510>
 765. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic stenosis: a meta-analysis. *JACC Cardiovasc Interv* 2021;**14**:1481–92. <https://doi.org/10.1016/j.jcin.2021.04.038>
 766. Mack M, Carroll JD, Thourani V, Vemulapalli S, Squiers J, Manandhar P, et al. Transcatheter mitral valve therapy in the United States: a report from the STS/ACC TVT Registry. *Ann Thorac Surg* 2022;**113**:337–65. <https://doi.org/10.1016/j.athoracsurg.2021.07.030>
 767. Saji M, Yamamoto M, Kubo S, Asami M, Enta Y, Shirai S, et al. Short-term outcomes following transcatheter edge-to-edge repair: insights from the OCEAN-Mitral registry. *JACC Asia* 2023;**3**:766–73. <https://doi.org/10.1016/j.jacasi.2023.06.008>
 768. Koell B, Orban M, Weimann J, Kassam M, Karam N, Neuss M, et al. Outcomes stratified by adapted inclusion criteria after mitral edge-to-edge repair. *J Am Coll Cardiol* 2021;**78**:2408–21. <https://doi.org/10.1016/j.jacc.2021.10.011>
 769. Stocker TJ, Stolz L, Karam N, Kalbacher D, Koell B, Trenkwalder T, et al. Long-term outcomes after edge-to-edge repair of secondary mitral

- regurgitation: 5-year results from the EuroSMR registry. *JACC Cardiovasc Interv* 2024;**17**:2543–54. <https://doi.org/10.1016/j.jcin.2024.08.016>
770. Heitzinger G, Pavo N, Koschatko S, Jantsch C, Winter MP, Spinka G, et al. Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum. *Eur J Heart Fail* 2023;**25**:857–67. <https://doi.org/10.1002/ehf.2858>
 771. Metra M, Tomasoni D, Adamo M, Anker SD, Bayes-Genis A, von Bardeleben RS, et al. Evidence generation and implementation of transcatheter interventions for atrioventricular valvular heart disease in heart failure: current status and future directions. *Circulation* 2025;**151**:1342–63. <https://doi.org/10.1161/CIRCULATIONAHA.124.070411>
 772. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. *N Engl J Med* 2023;**388**:1833–42. <https://doi.org/10.1056/NEJMoa2300525>
 773. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized clinical trial. *JAMA* 2025;**333**:124–32. <https://doi.org/10.1001/jama.2024.21189>
 774. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. Transcatheter valve replacement in severe tricuspid regurgitation. *N Engl J Med* 2025;**392**:115–26. <https://doi.org/10.1056/NEJMoa2401918>
 775. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized controlled trial. *Circulation* 2025;**151**:1630–8. <https://doi.org/10.1161/CIRCULATIONAHA.125.074536>
 776. Tomasoni D, Adamo M, Hausleiter J, Pezzola E, Kresoja KP, von Stein J, et al. Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: insights from EuroTR. *Eur J Heart Fail* 2025;**27**:1559–69. <https://doi.org/10.1002/ehf.3757>
 777. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet* 2014;**383**:1899–911. [https://doi.org/10.1016/S0140-6736\(14\)60685-1](https://doi.org/10.1016/S0140-6736(14)60685-1)
 778. Tomasoni D, Vitale C, Guidetti F, Benson L, Braunschweig F, Dahlstrom U, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2024;**26**:854–68. <https://doi.org/10.1002/ehf.3112>
 779. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 2003;**5**:659–67. [https://doi.org/10.1016/s1388-9842\(03\)00163-6](https://doi.org/10.1016/s1388-9842(03)00163-6)
 780. Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. *Eur J Heart Fail* 2020;**22**:1357–65. <https://doi.org/10.1002/ehf.1835>
 781. Vemmos K, Ntaios G, Savvari P, Vemmou AM, Koroboki E, Manios E, et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. *Eur J Heart Fail* 2012;**14**:211–8. <https://doi.org/10.1093/eurjhf/hfr172>
 782. Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. *J Card Fail* 2009;**15**:11–6. <https://doi.org/10.1016/j.cardfail.2008.09.001>
 783. Ois A, Gomis M, Cuadrado-Godia E, Jimenez-Conde J, Rodriguez-Campello A, Bruguera J, et al. Heart failure in acute ischemic stroke. *J Neurol* 2008;**255**:385–9. <https://doi.org/10.1007/s00415-008-0677-1>
 784. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. *Stroke* 2006;**37**:1715–9. <https://doi.org/10.1161/01.STR.0000227121.34717.40>
 785. Witt BJ, Gami AS, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. *J Card Fail* 2007;**13**:489–96. <https://doi.org/10.1016/j.cardfail.2007.01.009>
 786. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, et al. Ischemic stroke after heart failure: a community-based study. *Am Heart J* 2006;**152**:102–9. <https://doi.org/10.1016/j.ahj.2005.10.018>
 787. Lip GY, Rasmussen LH, Skjoth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. *BMJ Open* 2012;**2**:e000975. <https://doi.org/10.1136/bmjopen-2012-000975>
 788. Alberts VP, Bos MJ, Koudstaal P, Hofman A, Witteman JC, Stricker B, et al. Heart failure and the risk of stroke: the Rotterdam Study. *Eur J Epidemiol* 2010;**25**:807–12. <https://doi.org/10.1007/s10654-010-9520-y>
 789. Adelborg K, Szepligeti S, Sundboll J, Horvath-Puho E, Henderson VW, Ording A, et al. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. *Stroke* 2017;**48**:1161–8. <https://doi.org/10.1161/STROKEAHA.116.016022>
 790. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation* 2005;**112**:3738–44. <https://doi.org/10.1161/CIRCULATIONAHA.105.561423>
 791. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. *Circulation* 2010;**121**:1393–405. <https://doi.org/10.1161/CIRCULATIONAHA.109.909614>
 792. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. *Int J Cardiol* 2016;**203**:660–6. <https://doi.org/10.1016/j.ijcard.2015.10.220>
 793. McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. *J Am Heart Assoc* 2013;**2**:e005694. <https://doi.org/10.1161/JAHA.112.005694>
 794. Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. *Stroke* 2015;**46**:667–72. <https://doi.org/10.1161/STROKEAHA.114.007140>
 795. Uhm JS, Kim J, Yu HT, Kim TH, Lee SR, Cha MJ, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. *ESC Heart Fail* 2021;**8**:1582–9. <https://doi.org/10.1002/ehf2.13264>
 796. Chung S, Kim TH, Uhm JS, Cha MJ, Lee JM, Park J, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COMparison study of drugs for symptom control and complication prevention of atrial fibrillation [CODE-AF]). *Am J Cardiol* 2020;**125**:68–75. <https://doi.org/10.1016/j.amjcard.2019.09.035>
 797. Sharma JC, Fletcher S, Vassallo M, Ross I. Cardiovascular disease and outcome of acute stroke: influence of pre-existing cardiac failure. *Eur J Heart Fail* 2000;**2**:145–50. [https://doi.org/10.1016/s1388-9842\(00\)00067-2](https://doi.org/10.1016/s1388-9842(00)00067-2)
 798. Abdul-Rahim AH, Fulton RL, Frank B, McMurray JJ, Lees KR, collaborators V. Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. *Eur J Neurol* 2015;**22**:163–9. <https://doi.org/10.1111/ene.12548>
 799. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. *Nat Rev Cardiol* 2016;**13**:131–47. <https://doi.org/10.1038/nrcardio.2015.191>
 800. Kang SH, Kim J, Park JJ, Oh IY, Yoon CH, Kim HJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. *Int J Cardiol* 2017;**248**:182–7. <https://doi.org/10.1016/j.ijcard.2017.07.056>
 801. Ishiguchi H, Chen Y, Huang B, Gue Y, Correa E, Homma S, et al. Machine learning for stroke in heart failure with reduced ejection fraction but without atrial fibrillation: a post-hoc analysis of the WARCEF trial. *Eur J Clin Invest* 2025;**55**:e14360. <https://doi.org/10.1111/eci.14360>
 802. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA₂DS₂-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. *JAMA* 2015;**314**:1030–8. <https://doi.org/10.1001/jama.2015.10725>
 803. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med* 2012;**366**:1859–69. <https://doi.org/10.1056/NEJMoa1202299>
 804. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. *N Engl J Med* 2018;**379**:1332–42. <https://doi.org/10.1056/NEJMoa1808848>
 805. Shantsila E, Koziel M, Lip GY. Anticoagulation versus placebo for heart failure in sinus rhythm. *Cochrane Database Syst Rev* 2021;**5**:CD003336. <https://doi.org/10.1002/14651858.CD003336.pub4>
 806. Shantsila E, Lip GY. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. *Cochrane Database Syst Rev* 2016;**9**:CD003333. <https://doi.org/10.1002/14651858.CD003333.pub3>
 807. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gasecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. *Eur Stroke J* 2021;**6**:11. <https://doi.org/10.1177/23969873211012133>

808. Koskinas KC, Van Craenenbroeck EM, Antoniadou C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. *Eur Heart J* 2024;45:4063–98. <https://doi.org/10.1093/eurheartj/ehae508>
809. Obokata M, Reddy YNV, Melenovsky V, Sorimachi H, Jarolim P, Borlaug BA. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. *Eur J Heart Fail* 2022;24:353–61. <https://doi.org/10.1002/ehf.2377>
810. Corrà U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2014;16:929–41. <https://doi.org/10.1002/ehf.156>
811. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. *J Am Coll Cardiol* 2017;69:1129–42. <https://doi.org/10.1016/j.jacc.2016.11.081>
812. Larson K, Omar M, Sorimachi H, Omote K, Alogna A, Popovic D, et al. Clinical phenogroup diversity and multiplicity: impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2024;26:564–77. <https://doi.org/10.1002/ehf.3105>
813. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. *Circulation* 2017;136:6–19. <https://doi.org/10.1161/CIRCULATIONAHA.116.026807>
814. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. *J Am Coll Cardiol* 2018;71:2360–72. <https://doi.org/10.1016/j.jacc.2018.03.509>
815. Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. *Eur J Heart Fail* 2020;22:1009–18. <https://doi.org/10.1002/ehf.1788>
816. Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. *Mayo Clin Proc* 2019;94:1199–209. <https://doi.org/10.1016/j.mayocp.2018.11.037>
817. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2016;315:36–46. <https://doi.org/10.1001/jama.2015.17346>
818. Lee VYJ, Houston L, Perkovic A, Barraclough JY, Sweeting A, Yu J, et al. The effect of weight loss through lifestyle interventions in patients with heart failure with preserved ejection fraction—a systematic review and meta-analysis of randomised controlled trials. *Heart Lung Circ* 2024;33:197–208. <https://doi.org/10.1016/j.hlc.2023.11.022>
819. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. *Lancet* 2024;404:773–86. [https://doi.org/10.1016/S0140-6736\(24\)01498-3](https://doi.org/10.1016/S0140-6736(24)01498-3)
820. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. *Lancet* 2024;404:949–61. [https://doi.org/10.1016/S0140-6736\(24\)01643-X](https://doi.org/10.1016/S0140-6736(24)01643-X)
821. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2016;316:500–8. <https://doi.org/10.1001/jama.2016.10260>
822. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail* 2017;19:69–77. <https://doi.org/10.1002/ehf.657>
823. Mentias A, Desai MY, Aminian A, Patel KV, Keshvani N, Verma S, et al. Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity. *Circ Heart Fail* 2024;17:e010453. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.010453>
824. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. *Circulation* 2021;143:1468–80. <https://doi.org/10.1161/CIRCULATIONAHA.120.052386>
825. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. *Lancet* 2024;403:1635–48. [https://doi.org/10.1016/S0140-6736\(24\)00469-0](https://doi.org/10.1016/S0140-6736(24)00469-0)
826. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. *Am J Cardiol* 1996;77:1017–20. [https://doi.org/10.1016/s0002-9149\(97\)89163-1](https://doi.org/10.1016/s0002-9149(97)89163-1)
827. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;19:54–65. <https://doi.org/10.1002/ehf.679>
828. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. *Diabetes Care* 2017;40:671–8. <https://doi.org/10.2337/dc16-2016>
829. Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. *Nat Med* 2024;30:3758–64. <https://doi.org/10.1038/s41591-024-03264-4>
830. Böhm M, Pogue J, Kindermann I, Poss J, Koon T, Yusuf S. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. *Eur J Heart Fail* 2014;16:325–33. <https://doi.org/10.1002/ehf.23>
831. Jackson AM, Rørth R, Liu J, Kristensen SL, Anand JS, Claggett BL, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail* 2022;24:497–509. <https://doi.org/10.1002/ehf.2403>
832. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *Am Heart J* 2003;146:848–53. [https://doi.org/10.1016/S0002-8703\(03\)00403-4](https://doi.org/10.1016/S0002-8703(03)00403-4)
833. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. *Circ Heart Fail* 2016;9:e002560. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560>
834. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. *Eur Heart J* 2021;42:4887–90. <https://doi.org/10.1093/eurheartj/ehab704>
835. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab* 2018;20:1755–61. <https://doi.org/10.1111/dom.13260>
836. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. *N Engl J Med* 2017;377:2337–48. <https://doi.org/10.1056/NEJMoa1708337>
837. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. *Circ Heart Fail* 2013;6:395–402. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.000162>
838. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. *Diabetes Care* 2005;28:2345–51. <https://doi.org/10.2337/diacare.28.10.2345>
839. Andersson C, Olesen JB, Hansen PR, Weeke P, Nørgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. *Diabetologia* 2010;53:2546–53. <https://doi.org/10.1007/s00125-010-1906-6>
840. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Sævereid HA, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. *Cardiovasc Diabetol* 2019;18:156. <https://doi.org/10.1186/s12933-019-0960-8>
841. Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med* 2012;367:319–28. <https://doi.org/10.1056/NEJMoa1203858>
842. Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S, et al. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (outcome reduction with initial glargine intervention).

- Circulation* 2018;**137**:88–90. <https://doi.org/10.1161/CIRCULATIONAHA.117.030924>
843. Shen L, Rorth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, *et al.* Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. *Eur J Heart Fail* 2019;**21**:974–84. <https://doi.org/10.1002/ehjhf.1535>
 844. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, *et al.* Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. *Eur J Heart Fail* 2018;**20**:888–95. <https://doi.org/10.1002/ehjhf.1146>
 845. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, *et al.* Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;**369**:1317–26. <https://doi.org/10.1056/NEJMoa1307684>
 846. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007;**370**:1129–36. [https://doi.org/10.1016/S0140-6736\(07\)61514-1](https://doi.org/10.1016/S0140-6736(07)61514-1)
 847. Damman K, Testani JM. The kidney in heart failure: an update. *Eur Heart J* 2015;**36**:1437–44. <https://doi.org/10.1093/eurheartj/ehv010>
 848. George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar-Zadeh K, *et al.* Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. *Circ Heart Fail* 2017;**10**:e003825. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003825>
 849. Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, *et al.* Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. *Eur J Heart Fail* 2018;**20**:1257–66. <https://doi.org/10.1002/ehjhf.1202>
 850. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J* 2014;**35**:455–69. <https://doi.org/10.1093/eurheartj/ehs386>
 851. Chatur S, Vaduganathan M, Peikert A, Claggett BL, McCausland FR, Skali H, *et al.* Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial. *Eur J Heart Fail* 2022;**24**:1906–14. <https://doi.org/10.1002/ehjhf.2638>
 852. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;**351**:1296–305. <https://doi.org/10.1056/NEJMoa041031>
 853. Khayat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. *JACC Heart Fail* 2021;**9**:100–11. <https://doi.org/10.1016/j.jchf.2020.09.006>
 854. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, *et al.* Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. *J Am Soc Nephrol* 2007;**18**:1307–15. <https://doi.org/10.1681/ASN.2006101159>
 855. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, *et al.* How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2024;**26**:1278–97. <https://doi.org/10.1002/ehjhf.3295>
 856. Damman K, Tang WH, Felker GM, Lassus J, Zannad F, Krum H, *et al.* Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. *J Am Coll Cardiol* 2014;**63**:853–71. <https://doi.org/10.1016/j.jacc.2013.11.031>
 857. Butler J, Packer M, Siddiqi TJ, Bohm M, Brueckmann M, Januzzi JL, *et al.* Efficacy of empagliflozin in patients with heart failure across kidney risk categories. *J Am Coll Cardiol* 2023;**81**:1902–14. <https://doi.org/10.1016/j.jacc.2023.03.390>
 858. Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, *et al.* Impact of renal impairment on beta-blocker efficacy in patients with heart failure. *J Am Coll Cardiol* 2019;**74**:2893–904. <https://doi.org/10.1016/j.jacc.2019.09.059>
 859. Chatur S, Vaduganathan M, Claggett BL, McCausland FR, Desai AS, Jhund PS, *et al.* Dapagliflozin in patients with heart failure and deterioration in renal function. *J Am Coll Cardiol* 2023;**82**:1854–63. <https://doi.org/10.1016/j.jacc.2023.08.026>
 860. McCausland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, *et al.* Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. *J Am Coll Cardiol* 2025;**85**:159–68. <https://doi.org/10.1016/j.jacc.2024.10.091>
 861. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, *et al.* Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. *Nat Med* 2025;**31**:544–51. <https://doi.org/10.1038/s41591-024-03374-z>
 862. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, *et al.* Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024;**391**:109–21. <https://doi.org/10.1056/NEJMoa2403347>
 863. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. *Eur Heart J* 2012;**33**:2135–42. <https://doi.org/10.1093/eurheartj/ehs205>
 864. Ter Maaten JM, Mebazaa A, Davison B, Edwards C, Adamo M, Arrigo M, *et al.* Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure. *Eur J Heart Fail* 2023;**25**:2230–42. <https://doi.org/10.1002/ehjhf.3074>
 865. Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ, *et al.* Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm Creatinine Measurements collaborative project. *Eur J Heart Fail* 2023;**25**:1270–80. <https://doi.org/10.1002/ehjhf.2879>
 866. Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. *Eur Heart J* 2023;**44**:14–27. <https://doi.org/10.1093/eurheartj/ehac569>
 867. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. *Circulation* 2018;**138**:80–98. <https://doi.org/10.1161/CIRCULATIONAHA.118.030099>
 868. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. *Nat Rev Cardiol* 2015;**12**:659–69. <https://doi.org/10.1038/nrcardio.2015.109>
 869. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, *et al.* Criteria for iron deficiency in patients with heart failure. *J Am Coll Cardiol* 2022;**79**:341–51. <https://doi.org/10.1016/j.jacc.2021.11.039>
 870. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, *et al.* Redefining iron deficiency in patients with chronic heart failure. *Circulation* 2024;**150**:151–61. <https://doi.org/10.1161/CIRCULATIONAHA.124.068883>
 871. Beavers CJ, Ambrosy AP, Butler J, Davidson BT, Gale SE, Pina IL, *et al.* Iron deficiency in heart failure: a scientific statement from the Heart Failure Society of America. *J Card Fail* 2023;**29**:1059–77. <https://doi.org/10.1016/j.cardfail.2023.03.025>
 872. Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, *et al.* Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. *Eur J Heart Fail* 2023;**25**:1080–90. <https://doi.org/10.1002/ehjhf.2860>
 873. Martens P, Augusto SN Jr, Mullens W, Tang WHW. Meta-analysis and meta-regression of the treatment effect of intravenous iron in iron-deficient heart failure. *JACC Heart Fail* 2024;**12**:525–36. <https://doi.org/10.1016/j.jchf.2023.11.006>
 874. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, *et al.* Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. *Eur Heart J* 2023;**44**:5077–91. <https://doi.org/10.1093/eurheartj/ehad586>
 875. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, *et al.* Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015;**36**:657–68. <https://doi.org/10.1093/eurheartj/ehu385>
 876. Anker SD, Comin-Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, *et al.* Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;**361**:2436–48. <https://doi.org/10.1056/NEJMoa0908355>
 877. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, *et al.* The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. *Eur Heart J* 2013;**34**:30–38. <https://doi.org/10.1093/eurheartj/ehr504>
 878. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, *et al.* Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. *Circulation* 2017;**136**:1374–83. <https://doi.org/10.1161/CIRCULATIONAHA.117.027497>
 879. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, *et al.* Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. *Lancet* 2022;**400**:2199–209. [https://doi.org/10.1016/S0140-6736\(22\)02083-9](https://doi.org/10.1016/S0140-6736(22)02083-9)
 880. von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M, *et al.* Ferric carboxymaltose and exercise capacity in heart failure with preserved

- ejection fraction and iron deficiency: the FAIR-HFpEF trial. *Eur Heart J* 2024; **45**:3789–3800. <https://doi.org/10.1093/eurheartj/ehae479>
881. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric carboxymaltose in heart failure with iron deficiency. *N Engl J Med* 2023;**389**:975–86. <https://doi.org/10.1056/NEJMoa2304968>
 882. Vukadinovic D, Abidin A, Emrich I, Schulze PC, von Haehling S, Bohm M. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. *Clin Res Cardiol* 2023;**112**:954–66. <https://doi.org/10.1007/s00392-023-02207-2>
 883. Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. *Eur J Heart Fail* 2023;**25**:528–37. <https://doi.org/10.1002/ehfj.2810>
 884. Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. *ESC Heart Fail* 2023;**10**:1473–80. <https://doi.org/10.1002/ehf2.14310>
 885. Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. *JAMA* 2025;**333**:1965–76. <https://doi.org/10.1001/jama.2025.3833>
 886. Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. *Nat Med* 2025;**31**:2640–6. <https://doi.org/10.1038/s41591-025-03671-1>
 887. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med* 2013; **368**:1210–19. <https://doi.org/10.1056/NEJMoa1214865>
 888. Bhatia K, Sabharwal B, Gupta K, Lopez PD, Kaur A, Bhatia HK, et al. Clinical outcomes of intravenous iron therapy in patients with heart failure and iron deficiency: meta-analysis and trial sequential analysis of randomized clinical trials. *J Cardiol* 2024;**83**:105–12. <https://doi.org/10.1016/j.jcc.2023.06.012>
 889. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;**37**: 2768–801. <https://doi.org/10.1093/eurheartj/ehw211>
 890. Rakisheva A, Farmakis D, Attanasio A, Genis AB, Cohen-Solal A, Gulati G, et al. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors: a clinical consensus statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. *Eur J Heart Fail* 2025;**27**:2084–99. <https://doi.org/10.1002/ehfj.3753>
 891. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol* 2020;**31**: 171–90. <https://doi.org/10.1016/j.annonc.2019.10.023>
 892. Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, et al. Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. *JACC Heart Fail* 2019;**7**:823–33. <https://doi.org/10.1016/j.jchf.2019.05.009>
 893. Canepa M, Straburzynska-Migaj E, Drozd J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. *Eur J Heart Fail* 2018;**20**:100–10. <https://doi.org/10.1002/ehfj.964>
 894. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. *Eur Heart J* 2013;**34**:2795–803. <https://doi.org/10.1093/eurheartj/ehf192>
 895. Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S. What can we learn from pulmonary function testing in heart failure? *Eur J Heart Fail* 2017;**19**:1222–29. <https://doi.org/10.1002/ehfj.946>
 896. Becher PM, Lindberg F, Benson L, Hage C, Dahlstrom U, Rosenkranz S, et al. Phenotyping patients with chronic obstructive pulmonary disease and heart failure. *ESC Heart Fail* 2024;**12**:900–11. <https://doi.org/10.1002/ehf2.15127>
 897. Paoillo S, Dell'Aversana S, Esposito I, Poccia A, Perrone Filardi P. The use of beta-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. *Eur J Intern Med* 2021;**88**:9–14. <https://doi.org/10.1016/j.ejim.2021.03.035>
 898. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. *Thorax* 2012;**67**:977–84. <https://doi.org/10.1136/thoraxjnl-2012-201945>
 899. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet* 2016;**387**:1817–26. [https://doi.org/10.1016/S0140-6736\(16\)30069-1](https://doi.org/10.1016/S0140-6736(16)30069-1)
 900. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. *Heart* 2017;**103**:1536–42. <https://doi.org/10.1136/heartjnl-2016-310897>
 901. Hohlfield JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. *Lancet Respir Med* 2018;**6**:368–78. [https://doi.org/10.1016/S2213-2600\(18\)30054-7](https://doi.org/10.1016/S2213-2600(18)30054-7)
 902. Cowie MR, Gallagher AM. Sleep disordered breathing and heart failure: what does the future hold? *JACC Heart Fail* 2017;**5**:715–23. <https://doi.org/10.1016/j.jchf.2017.06.016>
 903. Pearse SG, Cowie MR. Sleep-disordered breathing in heart failure. *Eur J Heart Fail* 2016;**18**:353–61. <https://doi.org/10.1002/ehfj.492>
 904. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *N Engl J Med* 2015;**373**:1095–105. <https://doi.org/10.1056/NEJMoa1506459>
 905. Bradley TD, Logan AG, Lorenzi Filho G, Kimoff RJ, Duran Cantolla J, Arzt M, et al. Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial. *Lancet Respir Med* 2024;**12**:153–66. [https://doi.org/10.1016/S2213-2600\(23\)00374-0](https://doi.org/10.1016/S2213-2600(23)00374-0)
 906. Baumert M, Immanuel S, McKane S, Linz D. Transvenous phrenic nerve stimulation for the treatment of central sleep apnea reduces episodic hypoxemic burden. *Int J Cardiol* 2023;**378**:89–95. <https://doi.org/10.1016/j.ijcard.2023.02.041>
 907. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *Lancet* 2016;**388**:974–82. [https://doi.org/10.1016/S0140-6736\(16\)30961-8](https://doi.org/10.1016/S0140-6736(16)30961-8)
 908. Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR, et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. *Eur J Heart Fail* 2018;**20**:1746–54. <https://doi.org/10.1002/ehfj.1312>
 909. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of anxiety in samples of patients with heart failure: meta-analysis. *J Cardiovasc Nurs* 2016;**31**:367–79. <https://doi.org/10.1097/JCN.0000000000000265>
 910. Angermann CE, Ertl G. Depression, anxiety, and cognitive impairment: comorbid mental health disorders in heart failure. *Curr Heart Fail Rep* 2018; **15**:398–410. <https://doi.org/10.1007/s11897-018-0414-8>
 911. Sbolli M, Fiuzat M, Cani D, O'Connor CM. Depression and heart failure: the lonely comorbidity. *Eur J Heart Fail* 2020;**22**:2007–17. <https://doi.org/10.1002/ehfj.1865>
 912. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. *J Am Coll Cardiol* 2019;**73**:1827–45. <https://doi.org/10.1016/j.jacc.2019.01.041>
 913. Massucci M, Bellicini MG, Adamo M, Pilotto A, Metra M, Padovani A, et al. Connecting the dots: a narrative review of the relationship between heart failure and cognitive impairment. *ESC Heart Fail* 2025;**12**:1119–31. <https://doi.org/10.1002/ehf2.15144>
 914. Balata M, Gbree MI, Elrashedy AA, Westenfeld R, Pfister R, Zimmer S, et al. Clinical effects of cognitive behavioral therapy in heart failure patients: a meta-analysis of randomized controlled trials. *BMC Complement Med Ther* 2023;**23**:280. <https://doi.org/10.1186/s12906-023-04117-2>
 915. Chernoff RA, Messineo G, Kim S, Pizano D, Korouri S, Danovitch I, et al. Psychosocial interventions for patients with heart failure and their impact on depression, anxiety, quality of life, morbidity, and mortality: a systematic review and meta-analysis. *Psychosom Med* 2022;**84**:560–80. <https://doi.org/10.1097/PSY.0000000000001073>
 916. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol* 2010;**56**: 692–99. <https://doi.org/10.1016/j.jacc.2010.03.068>

917. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. *JAMA* 2016;**315**:2683–93. <https://doi.org/10.1001/jama.2016.7635>
918. Vitale C, Berthelot E, Coats AJ, Loreena H, Albert NM, Tkaczyszyn M, et al. Assessment of frailty in patients with heart failure: a new Heart Failure Frailty Score developed by Delphi consensus. *ESC Heart Fail* 2025;**12**:1818–31. <https://doi.org/10.1002/ehf2.15187>
919. Villaschi A, Chiarito M, Pagnesi M, Stolfo D, Baldetti L, Lombardi CM, et al. Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: insights from the HELP-HF registry. *Eur J Heart Fail* 2024;**26**:1399–407. <https://doi.org/10.1002/ehf.3234>
920. Somech J, Joshi A, Mancini R, Chetrit J, Michel C, Sheppard R, et al. Comparison of questionnaire and performance-based physical frailty scales to predict survival and health-related quality of life in patients with heart failure. *J Am Heart Assoc* 2023;**12**:e026951. <https://doi.org/10.1161/JAHA.122.026951>
921. Uchmanowicz I, Lee CS, Vitale C, Manulik S, Denfeld QE, Uchmanowicz B, et al. Frailty and the risk of all-cause mortality and hospitalization in chronic heart failure: a meta-analysis. *ESC Heart Fail* 2020;**7**:3427–37. <https://doi.org/10.1002/ehf2.12827>
922. Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. *Eur J Heart Fail* 2019;**21**:1299–305. <https://doi.org/10.1002/ehf.1611>
923. Yang X, Lupon J, Vidan MT, Ferguson C, Gastelurrutia P, Newton PJ, et al. Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta-analysis. *J Am Heart Assoc* 2018;**7**:e008251. <https://doi.org/10.1161/JAHA.117.008251>
924. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). *Eur J Prev Cardiol* 2022;**29**:216–27. <https://doi.org/10.1093/eurjpc/zwaa167>
925. Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, et al. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. *Eur J Heart Fail* 2018;**20**:295–303. <https://doi.org/10.1002/ehf.901>
926. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. *JACC Heart Fail* 2016;**4**:464–72. <https://doi.org/10.1016/j.jchf.2016.02.017>
927. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. *JAMA* 2015;**313**:264–74. <https://doi.org/10.1001/jama.2014.18229>
928. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. *Eur J Heart Fail* 2020;**22**:957–66. <https://doi.org/10.1002/ehf.1871>
929. Rey JR, Caro-Codon J, Rosillo SO, Iniesta AM, Castrejon-Castrejon S, Marco-Clement I, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. *Eur J Heart Fail* 2020;**22**:2205–15. <https://doi.org/10.1002/ehf.1990>
930. Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, et al. Clinical outcomes in patients with heart failure hospitalized with COVID-19. *JACC Heart Fail* 2021;**9**:65–73. <https://doi.org/10.1016/j.jchf.2020.11.003>
931. Gotsman I, Shuvy M, Tahiroglu I, Zwas DR, Keren A. Influenza vaccination and outcome in heart failure. *Am J Cardiol* 2020;**128**:134–39. <https://doi.org/10.1016/j.amjcard.2020.05.019>
932. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et al. Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. *JACC Heart Fail* 2016;**4**:152–58. <https://doi.org/10.1016/j.jchf.2015.10.012>
933. Modin D, Jorgensen ME, Gislason G, Jensen JS, Kober L, Claggett B, et al. Influenza vaccine in heart failure. *Circulation* 2019;**139**:575–86. <https://doi.org/10.1161/CIRCULATIONAHA.118.036788>
934. Anderson CS, Hua C, Wang Z, Wang C, Jiang C, Liu R, et al. Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China. *Lancet* 2025;**406**:1020–31. [https://doi.org/10.1016/S0140-6736\(25\)01485-0](https://doi.org/10.1016/S0140-6736(25)01485-0)
935. Heidecker B, Libby P, Vassiliou VS, Roubille F, Vardeny O, Hassager C, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. *Eur Heart J* 2025;**46**:3518–31. <https://doi.org/10.1093/eurheartj/ehaf384>
936. Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, et al. Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. *Lancet Glob Health* 2022;**10**:e1835–44. [https://doi.org/10.1016/S2214-109X\(22\)00432-6](https://doi.org/10.1016/S2214-109X(22)00432-6)
937. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. *Nat Rev Cardiol* 2017;**14**:39–55. <https://doi.org/10.1038/nrcardio.2016.174>
938. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation* 2012;**126**:1040–49. <https://doi.org/10.1161/CIRCULATIONAHA.112.096024>
939. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. *JAMA* 2018;**320**:1349–59. <https://doi.org/10.1001/jama.2018.13770>
940. Peeters RP. Subclinical hypothyroidism. *N Engl J Med* 2017;**376**:2556–65. <https://doi.org/10.1056/NEJMc1611144>
941. Peng CC, Huang HK, Wu BB, Chang RH, Tu YK, Munir KM. Association of thyroid hormone therapy with mortality in subclinical hypothyroidism: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2021;**106**:292–303. <https://doi.org/10.1210/clinem/dgaa777>
942. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. *Eur J Heart Fail* 2008;**10**:1102–07. <https://doi.org/10.1016/j.ejheart.2008.07.013>
943. Borghi C, Palazzuoli A, Landolfo M, Cosentino E. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. *Heart Fail Rev* 2020;**25**:43–51. <https://doi.org/10.1007/s10741-019-09869-z>
944. Borghi C, Tykarski A, Widecka K, Filipiak KJ, Domienik-Karłowicz J, Kostka-Jeziorny K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. *Cardiol J* 2018;**25**:545–63. <https://doi.org/10.5603/CJ.2018.0116>
945. Borghi C, Domienik-Karłowicz J, Tykarski A, Widecka K, Filipiak KJ, Jaguszewski MJ, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. *Cardiol J* 2021;**28**:1–14. <https://doi.org/10.5603/CJ.a2021.0001>
946. Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. *BMJ* 2016;**354**:i4857. <https://doi.org/10.1136/bmj.i4857>
947. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. *Heart* 2006;**92**:1610–15. <https://doi.org/10.1136/hrt.2005.082388>
948. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. *Lancet* 2004;**363**:1751–56. [https://doi.org/10.1016/S0140-6736\(04\)16299-5](https://doi.org/10.1016/S0140-6736(04)16299-5)
949. Jaarsma T. Sexual function of patients with heart failure: facts and numbers. *ESC Heart Fail* 2017;**4**:3–7. <https://doi.org/10.1002/ehf2.12108>
950. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. *J Am Coll Cardiol* 2006;**48**:1111–19. <https://doi.org/10.1016/j.jacc.2006.05.052>
951. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, Badagliacca R, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. *BMC Med* 2014;**12**:185. <https://doi.org/10.1186/s12916-014-0185-3>
952. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. *J Am Coll Cardiol* 2024;**83**:417–26. <https://doi.org/10.1016/j.jacc.2023.10.041>
953. Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk

- cardiovascular disease: a randomized clinical trial. *JAMA* 2021;**325**:39–49. <https://doi.org/10.1001/jama.2020.23649>
954. Gupta C, Sachdeva A, Khamar J, Bu C, Bartoszko J, Loeb M. Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: a systematic review and meta-analysis. *Vaccine* 2022;**40**:3433–43. <https://doi.org/10.1016/j.vaccine.2022.04.039>
 955. McDonagh TA, Blue L, Clark AL, Dahlstrom U, Ekman I, Lainscak M, et al. European Society of Cardiology Heart Failure Association standards for delivering heart failure care. *Eur J Heart Fail* 2011;**13**:235–41. <https://doi.org/10.1093/eurjhf/hfq221>
 956. Kalogirou F, Forsyth F, Kyriakou M, Mantle R, Deaton C. Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction. *ESC Heart Fail* 2020;**7**:194–212. <https://doi.org/10.1002/ehf2.12559>
 957. White-Williams C, Rossi LP, Bittner VA, Driscoll A, Durant RW, Granger BB, et al. Addressing social determinants of health in the care of patients with heart failure: a scientific statement from the American Heart Association. *Circulation* 2020;**141**:e841–63. <https://doi.org/10.1161/CIR.0000000000000767>
 958. Forsyth P, Young S, Hughes K, James R, Oxley C, Kelly R, et al. Multiprofessional heart failure self-development framework. *Open Heart* 2024;**11**:e002554. <https://doi.org/10.1136/openhrt-2023-002554>
 959. Parajuli DR, Kourbelis C, Franzon J, Newmann P, McKinnon RA, Shakib S, et al. Effectiveness of the pharmacist-involved multidisciplinary management of heart failure to improve hospitalizations and mortality rates in 4630 patients: a systematic review and meta-analysis of randomized controlled trials. *J Card Fail* 2019;**25**:744–56. <https://doi.org/10.1016/j.cardfail.2019.07.455>
 960. Li M, Li Y, Meng Q, Li Y, Tian X, Liu R, et al. Effects of nurse-led transitional care interventions for patients with heart failure on healthcare utilization: a meta-analysis of randomized controlled trials. *PLoS One* 2021;**16**:e0261300. <https://doi.org/10.1371/journal.pone.0261300>
 961. Li Y, Fang J, Li M, Luo B. Effect of nurse-led hospital-to-home transitional care interventions on mortality and psychosocial outcomes in adults with heart failure: a meta-analysis. *Eur J Cardiovasc Nurs* 2022;**21**:307–17. <https://doi.org/10.1093/eurjcn/zvab105>
 962. Cannata A, Mizani MA, Bromage DI, Piper SE, Hardman SMC, Sudlow C, et al. Heart failure specialist care and long-term outcomes for patients admitted with acute heart failure. *JACC Heart Fail* 2024;**13**:402–13. <https://doi.org/10.1016/j.jchf.2024.06.013>
 963. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. *Circulation* 2003;**108**:184–91. <https://doi.org/10.1161/01.CIR.0000080290.39027.48>
 964. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. *Cochrane Database Syst Rev* 2019;**1**:CD002752. <https://doi.org/10.1002/14651858.CD002752.pub4>
 965. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. *Eur J Heart Fail* 2017;**19**:1427–43. <https://doi.org/10.1002/ehfj.765>
 966. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. *Ann Intern Med* 2014;**160**:774–84. <https://doi.org/10.7326/M14-0083>
 967. Gandhi S, Mosleh W, Sharma UC, Demers C, Farkouh ME, Schwalm JD. Multidisciplinary heart failure clinics are associated with lower heart failure hospitalization and mortality: systematic review and meta-analysis. *Can J Cardiol* 2017;**33**:1237–44. <https://doi.org/10.1016/j.cjca.2017.05.011>
 968. Herrero-Torres M, Badosa N, Roqueta C, Ruiz-Bustillo S, Sole-Gonzalez E, Belarte-Tornero LC, et al. Randomized controlled trial comparing a multidisciplinary intervention by a geriatrician and a cardiologist to usual care after a heart failure hospitalization in older patients: the SENECOR study. *J Clin Med* 2022;**11**:1932. <https://doi.org/10.3390/jcm11071932>
 969. Marques M, Cobo M, Lopez-Sanchez P, Garcia-Magallon B, Salazar MLS, Lopez-Ibor JV, et al. Multidisciplinary approach to patients with heart failure and kidney disease: preliminary experience of an integrated cardiorenal unit. *Clin Kidney J* 2023;**16**:2100–7. <https://doi.org/10.1093/cjki/sfad169>
 970. Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. *Circ Cardiovasc Qual Outcomes* 2020;**13**:e007264. <https://doi.org/10.1161/CIRCOUTCOMES.120.007264>
 971. Parent M, Leclerc J, O'Meara E, Barrette R, Levesque S, Parent MC, et al. Clinical heart failure management program: changing the practice by partnering primary care and specialists (CHAMP-HF). *Int J Cardiol Heart Vasc* 2024;**50**:101330. <https://doi.org/10.1016/j.ijcha.2023.101330>
 972. Raat W, Smeets M, Janssens S, Vaes B. Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta-analysis. *ESC Heart Fail* 2021;**8**:802–18. <https://doi.org/10.1002/ehf2.13152>
 973. Neubeck L, Ross C, Jones J, Simpson M, Mindham R, Jaarsma T, et al. The core curriculum for cardiovascular nurses and allied professionals. *Eur J Cardiovasc Nurs* 2023;**22**:e62–113. <https://doi.org/10.1093/eurjcn/zvad035>
 974. Mullens W, Coats A, Seferovic P, Metra M, Mebazaa A, Ruschitzka F, et al. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2022;**24**:249–53. <https://doi.org/10.1002/ehf2.2430>
 975. Herrmann JJ, Brunner-La Rocca HP, Baltussen L, Beckers-Wesche F, Bekkers S, Bellersen L, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. *Nat Med* 2025;**31**:2062–68. <https://doi.org/10.1038/s41591-025-03628-4>
 976. Mullens W, Damman K, Dhont S, Banerjee D, Bayes-Genis A, Cannata A, et al. Dietary sodium and fluid intake in heart failure: a clinical consensus statement of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2024;**26**:730–41. <https://doi.org/10.1002/ehfj.3244>
 977. Jonkman NH, Westland H, Groenewold RH, Agren S, Atienza F, Blue L, et al. Do self-management interventions work in patients with heart failure? An individual patient data meta-analysis. *Circulation* 2016;**133**:1189–98. <https://doi.org/10.1161/CIRCULATIONAHA.115.018006>
 978. Ozasa N, Kato T, Morimoto T, Yaku H, Yamamoto E, Inuzuka Y, et al. Polypharmacy and clinical outcomes in hospitalized patients with acute decompensated heart failure. *J Cardiovasc Nurs* 2023;**38**:33–43. <https://doi.org/10.1097/JCN.0000000000000885>
 979. Fabbri M, Murad MH, Wennberg AM, Turcano P, Erwin PJ, Alahdab F, et al. Health literacy and outcomes among patients with heart failure: a systematic review and meta-analysis. *JACC Heart Fail* 2020;**8**:451–60. <https://doi.org/10.1016/j.jchf.2019.11.007>
 980. DeWalt DA, Malone RM, Bryant ME, Kosnar MC, Corr KE, Rothman RL, et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial [ISRCTN1535170]. *BMC Health Serv Res* 2006;**6**:30. <https://doi.org/10.1186/1472-6963-6-30>
 981. Ruppert TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and re-admission rates: systematic review and meta-analysis of controlled trials. *J Am Heart Assoc* 2016;**5**:e002606. <https://doi.org/10.1161/JAHA.115.002606>
 982. Siabani S, Leeder SR, Davidson PM. Barriers and facilitators to self-care in chronic heart failure: a meta-synthesis of qualitative studies. *Springerplus* 2013;**2**:320. <https://doi.org/10.1186/2193-1801-2-320>
 983. Butler J, Petrie MC, Bains M, Bawtinheimer T, Code J, Levitch T, et al. Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post-hospital discharge period. *Res Involv Engagem* 2023;**9**:23. <https://doi.org/10.1186/s40900-023-00412-x>
 984. Jankowska EA, Andersson T, Kaiser-Albers C, Bozkurt B, Chioncel O, Coats AJS, et al. Optimizing outcomes in heart failure: 2022 and beyond. *ESC Heart Fail* 2023;**10**:2159–69. <https://doi.org/10.1002/ehf2.14363>
 985. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. *J Am Coll Cardiol* 2019;**73**:2365–83. <https://doi.org/10.1016/j.jacc.2019.02.015>
 986. Mwansa H, Lewsey S, Mazimba S, Breathett K. Racial/ethnic and gender disparities in heart failure with reduced ejection fraction. *Curr Heart Fail Rep* 2021;**18**:41–51. <https://doi.org/10.1007/s11897-021-00502-5>
 987. Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlstrom U, et al. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2023;**25**:1648–58. <https://doi.org/10.1002/ehfj.2971>
 988. Fu M, Vedin O, Svennblad B, Lampa E, Johansson D, Dahlstrom U, et al. Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. *ESC Heart Fail* 2020;**7**:3633–43. <https://doi.org/10.1002/ehf2.12883>
 989. Schrage B, Lund LH, Benson L, Dahlstrom U, Shadman R, Linde C, et al. Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. *Eur J Heart Fail* 2022;**24**:1212–22. <https://doi.org/10.1002/ehf2.2530>
 990. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization

- therapy: results from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2017;**19**:1270–79. <https://doi.org/10.1002/ehf.781>
991. Oyangueren J, Garcia-Garrido L, Nebot-Margalef M, Latorre-Garcia P, Torcal-Laguna J, Comin-Colet J, et al. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. *Rev Esp Cardiol (Engl Ed)* 2021;**74**:533–43. <https://doi.org/10.1016/j.rec.2020.04.016>
 992. Driscoll A, Meagher S, Kennedy R, Currey J. Effect of intensive nurse-led optimization of heart failure medications in patients with heart failure: a meta-analysis of randomized controlled trials. *J Cardiovasc Nurs* 2024;**39**:417–26. <https://doi.org/10.1097/JCN.0000000000001068>
 993. Campbell G, Doherty C, D'Silva A, Carr-White G, Webb J, Ismail TF. Implementation and evaluation of specialist heart failure pharmacist prescribing clinics. *Int J Clin Pharm* 2025;**47**:8–14. <https://doi.org/10.1007/s11096-024-01808-9>
 994. Spahillari A, Cohen LP, Lin C, Liu Y, Tringale A, Sheppard KE, et al. Efficacy, safety and mechanistic impact of a heart failure guideline-directed medical therapy clinic. *JACC Heart Fail* 2025;**13**:554–68. <https://doi.org/10.1016/j.jchf.2024.08.017>
 995. Stolfo D, Iacoviello M, Chioncel O, Anker MS, Bayes-Genis A, Braunschweig F, et al. How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2025;**27**:747–59. <https://doi.org/10.1002/ehf.3642>
 996. Savarese G, Lindberg F, Cannata A, Adamo M, Ambrosio G, Ameri P, et al. Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy. *Eur J Heart Fail* 2025;**27**:2716–31. <https://doi.org/10.1002/ehf.70090>
 997. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009;**301**:1439–50. <https://doi.org/10.1001/jama.2009.454>
 998. Molloy C, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2024;**3**:CD003331. <https://doi.org/10.1002/14651858.CD003331.pub6>
 999. Bjarnason-Wehrens B, Nebel R, Jensen K, Hackbusch M, Grilli M, Gielen S, et al. Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis. *Eur J Prev Cardiol* 2020;**27**:929–52. <https://doi.org/10.1177/2047487319854140>
 1000. Sebastian SA, Padda I, Johal G. Supervised exercise training in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. *Curr Probl Cardiol* 2024;**49**:102426. <https://doi.org/10.1016/j.cpcardiol.2024.102426>
 1001. Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. *Heart Fail Rev* 2019;**24**:535–47. <https://doi.org/10.1007/s10741-019-09774-5>
 1002. Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. *N Engl J Med* 2021;**385**:203–16. <https://doi.org/10.1056/NEJMoa2026141>
 1003. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. *J Am Coll Cardiol* 2019;**73**:1430–43. <https://doi.org/10.1016/j.jacc.2018.12.072>
 1004. Adamopoulos S, Corra U, Laoutaris ID, Pistono M, Agostoni PG, Coats AJS, et al. Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;**21**:3–13. <https://doi.org/10.1002/ehf.1352>
 1005. Mahfood Haddad T, Saurav A, Smer A, Azzouz MS, Akinapelli A, Williams MA, et al. Cardiac rehabilitation in patients with left ventricular assist device: a systematic review and meta-analysis. *J Cardiopulm Rehabil Prev* 2017;**37**:390–96. <https://doi.org/10.1097/HCR.0000000000000254>
 1006. Kerrigan DJ, Williams CT, Ehrman JK, Saval MA, Bronsteen K, Schairer JR, et al. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the Rehab-VAD randomized controlled trial. *JACC Heart Fail* 2014;**2**:653–59. <https://doi.org/10.1016/j.jchf.2014.06.011>
 1007. Tenenbaum A, Freimark D, Ahron E, Koren-Morag N, Schwammenthal E, Fisman EZ, et al. Long-term versus intermediate-term supervised exercise training in advanced heart failure: effects on exercise tolerance and mortality. *Int J Cardiol* 2006;**113**:364–70. <https://doi.org/10.1016/j.ijcard.2005.11.098>
 1008. Simonenko M, Hansen D, Niebauer J, Volterrani M, Adamopoulos S, Amarelli C, et al. Prevention and rehabilitation after heart transplantation: a clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT. *Eur J Heart Fail* 2024;**26**:1876–92. <https://doi.org/10.1002/ehf.3185>
 1009. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019;**1**:CD003331. <https://doi.org/10.1002/14651858.CD003331.pub5>
 1010. Taylor JL, Myers J, Bonikowske AR. Practical guidelines for exercise prescription in patients with chronic heart failure. *Heart Fail Rev* 2023;**28**:1285–96. <https://doi.org/10.1007/s10741-023-10310-9>
 1011. Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. *J Am Coll Cardiol* 2021;**77**:1454–69. <https://doi.org/10.1016/j.jacc.2021.01.030>
 1012. Imran HM, Baig M, Erqou S, Taveira TH, Shah NR, Morrison A, et al. Home-based cardiac rehabilitation alone and hybrid with center-based cardiac rehabilitation in heart failure: a systematic review and meta-analysis. *J Am Heart Assoc* 2019;**8**:e012779. <https://doi.org/10.1161/JAHA.119.012779>
 1013. Lundgren KM, Langlo KAR, Salvesen O, Zanaboni P, Cittanti E, Mo R, et al. Feasibility of telerehabilitation for heart failure patients inaccessible for outpatient rehabilitation. *ESC Heart Fail* 2023;**10**:2406–17. <https://doi.org/10.1002/ehf2.14405>
 1014. Okamura M, Shimizu M, Yamamoto S, Nishie K, Konishi M. High-intensity interval training versus moderate-intensity continuous training in patients with heart failure: a systematic review and meta-analysis. *Heart Fail Rev* 2023;**28**:1113–28. <https://doi.org/10.1007/s10741-023-10316-3>
 1015. Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2021;**28**:460–95. <https://doi.org/10.1177/2047487320913379>
 1016. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. *Cochrane Database Syst Rev* 2017;**6**:CD007130. <https://doi.org/10.1002/14651858.CD007130.pub4>
 1017. Cooper LB, Mentz RJ, Sun JL, Schulte PJ, Fleg JL, Cooper LS, et al. Psychosocial factors, exercise adherence, and outcomes in heart failure patients: insights from Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). *Circ Heart Fail* 2015;**8**:1044–51. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002327>
 1018. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011;**13**:347–57. <https://doi.org/10.1093/eurjhf/hfr017>
 1019. Gomes-Neto M, Duraes AR, Reis H, Neves VR, Martinez BP, Carvalho VO. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2017;**24**:1696–1707. <https://doi.org/10.1177/2047487317728370>
 1020. Franssen WMA, Franssen G, Spaas J, Solmi F, Eijnde BO. Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials. *Int J Behav Nutr Phys Act* 2020;**17**:57. <https://doi.org/10.1186/s12966-020-00955-2>
 1021. Molloy CD, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure: 2023 Cochrane systematic review and meta-analysis. *Eur J Heart Fail* 2023;**25**:2263–73. <https://doi.org/10.1002/ehf.3046>
 1022. Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. *J Am Coll Cardiol* 2012;**60**:1521–28. <https://doi.org/10.1016/j.jacc.2012.06.036>
 1023. Wang Y, Wu Y, Wei S, Lu S, Zhao J, Zhang Y, et al. Effectiveness of exercise-based cardiac rehabilitation for patients with left ventricular assist device: a systematic review and meta-analysis. *Perfusion* 2025;**40**:317–27. <https://doi.org/10.1177/02676591241245876>
 1024. Liang Q, Wang Z, Liu J, Yan Z, Liu J, Lei M, et al. Effect of exercise rehabilitation in patients with acute heart failure: a systematic review and

- meta-analysis. *J Cardiovasc Nurs* 2024;**39**:390–400. <https://doi.org/10.1097/JCN.0000000000001010>
1025. Meng Y, Zhuge W, Huang H, Zhang T, Ge X. The effects of early exercise on cardiac rehabilitation-related outcome in acute heart failure patients: a systematic review and meta-analysis. *Int J Nurs Stud* 2022;**130**:104237. <https://doi.org/10.1016/j.ijnurstu.2022.104237>
 1026. Nakaya Y, Akamatsu M, Ogimoto A, Kitaoka H. Early cardiac rehabilitation for acute decompensated heart failure safely improves physical function (PEARL study): a randomized controlled trial. *Eur J Phys Rehabil Med* 2021;**57**:985–93. <https://doi.org/10.23736/S1973-9087.21.06727-7>
 1027. Clemente MRC, Felix N, Navalha DDP, Pasqualotto E, Morgado Ferreira RO, Braga MAP, et al. Long-term impact of home-based monitoring after an admission for acute decompensated heart failure: a systematic review and meta-analysis of randomised controlled trials. *EclinicalMedicine* 2024;**71**:102541. <https://doi.org/10.1016/j.eclinm.2024.102541>
 1028. Masotta V, Dante A, Caponnetto V, Marcotullio A, Ferraiuolo F, Bertocchi L, et al. Telehealth care and remote monitoring strategies in heart failure patients: a systematic review and meta-analysis. *Heart Lung* 2024;**64**:149–67. <https://doi.org/10.1016/j.hrtlng.2024.01.003>
 1029. Scholte NTB, Gurgoz MT, Aydin D, Theuns D, Manintveld OC, Ronner E, et al. Telemonitoring for heart failure: a meta-analysis. *Eur Heart J* 2023;**44**:2911–26. <https://doi.org/10.1093/eurheartj/ehad280>
 1030. Caiani EG, Kemps H, Hoogendoorn P, Asteggiano R, Bohm A, Borregaard B, et al. Standardized assessment of evidence supporting the adoption of mobile health solutions: a clinical consensus statement of the ESC Regulatory Affairs Committee: developed in collaboration with the European Heart Rhythm Association (EHRA), the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC, the Heart Failure Association (HFA) of the ESC, the ESC Young Community, the ESC Working Group on e-Cardiology, the ESC Council for Cardiology Practice, the ESC Council of Cardio-Oncology, the ESC Council on Hypertension, the ESC Patient Forum, the ESC Digital Health Committee, and the European Association of Preventive Cardiology (EAPC). *Eur Heart J Digit Health* 2024;**5**:509–23. <https://doi.org/10.1093/ehjdh/ztae042>
 1031. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Bohm A, et al. ESC e-Cardiology Working Group position paper: overcoming challenges in digital health implementation in cardiovascular medicine. *Eur J Prev Cardiol* 2019;**26**:1166–77. <https://doi.org/10.1177/2047487319832394>
 1032. Santobuono VE, Favale S, D'Onofrio A, Manzo M, Calo L, Bertini M, et al. Performance of a multisensor implantable defibrillator algorithm for heart failure monitoring related to co-morbidities. *ESC Heart Fail* 2023;**10**:2469–78. <https://doi.org/10.1002/ehf2.14416>
 1033. Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. *JACC Heart Fail* 2017;**5**:216–25. <https://doi.org/10.1016/j.jchf.2016.12.011>
 1034. Bohm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. *Eur Heart J* 2016;**37**:3154–63. <https://doi.org/10.1093/eurheartj/ehw099>
 1035. van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. *Circulation* 2011;**124**:1719–26. <https://doi.org/10.1161/CIRCULATIONAHA.111.043042>
 1036. Zito A, Princi G, Romiti GF, Galli M, Basili S, Luzzo G, et al. Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis. *Eur J Heart Fail* 2022;**24**:2333–41. <https://doi.org/10.1002/ehf2.2655>
 1037. Kapelios CJ, Liori S, Bonios M, Abraham WT, Filippatos G. Effect of pulmonary artery pressure-guided management on outcomes of patients with heart failure outside clinical trials: a systematic review and meta-analysis of real-world evidence with the CardioMEMS Heart Failure System. *Eur J Heart Fail* 2025;**27**:1857–65. <https://doi.org/10.1002/ehf2.3687>
 1038. de Juan Baguda J, Gavira Gomez JJ, Pachon Iglesias M, Cozar Leon R, Escolar Perez V, Gonzalez Fernandez O, et al. Remote heart failure management using the HeartLogic algorithm. RE-HEART registry. *Rev Esp Cardiol (Engl Ed)* 2022;**75**:709–16. <https://doi.org/10.1016/j.rec.2021.09.015>
 1039. Hajduczuk AG, Muallem SN, Nudy MS, DeWaters AL, Boehmer JP. Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. *Heart Fail Rev* 2022;**27**:1281–1300. <https://doi.org/10.1007/s10741-021-10150-5>
 1040. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet* 2011;**377**:658–66. [https://doi.org/10.1016/S0140-6736\(11\)60101-3](https://doi.org/10.1016/S0140-6736(11)60101-3)
 1041. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *Lancet* 2016;**387**:453–61. [https://doi.org/10.1016/S0140-6736\(15\)00723-0](https://doi.org/10.1016/S0140-6736(15)00723-0)
 1042. Brugs JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. *Lancet* 2023;**401**:2113–23. [https://doi.org/10.1016/S0140-6736\(23\)00923-6](https://doi.org/10.1016/S0140-6736(23)00923-6)
 1043. Clephas PRD, Radhoe SP, Boersma E, Gregson J, Jhund PS, Abraham WT, et al. Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. *Eur Heart J* 2023;**44**:3658–68. <https://doi.org/10.1093/eurheartj/ehad346>
 1044. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmannshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. *Lancet* 2021;**398**:991–1001. [https://doi.org/10.1016/S0140-6736\(21\)01754-2](https://doi.org/10.1016/S0140-6736(21)01754-2)
 1045. Lindenfeld J, Costanzo MR, Ducharme A, Troughton R, Maisel A, et al. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol* 2024;**83**:682–94. <https://doi.org/10.1016/j.jacc.2023.11.030>
 1046. Guichard JL, Bonno EL, Nassif ME, Khumri TM, Miranda D, Jonsson O, et al. Seated pulmonary artery pressure monitoring in patients with heart failure: results of the PROACTIVE-HF trial. *JACC Heart Fail* 2024;**12**:1879–93. <https://doi.org/10.1016/j.jchf.2024.05.017>
 1047. Sharif F, Rosenkranz S, Bartunek J, Kempf T, Assmus B, Mahon NG, et al. Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial. *ESC Heart Fail* 2022;**9**:2862–72. <https://doi.org/10.1002/ehf2.14006>
 1048. Sharif F, Rosenkranz S, Bartunek J, Kempf T, Assmus B, Mahon NG, et al. Twelve-month follow-up results from the SIRONA 2 clinical trial. *ESC Heart Fail* 2024;**11**:1133–43. <https://doi.org/10.1002/ehf2.14657>
 1049. Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail* 2020;**22**:1891–901. <https://doi.org/10.1002/ehf2.1943>
 1050. Cowie MR, Flett A, Cowburn P, Foley P, Chandrasekaran B, Loke I, et al. Real-world evidence in a national health service: results of the UK CardioMEMS HF system post-market study. *ESC Heart Fail* 2022;**9**:48–56. <https://doi.org/10.1002/ehf2.13748>
 1051. Desai AS, Bhimaraj A, Bharmi R, Jernyn R, Bhatt K, Shavelle D, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in 'real-world' clinical practice. *J Am Coll Cardiol* 2017;**69**:2357–65. <https://doi.org/10.1016/j.jacc.2017.03.009>
 1052. Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. *Circ Heart Fail* 2020;**13**:e006863. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006863>
 1053. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. *Cochrane Database Syst Rev* 2015;**2015**:CD007228. <https://doi.org/10.1002/14651858.CD007228.pub3>
 1054. Schou M, Gislason G, Videbaek L, Kober L, Tuxen C, Torp-Pedersen C, et al. Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study. *Eur J Heart Fail* 2014;**16**:1249–55. <https://doi.org/10.1002/ehf2.176>
 1055. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, et al. Association between enrolment in a heart failure quality registry and subsequent mortality: a nationwide cohort study. *Eur J Heart Fail* 2017;**19**:1107–16. <https://doi.org/10.1002/ehf2.762>
 1056. Maligne J, Wilde MI, Brunner-La Rocca HP, Emans ME, De Boer GA, Siegers CEP, et al. Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy. *Eur Heart J* 2025;**46**:2394–405. <https://doi.org/10.1093/eurheartj/ehaf244>
 1057. Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, et al. Multiregional implementation initiative's impact on guideline-based performance measures for patients hospitalized with heart failure: IMPLEMENT-HF. *Circ Heart Fail* 2025;**18**:e012547. <https://doi.org/10.1161/CIRCHEARTFAILURE.124.012547>
 1058. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal

- brain natriuretic peptide (N-BNP) concentrations. *Lancet* 2000;**355**: 1126–30. [https://doi.org/10.1016/s0140-6736\(00\)02060-2](https://doi.org/10.1016/s0140-6736(00)02060-2)
1059. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. *Eur Heart J* 2014;**35**:16–24. <https://doi.org/10.1093/eurheartj/ehd463>
 1060. McLellan J, Heneghan CJ, Perera R, Clements AM, Glasziou PP, Kearley KE, et al. B-type natriuretic peptide-guided treatment for heart failure. *Cochrane Database Syst Rev* 2016;**12**:CD008966. <https://doi.org/10.1002/14651858.CD008966.pub2>
 1061. Goldstein NE, Mather H, McKendrick K, Gelfman LP, Hutchinson MD, Lampert R, et al. Improving communication in heart failure patient care. *J Am Coll Cardiol* 2019;**74**:1682–92. <https://doi.org/10.1016/j.jacc.2019.07.058>
 1062. O'Donnell AE, Schaefer KG, Stevenson LW, DeVoe K, Walsh K, Mehra MR, et al. Social worker-aided palliative care intervention in high-risk patients with heart failure (SWAP-HF): a pilot randomized clinical trial. *JAMA Cardiol* 2018;**3**:516–9. <https://doi.org/10.1001/jamacardio.2018.0589>
 1063. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. *J Am Coll Cardiol* 2017;**70**:331–41. <https://doi.org/10.1016/j.jacc.2017.05.030>
 1064. Datla S, Verberkt CA, Hoyer A, Janssen DJA, Johnson MJ. Multi-disciplinary palliative care is effective in people with symptomatic heart failure: a systematic review and narrative synthesis. *Palliat Med* 2019;**33**:1003–16. <https://doi.org/10.1177/0269216319859148>
 1065. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart failure. *Heart Fail Clin* 2015;**11**:479–98. <https://doi.org/10.1016/j.hfc.2015.03.010>
 1066. Sahlolbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. *Eur J Heart Fail* 2020;**22**:2340–6. <https://doi.org/10.1002/ejhf.1783>
 1067. Diop MS, Rudolph JL, Zimmerman KM, Richter MA, Skarf LM. Palliative care interventions for patients with heart failure: a systematic review and meta-analysis. *J Palliat Med* 2017;**20**:84–92. <https://doi.org/10.1089/jpm.2016.0330>
 1068. Zhou K, Mao Y. Palliative care in heart failure: a meta-analysis of randomized controlled trials. *Herz* 2019;**44**:440–4. <https://doi.org/10.1007/s00059-017-4677-8>
 1069. Eggleton EJ, McMurrugh KJ, Aiken CE. Maternal pregnancy outcomes in women with cardiomyopathy: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2022;**227**:582–92. <https://doi.org/10.1016/j.ajog.2022.05.039>
 1070. Mehta LS, Sharma G, Creanga AA, Hameed AB, Hollier LM, Johnson JC, et al. Call to action: maternal health and saving mothers: a policy statement from the American Heart Association. *Circulation* 2021;**144**:e251–69. <https://doi.org/10.1161/CIR.0000000000001000>
 1071. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Domenach MT, Grando-Ting J, Estensen M, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. *Heart* 2014;**100**:231–8. <https://doi.org/10.1136/heartjnl-2013-304888>
 1072. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J* 2016;**80**:2221–6. <https://doi.org/10.1253/circj.CJ-15-0617>
 1073. Ramlakhan KP, Roos-Hesselink JW, Basso T, Greenslade J, Flint RB, Krieger EV, et al. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC). *Int J Cardiol* 2024;**410**:132234. <https://doi.org/10.1016/j.ijcard.2024.132234>
 1074. van der Zande JA, Ramlakhan KP, Proksey K, Munoz-Ortiz E, Baroudidou A, Lipczynska M, et al. ACE inhibitor and angiotensin receptor blocker use during pregnancy: data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC). *Am J Cardiol* 2024;**230**:27–36. <https://doi.org/10.1016/j.amjcard.2024.08.004>
 1075. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. *Hypertension* 2012;**60**:444–50. <https://doi.org/10.1161/HYPERTENSIONAHA.112.196352>
 1076. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. *Front Endocrinol (Lausanne)* 2023;**14**:1215356. <https://doi.org/10.3389/fendo.2023.1215356>
 1077. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2021;**42**:1554–68. <https://doi.org/10.1093/eurheartj/ehab072>
 1078. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. *Circulation* 2019;**140**:16–26. <https://doi.org/10.1161/CIRCULATIONAHA.118.038169>
 1079. Ney S, Ihle P, Ruhnke T, Gunster C, Michels G, Seuthe K, et al. Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018. *Clin Res Cardiol* 2023;**112**:401–8. <https://doi.org/10.1007/s00392-022-02114-y>
 1080. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. *Cardiovasc Res* 2023;**118**:3517–35. <https://doi.org/10.1093/cvr/cvac119>
 1081. Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol* 2022;**4**: 427–41. <https://doi.org/10.1016/j.jacc.2022.08.009>
 1082. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;**379**:1007–16. <https://doi.org/10.1056/NEJMoa1805689>
 1083. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. *N Engl J Med* 2024;**390**:132–42. <https://doi.org/10.1056/NEJMoa2305434>
 1084. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med* 2025;**392**:33–44. <https://doi.org/10.1056/NEJMoa2409134>
 1085. Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRIBUTE-CM trial. *Circulation* 2024;**151**:601–11. <https://doi.org/10.1161/CIRCULATIONAHA.124.072771>
 1086. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. *N Engl J Med* 2023;**389**:1553–65. <https://doi.org/10.1056/NEJMoa2300757>
 1087. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. *Eur Heart J* 2023;**44**:2893–907. <https://doi.org/10.1093/eurheartj/ehad347>
 1088. Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT. *JACC Heart Fail* 2021;**9**:795–802. <https://doi.org/10.1016/j.jchf.2021.06.007>
 1089. Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, et al. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. *Eur J Heart Fail* 2024;**26**:938–47. <https://doi.org/10.1002/ejhf.3198>
 1090. Porcari A, Cappelli F, Nitsche C, Tomasoni G, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. *J Am Coll Cardiol* 2024;**83**:2411–22. <https://doi.org/10.1016/j.jacc.2024.03.429>
 1091. Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy. *Am J Cardiol* 2025;**243**:15–18. <https://doi.org/10.1016/j.amjcard.2025.01.012>
 1092. Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M, et al. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. *Eur Heart J* 2026;**47**:22–36. <https://doi.org/10.1093/eurheartj/ehaf710>
 1093. Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. *J Am Coll Cardiol* 2024;**83**:1276–91. <https://doi.org/10.1016/j.jacc.2023.12.036>
 1094. Sinigiani G, Sanna GD, Aimo A, Porcari A, Bonacchi G, De Michieli L, et al. Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis. *JACC Heart Fail* 2025;**13**:102549. <https://doi.org/10.1016/j.jchf.2025.102549>
 1095. Writing C, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2023;**81**:1076–126. <https://doi.org/10.1016/j.jacc.2022.11.022>

1096. Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, *et al.* No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. *JACC Clin Electrophysiol* 2019;5:1473–4. <https://doi.org/10.1016/j.jacep.2019.10.013>
1097. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. *JACC Clin Electrophysiol* 2020;6:351–61. <https://doi.org/10.1016/j.jacep.2020.01.004>
1098. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, *et al.* Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. *J Am Coll Cardiol* 2019;73:589–97. <https://doi.org/10.1016/j.jacc.2018.10.079>
1099. Cooper LT Jr, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. *Glob Heart* 2014;9:121–9. <https://doi.org/10.1016/j.ghheart.2014.01.007>
1100. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, *et al.* Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy Registry. *Circulation* 2018;138:1088–99. <https://doi.org/10.1161/CIRCULATIONAHA.118.035319>
1101. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, *et al.* Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. *Circulation* 2013;128:2384–94. <https://doi.org/10.1161/CIRCULATIONAHA.113.003092>
1102. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, *et al.* Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. *Circulation* 2017;136:529–45. <https://doi.org/10.1161/CIRCULATIONAHA.117.026386>
1103. Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, *et al.* Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 2019;74:299–311. <https://doi.org/10.1016/j.jacc.2019.04.063>
1104. Baritussio A, Schiavo A, Basso C, Giordani AS, Cheng CY, Pontara E, *et al.* Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. *Eur J Heart Fail* 2022;24:1033–44. <https://doi.org/10.1002/ehf.2496>
1105. Khairy P, Ionescu-Iltu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. *J Am Coll Cardiol* 2010;56:1149–57. <https://doi.org/10.1016/j.jacc.2010.03.085>
1106. Agarwal S, Sud K, Menon V. Nationwide hospitalization trends in adult congenital heart disease across 2003–2012. *J Am Heart Assoc* 2016;5:e002330. <https://doi.org/10.1161/JAHA.115.002330>
1107. Burstein DS, Rossano JW, Griffiths H, Zhang X, Fowler R, Frischertz B, *et al.* Greater admissions, mortality and cost of heart failure in adults with congenital heart disease. *Heart* 2021;107:807–13. <https://doi.org/10.1136/heartjnl-2020-318246>
1108. Arslani K, Roffler N, Zurek M, Greutmann M, Schwerzmann M, Bouchardy J, *et al.* Patterns of incidence rates of cardiac complications in patients with congenital heart disease. *Can J Cardiol* 2018;34:1624–30. <https://doi.org/10.1016/j.cjca.2018.09.010>
1109. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, *et al.* Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. *Circulation* 2015;132:2118–25. <https://doi.org/10.1161/CIRCULATIONAHA.115.017202>
1110. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, *et al.* Mortality in adult congenital heart disease. *Eur Heart J* 2010;31:1220–9. <https://doi.org/10.1093/eurheartj/ehq032>
1111. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, *et al.* 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021;42:563–645. <https://doi.org/10.1093/eurheartj/ehaa554>
1112. Lui GK, Saidi A, Bhatt AB, Burchill LJ, Deen JF, Earing MG, *et al.* Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. *Circulation* 2017;136:e348–92. <https://doi.org/10.1161/CIR.0000000000000535>
1113. D'Alto M, Giannakoulas G, Aboulhosn J, Akagi T, Arvanitaki A, Badagliacca R, *et al.* Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing & Allied Professions of the ESC. *Eur J Heart Fail* 2026. <https://doi.org/10.1093/ehf/xaag059>